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i
Abstract
The number of primary total hip replacement (THR) procedures is increas-
ing worldwide. An increase in early post-operative mortality is associated
with THR while in the long term, advancements in lifestyle factors and sur-
gical techniques for THR suggest an improvement in survival following the
procedure. Mortality after primary THR is affected by a large number of
confounding variables each of which must be considered to enable valid in-
terpretation. Routinely collected data by general practices can provide useful
insights on variations in short and long term mortality after primary THR
procedure.
The primary objectives of this research were to investigate how a history
of various medical conditions before THR procedures affect the short and
long term mortality risk after the surgery for patients in the United King-
dom.
Medical records from 1987 to 2011 from general practices contributing
to The Health Improvement Network (THIN) database were used to develop
two specific mortality models: to estimate odds ratio of death during the first
24 months after the procedure and to estimate the long term hazard ratio
of all-cause mortality following THR. Both mortality models were multilevel
and included preoperative comorbidities, lifestyle and socio-demographic fac-
tors. These models produced accurate estimates of mortality risk after THR
procedures that could inform professional healthcare on future medical man-
agement of THR patients and financial planning for retirement by patients,
the actuarial industry, and the government.
This research found that in the first 24 months after THR, an excess
mortality risk is associated with THR cases compared to controls and preop-
erative overweight, obesity, smoking, myocardial infarction and male gender
increased short term odds of death for all types of THR procedures, compared
to controls without these conditions. In the long term, hazard of all-cause
mortality for THR cases was lower than controls, and was higher for patients
with preoperative hypercholesterolemia, myocardial infarction, osteoarthritis
and smoking compared to those without these conditions. However over-
weight and obese THR cases had better survival prospects than controls and
THR cases with normal BMI.
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1 Introduction And Background Information
1.1 Introduction
Over the last two decades, there has been a rapid increase in the number
of medical registries and other sources of electronically collected medical
data. These medical databases permit researchers to carry out prospective,
retrospective or cross-sectional studies. The availability of huge number of
databases containing specialised information, has contributed vastly to inter-
disciplinary research. One such example is the use of primary care records
to extract conclusive and essential information for medical and actuarial ap-
plication. In this research, the main objective is to develop survival models
that will explain variations in mortality risks after total hip replacement, for
adults in the United Kingdom using data from primary care records. The
following topics are presented in this introductory chapter: description of
the surgical procedure of total hip replacement, trends in number of total
hip replacements, actuarial and medical interests in mortality analysis after
total hip replacement, objectives and aims of this research and the outline of
this thesis.
1.2 An Overview of Total Hip Replacement Procedure
Structure of Hip Joint in Adults
Figure 1 (McCarthy et al., (2016)) below illustrates the structure of hip joints
in adults. An adult hip joint is scientifically known as the acetabulo-femoral
joint. It is the joint connecting the femur and acetabulum of the pelvis. Its
primary function is to support the weight of the body while being stationary
(for example standing) and during motions (for example walking or running).
Therefore, hip joints are the most important part in retaining balance and
hence, any condition affecting the hip joint will cause painful distress to the
individual’s physical movements.
1
Figure 1: Frontal illustration of structure of hip in adults (McCarthy et al.,
(2016))
Hip Pain in Adults
Conditions affecting the hip joints are qualified as musculoskeletal. These are
long term conditions that can cause a deterioration of an individual’s quality
of life due to pain in muscles, bones and joints. The most common problem
with hip joint is hip pain. Such a condition is mainly caused by a degener-
ative disease known as osteoarthritis (commonly referred to as coxarthrosis)
(McCarthy et al., (2016)). The term osteoarthritis (OA) is derived from
three Greek words meaning bone, joint, and inflammation. OA is a progres-
sive disorder of the joints caused by gradual loss of cartilage that acts as a
protective cushion between the acetabulum ball and the pubis. As the car-
tilage is gradually worn away, the bone forms areas of abnormal hardening
(commonly referred as spurs) and fluid-filled pockets (known as subchondral
cysts) in the joint. As the disorder continues, pain results from deforma-
tion of the bones and fluid accumulation in the joints. Such a condition
causes painful distress to the individual during physical movements. Figure
2 (Sanders, (2003)) below illustrates the gradual loss of cartilage between
joints due to OA. In the advanced stage of OA, it can be observed that the
cartilage is completely worn out causing the bone to erode as well causing
uncomfortable pain to the individual.
2
Figure 2: Loss of cartilage due to OA (Sanders, (2003))
History of Total Hip Replacement Procedures
Hstory of hip arthroplasty spans over more than 100 years. It has been seen
as a landmark in twentieth-century surgery. The first known attempt to re-
model a completely destroyed hip occurred in 1885 (Ollier,(1888)). Gluck
(1891) was the first one to use foreign materials in the form of ivory com-
ponents with nickel-plated steel screws for fixation. In the early twentieth
century, the use of organic (fascia, fat) or inorganic (gold foil) materials
in the form of membranes was common during resurfacing of hip. Mould
arthroplasty (Smith-Petersen, (1948)) from 1923 and onwards, became fa-
mous while hemiprostheses of different designs and materials then prevailed
until the early 1960’s.
Since the early 1960, THR procedure has played an important role in
alleviating pain and restoring mobility to millions of people suffering from
arthritic joints. The success of THR was not the result of one single break-
through. Its origins lay in the inter-positional and arthroplasty techniques
developed between 1920 and 1950 in Europe and the United States. The
evolution of procedures for putting materials between the articulating sur-
faces or for replacing one side of the hip joint led to materials, designs and
surgical techniques that proved crucial to its success (Reynolds and Tansey,
(2006)). However, THR was primarily a British innovation that started to
take off in the late 1950s, under the National Health Service, but mainly in
district general hospitals rather than in teaching hospitals. It was created
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in hospital units in Norwich, Wrightington (near Wigan), Stanmore, Redhill
and later Exeter (Parsons (1972), Duff-Barclay and Spillman (1966), Walker
(1977), Klenerman (2002)).
The most important and highlighted breakthrough in the history of THR
procedures occurred in the 1960s when Sir John Charnley introduced a new
design of cemented hip prosthesis (Charnley, (1951)). Charnley hip prosthe-
sis design is the standard reference to which new types of prosthesis are often
compared to. The basic idea of Charnley was to use a cemented polyethy-
lene acetabular cup and a small 22 mm femoral head that gave a low torque
and low wear on a cemented femoral stem made of stainless steel. Further
developments in the early 1970’s concerned a new operation environment for
THR procedures (Charnley (1972a, 1972b)).
Several designs with some attributes similar to the Charnley prosthesis
but including new ideas were introduced to the market of hip prostheses in the
1970’s. For example, the Norwegian orthopaedic surgeon Tor Christiansen
designed a prosthesis (Christiansen (1969), Sudmann et al., (1983)) that was
more anatomically correct and with a larger femoral head (37 mm wide) than
the small Charnley prosthesis head (22 mm wide). Other prostheses from
the 1970’s and 1980’s were the uncemented Bio-Fit femur prosthesis with a
smooth surface and the double cup prostheses such as the Wagner prosthesis
(Howie et al., 1990).
The history of hip replacement includes the use of several types of hip
prostheses. However, there does not exist a general consensus on which type
of prostheses are the best although cemented prostheses have been accepted
as the best hip replacement technique for older patients. The debate on which
type of hip replacement is most suitable for younger and active patients is
still on although Lie (2002) showed a preference for newer uncemented de-
signs with hydroxyapatite coating for younger and active patients.
Mechanism of Total Hip Replacement Procedure
The concept of total hip replacement consists of using a biochemical device,
also known as a hip prosthesis, designed to completely replace the native
joint (Figure 1) that has been painfully affected. The hip prosthesis consists
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of a femoral head and an acetabular cup. The femoral stem is either of a
modular or monoblock design as shown in Figure 3 (Hallan, (2007)). Under
the monoblock design, the femoral head and stem come in one piece while
under the modular design, the femoral head is free from the stem and is
attached to the stem by using a taper locking mechanism. Similarly, the
acetabular cup can either be monoblock where the cup comes together with
the stem as one piece or modular where the cup consists of a shell that is
attached to the pelvic bone and an insert (liner), which is fixed inside the
shell. The bearing surface of the artificial joint is composed of a metal or
ceramic femoral head while the inner surface of the cup is typically made of
polyethylene (plastic), ceramics or metal.
The types of THR procedures are determined by the types of fixation tech-
nique used for total joint replacement. THR procedures involving artificial
femoral head and acetabular cup of the joint fixed into the bone with acrylic
cement, are referred as cemented THR (Morley et al., (2014)). Uncemented
THR procedures involve fixing the artificial hip joint to the bone without
using acrylic cement at all. The surface of the prosthetic joint is roughed up
and often coated with bioactive materials such as hydroxyapatite and trical-
cium phosphate to encourage the growth of bone onto the prosthetic joint so
as to secure the prosthesis in place (Yamada et al., (2009)). THR procedures
in which the femoral component is cemented into the bone while the cup
is fixed without cement, is called hybrid THR procedures. Reverse hybrid
THR procedures involve fixing the femoral component to the bone without
cement while the acetabular cup is cemented into the bone (NICE, (2014)).
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Figure 3: Illustration of hip prostheses (Hallan, (2007))
1.3 Increasing Number of Total Hip Replacement Pro-
cedures
There has been a rapid increase in the annual number of THR procedures
performed worldwide. In 1980, the estimated number of THR procedures was
between 300,000 and 400,000, per year. A decade later, the estimated number
of THR cases jumped to approximately 800,000 annually (Levy et al., (1985))
and by 1991, over 1 million THR procedures per year were reported worldwide
(So¨derman, (2000)). In England and Wales only, the National Joint Registry
(NJR) reported an increase of 80% in the number of THR procedures from
2003 to 2012 as shown by Figure 4 below (NJR, (2016)). This represents
an average annual increase of 8% each year in England and Wales alone and
therefore, the number of THR procedures is likely to keep on increasing with
time. In this section, a summary of the impacts of the increasing trend in
number of THR procedures on individual retirement planning, the actuarial
and medical industry is provided.
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Figure 4: Total primary hip replacement procedures entered into the NJR between
2003 and 2013 (NJR, (2016))
1.3.1 Retirement Planning in UK
Retirement planning is the process of determining retirement income goals
and the actions and decisions necessary to achieve those goals. It includes
identifying income and expenses sources, implementing a savings program
and managing assets for present and future access. In the UK, sources of
income at retirement are (1) a pension provided by the state, (2) pension
provided by employers, (3) defined benefits or defined contributions pension
schemes and (4) personalised pension schemes (Office for National Statistics,
(2013)). Access to the pension fund built up during the contribution years of
the individual is allowed at the minimum retirement age, which is 55 years
in the UK as at 2017 and this will be raised to 57 years in 2018 (Lain, (2016)).
Pension fund reforms enforced by the British government in April 2015
provided individuals with a greater flexibility in choosing retirement age and
accessing their pension pots. From April 2015 onwards, people are allowed
a 25% tax-free lump-sum from their total pension fund and then provided
with the following options for the remaining 75% of the pension pot (Lain,
(2016)):
(1) Withdrawal of the remaining 75% of the pension pot at the UK marginal
tax rate
(2) Purchase of a life or term annuity from the government or private sector
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(3) Purchase of flexible drawdown products, whereby individuals reinvest
the remaining 75% of the pension pot in funds specifically designed
and managed for providing an income after retirement. The income
received, will vary depending on the fund’s performance and is not
guaranteed for life.
Changes in pension legislation in April 2015 were brought for two main
reasons. Firstly, the life expectancy in the UK is increasing. The expected
lifetime of a 65 years old in the UK was 16.1 years in 2001-2003 and 18.5
years in 2013-2015 for males and 19.1 years in 2001-2003 and 20.9 years in
2013-2015 for females, respectively (Office for National Statistics, (2016)).
Secondly, the lifestyle of retired individuals have also changed. There are
more active retired persons in the UK than there were 20 years ago (Lain,
(2016)). Given that THR procedure is dominantly common among patients
aged 55 or more (NJR (2017)), informing individuals who are planning for
their retirement about mortality risk after THR, will assist them in mak-
ing the appropriate choice for their pension fund, such that they have the
optimum pension benefits at retirement.
1.3.2 Actuarial Impacts
Understanding and management of the longevity risks from various medical
conditions and surgical interventions is an important part of actuarial re-
search in the area of life insurance and pensions. The pricing of products sold
to customers in the field of life insurance and pensions is highly dependent
on the assumption or model used to estimate longevity risks for customers.
An accurate estimation of longevity risks of customers is therefore highly de-
sired in the insurance industry. In actuarial terms, longevity risk is defined
as the uncertainty caused by future significant changes in mortality rates
(Barrieu et al., (2012)). With the increasing number of THR procedures,
the potential number of customers for life insurance companies undergoing
THR procedures rises. Therefore it becomes important to know whether the
longevity risks associated with this category of customers (those undergoing
THR) are significantly different from those of the average customers. In this
section, a summary of potential impacts caused by an increasing trend in
number of THR procedures on the insurance and pensions industry, is pro-
vided.
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The impact of THR procedures on life expectancy is still a controversial
issue with conflicting results from epidemiological studies. If the life ex-
pectancy of patients undergoing THR procedures is improving, this presents
challenges for life insurance and pension management companies in the way
they adjust their existing assumptions on mortality during their pricing, re-
serving and profitability testing models.
Categorising THR patients as a group of individuals with different longevity
risk allows insurers to build or adjust their pricing mechanism model of their
products differently for customers with THR procedures and those without.
For instance, when a group of individuals with a well defined medical condi-
tion, for example THR procedure, is identified to be associated with a higher
risk of longevity, they are penalised in terms of the benefits they receive from
pension and annuity products they bought, compared to insurance customers
with a lower longevity risk. This benefit adjustment is referred as managing
basis risk. In the insurance sector, basis risk is defined as the uncertainty as-
sociated with differences in assumptions that have been used for a particular
model and the conditions observed in real life. Assuming a similar longevity
risk for customers undergoing THR procedures as the average customers may
represent a source of basis risk for the insurance and pension sector because
of the existing uncertainty in the magnitude of the improvement in the life
expectancy of individuals after THR procedures in the long run.
In addition, identifying sub-groups of individuals with different medical
characteristic and classifying them according to their longevity risk, assist
actuaries to design new types of enhanced annuities products that are tai-
lored and more suitable to the customers’ needs. In this way, life insurance
and pension companies become more competitive in the insurance market.
Managing longevity risks via categorisation of customers reduces the risk
of overpricing or under-pricing their products. Therefore an educated man-
agement of longevity risk associated with THR procedures is of immense
importance.
A common practice in the actuarial field is the categorisation of longevity
risks according to their customers residential address or socio-economic fac-
tors such as Townsend and Mosaic scores. The use of postcodes in mortality
investigations has become increasingly common in the UK, both for individ-
ual annuity and pension pricing. Therefore arises the need to investigate
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how longevity risks associated with THR procedures, vary across residential
areas with different socio-economic factors because such an investigation will
aid the life insurance industry to identify areas of high or low longevity risks
after THR procedures.
With increasing number of medical registries available today, insurers are
looking to make better use of these huge databases. The appeal for the life
insurance and pension industry is simple: “If you have already collected the
data, then it is like leaving money on the table if it is not being exploited
to the full. Worse, if your competitors make better use of their data, you
can be selected against and lose money”(Richards, (2014)). As mentioned
previously, use of residential addresses is increasingly common in the actuar-
ial field. The biggest change has been in insurers’ attitude towards the use
of postcode related variables to analyse variability in longevity or mortality
risk. Large medical databases are often linked to post-code related informa-
tion and thus any extra value which can be squeezed out of these, represent
a low-cost bonus information that insurance companies can use to edge out
in the competitive insurance market.
Over the years, the insurance sector has employed gender as an under-
writing factor when developing pension and annuity products. Women are
statistically known to have higher life expectancy than men and thus the cost
associated with insurance and pension policies sold to women is higher than
males. This status quo is today challenged by the European Union with the
introduction and implementation of the directive which requires all states of
the European Union to ensure the respect of gender equality in all insurance
contracts, as mentioned by the 5th Article of the European Council Direc-
tive (European Union Convention, (2004)). This challenging directive forces
actuaries in the insurance sector to identify new sources of longevity risks.
Understanding and learning from the longevity risk after medical procedures
such as THR provides a tool for actuaries to identify new sources to explain
variability in mortality or longevity risk.
In the light of the above arguments, there is a strong case to argue that
the increasing trend in number of THR procedures in the United Kingdom
and worldwide, will impact on the actuarial methods of managing mortal-
ity and longevity risk as it increases the likelihood that more customers of
insurance and pension products will undergo THR procedures. Hence actu-
10
arial determination to price insurance and pension products, to reserve for
future benefits and claims payment and to calculate the profitability of these
products will be affected.
1.3.3 Medical and Healthcare Sector
Survival after THR or longevity risks associated with THR procedures is
one of the main concerns of healthcare professional because of the growing
demand for THR procedures. An increase in surgery age of patients undergo-
ing the procedure, warrants an investigation of post-operative mortality rate
after THR procedures. With an expected increase in number of THR pro-
cedures, medical professionals expect a larger distribution of ages at surgery
time. Therefore, an analysis of mortality risks for different age groups at
THR surgery will support medical professionals to identify age groups who
are at high mortality risk.
Post-operative mortality risk associated with patients with a history of
co-morbidities before their THR procedures, is still an area under develop-
ment. Usually patients undergo a pre-selection assessment before their THR
surgery. The medical history of patients is thoroughly checked for any car-
diovascular diseases, kidney problems or any coronary heart disease before
the surgery. With an expected increasing number of THR cases, surgeons
face increasing difficulties in identifying patients at high mortality risk. This
highlights the need to build a survival model that will determine the mor-
tality risk of the patients given their medical history, prior to THR procedure.
Demand for THR prostheses is expected to increase in the future. As a
result, new types of prostheses are expected to be offered into the market.
Unfortunately, the impact of different types of prostheses on survival after
THR is still a debatable area that needs to be addressed. The systematic
reviews by Kynaston-Pearson et al. (2013) on primary hip replacement pros-
theses in 2013 found that 24% of all hip replacement implants available to
surgeons in the UK have no evidence for their clinical effectiveness. This
review also showed that 7.8% of the 136,593 components used in primary hip
replacements in 2011 were implanted without readily identifiable evidence of
clinical effectiveness. This points out that a considerable proportion of pros-
theses available to orthopaedic surgeons, have no readily available evidence
of clinical effectiveness to support their use. A survival model estimating
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post-THR mortality risk for different of types of THR prostheses will help
to identify which types of prostheses are beneficial for survival after THR
procedures.
With an ageing population in the United Kingdom, prevalence of chronic
medical conditions such as chronic kidney diseases and cardiovascular dis-
eases increases (Vos et al. (2015)). Higher prevalence of such medical con-
ditions enhances the understanding in variability of mortality risks. With
an increasing prevalence of chronic medical conditions, a higher degree of
differentiation between patients is possible, including interaction of medi-
cal conditions with socio-demographic and lifestyle factors and treatments
received. Hence a survival model assessing variations in mortality risk for
patients with different chronic diseases prior to their THR surgery will pro-
vide an enhanced understanding of the role played by pre-existing medical
conditions on individual mortality risk after THR procedures.
With increasing number of THR procedures in the UK, the prevalence
of THR patients who receive drug therapy treatments for chronic conditions
such as hypercholesterolemia, hypertension or type 2 diabetes, prior to their
surgery, may also increase. The effects of drug therapy on mortality risk
after THR procedures may vary across different socio-demographic, medical
and lifestyle factors (Platt et al. (2008)). A survival model will help decision
makers in the health sector to estimate the differences in effectiveness of drug
therapy for THR patients, given that they were receiving treatments before
their surgery.
The rising demand for THR procedures in UK also put pressure on pro-
fessional healthcare providers such as clinicians, surgeons or policy makers.
Allocation of resources may be more efficiently and strategically carried out
to satisfy the increasing demand for THR procedures if a post-THR survival
model is used to classify patients into categories of high or low mortality risk
after surgery. Such an approach will aid professional healthcare providers in
identifying group of THR patients with different risks of mortality and thus
allocate their resources for the benefits of the patients, more efficiently.
In conclusion, there are strong reasons to argue that increasing number
of THR procedures in the UK poses a challenge to healthcare professionals
to provide their services more efficiently. Firstly, surgeons and general prac-
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titioners need to assess the mortality risk for different age groups at time of
THR procedures for patients with different medical conditions as demand for
THR procedure at a younger age or for patients with different co-morbidities
prior to surgery, may increase. Secondly, there is a strong need to understand
the effects of different prostheses on mortality risk after THR procedures to
assess their effectiveness. Thirdly, with increasing prevalence of THR pro-
cedures, effects of different drug therapy treatments on survival after THR
procedures need a close examination. Therefore, the use of a survival model
for mortality risk estimation after THR procedures will help to answer these
questions and will provide a tool for health care service providers to work
more efficiently and strategically.
1.4 Objectives and Aims of Research
The primary objectives of this research are to investigate mortality risks
in the UK after THR procedure for individuals with different preoperative
medical history and from different socio-economic groups. Using primary
health care records from The Health Improvement Network (THIN) database,
survival models to analyse variations in short and long term mortality risk
after THR procedures, are developed, with the following goals:
(1) Estimate the mortality risk after primary THR procedures in the short
and long term.
(2) Identify a list of risk factors or interactions between risk factors that
cause variations in post-THR surgery mortality risk and estimate their
effect size.
(3) Explain the medical and actuarial implications from estimated mortal-
ity risk after THR procedures.
The aims of the research are as follows:
(1) Select primary care records from the THIN database for identification
of patients undergoing THR procedures.
(2) Determine the prevalence of co-morbidities such as angina, myocardial
infarction, stroke and chronic conditions such as chronic kidney disease,
type 2 diabetes, osteoarthritis and rheumatoid arthritis and modifiable
conditions such as hypercholesterolemia, hypertension, body mass in-
dex and smoking status, prior to time of THR procedure of patients.
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(3) Establish the prevalence of missing data among records extracted from
the THIN database and determine the effects of missingness in the
dataset on survival models after THR procedures.
(4) Estimate the effects of different types of THR procedures on mortality
risk after THR procedures.
(5) Investigate whether the preoperative medical history (listed in aim (2))
and hormone replacement therapy (oestrogen, progesterone and testos-
terone) affect short and long term survival following THR.
(6) Investigate how mortality risks after THR procedures vary across demo-
graphic variables and socio-economic factors such as Townsend scores,
Mosaic groups and index of multiple deprivation.
(7) Impact of research findings on clinical and actuarial management of
patients undergoing THR procedures.
1.5 Thesis Outline
This section provides the outline of the following chapters of the thesis.
Chapter 2 is a review of mortality risk after primary total hip replace-
ment. Two reviews are presented in this chapter; one for short term review
of early post-operative mortality risk and another one for long term review
of survival analysis following primary total hip replacement.
Chapter 3 is a review of statistical methods for survival analysis of cen-
sored hierarchical data. Firstly, two separate survival models, namely the
Cox proportional hazards model with frailty and the logistic regression model
with random effects, and their assumptions for model fitting, are, respec-
tively, described in this chapter. Secondly, the process of model development
with regard to the selection of covariates is described. Thirdly, the methodol-
ogy in handling missing values in survival analysis is presented and fourthly,
the assessment of the final survival models performance is explained.
Chapter 4 is a review of study designs used in the field of epidemiology,
and primary care data in the UK and its use. Firstly, observational study
designs are compared to experimental study designs. Secondly. an overview
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of sources of primary care data and database in UK is discussed, in particular
The Health Improvement Network (THIN) database, which is used in this
research. Thirdly, a discussion on the generalisability of the THIN database
is presented.
Chapter 5 describes the data set extracted from the THIN database for
survival analysis after primary total hip replacement (THR). Firstly the cri-
teria for identification of THR case and controls is described. Secondly, the
distribution of patients across several demographic, life style and medical
variables, is presented and compared to the UK population. Thirdly, a dis-
cussion on the proportion of missing data is provided.
Chapter 6 presents the short term survival model that estimated the all-
cause odds of death during the first 24 months after THR procedure. Firstly,
the model development strategy and the analysis procedure are described.
Secondly, variations in short term odds of death are presented. Thirdly, an
assessment and diagnostics of the survival model is provided. Finally the
survival model and the variations in estimated short term odds of death are
assessed and compared with the results of previous studies.
Chapter 7 presents the long term survival model that estimated the haz-
ards of all-cause mortality after primary total hip replacement. The model
development and analysis procedure is explained firstly. Secondly, the esti-
mated variations in hazards of mortality are presented and compared with
the results of previous studies. Thirdly, a discussion of the effect of THR
procedures on effective age of THR cases with various preoperative medical
conditions, is provided.
Chapter 8 is a discussion on the findings of this research. The main
results of the short and long term models and their contributions to the
existing evidence, are presented. Then the strengths and limitations of the
research are discussed. Finally, the implications of this research findings in
medical management and retirement planning for THR cases are presented
by addressing the research aims.
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2 Review Of Mortality Risk After Total Hip
Replacement
2.1 Search strategy
This chapter is a literature review of mortality risk after primary unilateral
total hip replacement (THR) procedures. The objectives of this review are
to survey the existing mortality risk and survival models after THR proce-
dures, report estimated risk of dying after THR procedures and produce a
summary of the significant risk factors that contributed in explaining vari-
ations in mortality risks after THR procedures. A comprehensive review of
all studies published between January 1990 and December 2017 inclusive in
the English literature and containing mortality data for patients who had
a primary THR procedure, was conducted electronically using the following
online databases: MEDLINE, Google Scholar, the Journal of Bone and Joint
Surgery, ACTA Orthopedica and the Journal of Arthroplasty, respectively.
The search terms employed to identify relevant publications were: total hip
replacement (THR), total hip arthroplasty (THA), hip joint replacement, hip
joint arthroplasty, short term THR or THA, long term THR or THA, sur-
vival analysis after THR or THA, multi-centre survival analysis after THR
or THA, life expectancy after THR or THA and mortality risk after THR or
THA, respectively.
In total, 42 published journal articles were selected in this literature re-
view. Mortality risk models after THR procedures were either developed
to investigate survival in the short term or in the long term. It is essential
to define the follow-up time of these 32 selected studies in order to classify
them as either short or long term, respectively. According to the systematic
review carried out by Berstock et al. (2014), an excess mortality risk in the
short term (1, 3, 6 months and 2 years after THR procedure, respectively)
is observed for individuals who underwent a THR procedure while in the
long term, post-THR life expectancy is improved. Therefore mortality risk
models presented in selected published studies in this review, were developed
to investigate variations in survival after THR surgery either for the short
or long term only. In this review, studies with a follow-up time smaller than
24 months after THR procedure are categorised as short term while studies
with longer follow-up time are referred as long term. 17 studies (see Table
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1) analysed mortality data in the short term while, 15 studies (see Table 4)
reported estimated mortality risk in the long term after THR procedures.
11 studies were classified as controlled trial evidences of the effects of THR
procedures on mortality risk after surgery (see Table)
The following items were derived from each published article and used as
a basis of comparison, in this chapter, between different studies:
(1) Follow-up time: Length of study period over which individuals were
observed after THR surgery.
(2) Size: Number of participants selected in the study.
(3) Country : Location of study.
(4) Data source: Database used as source of data to determine survival
after THR procedures.
(5) Study design: Types of study carried out (Case-control, cohort matched,
observational study).
(6) Variables : List of variables investigated to explain variations in mor-
tality risk after THR procedures and identified risk factors.
(7) Survival model : Statistical model employed to estimate mortality risk.
(8) Outcomes : Reported mortality risk after THR procedures using dif-
ferent survival measures such as hazard of death (HR), odds of dying
(OR), standardised mortality rate (SMR), crude mortality rate (CMR),
Kaplan Meier survival estimate and percentage survivorship after THR
procedures.
2.2 Short term review of mortality following THR pro-
cedure
17 studies out of 32 selected publications, listed in Table 1, reported mor-
tality risk after THR procedures in the short term. Lie et al. (2000, 2002),
Pedersen et al. (2007) and Boniello et al. (2017), respectively, investigated
mortality risk after THR procedure exactly one month after the surgery while
Lie et al. (2000) and Aynardi et al. (2009), respectively, had a follow-up time
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of 2 months. The most common length of follow-up time in the short term is
3 months (9 studies out of 17: Lie et al. (2010), Blom et al. (2006), Williams
et al. (2002), Fender et al. (1997), Hunt et al. (2013), Lovald et al. (2014),
Barrett et al. (2005), Smith et al. (2015), Xu et al. (2017)). Only 2 studies
investigated mortality risk in the short term with a follow-up time longer
than 3 months; Jones et al. (2014) and Nunley and Lachiewicz (2003) anal-
ysed mortality risk 12 and 24 months after THR procedures, respectively.
The studies reporting short term mortality risk after THR procedures
were carried out in various countries: England (3), England and Wales (3),
Scotland (1), Denmark (1), Norway (3) and the United States (US) (6), re-
spectively. The sample size of these 17 selected short term published articles
on mortality risk after THR procedures vary between 835 patients for the
smallest study in US (Nunley and Lachiewicz (2002)) and 409, 096 patients
for the largest study, carried out in England and Wales (Hunt et al. (2013)),
respectively. In all 17 studies, the ratio of males to females in the sample
size was always less than one (see Table 1), indicating that THR procedures
are more prevalent among women than men, in various locations.
9 studies out of 17 used a register database as data source for sur-
vival analysis. A national registry database on patients who underwent
THR procedures were used for studies carried out in Norway (Lie et al.
(2002, 2000, 2010)), Denmark (Pedersen et al. (2011)), UK (Hunt et al.
(2013) and Jones et al. (2014)), England alone via private surveys from var-
ious THR surgery centres located in East Anglia, Oxford, Trent, Northern
and Yorkshire regions (Williams et al. (2002)) and US (Aynardi et al. (2009)
and Boniello et al. (2017)), respectively. The source of data in all these 9
studies were therefore obtained from different surgery centres, hospitals or
private clinics. None of these 9 studies accounted for the cluster effects due
to grouping individuals by their surgery centre, hospital or private clinics in
the database, to investigate mortality risk variations between each centre of
data collection.
The remaining 8 short term studies investigate mortality after THR pro-
cedures using data from a single surgery centre, hospital or private clinic
in their studies; Fender et al. (1997), Nunley and Lachiewicz (2003), Bar-
rett et al. (2005), Ramiah et al. (2007), Blom et al. (2006), NHS Scotland
(2002) and Lovald et al. (2014) used data from a single hospital or private
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clinic while the US based study, Xu et al. (2017), used a private insurance
company database in the US as a source of data to investigate short term
mortality after THR procedures among insured customers. None of the 17
short term studies used primary care records as a source of data. Developing
mortality risk models using primary care records can lead to different results
in variations of mortality risk after THR procedures. Compared to registry
or single centre database, primary care data has an extensive volume of socio-
demographic, lifestyle and medical information, with a greater coverage or
follow up of patients selected in a study. All these additional information
can be used to explain post-operative mortality risk variations in the short
term.
Nine studies out of seventeen studies reviewed were set up as a case-
control study design using age at THR surgery, gender and year of birth as the
main matching factors for selection of controls. Lie et al. (2000, 2002, 2010),
Aynardi et al. (2009), Pedersen et al. (2011), Lovald et al. (2014) and Jones
et al. (2014), respectively used age at time of THR procedure and gender
as matching factors for selection of controls while Ramiah et al. (2007) used
only age group at time of procedure. Barrett et al. (2005) used year of birth,
age at time of surgery and race as matching factors for selection of controls
for their study. The estimated effects of THR intervention on short term
mortality risk in these case-control studies have a greater degree of gener-
alisability than the cohort type studies (Blom et al. (2006), Williams et al.
(2002), Fender et al. (1997), Hunt et al. (2013), Smith et al. (2015), Xu et al.
(2017) and Boniello et al. (2017)) which investigated short term mortality
risk after THR procedures by post-THR causes of death primarily, while
Nunley and Lachiewicz (2003) estimated mortality risk after THR procedure
across types and prognosis of THR procedure.
Among the variables used to explain variations in short term mortality
risk in the seventeen studies reviewed, age at time of THR procedure, gender
and osteoarthritis diagnosis prior to THR procedure (17) were the most com-
mon ones, followed by rheumatoid arthritis and myocardial infarction event
(9), angina, stroke and osteoporosis (6), chronic kidney disease and revision
surgery (5), respectively. Lie et al. (2000) and Nunley and Lachiewicz (2003)
also compared variations in short term mortality for different types of THR
procedure while Lie et al. (2002), Aynardi et al. (2009), Williams et al. (2002)
and Xu et al. (2017) used revision surgery to compare short term mortality.
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Hunt et al. (2013) was the only study to adjust for age, gender, body mass
index, osteoarthritis, diabetes, chronic kidney disease, myocardial infarction,
rheumatoid arthritis and osteoporosis, simultaneously in their analysis of
short term mortality. Furthermore, variations in short term mortality were
explained by ethnicity by Lovald et al. (2014) and Xu et al. (2017), while
social deprivation index and hypertension were used additionally by Xu et al.
(2017) to compare short term mortality.
Several statistical methods of mortality risk estimation were employed
in the seventeen articles reviewed. Cox regression model and standardised
mortality ratio were the most common methods used to estimate of mortal-
ity risks (5), followed by multivariate logistic regression (4), crude mortality
rate and Kaplan Meier survival analysis (2), respectively. Furthermore, only
one study reported proportion of missing values in their study; Hunt et al.
(2013) reported that 10% of their whole study population had missing values
and adjusted for this in their data analysis by employing multiple imputa-
tion technique assuming data were missing at random. The authors used
imputation models that included all variables used in their Cox regression
survival model to estimate mortality risk and also used the outcome variable
(whether the patient is alive or dead by the end of the investigation) because
the latter consist of information about missing values of the predictors of the
imputed models.
In addition to the 17 publications listed in Table 1, the systematic review
on short term mortality risk after THR procedures by Berstock et al. (2014)
is also included. The authors critically estimated the 30- and 90-days over-
all mortality through meta-analysis of 32 published articles between 0.22%-
0.38% and 0.50%-0.81%, respectively. Among the 17 studies reviewed in
this section, Fender et al. (1997), Lie et al. (2002), Nunley and Lachiewicz
(2003), Blom et al. (2006), Pedersen et al. (2011) and Jones et al. (2014)
estimated the 30-, 60- and 90-days mortality rate after THR procedures be-
tween 0.27%-0.41%, 0.27%-0.75%, 0.45%-0.93%, respectively. Only Nunley
and Lachiewicz (2003) reported 1-year mortality (1.66%) and 2-year mortal-
ity (4.0%) after THR procedure.
Among selected case-control studies, Lie et al. (2000), Williams et al.
(2002), Ramiah et al. (2007), Aynardi et al. (2009) and NHS Scotland (2002),
respectively, reported an estimated 30-, 60- and 90-days standardised mortal-
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ity rate between 0.08%-0.10%, 0.06%-0.40% and 0.40%-0.90%, respectively
while Lie et al. (2000), Hunt et al. (2013), NHS Scotland (2002) and Lo-
vald et al. (2014) estimated the short term hazard ratio of death after THR
procedures at 1.11 and 1.05-1.13, 60 and 90 days after THR procedures, re-
spectively.
Based on these reported estimates of mortality rates or hazard ratio of
death, it can be concluded that there is an excess mortality in the short term,
at 30, 60, 90-days, 1 year and 2 years after THR procedure. There is strong
evidence to suggest that mortality rates following THR procedures decrease
with time; Hunt et al. (2013) reported a stable decrease of 90-days mortality
rate from 0.56% in 2003, to 0.29% in 2011. These findings were based on
a cohort of 409 096 patients with primary THR procedures in England and
Wales and are also consistent with similar trends reported by Cram et al.
(2011). Furthermore, Barrett et al. (2005) also investigated the increase in
the short term mortality risk following THR surgery to estimate the dura-
tion of excess mortality among THR cases. The authors reported a crossing
of survival curves of THR cases and age and gender matched controls at
about 90 days, including adjustments for comorbidities. Barrett et al. (2005)
also used a graph of smoothed Nelson–Aalen cumulative hazard estimates to
demonstrate varying mortality risk over the first 90-days post-surgery. They
found that the risk is highest in the first 30 days and plateaus at about 90
days, suggesting that short term mortality risk decreases with time after THR
procedure until it has returned to its baseline level in patients undergoing
THR. Similar trend for short term mortality is reported by Lie et al. (2002)
with the duration of excess mortality continuing up to 24 months after THR
procedures.
Ten studies out of 17 also reported short term survival after THR pro-
cedure by cause of death (see Table 1). Blom et al. (2006) reported that
cardiovascular disease was the major cause of death (41.1%), followed by
cerebrovascular diseases (23.1%) and pulmonary embolism (11.8%). Out
of ten studies reporting post-THR survival by causes of death, six found
myocardial infarction and pulmonary embolism, respectively, as the lead-
ing causes of death after the procedure (Blom et al. (2006), Aynardi et al.
(2009), Pedersen et al. (2011), Hunt et al. (2013), NHS Scotland (2002) and
Jones et al. (2014)), while in one small study, Nunley and Lachiewicz (2003)
reported cerebrovascular events as the main cause of death. In study with
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short term follow up over more than 2 months period post surgery, other
causes of death such as malignancy (Pedersen et al. (2011)), rheumatic dis-
ease, mild liver disease, diabetes (Hunt et al. (2013)) and chronic kidney
diseases (Boniello et al. (2017)) become significant cause of mortality. The
pattern of mortality causes presented here is reflected by the conclusions of
Singh et al. (2011) who estimated the short term incidence of adverse events
after THR procedures. The authors reported that highest incidence was
associated with cardiovascular complications (6.9%) followed by pulmonary
embolism (4.0%), within 90 days post-THR procedure.
Reported risk factors for short term mortality in this review were either
modifiable or non-modifiable. There is strong evidence which suggests that
increasing age and male gender cause a significant increase in mortality risk
following THR procedure. All studies but one (Aynardi et al. (2009)) found
significant association between male gender and increased short term mor-
tality risk. The 30- and 90-day mortality risk reported in the fourteenth
(2017) Annual Report of the National Joint Registry for England, Wales and
Northern Ireland ranges from 0.06% (both gender) and 0.16%, respectively,
for men aged less than 55 (versus 0.06% and 0.21%, respectively, for women
below 55) to 1.18% and 3.09%, respectively, for men aged over 80 years (ver-
sus 0.82% and 1.81%, respectively, in women aged above 80) (NJR (2017)).
Furthermore, increasing age at time of surgery predisposes to a premature
short term rise in mortality rate. In Hunt et al. (2013) study, Kaplan Meier
estimates of mortality rate at 90 days were determined for different age group
at time of THR procedure. The authors reported that 90 days mortality rate
ranged from 0.08% in men aged less than 55 (versus 0.05% among women
below 55) to 1.90% among men above 80 years (versus 1.13% among women
above 80) and a strong association between increasing age at time of surgery
and mortality rate.
Several studies investigated risk factors for variations in short term mor-
tality rate after THR procedures by controlling for confounding variables
using a multivariate regression analysis. In this review, a Charlson comor-
bidity index greater than three (Aynardi et al. (2009), Singh et al. (2011),
Bozic et al. (2012) and Gaston et al. (2007)), use of general anaesthesia
(Aynardi et al. (2009), Hunt et al. (2013)) and prior cardiovascular dis-
eases (Ma¨kela¨ et al. (2014), Bozic et al. (2012), Memtsoudis et al. (2012))
were modifiable preoperative risk factors for early mortality following THR.
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Comba et al. (2012) also reported that a history of cardiovascular diseases
prior to THR procedure increased the risk of mortality by eight-fold. Bozic
et al. (2012) reported a significant increase in 90-day hazard ratio of death
among patients with metastatic cancer (HR=3.14), congestive heart failure
(HR=2.11), dementia (HR=2.04), renal disease (HR=1.98), cerebrovascular
disease (HR=1.40) and chronic pulmonary disease (HR=1.32) before their
THR procedure. Hunt et al. (2013) estimated a ten-fold increase in mor-
tality risk for patients with moderate to severe liver disease, a three-fold
increase after myocardial infarction and two-fold increase following diabetes
with complications and renal disease, with all conditions diagnosed prior to
THR.
In addition to the articles listed in Table 1, Gaston et al. (2007) inves-
tigated the effects of pre-operative cardiovascular diseases and hypertension
on short term mortality risk after THR procedures. The authors analysed
prospectively collected data on 1744 patients who underwent primary elective
THR between 1998 and 2004, inclusive and reported that 34% of THR pa-
tients were diagnosed with hypertension prior to their procedure. They found
no statistically significant increased mortality rate at 3 months for both male
and female patients with a history of cardiovascular disease and hyperten-
sion prior to their surgery, after adjusting for age and BMI. Similarly, the
case-control study by Pedersen et al. (2011) analysed 90-days mortality rate
after THR among patients with Type 2 diabetes, prior to their surgery. The
authors concluded that mortality rate at 90 days was lower among THR
cases with Type 2 diabetes than among the control population with Type 2
diabetes and hence, found no significant increase in 90 days mortality rate
after THR for patients diagnosed with preoperative Type 2 diabetes.
Bozic et al. (2012) and Hunt et al. (2013) data analyses of the NJR
database for England and Wales demonstrated that a lower 90-day hazard
ratio of death was significantly associated with a body mass index (BMI)
between 26 Kg/m2 and 30 Kg/m2 (HR=0.76), inclusive, relative to patients
with a normal BMI between 19 Kg/m2 and 25 Kg/m2 (HR=1.00), inclu-
sive. This suggests that there is a statistically significant protective effect
of being overweight and obese, prior to THR, for overall short term hazard
ratio of death in patients. This is known as the obesity paradox and is ob-
served among other chronic conditions (Curtis et al. (2005), Bakaeen and
Chu (2011), Stamou et al. (2011)). Obesity is in itself, strongly linked with
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an increased risk of developing conditions such as cardiovascular disease or
hypercholesterolemia. However once the condition is manifested, obesity pro-
tects against premature mortality when compared with non-obese patients.
6 studies reported variations in short term mortality risk after THR by
types of fixation techniques used during the procedure. Lie et al. (2000),
Nunley and Lachiewicz (2003), Ramiah et al. (2007), Hunt et al. (2013) and
Bozic et al. (2012) estimated that 0 to 90 days hazard ratio of death fol-
lowing THR is between 1.07 and 1.13 for uncemented procedures and 0.85-
1.08 for hybrid procedures, respectively, compared to cemented procedures
(HR=1.00). Therefore, these studies suggest that uncemented and hybrid
THR procedures are significantly associated with a higher short term haz-
ard ratio of death than among cemented procedures. Aynardi et al. (2009)
estimated short term mortality rates for 7478 THR procedures consisting of
both primary and revision cases. The authors reported that overall 90-days
mortality rate with revision surgery was 1.24%, compared to 0.41% for pa-
tients without revision surgery and also demonstrated that it decreases with
increasing age group at THR surgery. A similar conclusion is reported by Lie
et al. (2002) who estimated a significant association between increased short
term mortality rate and revision surgery within 90 days after the procedure
(odds of dying=1.20-1.90).
Among the diagnoses, osteoarthritis (OA) and rheumatoid arthritis (RA)
were the main reasons patients chose to undergo THR procedures in all 17
studies while, Lie et al. (2002) also compared OA and RA to hip fracture. Es-
timated standardised mortality rate for THR cases with OA and RA ranged
between 0.06%–1.60% and 0.20%–4.80%, across all age groups, respectively,
in all reviewed studies. Lie et al. (2002, 2000) estimated short term odds
ratio of death following THR between 1.40 and 3.90, respectively, among RA
patients, compared to patients diagnosed with OA. Hence in the short term,
RA is significantly associated with an elevated odds of death after THR pro-
cedures, compared to OA diagnosis prior to THR.
A number of studies have suggested that low surgeon experience and hos-
pital volume is significantly associated with increased short term mortality
risk after THR (Judge et al. (2006), SooHoo et al. (2010), Memtsoudis et al.
(2012) and Clement et al. (2011)). They examined surgeon procedure vol-
umes and observed a lower rate of adverse events and mortality rate after
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THR in patients who received treatments by surgeons who performed on av-
erage more than 25 procedures per year (estimated mortality rate=0.57%),
compared to surgeons performing less than 10 procedures, on average per
year (estimated mortality rate=2.55%). The systematic review on short term
mortality risk by Berstock et al. (2014) stated that it is difficult to make a
firm conclusion regarding the effect of surgeon or surgery centre volume size
on mortality because of the vast differences in surgeon’s training and health-
care organisation across different locations. Similarly, Clement et al. (2011)
investigated the effect of social deprivation index (using the Carstairs index)
on 90-day mortality risk after THR procedures. The authors reported that
odds of dying at 90 days after THR is about three times higher for patients
from the most deprived areas (odds ratio=3.2), compared to patients from
low deprivation index residential areas.
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2.3 Long term review of mortality after THR proce-
dure
15 studies out of 32 selected publications, listed in Table 4, reported mortal-
ity risk after THR procedures in the long term with follow-up time greater
than 24 months. The shortest and longest mean follow-up time among stud-
ies reviewed, is 3 years (McMinn et al. (2012)) and 15 years (Ma¨kela¨ et al.
(2014)), respectively. Mean follow-up of 5 years (Paavolainen et al. (2002),
Barrett et al. (2005), Whitehouse et al. (2014)) and 10 years (Ritter et al.
(1998), Visuri et al. (1994), Ramiah et al. (2007)) are the most common. The
remaining publications had a mean follow-up time of 6 years (NHS Scotland
(2002), Holmberg (1992)), 7 years (Lovald et al. (2014)), 8 years (Lie et al.
(2000), Maradit-Kremers et al. (2016)), 12 years (Visuri et al. (1997)) and
13 years (Pedersen et al. (2011)), respectively.
The fifteen long term studies were carried out in various locations: US
(4), England and Wales (3), Finland (3), Norway (1), Denmark (1), Swe-
den (1), Scotland (1) and Scandinavian region (1), respectively. The sample
size for these fifteen studies vary between 646 patients for the smallest study
(Holmberg 1992) and 438733 patients for the largest study (Ma¨kela¨ et al.
(2014)). In all 15 studies, the ratio of men to women is always less than one
(see Table 4), demonstrating that proportion of females undergoing THR
procedures is always higher than males.
9 studies out of 15 used a register database as data source for sur-
vival analysis. A national registry database on patients who underwent
THR procedures was used for studies carried out in the Scandinavian region
(Ma¨kela¨ et al. (2014)), Norway (Lie et al. (2010)), Denmark (Pedersen et al.
(2011)), Finland (Paavolainen et al. (2002)), England and Wales (McMinn
et al. (2012), Ramiah et al. (2007), Whitehouse et al. (2014)), Scotland via
private surveys from various THR surgery centres (NHS Scotland (2002))
and US (Maradit-Kremers et al. (2016)), respectively. The source of data
in all these 9 studies were therefore obtained from different surgery centres,
hospitals or private clinics. None of these 9 studies accounted for the cluster
effects due to grouping individuals by their surgery centre, hospital or private
clinics in the database, to investigate mortality risk variations between each
centre of data collection. The following six studies investigated mortality
after THR procedures using data from a single surgery centre, hospital or
32
private clinic in their studies and are all based in the US: Ritter et al. (1998),
Visuri et al. (1994), Ma¨kela¨ et al. (2014), Lovald et al. (2014), Barrett et al.
(2005), Holmberg (1992). None of the 15 long term studies used primary
care records as a source of data.
Five studies out of fifteen were set up as a cohort study designs to esti-
mate long term mortality risk after THR procedure (NHS Scotland (2002),
Ma¨kela¨ et al. (2014), McMinn et al. (2012), Whitehouse et al. (2014), Maradit-
Kremers et al. (2016)). The remaining 10 studies were set up under a case
control study design. Age and gender were the most common matching fac-
tors employed in six studies for selection of controls (Visuri et al. (1997),
Paavolainen et al. (2002), Holmberg (1992), Ritter et al. (1998), Lie et al.
(2000), Lovald et al. (2014)). Visuri et al. (1994) and Ramiah et al. (2007)
used only gender and age group, respectively, as matching factors while Ped-
ersen et al. (2011) used gender and year of birth as matching factors for
selection of controls. The US based study by Barrett et al. (2005) used year
of birth, gender and race as matching factors.
Among variables used to explain long term mortality risk after THR pro-
cedures, gender and age at time of procedure (12) were the most common,
followed by osteoarthritis preoperative diagnosis (8), procedure types, pre-
operative rheumatoid arthritis, preoperative osteoporosis (5), angina, my-
ocardial infarction, stroke (3) and chronic kidney disease (2), respectively.
Variables related to the THR surgery directly and investigated in the studies
reviewed are prognosis of THR (6), types of procedure (3), revision surgery
(1), respectively. Other long term studies in this review also used ethnic
backgrounds and Charlson comorbidity index (Pedersen et al. (2011), Lo-
vald et al. (2014)), body mass index and preoperative cardiovascular disease
and Type 2 diabetes (Pedersen et al. (2011)) and social deprivation index
(Whitehouse et al. (2014)) to investigate long term mortality risk following
THR procedures. None of the studies reviewed reported the effects of preop-
erative smoking status, hypercholesterolemia and hypertension on long term
mortality risk after THR.
Among the statistical methods of survival analysis employed, the most
popular was Cox regression model (8) followed by standardised mortality rate
and Kaplan Meier survival analysis (5), respectively. Only Pedersen et al.
(2011) used crude mortality rate and McMinn et al. (2012) used a Royston-
33
Parmar survival model to estimate long term mortality risk following THR,
respectively. Only one study (Ma¨kela¨ et al. 2014) reported that 0.5% of their
data were missing because the records of these patients were incomplete and
were therefore, excluded from the study.
Table 2 below summarises the reported long term mortality risks after
THR that have been aggregated from several available published articles at
each length of follow-up time. Between 3 to 15 years following THR pro-
cedure, mortality risks of THR cases are lower than matched controls or
mortality of the general population who did not undergo THR in the re-
viewed articles. Across genders, reported long term mortality of male THR
cases is higher than female counterparts 5, 10 and 12.7 years, respectively,
post-surgery while no difference in mortality risk between males and females
after THR procedures were found 3 and 12 years after the procedure (see
Table 2). Only Ma¨kela¨ et al. (2014) reported a higher estimated mortality
risk among women aged above 60 than men of the same age group, 8 years
after the procedure.
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All 12 studies suggested that mortality varies significantly for different age
groups at surgery. 3 and 5 years after the procedure, hazard ratio of death
increases by 9% (McMinn et al. (2012)) and 8% (Whitehouse et al. (2014)),
respectively, per yearly increase in age at surgery for both gender. Lie et al.
(2000) and Ramiah et al. (2007) concluded that 8 and 10 year mortality rate
in their study also rises with increasing age at time of THR, respectively. For
studies carried out in the Scandinavian region, 12.7 and 15 year mortality
also increases with increasing age and for male THR cases (Pedersen et al.
(2011), Ma¨kela¨ et al. (2014)). For England and Wales combined, the 14th
National Joint Registry annual review on joint replacement procedures (NJR
(2017)) estimated long term mortality rate at 3, 5, 7, 10, 11 and 13 years
after THR (see Table 3). This annual report also suggests that long term
mortality rate following THR procedures, is higher among men than women
for all age groups and increases for older ages at surgery time.
Age group
Years after THR
3 5 7 10 11 13
Males <55 1.36% 2.21% 3.30% 4.93% 5.63% 6.88%
55-59 1.86% 3.28% 5.05% 8.36% 9.96% 13.30%
60-64 2.64% 4.81% 7.30% 12.56% 14.45% 18.60%
65-69 3.61% 6.92% 11.07% 18.78% 21.67% 29.51%
70-74 5.60% 10.67% 16.92% 29.39% 34.23% 44.83%
75-79 8.63% 16.96% 27.75% 46.23% 52.96% 66.38%
80-84 13.57% 27.08% 42.76% 66.42% 72.78% 83.81%
85+ 23.82% 44.00% 63.34% 85.70% 90.30% 95.72%
Females <55 1.63% 2.49% 3.45% 4.93% 5.39% 6.37%
55-59 1.71% 3.03% 4.47% 6.96% 7.90% 9.71%
60-64 2.02% 3.76% 5.68% 9.44% 11.06% 14.87%
65-69 2.55% 4.82% 7.70% 13.66% 15.98% 21.48%
70-74 3.53% 7.19% 11.79% 21.63% 25.58% 34.74%
75-79 5.61% 11.68% 19.34% 34.85% 40.73% 52.70%
80-84 9.07% 18.69% 31.48% 53.57% 61.47% 74.63%
85+ 16.24% 32.12% 50.33% 74.08% 80.36% 90.19%
Table 3: Long term cumulative mortality rate reported by the 14th National Joint
Registry annual report (NJR (2017))
Three studies also reported variations in long term mortality risk by
causes of death (Visuri et al. (1997), Paavolainen et al. (2002, Lovald et al.
(2014)). For a mean follow-up time of 5 years, Paavolainen et al. (2002) re-
ported that myocardial infarction (SMR=0.85), followed by hypertensive dis-
ease (SMR=0.85), cerebrovascular disease (SMR=0.86) and cancer (SMR=0.70),
respectively, were the most common cause of death following THR. 7 years
after THR procedure, Lovald et al. (2014) concluded that hazard of death
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(HR) was only higher among THR cases who had an event of cardiovascular
disease after surgery (HR=1.15), compared to those without these cardio-
vascular events after surgery and among THR cases diagnosed with diabetes
after surgery (HR=1.02), relative to THR cases without diabetes, respec-
tively. Similarly, Lovald et al. (2014) also reported cardiovascular diseases
as the most common long term cause of death following THR. With a mean
follow-up time of 12 years, Visuri et al. (1997) concluded that circulatory
disease (relative mortality risk=1.50) was the most common cause of death,
followed by cancer (relative mortality risk= 0.74) after THR procedure.
Four studies investigated difference in long term mortality risk for THR
cases diagnosed with osteoarthritis (OA) or rheumatoid arthritis (RA). Lie
et al. (2000) estimated that the relative mortality risk for THR cases diag-
nosed with RA is 2.57 times higher than OA while Whitehouse et al. (2014)
concluded that RA increased hazard ratio of death to 1.66, compared to THR
cases diagnosed with OA (HR=1.00). Maradit-Kremers et al. (2016) com-
pared THR patients diagnosed with OA to those without OA and found that
the standardised mortality rate among OA THR cases was 0.82%. A similar
trend is reported by Holmberg (1992). All these studies provide evidence
that estimated mortality risk is higher for THR cases diagnosed with RA,
compared to OA THR cases.
Lie et al. (2000), McMinn et al. (2012) and Whitehouse et al. (2014) also
reported the effect of different fixation techniques (cemented, uncemented
and hybrid fixations) employed during the procedure on long term mortality
risk. Lie et al. (2000) estimated lower relative mortality risk (RMR) for unce-
mented (RMR=0.78) and hybrid (RMR=0.94) fixation techniques, compared
to cemented procedures while McMinn et al. (2012) and Whitehouse et al.
(2014) demonstrated that the long term hazard ratio of death falls to 0.84-
0.90 for uncemented procedures and 0.87 for hybrid procedures, compared to
cemented fixation technique. Only McMinn et al. (2012) analysed the effect
of revision surgery on long term mortality following THR procedure. The
authors found that revision surgery after uncemented procedures increases
hazard ratio of death to 1.60, compared to cemented procedures. In addition,
Whitehouse et al. (2014) reported significant association between variations
in long term mortality and types of surgical approach during THR inter-
ventions. This study concluded that, relative to lateral surgical approach,
hazard ratio of death decreases to 0.93 and 0.82 for posterior and anterior
39
surgical approach, respectively.
Pedersen et al. (2011) compared mortality rates after mean follow-up of
12.7 years for patients with low, moderate and high Charlson’s comorbidity
index (C-index), prior to THR. The authors found that estimated mortality
rates were 6.9%, 13.7% and 23.1% for THR cases with low, moderate and
high C-index, respectively (versus 8.2%, 20.2% and 40.6% in the control pop-
ulation for low, moderate and high C-index, respectively). Hence mortality
risk increases for THR cases with high number of preoperative comorbidities
and is lower than control population. Furthermore, Pedersen et al. (2011)
also reported that estimated mortality rates (MR) for THR cases with pre-
operative cardiovascular diseases (MR=17.8%), diabetes (MR=17.0%) and
cancer (MR=16.1%), respectively, were lower among THR cases than controls
(MR=28.5%, 27.0% and 24.7% for controls with a history of cardiovascular
diseases, diabetes and cancer, respectively). This may be due to the fact
that relatively healthy patients are allowed to undergo THR procedure and
thus prevalence of preoperative comorbidities is lower among THR patients,
compared to controls, as highlighted by Barrett et al. (2005), which reported
that prevalence of comorbidities among THR cases, was on average 30% less
than in controls, in their study.
McMinn et al. (2012) also compared the long term mortality risk for pa-
tients with different physical status prior to THR procedures. In this study,
patients physical status was grouped into the following categories: category
A for healthy person, category B for mild systemic disease, category C for
severe systemic disease, category D for severe systemic disease that is a con-
stant threat to life and category E for moribund person who is not expected
to survive without the operation, respectively. The authors concluded that
relative to category A, hazard ratio of death 3 years after THR increases to
1.17, 2.14 and 3.58 for categories B, C and D, respectively while hazard of
death for category E does not differ significantly to category A. Addition-
ally, Whitehouse et al. (2014) reported that long term hazard ratio of death
varies significantly for different providers of the intervention. The authors
concluded that hazard ratio of death decreases to 0.92, 0.74 and 0.59 in NHS
private treatment centres, private hospitals and independent clinics, respec-
tively, compared to public hospitals in the UK. Hence private surgery centres
are significantly associated with a lower long term mortality risk after THR
procedure, partly due to the fact that majority of surgeons in private surgery
40
centres have high level of experience in THR procedures and also because the
waiting time to have the procedure is longer in public hospitals, than in pri-
vate clinics or hospitals.
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2.4 Review of randomised controlled trial evidence of
effects of THR procedures on mortality
In this section, published studies reporting evidences from randomised con-
trolled trials (RCTs) evidences of the effect of THR procedures on mortality
are reviewed. A comprehensive search from multiple databases (see section
2.1) was performed to identify 25 publications that investigated the clinical
effects of THR procedures under a RCT study design. Reports on mortal-
ity after THR procedures in these studies were produced as the number of
deaths during the follow-up time. This is mainly because these studies were
interested in the survival of the prosthesis with revision surgery as end-point.
The 25 studies reviewed did not include any survival or mortality risk
model for estimation of the effect of THR procedures on mortality risk. How-
ever the authors produced adequate information with respect to the number
of deaths for mortality investigation. Table 5 below summarises the details
of the included RCTs in this section. It can be observed that the number of
deaths among patients undergoing metal-on-metal (MOM) THR procedures
is lower than that of non-metal-on-metal (non-MOM) THR procedures in
all studies. However these details do not provide conclusive evidence for the
effect of THR procedures on mortality risk under RCT set up, as opposed to
the observational studies reviewed in sections 2.2 and 2.3, respectively.
Findings from short term RCTs (follow-up≤ 2years - Pabinger (2003),
Zagra (2013), Grubl (2006), Schouten (2012), Jensen (2011), Zijlstra (2011),
Hanna (2012), Wessinger (2011), Tiusanen (2013), Penny (2012) and Gau-
thier (2013)) showed that the number of Non-MOM procedures was more
prevalent than MOM procedures and that there was no death observed dur-
ing the first year after the surgery for both procedures. However number
of deaths during the second year of rehabilitation after surgery was one for
MOM compared to three for non-MOM procedures. Similarly among long
term RCTs reviewed ( Brodner (2003), Macdonald (2005), Malviya (2011),
Gustafson (2014), Wang (2012), Engh (2014), Bjorgul (2013), Zerahn (2011),
Hailer (2011), Howie (2005), Desmarchelier (2013) and Ziljstra (2010)), there
were 715 MOM procedures versus 997 non-MOM procedures, respectively
while the number of deaths was higher among non-MOM (76) in comparison
to 67 deaths among MOM procedures.
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In addition, Pijls et al. [2016] carried out a systematic review of 25 RCT
studies with mortality investigation as one of the outcomes and that included
the first 12 publications listed in Table 5. The authors estimated through
meta-analysis, that the overall mortality risk was higher for non-MOM THR
procedures related to MOM ones in the short term, with follow-up less than
2 years. However for longer follow-up investigations, the same authors found
no evidence of difference in overall mortality risk and that the death was
independent of modifying factors such as procedure types.
Similarly, Abdulkarim et al. [2013] critically reviewed nine RCTs publi-
cations (not listed in Table 5) through meta-analysis of data on 778 patients,
with mean age of 60.5 years and average follow-up period of 4.3 years (range:
2-8 years), comparing cemented to uncemented THR procedures. The au-
thors concluded that uncemented THR provides an immediate postoperative
benefit not only in terms of a reduction in mortality risk, but also improved
other outcomes such as relief of joint pain after the procedure and risk of re-
vision surgery. These conclusions are also in agreement with Morshed et al.
[2007], a meta-analysis observational study comparing cemented procedures
to uncemented ones with respect to mortality and revision surgery.
Although RCT studies benefits from strong experimental design to pro-
vide high level evidence, very few RCTs that estimated the effects of THR
procedures on mortality were available in literature. Almost all published
RCTs were primarily designed to investigate rate of revision surgery and
patients’ pain score after the procedure. Therefore statistics on mortality
risk after THR were rarely reported in these papers with the few evidences
provided by Abdulkarim et al. [2013] and Pijls et al. [2016], who respectively,
reported an increase in mortality risk associated with MOM procedures in the
short term and cemented THR procedures for long term follow-up studies,
respectively.
2.5 Discussion of findings from review of short and
long term mortality after THR procedure
The definition of follow-up time varies across different short and long term
studies. In the short term studies, mortality risk was estimated at 1, 3, 6,
12 and 24 months following THR procedure while long term studies had a
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mean follow-up of at least 3 years after the procedure. Hence in this re-
search, mortality risk estimation is carried out for the first 24 months (short
term mortality model) to investigate early post-operative excess mortality
after THR and then in the long term for patients who survived more than
24 months after their THR procedure.
25 studies out of 32 reviewed in this chapter used data from multiple hos-
pitals, clinics and private surgery centres or from secondary registry database.
None of these studies accounted for the grouping effects that these hierarchi-
cal data could have on mortality risk estimation. The authors assumed that
there was no significant differences in mortality risk between different hospi-
tals. In case that this assumption is violated, failing to adjust for grouping
effect can lead to false precision (Therneau and Grambsch 2013). In this
research, for both short and long term mortality models, a random effect due
to groupings of patients by different general practices, is added to investigate
variations in mortality risk across different general practices.
None of the 32 studies reviewed, used primary care database as a source
of information to investigate mortality risk after THR. Their source of data
were either from secondary care database, single hospital/clinic, regional sur-
veys or county based insurance database for US based studies. This research
aims at developing mortality risk models using primary care records. It can
lead to different results on variations of mortality risk after THR procedures.
Volume of socio-demographic and medical information in primary care data
is greater than registry or single centre database, and can thus be extensively
used to explain long term variations in mortality risk following THR proce-
dures.
Four short term studies (Aynardi et al. (2009), Singh et al. (2011), Bozic
et al. (2012) and Gaston et al. (2007)) and two long term studies (Pedersen
et al. (2011), Lovald et al. (2014)) assessed the physical and health status
of patients prior to their THR procedures using Charlson’s comorbidity (C-)
index (Charlson et al. (1987)) or the American Society of Anaesthesiologists
(ASA) classification (Daabiss 2011) of the physical status of patients prior
to their THR procedure. These two classifications are not validated for or-
thopaedic patients such as THR cases. The ASA has been criticised for being
inflexible in its definition of comorbidities used to classify patients’ preoper-
ative physical fitness for anaesthesia (Whitehouse et al. 2014). Additionally,
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it is established that different anaesthetists assign different ASA grades to
the same patient (Little, (1995), Mak et al. (2002)). Therefore the ASA
cannot be used for a full assessment of a patient’s comorbid status. The
only validated gradings of the comorbid status for orthopaedic patients, is
the POSSUM classification (Mohamed et al. (2002)). However, there is no
evidence that it can be validated for surgical and orthopaedic interventions
such as THR procedure. In this research, the extensive availability of primary
care data provides important information on the preoperative comorbidities
among THR patients and thus, no physical status classification is used.
For short term mortality models reviewed, only the following preoper-
ative conditions were included in the data analysis among the 17 studies
reviewed: body mass index (BMI), diabetes, chronic kidney diseases, cardio-
vascular diseases (angina, myocardial infarction, stroke), diagnosis for THR
(osteoarthritis, rheumatoid arthritis, other arthritic diseases, osteoporosis)
and hypertension. Similarly, the following preoperative comorbidities were
assessed for long term mortality models reviewed: chronic kidney diseases,
cardiovascular diseases (angina, myocardial infarction, stroke) and diagnosis
for THR (osteoarthritis, rheumatoid arthritis, other arthritic diseases, osteo-
porosis). No studies investigated mortality risk after THR for the following
preoperative conditions: BMI, diabetes and hypertension (long term only)
and hypercholesterolemia (short and long terms), respectively. In this re-
search, all reported risk factors for mortality risks following THR in this
review are investigated together with BMI, diabetes, hypertension and hy-
percholesterolemia using primary care data, to investigate the effects of these
preoperative comorbidities on mortality risk variations.
No studies distinguished between smokers and non-smokers in their data
analysis. It is well established that mortality risk for smokers is significantly
higher than non-smokers (Doll et al. (2004)). Hence failing to adjust for
smoking status in the mortality model may lead to less precise estimates of
mortality risk. All studies but one used secondary care database or single
hospital/clinic data for their research and may therefore do not have access to
lifestyle variables such as smoking status. In this research, it is important to
adjust for smoking status in the survival model since smoking increases mor-
tality risk. The Health Improvement Network (THIN) primary care database
is used as source of data and consists of lifestyle information such as smoking
that can be used for estimation of mortality risks after THR procedure.
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2.6 Chapter summary
In this chapter, a review of short and long term mortality risk after total hip
replacement procedures among adults for any reasons other than hip frac-
ture and accident, is presented. For both short and long term, age at surgery,
gender, types of THR procedures and fixations, and index of multiple depri-
vation were significantly associated with variations in mortality risk. Among
preoperative risk factors for post-THR mortality risks discussed, cardiovas-
cular diseases, diabetes, osteoarthritis, rheumatoid arthritis and osteoporosis
were the most common. Overall, in the first 2 years after the procedure, THR
cases have higher mortality risk than controls, with the excess mortality risk
peaking at 1 and 3 months after the procedure and then decreasing until it
converges to that of controls at about 24 months after the intervention. On
the contrary, the literature reviewed in this chapter suggests that patients
who survived the first 2 years after THR, have a lower mortality risk than
control population that did not undergo THR. Therefore, it can be deduced
that THR procedure improve survival in the long term only.
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3 Review Of Statistical Methods For Survival
Analysis
Introduction
Survival analysis is a set of statistical methods used to explain variations in
data that measure the time taken for some event to occur. It is an essential
analytical tool in many fields like medicine, biology, epidemiology, demogra-
phy and engineering. It is used to model the time from the beginning of a
follow-up of a subject until a pre-defined event occurs. Often the event is
associated with failure. For example, in epidemiological studies, the event
corresponds to death or the occurrence of a complication or disease among
individuals who have undergone a particular treatment. In the field of eco-
nomics, event may be an acceptance of a job offer for unemployed individuals
while in the engineering sector, failure may be of interest for a component in
an engine to stop working. The time for the event to occur is referred as the
survival or failure time. This chapter details the different survival modelling
strategies that exist in the analysis of epidemiological survival data and the
techniques to fit these survival models. It covers a number of parametric
and non-parametric survival models that are available in literature for the
analysis of survival data.
3.1 Basic Ideas
According to Cox and Oakes (1984), to apply survival techniques to different
situations, three components are needed: (1) determining a time origin that
is well-defined at the start of the investigation period; (2) a scale to measure
the change in time and (3) an exact definition of failure. Consider a set
of homogeneous data where T is a positive random variable representing
failure time, with distribution function, F(t) and unique probability density
function, f(t). For continuous time T, the survival function S(t) is defined
as the probability that an individual survives beyond time t:
S(t) = P (T > t) =
∫ ∞
t
f(t)dt ; 0 < t <∞ (3.1)
where 0<S(t)≤1.
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The hazard function or the force of mortality, λ(t), at time t, is a funda-
mental quantity in survival analysis defined as
λ(t) =
f(t)
1− F (t) (3.2)
λ(t) can be interpreted as probability that failure occurs in the interval
(t,t+δt) given that the individual survives past time t, i.e,
λ(t)δt ∼= P (t < T < t+ δt|T > t) (3.3)
In terms of the survival function S(t), the hazard function can be written as
the probability density function divided by the probability that an event has
not occurred before time t, as shown below.
λ(t) =
f(t)
S(t)
=
−dS(t)
dt
S(t)
=
−d log(S(t))
d(t)
(3.4)
Integrating λ(t) with respect to time t, the cumulative hazard function, Λ(t),
is obtained as
Λ(t) =
∫ t
0
λ(u)du =
∫ t
0
f(u)
1− F (u)du = − log(1− F (t)) = − logS(t) (3.5)
Thus the survival function, S(t), expressed in terms of the hazard function,
is given by
S(t) = exp(−
∫ t
0
λ(u)du) (3.6)
3.2 Censoring
Censoring is a common characteristic of survival data where an observation
does not contain complete survival information. In mortality data, some
individuals cannot be followed-up completely during the investigation for
practical and personal reasons. Therefore the time at which the event of
interest occurs, is unknown to the researcher. Right censoring happens when
a subject joins an experiment at the start of the study and leaves the inves-
tigation without experiencing failure (death). Right censoring is the most
common form of censoring and usually occurs because either the study fin-
ishes before the subject experiences failure or because the individual is lost
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to follow up or leaves the study before it actually ends. If the study started
at time 0 and ended at time t, then the subject is said to be right-censored
at time t and is assumed to have survived for a period of [0,t].
Left censoring is present when the subject experiences failure at a time
before the investigation period occurs. It is a rare occurrence in real life
data set. Suppose a subject who enrolled in an experiment at the start,
experiences failure at a time that is unknown but before the starting time
of the investigation period. The subject is said to be left censored and the
subject’s failure time is unknown. Interval censoring occurs when the event
of interest happened within a time interval with the exact time of occurrence
being unknown.
3.3 Parametric Modelling
Introduction
There exists a number of situations where survival data has a known distri-
bution, or sometimes it is reasonable to assume that the data has a certain
parametric specification. A selection of the distributions that are commonly
used to fit such data, is detailed in this section. Fitting parametric models to
survival data offers some advantages in comparison to non-parametric mod-
elling. They have fully specified hazard functions that are dependent on the
parameters that determine the overall distributional form. These parameters
can be estimated to fit the model at any point in time and can be used to
predict the hazard at future time points.
3.3.1 Selected survival distributions
Exponential distribution
If the hazard rate (equation (3.6)) is equal to a constant positive scale pa-
rameter, λ, the survival time is said to follow an exponential distribution,
with parameter λ. The density function is given by
f(t) = λ exp(−λt), for λ > 0 (3.7)
and therefore, the survivor function is given by
S(t) = exp(−λt). (3.8)
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The Weibull distribution
The Weibull distribution is a generalisation of the exponential distribution
where the hazard function takes the form of h(t) = αλtα
−1 (λ, α > 0). λ and
α are referred as the scale and shape parameter, respectively. Under this
distribution, survival time is assumed to follow a Weibull distribution with
parameter λ and α, respectively, where the density function is given by
f(t) = αλtα
−1
exp(−λtα), for λ, α > 0, (3.9)
and the survivor function is written as
S(t) = exp(−λtα), for λ, α > 0. (3.10)
The Log-Normal distribution
If survival time, T is assumed to be log-normally distributed with mean µ
and variance σ2, i.e. ln(T ) ∼ N(µ, σ2), then the survivor function is given
by
S(t) = 1− P (T < t) = 1− P (ln(T ) < ln(t))
= 1− P
(
ln(T )− µ
σ
<
ln(t)− µ
σ
)
= 1− Φ
(
ln(t)− µ
σ
)
,
(3.11)
where Φ is the cumulative probability distribution function of a standard
normal distribution.
The generalised Gamma distribution
The generalised gamma distribution is given by
f(t) =
(
t−µ
β
)γ−1
exp
(
− t−µ
β
)
βΓ(γ)
(3.12)
where γ is the shape parameter, µ is the location parameter, β is the scale
parameter and Γ is the gamma function which has the formula
Γ(a) =
∫ ∞
0
sa−1 exp(−s)ds, for a > 0
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The case where µ = 0 and β = 1 is called the standard gamma distribution
and the distribution is reduced to
f(t) =
tγ−1 exp(−t)
Γ(γ)
, for t ≥ 0 and γ > 0.
Since the general form of the probability functions for the gamma distribu-
tion can be expressed in terms of the standard distribution, all subsequent
formulas in this section are given for the standard form of the function. The
hazard function of the gamma distribution is
h(t) =
tγ−1 exp(−t)
Γ(γ)− Γt(γ) , (3.13)
where t ≥ 0, γ > 0 and Γt(γ) is the gamma function evaluated at time t.
The cumulative hazard function is given by
H(t) = − log
(
1− Γt(γ)
Γ(γ)
)
, for t ≥ 0 and γ > 0, (3.14)
and therefore, the survival function is given by
S(t) = 1− Γt(γ)
Γ(γ)
, for t ≥ 0 and γ > 0. (3.15)
The Log-Logistic distribution
The survival time, T , is assumed to have a log-logistic distribution with
location parameter, α, and scale parameter, β, if ln(T ) = α + βZ, where Z
Z =
ln(T )− α
β
,
follows a standard logistic distribution with density function
f(Z) =
exp(z)
(1 + exp(z))2
and cumulative distribution function
F (Z) =
exp(z)
1 + exp(z)
.
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Therefore, the survivor function in terms of Z, is given by
S(z) = 1− F (Z) = 1
1 + exp(z)
.
Z can be transformed back to T using α = − log(λ), where λ is the hazard
rate, and letting p = β−1. Hence the survival function, in terms of T , is
re-written as
S(t) =
1
1 + (λt)p
, (3.16)
while differentiating S(t) with respect to t, the hazard function, λ(t), is given
by
λ(t) =
λp(λt)p−1
1 + (λt)p
. (3.17)
3.3.2 Parametric model fitting
Estimation of model parameters is commonly done either via methods of
moment estimation or Maximum Likelihood Method (MLE). In this section,
MLE method is described for estimation of parameters under a parametric
modelling set up, since it is the most common approach in literature. Suppose
there are n observations that are randomly censored. For a model consisting
of p parameters, θ=(θ1, ..., θp)
′, the likelihood function is written as
L(θ) = Πni=1[f(ti|xi, θ1, ..., θp]δi [S(ti|xi, θ1, ..., θp)]δ1−i , (3.18)
where the binary variable δi (for i = 1, ..., n) is equal to 1 if the individual
experiences failure or 0 if they are censored. In this way, censored observa-
tions of individuals surviving the interval [0,t], contribute to the likelihood.
To estimate a parameter, θj, equation (3.18) is differentiated with respect to
θj, to obtain the score equation
∂ log(L(θ))
∂θj
=
n∑
i=1
∂ log(Lθ(yi, θi))
∂θj
= 0 (3.19)
Solving equation (3.19) is not a straight-forward process as it requires
the use of iterative methods. The most common methods to optimise equa-
tion (3.19) are the Newton-Raphson Method and the Method of Scoring.
The likelihood functions for j=1,...,p are given by equation (3.18). Let
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θˆ
0
= (θ01, ..., θ
0
p) be the initial guess for the solution to equation (3.19). Usu-
ally the first guess is obtained by a simpler method, for instance method of
moments. Expanding equation (3.19) about θˆ
0
using the Taylor series, gives
∂ logL(θˆ)
∂θ
=
∂ logL(θˆ0)
∂θ
+
∂2 logL(θˆ0)
∂θ2
(
θˆ − θˆ0
)
+ ... = 0 (3.20)
Ignoring third order and higher terms, let θ1 be the solution to (3.20). Then
(3.20) can be written as
θˆ
1
= θˆ
0
+
−∂2 logL(θˆ0)
∂θˆ
2
−1∂ logL(θˆ0)
∂θˆ
 , (3.21)
where
∂ logL(θˆ)
∂θ
is known as the score function at θˆ and
I(θˆ) = −∂
2 logL(θˆ)
∂θ2
is referred as the sample information matrix at θˆ. The Fisher information,
I(θ), is obtained by taking expectation of I(θˆ), as shown below.
E
(
I(θˆ)
)
= −E
(
∂2 logL(θˆ)
∂θk∂θj
)
= I(θ) =
n∑
i
I i(θ) = n I i(θ)
Equation (3.21) is called the Newton-Raphson equation. Substituting in the
the Fisher Information instead of the sample information in (3.21)
θˆ
1
= θˆ
0
+ I−1(θˆ
0
)
∂ logL(θˆ
0
)
∂θ
. (3.22)
This iterative method is known as the method of scoring. Once the estimate
θˆ
1
is obtained, (3.21) is expanded about θˆ
1
again, using Taylor series and a
new solution, θˆ
2
, that satisfies (3.19) is determined. This step is repeated
until convergence is achieved. At convergence, the new estimate of θ is kept
as the final result of the iteration and is referred as the MLE estimator, θˆ
(Cox and Oakes 1984).
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3.4 Non-parametric Modelling
Introduction
Non-parametric models offer the possibility to explore survival data that
are not restricted to any particular distributional form. In this section, the
techniques of estimating and modelling the survivor function under a non-
parametric framework are detailed. The methods summarised include the
empirical survivor function, life table, actuarial method of survival estima-
tion, the product limit (Kaplan Meier) survival estimator and the Nelson-
Aalen survival function.
Empirical Survivor Function
In the absence of censored data, the empirical survivor function is used to
estimate the survivor function at a specific time, t. This method estimates
the probability that a subject survives beyond a time point, t, by determining
the proportion of individuals who are still alive after time t. Thus the survival
function, S(t) is given by
Sˆ(t) =
Number of subjects with survival time > t
Number of subjects in data set
(3.23)
However, survivor function (3.23) is invalid when censored data are present.
Alternatively, one can divide the study period into a set of discrete time
intervals and the survival function is estimated exactly at the end of each of
these discrete time intervals. In this case the survival estimates are assumed
to be proportional to the total number of individuals deemed at-risk in each
time interval (Cox and Oakes (1984)).
Product Limit Estimator
The Product Limit (PL) estimation, also known as the Kaplan-Meier (KM)
estimation method, offers an alternative way to estimate the survival func-
tion, S(t), under a non-parametric framework and produces better estimate
of S(t) than the empirical survivor function since it does not exclude any
information during the computation of S(t). Consider n individuals in an in-
vestigation where time period is divided into time intervals of variable length.
Assuming that failure (or death) occurs at the start of each interval, then
a series of intervals that contain only one failure at a time can be formed.
61
If there are r ≤ n failures, then we can have tj (j=1,...,r), as the series of
ordered failure times. Let nj and dj be the number of individuals at risk prior
to tj and the number of failures at tj, respectively. Assuming independent
failures, survival between tj and tj+1 is given by (nj − dj)/nj and the KM
estimate of S(t) for tj≤t< tj+1, is given by
SˆKM(t) =
r∏
j=1
(
nj − dj
nj
)
, (3.24)
It can be observed that SˆKM(t) is a decreasing step-function where SˆKM(0)
is equal to 1 and SˆKM(t) remains unchanged over each time interval tj≤t<
tj+1, j=1,...,r, where tr+1=∞. SˆKM(t) allows the derivation of several quan-
tities of interest such as mean, median, quartiles, associated standard errors,
confidence intervals for SˆKM(t), hazard and cumulative hazard functions. It
also permits development of plots that provide useful inference about the
form of the survival distribution. (Cox and Oakes (1984))
Nelson-Aalen Estimate
This method estimates the cumulative hazard of failure non-parametrically.
The Nelson-Aalen cumulative hazard up to the kth interval, is directly esti-
mated as the cumulative sum of the ratio of the number of deaths (dj) to the
number of exposed subjects (nj) for each time interval, tj, i.e.,
λˆ(tk) =
k∑
j=1
dj
nj
(3.25)
To estimate the survival function from the Nelson-Aalen cumulative hazard
function, Breslow (1972) suggested to use
Sˆ(t) = exp
(
−λˆ(t)
)
. (3.26)
The Breslow estimator and the KM estimator for the survivor function, Sˆ(t)
are asymptotically equivalent, and usually are quite close to each other, par-
ticularly when the number of deaths is small relative to the number exposed.
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3.5 Cox Proportional Hazards Model
3.5.1 Model definition
The most important issue in survival modelling is to investigate the effect of
covariates on survival time. Cox (1972) proposed the use of the proportional
hazards (PH) model. He suggested that for an individual with a vector of
covariates x, the hazard at time t is made up of firstly, a baseline hazard
function which does not depend on the covariates, x, and secondly, a para-
metric function that represents the effects of the covariates on the failure
time, over and above the baseline hazard. Under the PH model, no under-
lying distribution is assumed for the survival data. Cox (1972) defines the
model as
h(t, x) = h0(t) exp(β;x) (3.27)
where x is a vector of length p, containing explanatory variables, h0(t) is an
unspecified baseline hazard function (when x = 0) and β is a vector of p
parameters. The Cox PH model produces constant hazard ratio over time,
for two subjects with fixed covariate vectors, X1 and X2.
h1(t)
h2(t)
=
h0(t) exp(β;X1)
h0(t) exp(β;X2)
=
exp(β;X1)
exp(β;X2)
(3.28)
Hence the name of proportional hazards is given to the model. The PH
model is popular because it allows to model the relationship of survival time,
through its hazard function, to many covariates simultaneously. Similarly,
Cox’s survival model can easily accommodate censored data and the oc-
currence of multiple failures. Moreover, although the underlying survival
distribution is unspecified, the model is easily fitted.
3.5.2 Model Fitting
Coefficients β’s in the Cox’s model are estimated through the maximisation of
the partial log likelihood function of the Cox’s model (Hosmer et al. (2011)).
The likelihood function for the Cox’s model is partial because it is based
only on the number of individuals, k, who experienced failure during the
investigation period instead of all N subjects who may or may not experience
failure. Let the set R consists of individuals who experienced failure at the
specified time or during the investigation period. Thus the partial likelihood
function for the Cox’s model is given by the product of the ith individual
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probability of experiencing failure at time t instead of other subjects j in the
risk set, R. With distinct survival times arranged in ascending order, the
partial likelihood function for the Cox’s model is given by
PL(β) =
k∏
i=1
{
exp(βXi)∑
j∈R(ti) exp(βXj)
}
(3.29)
The log partial likelihood, `(β), is written as
`(β) =
n∑
i=1
βXi − log
 ∑
j∈R(ti)
exp(βXj)

 (3.30)
Differentiating (3.30) with respect to β produces the score vector, U(β),
given by
U(β) =
n∑
i=1
(
Xi −
∑
j∈R(ti) Xj exp(βXj)∑
j∈R(ti) exp(βXj)
)
=
n∑
i=1
Xi − ∑
j∈R(ti)
wij(β)Xj

=
n∑
i=1
(
Xi − Xˆwi
)
,
(3.31)
where
∑
j∈R(ti) wijXj is the weighted mean of X, over those individuals still
at risk at time ti. The second derivative of the partial log-likelihood function
with respect to β is called the Fisher’s Information Matrix, and is given by
I(β) =
n∑
i=1

(∑
j∈R(ti) exp(βXj)
)(∑
j∈R(ti) X
2
j exp(βXj)
)
−
(∑
j∈R(ti) Xj exp(βXj)
)2
(∑
j∈R(ti) exp(βXj)
)2

=
n∑
i=1
∑
j∈R(ti)
wij(β)
(
Xj − Xˆwij
)2
(3.32)
Partial likelihood estimator of β, denoted by βˆ, is obtained by solving the
score equation U(βˆ) = 0 using the Newton-Raphson method presented in
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Section 3.3.2. The variance of βˆ is derived by taking the inverse of the
Fisher’s Information Matrix, i.e.,
Var(βˆ) = I(βˆ)−1 (3.33)
3.5.3 Stratified Cox Models
The Cox proportional hazard model allows the analysis of survival data that
has been divided into different disjoint groups (strata). Each stratum is
assigned a distinct baseline hazard function, h0k(t), but shares common val-
ues of the coefficients β (Therneau and Grambsch (2013). Let individuals
i = 1, ..., n1 be in group 1, individuals n1 + 1, ..., n1 + n2 be in group 2, and
so on, respectively. The hazard of a subject from the kth group is given by
h0k(t)exp(Xiβ), where h0k is the baseline hazard function associated with the
kth stratum of covariate Xi.
The log-likelihood function for stratified survival data with K groups, is
given by
`(β) =
K∑
k=1
`k(β) (3.34)
where `k(β) is exactly similar to the log-likelihood function (3.30), but summed
over only the individuals in the kth group. Similarly, the score vector U(β)
and the information matrix I(β) are given by U(β) =
∑
Uk(β) and I(β) =∑
Ik(β), respectively.
3.5.4 Hypothesis Testing and Confidence Interval for Estimated
Parameters
To test the statistical significance of covariates in the Cox’s regression model,
i.e., checking whether the model with the selected covariates explain an in-
dividual’s survival more accurately than the model without the selected co-
variates (empty model equivalent to taking the average survival time of the
whole population), the likelihood ratio test is used (Therneau and Grambsch
(2013).
Let β(0) be the true theoretical value of the coefficients and βˆ be the
estimated coefficients. To test the global null hypothesis H0 : βˆ = β
(0), the
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test statistic, denoted by LRT , for the likelihood ratio test is given by
LRT = 2(`(βˆ)− `(β(0)), (3.35)
i.e, twice the difference of the log partial likelihood function without any co-
variates given by `(β(0)), and that of the Cox PH model with p parameters,
given by `(βˆ). LRT follows a χ2 distribution with p degrees of freedom,
where p is equal to the difference in the number of estimated coefficients
under the model with all covariates being tested and that under the model
without the covariates being tested.
To check the statistical significance of a specific covariate x, i.e., to test
whether x is significantly associated with survival time, the Wald test is used
(Therneau and Grambsch (2013). The Wald test assesses the hypothesis that
the estimated coefficient for covariate x, denoted by βˆx, from the Cox’s model,
is significantly different from zero. The test statistic, Z, is given by
Z =
βˆx
ŝe(βˆx)
, (3.36)
where ŝe(βˆx) is the standard error associated with βˆx. The test statistic Z
follows a standard normal distribution and can also be used to formulate
confidence interval for βˆx. The (1 − α)% confidence interval (CI) for βˆx is
given by
CI(βˆx) = βˆx ± Z1−α/2ŝe(βˆx), (3.37)
where Zα represents the critical value at (1−α)% level from the standard nor-
mal distribution. When the (1−α)% CI of an estimated coefficient contains
zero, it means that the covariate associated with that estimated coefficient
does not significantly affect hazard of failure.
3.5.5 Tied or Grouped Observations
Survival data may be tied mainly because of two reasons. Firstly, for contin-
uous survival data, ties may exist because of rounding and thus they are in
a form of incomplete data, where the true times are not tied. Secondly, tied
survival data may arise when the survival times are discrete. Tied survival
data affect the form of the partial likelihood for the Cox model.
66
As shown by the equation (3.30), the partial likelihood function for untied
data is a product over event times of the likelihoods for different individuals.
In the presence of ties, the exact form of the partial likelihood cannot be
determined since the survival time data is not precise. To illustrate the
problem of tied survival data, consider k individuals in time order, with the
first two experiencing failures at the same recorded time. Let ri be the risk
score associated with the ith individual. In the absence of ties, the first two
terms of the log-likelihood function (i.e., for the first two subjects) are either(
r1
r1 + r2 + ...+ rk
)(
r2
r2 + r3 + ...+ rk
)
(3.38)
or (
r2
r1 + r2 + ...+ rk
)(
r1
r1 + r3 + ...+ rk
)
, (3.39)
but one cannot precisely select which of (3.38) or (3.39) is the true likelihood
function. To address this, Therneau and Grambsch (2013) presented three
approximation methods; namely (1) Breslow approximation, (2) Effron ap-
proximation and (3) Discrete method.
The Breslow approximation is one of the simplest methods to estimate the
likelihood function for tied survival data. It has been proposed independently
by Breslow (1972) and Peto (1972), and uses the complete sum of r1 + r2 +
... + rk as the denominator of the partial log-likelihood function (Equation
(3.40)) as shown below. Under this approximation, the fractions with the
biggest risk pool for each time-tied event are used.(
r1
r1 + r2 + ...+ rk
)(
r2
r1 + r2 + ...+ rk
)
(3.40)
Generalising (3.40) to the whole population for the example set up at the
beginning of this section, Breslow’s approximation is given by
k∏
i=1
exp(βX(i)+)∑
j∈R(ti)
(
exp(βXj)
)di (3.41)
where di is the number of failures at time ti. R(ti) represents the set of
individuals who experienced failure at time ti and Xi+ is the sum of the val-
ues of the covariates, i.e., Xi+ =
∑
j∈D(ti) Xj. According to Therneau and
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Grambsch (2013), the Breslow approximation method is the least accurate,
compared to the Effron and discrete method, because it accounts for failure
more than once in the denominator, thereby producing biased estimate of β.
Under the Efron (1977) approximation method, a more accurate partial
likelihood is derived by using the average denominator. The risk scores of
the individuals with time-tied events in subsequent risk groups are multiplied
by the probability that they will be in the subsequent risk group. Applying
the Effron approximation method to the example set up at the start of this
section, the risks of the two subjects are multiplied by a factor of 0.50 in
the second risk set. The argument behind this adjustment is that subject 1
and 2 both have a 50% probability of being in the second risk group. The
log-partial likelihood function (3.40) becomes(
r1
r1 + r2 + r3
)(
r2
0.5r1 + 0.5r2 + r3
)
(3.42)
Generalising (3.42) to the whole population study, the partial log-likelihood
function under the Effron approximation is given by
k∏
i=1
exp(βX(i)+)∏di
k=1
(∑
j∈R(ti) exp(βXj)− k−1di
∑
j∈D(ti) exp(βXj)
) . (3.43)
The discrete method does not assume any ordering of the tied events and
treats time as a discrete variable. For any failure at time t, a Cox model
with discrete event times is based on a proportional odds model where the
risk score is multiplied by the odds ratio of the baseline hazard instead of
the baseline itself (Therneau and Grambsch (2013)):
hˆi(t)
1 + hˆi(t)
=
(
hˆ0(t)
1 + hˆ0(t)
)
exp(βXi) (3.44)
Revisiting the scenario of two failures with tied times, under the discrete
method, the partial log-likelihood function determines the probability that
individual 1 and 2 belong to the group of individuals with time-tied failures
instead of other individuals in the risk set and can be written as (Therneau
and Grambsch (2013)):
r1r2
r1r2 + r1r3 + r2r3
. (3.45)
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In general terms, for the whole population, the partial log-likelihood function
under the discrete method is given by
k∏
i=1
exp(βXi+)∑
z∈Z(ti) exp(βXz)
, (3.46)
where Z represents all combinations of selected individuals with time-tied
events, z is one combination of time-tied individuals from the set Z, di is
the number of failures at time ti and Xz is the sum of the covariates values,
Xz =
∑di
j=1Xj.
In conclusion to this section on tied failure times, three different methods
of approximation for the estimation of the partial likelihood function have
been presented. The Breslow approximation is the simplest one but it pro-
duces biased estimates of β’s. The discrete partial likelihood produces better
approximation of the partial likelihood function than the Breslow method
but it is time consuming and computationally ineffective. The Efron approx-
imation method is the most reliable approximation among the three methods
as it is computationally efficient and does not produce bias in the estimation
of β’s. In this research, for a dataset with time-tied events, the Efron ap-
proximation method is used for the formulation of partial likelihood function
to estimate the model parameters.
3.5.6 Residuals
Introduction
In Cox PH model, the three common types of residuals of interest are the
Score residuals, the Schoenfeld residuals and the Martingale residuals, re-
spectively. In this section, a summary of the definitions and uses of these
residuals in assessing the assumptions and adequacy of the Cox PH model is
provided. To define these residuals, consider a set of n independent subjects
such that the counting process Ni ≡ {Ni(t), t ≥ 0} for the ith subject in
the set, indicates the number of observed failures over time t. Ni is therefore
analogous to a step function with increase of size +1 and Ni(0) = 0.
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Martingale Residuals
The Martingale process for the ith individual in a survival analysis is given
by
Mi(t) = Ni(t)− Ei(t) = Ni(t)−
∫ t
0
Yi(s)Hˆ0(s) exp(Xi(s)βˆ)ds, (3.47)
where Hˆ0 is the cumulative baseline hazard and Ni(t) is the counting process
(defined in the introduction of section 3.5.6) for the ith individual in the set
of subjects who experienced failure during the investigation (Therneau and
Grambsch (2013)). In simpler terms, the Martingale residuals are defined as
the difference between the observed number of failures and the conditionally
expected number of failures associated with the ith individual, given the fit-
ted model, follow-up time and the complete course of time-varying covariates
present in the fitted model. According to Therneau and Grambsch (2013),
Martingale residuals are important, firstly, as a direct assessment of obser-
vations that are poorly fitted by the model and secondly, for the evaluation
of the functional form of a covariate in the model.
Score residuals
For the ith individual in a survival analysis study, the score process is given
by
Ui(β, t) =
∫ t
0
[Xi(s)− x¯(β, s)]dMi(s), (3.48)
where x¯(β, s) is the weighted mean of the covariates over those at risk at time
s and Mi is the martingale residual for the i
th individual (given by equation
(3.47)). Ui(β, t) is a row vector of length p, where p is equal to the number
of covariates (Therneau and Grambsch (2013). The Score residuals are used
for the assessment of influential individual observations in the model fit and
to test for the robustness of the estimated variance of the Cox PH model.
Furthermore, Lin and Wei (1989) proposed the use of the score process to
assess the proportional hazards assumption of the fitted model globally.
Schoenfeld residuals
The Schoenfeld residual (Schoenfeld, (1980)), rk, for the k
th covariate in
a Cox model, are derived from the first derivative of the partial likelihood
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function (3.30) and is given by
rk =
m∑
i=1
(
Xik − Xˆqik
)
, (3.49)
where m is the total number of failures in the study, Xi is the set of measured
covariates for the ith individual with ordered survival time ti and X̂qik is the
conditional means of the covariates for the ith individual with ordered survival
time ti and at risk of encountering failure. Hence the Schoenfeld residuals for
the kth covariate associated with the ith individual who experienced failure
during the investigation period, can be written as
rˆik = Xik − Xˆqik (3.50)
The sum of the Schoenfeld residuals is expected to be zero since the co-
efficients, β, are estimated via the maximum likelihood method by equating
the first derivative of the partial log-likelihood function to zero. In presence
of censored data, the Shoenfeld residuals are not informative for the model
fit because the partial likelihood function does not account for censored in-
dividuals. To address this issue, Therneau and Grambsch (2013) proposed
the use of scaled Schoenfeld residuals. Under this approach, the Schoenfeld
residuals are scaled by their estimated variance. The variance of the vector of
Schoenfeld residuals associated with the kth covariate, for the ith individual,
denoted by rˆ′i = (rˆi1, rˆi2, ..., rˆik), is estimated by
r∗i =
rˆ′i
mV̂ar(βˆ)
, (3.51)
where m is the number of failures in the study and V̂ar(βˆ) is the estimated
variance-covariance matrix of the estimated coefficients, βˆ’s. Scaled Schoen-
feld residuals are used in the assessment of proportional hazards assumption
for the Cox model.
3.5.7 Assumption of proportional hazards
The key assumption in survival analysis of non-parametric data using the Cox
proportional hazards model is that the relative hazard for any two individuals
i and j, follows the time independent relationship
hi(t)
hj(t)
=
h0(t) exp(β;Xj)
h0(t) exp(β;Xj)
=
exp(β;Xj)
exp(β;Xj)
.
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In addition, the above relationship is valid for each single covariate in the
model. It provides the basis to explain the multiplicative effect of each covari-
ate in the hazards function on the fitted survival function, given the covariate
is time independent. Therefore the assumption of proportional hazards is key
and its assessment is crucial for model assessment and interpretation. Test-
ing proportional hazards assumption for Cox survival model is carried out
via (1) graphical test using the logarithmic form of the fitted survival curve
and the residuals associated with the Cox PH model and (2) statistical tests
using the scaled Schoenfeld residuals described in Section 3.5.6.
According to Therneau and Grambsch (2013), the simplest test to assess
the assumption of proportional hazards is the graphical check of the fitted
survival curve. Under the assumption of proportional hazards, the survival
function for the ith individual satisfies
Si(t) = exp(−h0(t)βXi),
hence rearranging Si(t) as
log[− log(Si(t))] = log[h0(t)]−Xiβ
shows that log[− log(Si(t))] is proportional to the measured covariate. If the
fitted Cox model is correct, the survival curves for the different levels of the
covariate, should be approximately parallel when plotted on the log-log scale,
showing that the impact of the covariate of interest on the estimated hazard,
is proportional. In the case when the covariate has many levels or is contin-
uous, this method does not help in assessing the assumption of proportional
hazards because the survival curves on the log-log scale become sparse and
do not yield a good estimate of how close to parallel are the curves.
The Schoenfeld residuals can be used to test the assumption of constant
proportional hazards for a fitted Cox model. Under the assumption of pro-
portional hazards, a plot of the cumulative Schoenfeld residuals (Grambsch
and Therneau (1994) and the cumulative score residuals (Lin et al. (1993)),
respectively, versus the study time, scaled to (0, 1), should yield a Brownian
bridge pattern (identified as a random walk beginning and ending at 0) for
each survival curve associated with each level. A major disadvantage with
these plots is that they are often difficult to interpret and visualise the pat-
tern required under the assumption of proportional hazards.
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A different approach for testing proportional hazards for individual co-
variates in the Cox’s model, firstly consists of ranking the survival time, t,
of each individuals in the study, in the order of the occurrence of failure, to
obtain the set of transformed survival times, denoted by t∗ = (1, 2, ...,m),
where m is the number of failures during the study. Secondly, the correla-
tion, ρk, between the scaled Schoenfeld residuals of the k
th covariate and t∗
is estimated and its significance is tested. ρk asymptotically follows a χ
2-
distribution with one degree of freedom. If ρk is not significantly different
from zero, then the assumption of proportional hazards holds for the kth co-
variate. In addition, a global test of proportional hazards over all covariates
that assesses the statistical significance of the estimated correlation, ρˆ∗, be-
tween the scaled Schoenfeld residuals of all covariates in the model together
and the transformed survival time, t∗, is also useful. If ρˆ∗ is not significantly
different from zero, then assumption of proportional hazards is not violated
(Grambsch and Therneau (1994)).
3.5.8 Time dependent covariates
A time-dependent covariate is an explanatory variable whose value changes
over time and thus does not satisfy the assumption of proportional hazards,
when incorporated in a Cox’s model. Time dependent covariates arise (1)
in investigation involving repeated measurements on a subject or (2) when
the effect of the covariate of interest changes with time as the investigation
period goes on. Under the presence of time-dependent covariates, two meth-
ods are proposed to account for time-varying effect of the covariates in the
Cox’s model. Firstly, the follow-up time is split in intervals over which the
assumption of proportional hazards hold and a Cox PH model is fitted to the
data for each interval. However such approach is highly dependent on the
definition of the follow-up interval where assumption of proportional hazards
are not violated.
Under the second method, an interaction between survival time, t and
the time-dependent covariate, is added to the Cox model. Under this set up,
the Cox’s model is no longer a proportional hazards model and is referred as
an extended Cox’s model, written as
h(t, x) = h0(t) exp(Xβ(t)), (3.52)
where the estimated coefficient, βˆ(t), is not constant and varies over time. A
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plot of βˆj(t), associated with the j
th covariate versus time therefore produces
a non-horizontal line, showing the variation of the covariate effect with re-
spect to time. An extended Cox model represented by (3.52), would compare
the risk of failure between each level of the covariate at each event time, and
would re-evaluate which risk group each person belonged in, based on the
level of the covariate. The hazard of failure at time t depends on the value
of the time dependent covariate at time t.
3.5.9 The Cox Model With Frailty
Introduction
The concept of frailty provides a convenient method to account for random
effects, relationships and unobserved heterogeneity in the models for survival
data. In its basic form, frailty is defined as an unknown random factor that
affects the hazard of failure associated with an individual or related individ-
uals. The concept of frailty was initiated by Greenwood and Yule (1920) and
introduced by Vaupel et al. (1979) for survival models at the univariate level,
while Clayton (1978) applied the concept of frailty to multivariate survival
model. The frailty term allows the investigator to account for unknown and
unmeasured covariates. In survival analysis, frailty model is a random effect
time-to-event model whereby the frailty has a multiplicative effect on the
baseline hazard function.
Univariate Cox model with frailty
The presumption of homogeneity of a study population in the field of epi-
demiology and medicine does not apply in many practical situations. The
impact of a particular epidemiological or medical intervention or the effect
of various explanatory variables vary greatly between different categories of
patients. Vaupel et al. (1979) proposed the use of univariate frailty models
in survival analysis to account for such unobserved heterogeneity among the
study population.
”The key idea is, that individuals possess different frailties, and
that those patients who are most frail will die earlier than the
others” (Vaupel et al. 1979).
There exist two major explanations as to why the inclusion of all impor-
tant variables at the individual level into the analysis, is impossible. Firstly,
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there may be too many covariates to be accounted for, in the model, and
secondly, the investigator is unable to measure all the appropriate variables.
Both arguments give rise to two sources of variability in survival data: (1)
variation due to measurable risk factors, which can theoretically be formu-
lated and (2) heterogeneity due to unknown covariates, which is therefore
theoretically unpredictable.
Under the proportional hazards model set up, ignoring a set of the impor-
tant covariates contributes to biased estimation of the regression coefficients
and the hazard rates. For example, if there are two groups of patients in
a study where one group experiences a higher risk of failure, then the re-
maining persons at risk, will to a large extent, have a lower risk of failure.
Without accounting for unobserved frailty, estimated individual hazard rate
would therefore be underestimated and the degree of underestimation would
be higher as time progresses.
The univariate frailty model is an extension of the Cox model (3.27),
where the hazard of failure is directly proportional to an unknown random
variable, Z, as shown below (Therneau and Grambsch (2013).
h(t, x) = Zh0(t) exp(β;x) (3.53)
The frailty Z is assumed to have an expected value of one and has a mul-
tiplicative effect on the individual hazard rate. It either increases (Z > 1)
or decreases (Z < 1) the individual risk of failure. The survival function, S,
which describes the proportion of individuals surviving, is given by
S(t|X,Z) = exp(−Z exp(φ(β;x)
∫ t
0
h0(s)ds) (3.54)
Under the setting of a shared frailty model, individuals in a study pop-
ulation are grouped into distinct homogeneous categories. The concept in
this setting is that individuals who are at risk of failure within a defined and
controlled environment, can be assumed to have the same level of frailty. For
example, individuals living in the same accommodation or patients receiving
treatments within the same ward, are exposed to the same level of unknown
risks and can thus be assumed to share the same frailty. Consider a study
population where individuals i (i = 1, ..., n), are grouped into j homogeneous
categories (j = 1, ..., q). The shared frailty Cox model, for the ith individual,
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is written as (Therneau and Grambsch (2013):
hi(t) = h0(t) exp(βXi + ωZi) , (3.55)
where Xi and Zi represent the i
th rows of the covariate matrices of size n×p,
for covariate set X and unknown frailty set Z, respectively. Under model
(3.55), X and β estimate the fixed effects due to the measurable covariates,
ω is the estimated vector of random effects (frailties) and Z is the design
matrix where its Zij element is equal to 1 for subject belonging to the same
frailty group j or 0 otherwise.
The shared frailties, Zi’s, are assumed to be identical and independently
distributed random variables from a Gamma distribution with mean equal to
1 and variance Θ. Since the hazard function is non-negative, Zi’s are chosen
to follow a Gamma distribution instead of a Gaussian distribution because
the former distribution only takes positive values (Therneau and Grambsch
(2013). The variance Θ determines the degree of variability between clusters
and the level of correlation within each cluster. Higher value of Θ indicates
that the cluster effects are more widespread between clusters and a stronger
correlation within clusters. Under the assumption of Gamma distributed
shared frailties, the correlation between individuals within the same cluster
is determined by Kendall’s τ , given by
τ =
Θ
2 + Θ
, (3.56)
where Θ is the estimated variance of the cluster effect.
Parameters of a shared frailty Cox proportional hazards model are esti-
mated by maximising the partial log-likelihood function of the model, with
respect to each of the parameters being estimated. Consider a population
of n individuals, grouped into K clusters where the ith group consists of ni
individuals. Let the number of failures in the ith group be Fi =
∑ni
j=1 fij and
Λ0(t) represent the cumulative baseline hazard. The partial log-likelihood
for a shared frailty Cox proportional hazards model, is given by (Therneau
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and Grambsch (2013):
`(Θ, β) =
K∑
i=1
(
Fi ln(Θ)− ln(Γ(Θ−1)) + ln(Γ(Θ−1 + Fi))
)
− (Θ−1 + Fi) ln
1 + Θ ni∑
j=1
Λ0(t) exp(βXij)

+
ni∑
j=1
fj
(
βXij + ln(Λ0(t))
)
(3.57)
The partial log-likelihood function, `(Θ, β), is maximised using the EM-
algorithm described in Section 3.5.2 and can be summarised as follows, when
applied to a shared frailty Cox’s model:
(1) Coefficients βˆ are estimated from the fitted model.
(2) The shared frailty terms, Zˆi, are estimated.
(3) Fitted Cox’s model is updated with the estimated Zˆi and new estimates
of βˆ are determined.
(4) Steps 2 and 3 are iterated until convergence of βˆ and Zˆi, respectively,
is achieved.
Statistical significance of estimated cluster effect, Θ̂ is checked using the
likelihood ratio test where the test statistics, LRT, is given by
LRT = 2
(
`(Θ̂, βˆ)− `(0, βˆ)
)
, (3.58)
where `(Θ̂, βˆ) and `(0, βˆ) are the partial log-likelihood function evaluated
at Θ = Θ̂ for the shared frailty Cox’s model and the partial log-likelihood
function evaluated at Θ = 0. LRT is assumed to follow a χ2-distribution
with one degree of freedom (Hosmer et al. (2011)).
3.5.10 Model Diagnostics
A key aspect in evaluating the adequacy of a survival model is through the
investigation of regression diagnostic statistics to identify subjects who (1)
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have irregular configuration of covariates, (2) influence the estimates of the
model parameters and (3) have a leverage on the model fit. In this section,
the methods used to identify influential subjects with high leverage, are sum-
marised.
Leverage is a statistical measure of how unusual are the values of a sub-
ject’s covariates. Under the Cox proportional hazards set-up, Hosmer et al.
(2011) used the score residuals, defined by equation (3.48) to assess leverage
for continuous variables. Hosmer et al. (2011) showed that the score residu-
als follow a linear regression leverage property for continuous variables, i.e.,
the further away is the value of the covariate from the mean, the larger is
the score residual value. A plot of the score residuals versus the continuous
variable should yield a fan shape display with no observations having unex-
pectedly large values.
To assess the influence of a subject on the estimators of the fitted model,
Cook’s distance and jackknife residuals are employed. Cook’s distance (Hos-
mer et al. (2011)) is defined as(
βˆ − βˆ−i
)′ [
v̂ar(β)
]−1 (
βˆ − βˆ−i
)
, (3.59)
while the jackknife residual (Therneau and Grambsch (2013), Ji, is defined
as
Ji =
(
βˆ − βˆ−i
)
, (3.60)
where βˆ and βˆ−i are the model estimators with all observations and without
the observations for the ith subject, respectively. A plot of the Cook’s dis-
tance and the jackknife residuals versus the martingale residuals (equation
(3.47)), respectively, yields a cup shaped figure where the largest values of
the Cook’s distance and the jackknife residuals, on either sides of the cup
shape, correspond to subjects that have been poorly fitted.
3.5.11 Overall goodness of fit
Goodness-of-fit of a model is defined as the degree to which the observed
data, used to fit a model, agrees with theoretical expected values. Several
authors such as Schoenfeld, (1980), O’Quigley and Pessione (1989), Weissfeld
(1990) and Lin et al. (1993) proposed different tests to assess the overall
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goodness-of-fit of a proportional hazards model. However these tests were
computationally difficult and time consuming to implement.
Grønnesby and Borgan (1996) proposed a test that was computationally
feasible. The authors firstly partition the dataset into K groups, based on
the ranked values of the estimated risk score. Secondly the test uses the sum
of the martingale residuals (equation (3.47)) of each of the K groups and then
compares the observed number of events to the model-based expected num-
ber of events. Grønnesby and Borgan (1996) showed that the test statistic
for this test (the difference between observed and theoretical expected num-
ber of events) follows Chi-square distribution with (K−1) degrees of freedom.
May and Hosmer (1998) showed that Grønnesby and Borgan (1996) method
is equivalent to the score test, where May and Hosmer (1998) approximated
the score test with the partial likelihood ratio test for computational feasi-
bility and effectiveness. The expected and observed number of events are
compared via the counting process theory. where the counting function is
approximated by a Poisson random variable with mean equal to the variance
of the cumulative hazard function. For large number of data points, the Pois-
son distribution can be approximated by the Normal distribution. Hence a
simplified way to compare the observed and expected counts of events, is to
determine the Z-score for each of the K groups by dividing the difference in
observed and expected number of events by the square-root of the expected
number of events. Then the two-tailed p-value of z-score is obtained from
the standard Normal distribution.
In addition, the graphical test proposed by Arjas (1988) can also be used
as an assessment technique for the goodness-of-fit of a Cox proportional haz-
ards model. The author proposed to plot the cumulative observed number
of events against the model-based cumulative estimated number of events
for uncensored observations, within each partition of the data to graphically
assess the model fit. Under a perfect model, the plotted points should follow
a straight line, angled at 45◦ with both axes and starting at the origin.
A further assessment of the performance of a fitted model under the Cox
proportional hazards set-up is the use of the R2 statistics (Hosmer et al.,
2011). The R2, adjusted R2 denoted by R2adj, or the predicted R
2 denoted by
R2p, statistics of a fitted model can be used to assess the performance of the
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model. R2 is the proportion of variability among the observed data points
that is explained by the fitted model. R2adj is a modified version of the R
2
and accounts for the number of covariates in the model, while R2p measures
the degree to which the model predicts responses for new observations. R2
and R2adj are defined as
R2 = 1− exp
(
2
n
(L0 − Lp)
)
,
R2adj = 1−
[
(1−R2)(n− 1)
(n− p− 1)
]
, (3.61)
where L0 is the partial log-likelihood function for the model with no covari-
ates, Lp is the partial log-likelihood function for the model with p covariates,
n is the number of observations in the data and p is the number of covariates
in the model. As demonstrated by Schemper and Stare (1996), there is no
straight-forward and easy method to determine the R2 measure of a propor-
tional hazards model. Furthermore, the measures are hugely dependent on
the proportion of censored data. A perfectly adequate model may have a low
R2 measure because of the high amount of censoring in the data. Therefore
assessment of model performance via the use of R2 or similar adjusted mea-
sures should be carried out conservatively.
Another measure for the goodness of fit of a model is the Harrell’s con-
cordance, also known as as C-index (Harrell, (2001)). It is the percentage
of all pairs of individuals whose survival times can be ordered such that the
individual with the higher predicted survival, is the one who survived longer.
Such a pair is known as a concordant pair (C). A discordant pair (D) is
one where the individual with the higher predicted survival, is the one who
has the shorter survival. A tied pair (T) is obtained when it is impossible
to determine which of the two individuals experienced failures first. The C-
index is a proportion of concordance (0 ≤ C-index ≤ 1) between observed
and predicted survival and is defined as
C-index =
C + T/2
C +D + T
, (3.62)
where C represents number of concordant pairs, D is the number of discor-
dant pairs and T is the number of tied pairs. A small value of C-index
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(C-index ≤ 50%), indicates a model that is poorly predicting the outcomes,
while a C-index close to one (C-index ≥ 70%) indicates a model with strong
prediction of the outcomes. In the field of survival data analysis, Therneau
and Grambsch (2013) suggested that an acceptable range for the C-index of
a strong model is between 60% and 70%.
3.5.12 Interpretation of Hazard Rate
In this research, the event of interest is all-cause death after THR surgery.
Adjusted hazard of death (HR) also referred to as risk of mortality, can be
interpreted as the average change in the risk of death after THR procedure
when comparing a group of subjects to the baseline category, with respect to
one particular covariate, during the whole follow-up period of the study while
adjusting for the remaining covariates (Therneau and Grambsch 2013). An
HR smaller than one causes a decrease in mortality risk after THR procedure
and thus survival after THR is significantly better than baseline group (con-
trols). When HR is equal to zero, there is no significant change in mortality
risk after THR and therefore cases and baseline group have similar survival.
An estimated HR greater than one leads to an increase in mortality risk after
THR and thus survival of cases is worse than baseline group.
Communicating statistically based risk information such as the HR is the
essential part of any research. The HR can be explained in terms of the num-
ber of years gained or lost in effective age. Given the hazard rate associated
with a particular subject, the effective age of this subject is defined as the
age at which the baseline individual (or matched control) will have the same
hazard rate as the former. In this research, effective age refers to the age at
which controls have the same estimated mortality risk as the individuals who
underwent THR surgery. The concept of effective age comes from the Gom-
pertz model in which the annual one year increase in mortality risk associated
with ageing is approximately unchanged for individuals aged between 30 and
95, respectively (Brenner et al., (1993), Vaupel, (2010)). In England and
Wales, the estimated increase in mortality risk for individuals aged between
30 and 95, inclusive, is roughly equal to 1.1 for 2010-2012 (Spiegelhalter,
(2016)). This means that the average risk of an individual in England and
Wales dying before his next birthday is increased by approximately 10% per
year. Assuming that the yearly increase in risk of mortality associated with
ageing remains constant with age and secondly, proportional hazards hold
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for the covariates over time (Brenner et al., (1993), the estimated number of
years gained or lost in effective age, δ(age), after THR procedure in England
and Wales is given by
δ(age) =
ln(ĤR)
ln(1.1)
w 10.49× ln(ĤR) (3.63)
3.6 Multiple Logistic Regression
3.6.1 Model Definition and parameter estimation
Logistic Regression
In many epidemiological studies, outcomes observed are often dichotomous
in nature; i.e., the outcome of interest is defined as a binary discrete variable
with two levels. For example, in survival analysis of longitudinal data, the
outcome observed is either death or alive by the end of the study period,
where the outcome variable is defined as one for death and zero for being
alive. Logistic regression is a mathematical approach, based on the theory of
generalised linear models of Nelder and Baker (1972), used to describe the
relationship between a dichotomous variable and a list of variables measured
during an experiment.
Consider a binary or dichotomous random variable Z that can take two
possible outcomes. For a dataset of independent observations and of sam-
ple size N , Z can be described as a column vector of N Bernoulli random
variables, Zi. Let the values 1 and 0 represent the occurrence (success) or
absence (failure) of the event of interest being investigated, respectively, for
the dichotomous variable, Z. Let I be the total number of clusters, each with
ni observations, n be a column vector with elements ni for i = 1 to I, where∑I
i=1 ni = N . Let Y denote a column vector of length N where its elements,
Yi, represent the number of occurrences for the event of interest (success)
and the column vector y is defined such that its elements yi represent the
counts of the number of successes for each cluster in the dataset. Let pi be a
column vector, of length I, with its members, pii = Pr(Zi = 1|i), representing
the probability of occurrence of the event of interest (success) for any given
observation from the ith cluster. For each cluster in the dataset, a set of
K independent covariates are measured. Let X represent the design matrix
composed of I rows and K + 1 columns, where the first element of each row
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X, xi0, is equal to one.
The general form of the logistic regression model for the above description
is written as
ln
(
pii
1− pii
)
=
K∑
k=0
xikβk, for i = 1, 2, ..., I. (3.64)
The transformation ln[pii/(1−pii)] is also referred as the logit transform. The
logistic regression (3.64) therefore, expressed the log-odds probability of an
occurrence of the event of interest being investigated to a linear combination
of the covariates X.
Parameter Estimation
The three common methods employed for estimation of parameters for logis-
tic regression model are the maximum likelihood method (Hosmer Jr et al.
(2013a)), non-iterative weighted least square method (Grizzle et al. (1969))
and discriminant function analysis method (Cornfield (1962)), respectively.
In this research, estimation of logistic regression parameters is carried out
via the maximum likelihood estimation (MLE) method and described in this
section. The aim of this approach is to estimate the K + 1 unknown pa-
rameters β in equation (3.64) by maximising the log-likelihood function of
equation (3.64) (Hosmer Jr et al. (2013a)).
The likelihood function for equation (3.64) is given by
L(β|y) =
I∏
i=1
ni!
yi!(ni − yi)!pi
yi
i (1− pii)ni−yi . (3.65)
The factorial terms in equation (3.65) does not contain any of the pii and are
constants that can be ignored when equation (3.65) is maximised to estimate
β. Re-arranging equation (3.65) and eliminating the factorial terms, the
likelihood function of equation (3.64) can be expressed as
L(β|y) 
I∏
i=1
(
pii
1− pii
)yi
(1− pii)ni . (3.66)
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Solving for pii in Equation (3.64) gives
pii =
(
exp(
∑K
k=0 xikβk)
exp(
∑K
k=0 xikβk) + 1
)
. (3.67)
Substituting the exponential of equation (3.64) and equation (3.67), for the
first and second term of the likelihood function (3.66), yields in
I∏
i=1
exp(yi K∑
k=0
xikβk)(1 + exp(
K∑
k=0
xikβk))
−ni
 . (3.68)
Equation (3.68) is referred as the kernel of the likelihood function. The
log-likelihood function of the logistic regression model, `(β), is given
`(β) 
I∑
i=1
yi
 K∑
k=0
xikβk
− ni ln(1 + exp( K∑
k=0
xikβk)). (3.69)
Hence, the first derivative of the log-likelihood function (3.69) with respect
to each βk is given by
∂`(β)
∂βk
=
N∑
i=1
yixik − nipiixik, (3.70)
The second derivative with respect to each βk estimates the variance-covariance
matrix for the estimates of βs and is written as
∂2`(β)
∂βk∂βk′
= −
N∑
i=1
nixik
∂
∂βk′
(
exp(
∑K
k=0 xikβk)
1 + exp(
∑K
k=0 xikβk)
)
(3.71)
and can be simplified to the following form according to Czepiel (2002):
∂2`(β)
∂βk∂βk′
= −
N∑
i=1
nixikpii(1− pii)xik′ (3.72)
To determine the MLE estimates of the β’s, equation (3.70) is set to zero.
This yields a system of K+1 non-linear equations, each with K+1 unknown
parameters. The most common approach to find the solution to such a
system of non-linear equations is the Newton-Raphson method (Hosmer Jr
et al. (2013a)). Applied to the logistic regression model, the steps involved
in the Newton-Raphson method to estimate βs are summarised below.
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(1) Using equation (3.70), the first step is expressed in the form of
β(1) = β(0) +
(
XTWX
)−1
XT (y − µ), (3.73)
where X is the design matrix defined in section 3.6.1, W is a square
matrix of order N , with elements nipii(1−pii) on the diagonal and zeros
everywhere else and µ is a column vector of length N with elements
µi = nipii.
(2) Substituting β(0) by the initial estimates of the βk, new estimate, β
(1)
is obtained from step 1.
(3) β(0) in step 1 is again substituted by the newly estimated β(1) from step
2.
(4) Steps (1)–(3) are repeated until the estimated βs have converged, i.e.,
there is no difference in the estimated βs of two consecutive iterations.
Shared frailty multilevel logistic regression model
In public health, demography and sociology, large-scale surveys often follow
a hierarchical data structure as the surveys are based on multi-stage strat-
ified cluster sampling. The appropriate approach to analysing such data is
therefore based on nested sources of variability which come from different
levels of the hierarchy. When the variance of the residual errors is correlated
between individual observations as a result of these nested structures, the
effect of clustering should be accounted for during the data analysis stage.
In this section, a multilevel logistic regression model with shared frailty effect
is presented.
Consider the dataset and notation defined in section 3.6.1. The dataset
is grouped into ni clusters. To account for this clustering effect, a random
effect, ui, for i = 1, ..., I, is added to the logistic regression model (3.64) to
create a 2-level hierarchical logistic regression model with shared frailty, as
shown below:
ln
(
pii
1− pii
)
=
K∑
k=0
xikβk + uizi, (3.74)
for i = 1, 2, ..., I and where ui is the estimated vector of random effects
(frailties) and Z is the design matrix where its Zi element is equal to 1 for
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the ith subject belonging to the same frailty group i or 0 otherwise. ui is
assumed to follow a normal distribution with expected value equal to zero
and variance that is estimated from the fitted data and denoted by σ2i . Under
the shared frailty set up, all subjects within the same cluster are assumed to
be at the same level of frailty due to clustering. In the field of epidemiology,
grouping patients via their GP practice commonly assumes that effect of
clustering is similar for all patients enrolled with the same GP practice as
they are exposed to the same level of unknown risks. In this research, GP
practice is used as a cluster and included as a random effect for mortality
analysis.
Estimation of random effects
The most common methods employed for the estimation of shared ran-
dom effects in a multi-level logistic regression model are the marginal quasi-
likelihood (MQL) method (Goldstein and Rasbash (1996), Snijders (2011))
and the Penalized Quasi Likelihood (PQL) method (Laird (1978), Breslow
and Clayton (1993)). The MQL method proceeds by linearising the model
(3.74) via Taylor series expansion about the entire predicted value for the
ith cluster, such that the following penalised quasi-likelihood algorithm is
derived from the first s terms of the Taylor series expansion:
Y
(s)
i = β
T
ikX
T
ik + Z
T
i ui, (3.75)
where Yi is a column vector of length I with its elements, Yi, denoting the
number of occurrences of the event of interest, s denotes the order at which
the Taylor series expansion has been restricted, Xik is the set of k observed
covariates for the ith cluster, βTik are the estimated effect due to the k
th
covariate observed in cluster i, Zi is the model matrix for the random effect
due to cluster i, ui is a vector of the random effect associated with the i
th
cluster and Yi is penalised using the following expression:
Y
(s)
i =
Yi − pi(s)i
ωi
+ ln
(
pii
1− pii
)
, (3.76)
where ωi is the penalty term used to penalise the likelihood function of model
(3.74) and is assumed to be equal to pii(1 − pii). Using the PQL algorithm
defined by equation (3.75), estimated frailty terms, uˆi, are obtained by the
following expression (Snijders (2011)
uˆ
(s)
i = (Z
T
i W
(s)
i Zi)
−1ZTi W
(s)
i (Y
(s)
i −Xiβˆ(s)i ), (3.77)
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where W
(s)
i = diag
{
ω
(s)
i , ..., ω
(s)
ni
}
. uˆ
(s)
i is interpreted as the combined effect
of all omitted subject-specific covariates that causes some subjects in cluster
i to be more frail to the event of interest than other subjects.
3.6.2 Hypothesis Testing and Confidence Intervals for Estimated
Parameters
To test the statistical significance of covariates in the multiple logistic regres-
sion model, the likelihood ratio test is used (Hosmer Jr et al. (2013a)). Let
β(0) be the hypothetical value of the coefficients and βˆ be the estimated coeffi-
cients from the fitted model. To test the global null hypothesis H0 : βˆ = β
(0),
the test statistic, denoted by LRT , for the likelihood ratio test is given by
LRT = 2(`(βˆ)− `(β(0)), (3.78)
i.e, twice the difference of the log partial likelihood function, evaluated at β(0)
and denoted by `(β(0)), and that of the multiple logistic regression model with
K covariates, evaluated at βˆ(0) and denoted by `(βˆ). LRT follows a χ2 dis-
tribution with K degrees of freedom.
To check the statistical significance of a specific covariate xk, the Wald
test is used (Hosmer Jr et al. (2013a)). The Wald test assess the hypothesis
that the estimated coefficient for covariate xk, denoted by βˆk, is significantly
different from zero. The test statistic, Z, is given by
Z =
βˆk
ŝe(βˆk)
, (3.79)
where ŝe(βˆk) is the standard error associated with βˆk. The test statistic Z
follows a standard normal distribution and can also be used to formulate
confidence interval for βˆk. The (1 − α)% confidence interval (CI) for βˆk is
given by
CI(βˆk) = βˆk ± Z1−α/2ŝe(βˆk), (3.80)
where Zα represents the critical value at (1−α)% level from the standard nor-
mal distribution. When the (1−α)% CI of an estimated coefficient contains
zero, it means that the covariate associated with that estimated coefficient
does not significantly affect odds of occurrence of the event of interest being
investigated.
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3.6.3 Model diagnostics and assessing model fit
In this section, a review of several methods for assessing the fit of a logistic
regression model is presented. To begin, the same description and notation
defined in section 3.6.1 is used to explain the different methods of assessing
the fit of a logistic regression model. Let the fitted value from the logis-
tic regression model, shown by equation (3.74) be denoted by yˆi = pˆi. pˆi
is the estimated probability that yi = 1 for the i
th observation (defined by
equation(3.67)). Model fit assessment for logistic regression model relies on
the analysis of two forms of the error component of a fitted logistic regression
model, namely deviance (D) and Pearson chi-square statistic (Hosmer and
Lemeshow (2000)).
The deviance, D, is given by
D =
N∑
i=1
d2i , (3.81)
where D follows a chi-square distribution with (N−k−1) degrees of freedom
for N number of observations in the study population and k number of
covariates in the fitted model, respectively. The individual components (di),
known as the deviance residuals, are defined as:
di =
(
2|ln(pii)|
)1/2
, if yi = 1,
di =
(
2|ln(1− pii)|
)1/2
, if yi = 0,
(3.82)
respectively. The Pearson chi-square statistic, χ2, is defined as
χ2 =
n∑
i=0
r2i , (3.83)
where χ2 follows a chi-square distribution with (N − k − 1) degrees of free-
dom for N subjects in the study population and k covariates in the fitted
model, respectively, and the individual components (ri), known as the Pear-
son residuals, are defined as:
ri =
yi − pˆii(
pˆii(1− pˆii)
)1/2 . (3.84)
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Plots of the ri and di, respectively, against the subject show which subject
has relatively too low or too high values for ri and di. A logistic model with
subjects having too high value or too low value for ri and di, respectively, in-
dicates a poorly fitted model for these subjects. If the removal of these poorly
fitted subjects affect the estimated model parameters, then these subjects are
assumed to be influential observations. One drawback in using ri and di to
assess the goodness of fit of a logistic regression model is that they can only
be analysed graphically and their aggregate statistics χ2 and D, respectively,
cannot be easily interpreted because their distribution under the hypothesis
of the fitted logistic regression, cannot be approximated by a chi-square dis-
tribution (Hosmer et al. (1991)).
An alternative approach to assess the goodness of fit for the logistic re-
gression model is the Hosmer and Lemeshow test (Hosmer Jr et al. (2013b)),
which is carried out via the following steps described below:
(1) The observations are firstly split into j groups, based on deciles of
the estimated probability of occurrence of the event of interest. The
common cutting points for expected risks in logistic regression are the
10th, 20th, ..., 100th percentiles.
(2) In each group, the sum of the probabilities of success is computed. This
sum is equal to the expected number of events within each decile.
(3) The differences in observed and expected number of events within
each decile are statistically compared using the Pearson goodness of
fit statistic given by (Hosmer and Lemesbow (1980))
χ2P =
1∑
k=0
j∑
l=1
(Okl − Ekl)2
Ekl
, (3.85)
where χ2P follows a chi-square distribution with (j − 2) degrees of free-
dom for a correctly fitted model, n is the number of subjects in the
investigation, j is the number of groupings used in the test, Okl repre-
sents the number of observed events of interest in the lth group and Ekl
represents the number of expected event of interest in the lth group,
with k = 1 for occurrence of the event of interest and k = 0 for non-
occurrence. If the p-value of the χ2P statistic is significant, then the
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null hypothesis that the data differ significantly from the fitted model,
is accepted and thus, the model is a poor fit for the dataset.
One common criticism associated with the Hosmer and Lemeshow test
is the choice of the number of clusters, j, to group the observations. Small
values of j provides less opportunity to detect misspecification in the fitted
model. Large values of j will group the observations into subsets of small
size that makes determination of differences between observed and expected
successes and failures due to chance or model misspecification, difficult. Hos-
mer Jr et al. (2013b) proposed to select the number of groupings based on
using the rule j > (K + 1), where K is the number of covariates in the fitted
model.
3.7 Model Selection Procedures
Model selection in regression analysis is an essential step in obtaining the op-
timal (best) model. The best model from a regression analysis is one where
its prediction error is minimised. Harrell (2001) defines the prediction error
as a measure of the difference between the observed and predicted outcomes
of a model. Estimating the prediction error takes into account both the bias
between observed and predicted outcomes and the variance of the predicted
outcomes. A model with minimised prediction error is regarded as the op-
timal regression model (Moptimal). A model that consists of more variables
than Moptimal, over-fits the data as it includes covariates that do not con-
tribute for prediction of outcomes. Therefore an over-fitted model will have
low bias and an inflated variance of the predicted outcomes. A model with
less variables than Moptimal under-fits the data and excludes covariates that
are essential in predicting outcomes. Hence an under-fitted model does not
capture the trend displayed by the data.
To find Moptimal, three methods of covariate selection for regression anal-
ysis are routinely used (Harrell (2001)). These methods are the forward
elimination, backward elimination and stepwise selection. They rely on a
mathematical information criteria that are used for estimation of the pre-
diction error. For selection of covariates in regression analysis, a model
with the lowest information criterion value, will be chosen over models with
higher information criterion value. The two most common information crite-
ria used for model selection are the Akaike information criterion (AIC) and
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the Bayesian information criterion (BIC) (Harrell (2001)). AIC and BIC are
respectively given by
AIC = −2`− 2k,
BIC = −2`+ k ln(n), (3.86)
where ` is the partial log-likelihood function of the regression model, k is the
number of estimated parameters in the regression model and n is the number
of events in the survival analysis. BIC penalizes larger models more heavily
as it depends on the number of events, n and tends to perform better for
smaller sample size model fitting in comparison to AIC.
Forward selection starts with an empty model. Covariates are added one
at a time starting with the covariate with the highest correlation with the
dependent variable to create model m0. Variables of greater theoretical im-
portance are usually entered first. Once selected, the covariate remains in the
model and the variable with the second highest correlation with the depen-
dent variable is entered into m0 to obtain model m1. If the estimated AIC of
m1 is smaller than that of m0, then model m1 is statistically more optimal
than m0. This process is repeated until the contributions of all remaining
covariates are checked, one by one, using AIC values. Under the backward
elimination method, all the covariates are entered into a full model (mall) and
deleted sequentially, one at a time, if they do not contribute to the regression
model. If the removal of a covariate increases the AIC of model mall, then
it contributes significantly to the optimal model and should be kept in the
model. Removal of covariates that decreases the AIC of mall is continued un-
til no decrease in AIC of mall is observed when the next covariate is removed.
3.8 Dealing with Missing data
Introduction
Routinely collected data from clinical databases, such as primary care databases
have long been recognised as rich data sources. However they include pro-
portion of incomplete data (missing data). Incomplete dataset is common
among observational studies with long follow-up time. Missing data cannot
be ignored during data analysis. It is essential to account for the type and
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degree of missingness in the dataset.
Datasets used in this research are from primary care records which con-
sist of missing data. MacDonald and Morant (2008) and Hippisley-Cox and
Coupland (2010a, 2010b) showed that there is a difference between observed
and missing data among medical variables such as records of hypertension,
hypercholesterol and chronic diseases. Marston et al. (2010) reported sys-
tematic difference between observed and unobserved data among lifestyle
variables such as body mass index measurement, smoking and alcohol con-
sumption. According to Shephard et al. (2011), there is a strong relationship
between ill-health and primary care records. Subjects who are ill are more
likely to have more complete records in primary care database, compared
to individuals that are healthier because ill patients are more likely to visit
their general practitioners more often than healthier patients. Furthermore,
Marston et al. (2010) and Bartley (2016) demonstrated that proportion of
missing data is lower among female patients, compared to male patients’ pri-
mary care records.
There are three types of missing data, namely: missing completely at
random (MCAR), missing at random (MAR) and missing not at random
(MNAR), respectively. In this section, the methodology of dealing with these
types of incomplete information is summarised. To explain these types of
missing information, consider a set Y of observations with k% of missing
data from a sample data set of X variables.
3.8.1 Types of missing data
Missing completely at random
Data are classified as missing completely at random (MCAR), when there is
no systematic difference between recorded and missing information. Infor-
mation is MCAR if the probability of missingness on Y is not related to other
measured variables, nor to the values of Y itself (Enders, (2010)). Subjects
with a full set of recorded information are therefore representative of those
with missing information and the opposite is also true. Hence when complete
case analysis is carried out on the data set, the estimates obtained from the
analysis are not biased. However under such an approach, the analysis ig-
nores subjects with missing information and thus the sample size is smaller
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and therefore produces less precise estimates. Enders (2010) proposed the use
of difference in mean value of complete case observations and that of missing
data observations as a test for the data that are MCAR while Little (2010)
suggests the use of likelihood ratio test to check for the MCAR assumption.
Missing at random
Data are missing at random (MAR) when the probability of missing data
in Y , is related to some other measured variables in the analysis model but
not to the values of Y itself. In other words, no relationship between the
propensity for missing data on Y and the values of Y , after partialling out
other variables, can be defined (Enders, (2010)). Although MAR means
that data are missing in a haphazard way, it also means that a systematic
relationship exists between one or more measured variables from the set
X and the probability of missing data. One major drawback of the MAR
mechanism is that there is no practical way to check if observations are MAR
or if probability of missing data on Y is solely dependent on other measured
variables from X. MAR mechanism is the most common assumption in the
literature associated with missing information among survival data as it is the
core rationale behind the use of maximum likelihood and multiple imputation
methods to deal with data MAR (Enders, (2010)).
Missing not at random
Data are described as missing not at random (MNAR) if the probability of
missing data in variable Y is dependent on Y itself even after adjusting for
other variables from X (Enders, (2010)). MNAR data are very common in
epidemiological and social sciences studies whereby the probability of missing
data is related to the missing data itself. For instance, subjects who do not
receive any drug prescription for hypertension, are less likely to visit their
general practitioners for blood pressure measurements, compared to subjects
who are on drug therapy for hypertension. Hence the propensity of missing
values for blood pressure measurement can be higher among individuals who
are suffering from hypertension and not on drug therapy.
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3.8.2 Missing data handling methodology
Traditional methods
Several methods have been proposed over time for handling incomplete dataset.
Presence of missing data affects the analysis of the data when proportion of
missingness in the dataset exceeds 5%. Under such a scenario, Spratt et al.
(2010) and van Buuren (2012) explained that the following methods of ac-
counting for missing information in the analysis, do not produce unbiased
and accurate analysis models:
• Analysis of complete records only (list-wise deletion)
• Excluding variables with missing data
• Grouping observations with missing data as one category
• Single imputation whereby missing data are replaced by an educated
or reasonable guess (usually the mean value of the covariate being im-
puted)
Under the list-wise deletion method, the analysis excludes subjects that
have missing information. Hence the sample size of the analysis is reduced
and the statistical power of tests involved in the analysis is lowered. This
method will also yield biased estimates of parameters involved in the analy-
sis if the records are not missing at random because the analysis is based
towards the complete records sample set rather than the whole dataset.
Similarly, removing covariates with missing data from the analysis results
in estimating predicted outcomes that have not been adjusted for, by the
excluded variables. Single imputation method and defining subjects with
incomplete records as a separate category during analysis, produce biased
estimates because they affect the correlation between covariates that has a
level categorised as missing and variables without missing records (Spratt
et al. (2010), van Buuren (2012)).
Multiple imputation method
An alternative and widely recommended method to handle missing data is
the multiple imputation technique developed by Rubin (1987). Compared to
the traditional imputation methods, multiple imputation technique is an an-
alytical method that consists of three distinct stages: the imputation phase,
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the analysis phase and the pooling phase, as shown in Figure 5. In this
section, all these phases, applied to longitudinal data, are summarised.
Figure 5: Illustration of multiple imputation analysis (Enders (2010))
For n imputations, mi’s (1 ≤ i ≤ n) represent the imputed datasets and Pi’s
(1 ≤ i ≤ n) are the set of estimated parameters obtained from analysing the mthi
imputed data set.
The imputation phase
The imputation stage is based on a data augmentation two-step procedure.
The first step uses an estimate of the mean vector and the covariance ma-
trix of variables with complete records to form a set of regression equations
(labelled as the imputation model design (IMD)) that forecast missing data
from set of observed variables (referred as the training set). Two key aspects
should be considered at this stage: (1) defining the appropriate regression
model as the IMD and (2) defining the measurement scale of covariates with
incomplete records.
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Firstly, van Buuren (2012) showed that the IMD used to impute the miss-
ing data, should include all covariates that are used for the data analysis and
all variables that are associated with the missing values as well. However
it may be impossible to account for all covariates in the imputation model
design mainly because of strong correlation between covariates or because of
limited computational capability to handle the complex nature of the model.
van Buuren (2012) limits the optimal number of covariates in the IMD to 30,
although he claimed that having more that 15 variables will hardly influence
the explained variance in the imputed datasets.
Secondly, it is essential to specify the measurement scale for each covari-
ates being imputed. According to van Buuren (2012) and Enders (2010),
variables that are continuous in nature are imputed using a linear regression
model as IMD. Binary variables are imputed via a logistic model, while in-
complete categorical covariates with more than 2 levels are imputed using a
multinomial regression model. In addition, variables that have been created
or derived from incomplete covariates should also be imputed and compared
to the imputed covariates used to derive the new variables to ensure consis-
tency between the covariates used during the analysis stage. For a dataset
with both continuous and categorical missing variables, joint modelling is
used for imputation. Under this approach, the data is assumed to belong
to a multivariate distribution (Gaussian distribution). Carrying out multi-
ple imputations under such distributional assumption has been proved to be
robust according to van Buuren (2012) and Enders (2010).
The second step of the imputation phase is a Bayesian iterative process
using Monte Carlo simulation, as described below (Enders,2010).
(1) Using the regression coefficients of the IMD, values of the covariates
with missing values are predicted. A random residual term which is
normally distributed with mean zero and variance equal to the resid-
ual variance from the regression of the missing covariate value on the
outcome variable, is added to the IMD. Adding random residual terms
to the mean vector and the covariance matrix of the IMD produces
parameter estimates that differ randomly to those that produced the
coefficient estimates of the first IMD set up in the first step of the
imputation phase. A new dataset (Dnew) with observed and imputed
values is obtained.
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(2) Using Dnew, the new sample means (µˆnew) and the covariance matrix
(Cˆnew) are determined.
(3) Using µˆnew and Cˆnew, a new posterior distribution is defined and used
to obtain a new set of plausible estimates for the missing values.
(4) Steps (1)–(3) are iterated continuously until convergence of the esti-
mated regression coefficients is achieved. This iteration process of con-
vergence is referred as the burn-in-length.
Once the designated number of burn-in-length has been completed, the
entire imputation process is repeated to generate multiple imputed datasets.
The observed data stays the same across the imputed datasets; only the val-
ues that had originally been missing will differ. Authors like van Buuren
(2012) and Enders (2010) indicated that between 5 to 10 imputed datasets
is sufficient while other authors such as Graham et al. (2007) and Harel and
Zhou (2007) suggests that, depending upon the amount of missing informa-
tion in the data, increasing the number of imputations to as many as 40
imputed datasets can improve power.
Originally intended for analyzing multiple MCMC chains, Rˆ is calculated,
in the context of multiple imputation, by discarding the burn-in iterations
and dividing the single MCMC chain for each parameter into multiple seg-
ments (Asparouhov and Muthe´n (2010)). The Rˆ statistic then compares the
variance within and between imputed datasets in order to detect a potential
“drifting” of the chain, that is, regression chains used to simulate missing
values that are more variable overall than one would expect, based on the
variability within segments. Ideally, Rˆ should be close to one for all pa-
rameters (Gelman and Rubin, 1992). If larger values of Rˆ occur, a longer
burn-in period is required (Enders (2010)). The second option to check con-
vergence of parameters is through diagnostic plots. For each parameter in
the imputation model, a trace plot for all iterations during and/or after burn-
in is produced. The trace plot is a graphical representation of the MCMC
chain for each parameter, and it shows the values of that parameter at each
iteration.
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The analysis phase
The imputation phase generated n imputed datasets, each of which contains
different estimates of missing values. The purpose of the analysis phase is
to analyse the imputed data set and involves n statistical analyses such as
fitting a Cox regression model to each of the n imputed datasets using the
same analysis procedure and software. This will result in obtaining n sets of
estimated parameters for each of the imputed datasets.
The pooling phase
The analysis phase produces n sets of unbiased estimated parameters, αˆ =
(αˆ1, αˆ2, ..., αˆn), for MAR data. In the pooling phase, multiple imputation
analysis combines the n estimated parameters into a single point estimate, α¯,
using Rubin (1987) definition of multiple imputation point estimate (Enders,
(2010))
α¯ =
1
n
n∑
i=1
αˆi. (3.87)
Rubin (1987) definition of multiple imputation point estimate is analogous
to the formula for the sample mean, where the parameter estimates are used
as data points to determine the sample mean. Although multiple imputation
technique has been developed under a Bayesian framework, the pooled point
estimate of the parameters is highly meaningful under a frequentist frame-
work where α¯ is the point estimate of a fixed population parameter.
The analysis phase also yields in n estimates of standard errors associated
with the parameters estimated for each of the n imputed datasets. Multiple
imputation standard errors come from two sources of sampling fluctuation:
(1) variance within imputation and (2) between imputation variance. Again
Rubin (1987) definition of multiple imputation point estimate (equation 3.87)
is applied to pool the n estimated standard errors into a point estimator.
However, Rubin (1987) pooling formula (equation 3.87) works on a sampling
variance metric. Hence the standard errors are scaled into their variances
before applying equation 3.87. To illustrate this, consider n sets of imputed
datasets. Let αˆi (1 ≤ i ≤ n) be the estimated coefficients of the fitted model
to the ith imputed dataset and ŝei be the estimated standard errors associated
with each αˆi. Using Rubin (1987) pooling formula, the within imputation
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variance of the parameter estimates, ω̂, across the n imputed datasets, is
therefore given by
ω̂ =
1
n
n∑
i=1
ŝe2i (3.88)
The between imputation variance, VˆB, measures the variability of the param-
eter estimates across the n imputed data sets and is given by
VˆB =
1
n− 1
n∑
i=1
(αˆi − α¯)2 (3.89)
Hence the variance of α¯, denoted by Vˆα, is estimated as (Rubin (1987))
Vˆα = ωˆ +
(
1 +
1
n
)
VˆB (3.90)
Significance testing and confidence intervals for multiple imputa-
tion analysis
In the context of multiple imputation, Rubin (1987) proposed the use of an
analogous t-statistic, T , defined below, to test whether the pooled estimate
of the model coefficients is significantly different from a hypothesized value,
α0.
T =
α¯− α0√
Vˆα
, (3.91)
where α¯ and Vˆα are given by equations 3.87 and 3.90, respectively and T
follows a student t-distribution with the number of degrees of freedom, DF,
given by (Rubin, (1987))
DF = (n− 1)
(
ωˆ + VˆB(1 + 1 n)
VˆB(1 + 1 n)
)2
, (3.92)
where ωˆ and VˆB are given by equations 3.88 and 3.89, respectively. The
(1− k)% confidence interval for the pooled estimate of the model coefficient,
α¯, is given by (Enders, (2010))
α¯± tp,1−k/2
√
Vα, (3.93)
where tp,1−k/2 is the critical value of a t distribution with p degrees of freedom
and Vα is the pooled variance of α¯.
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3.9 Chapter Summary
In this chapter, a review of the statistical methods used in the analysis of mor-
tality data, is presented. Parametric models are employed for survival data
assuming a particular distribution while non-parametric models are used for
the analysis of data with no distributional assumption. In addition, the Cox
proportional hazards model presented in this chapter can be extended to ac-
commodate time-dependent, stratified variables and frailties. However when
proportional hazards assumption fails, multiple logistic regression model with
random effects can be used as an alternative approach for estimation of mor-
tality risk.
100
4 Review Of Study Design And Primary Care
Data In The United Kingdom
Introduction
This chapter is a review of the different study designs that are used in the
field of epidemiology and sources of medical primary care data in the UK.
Firstly a summary of the description of different study designs are provided,
followed secondly by a discussion on the methods of data collection in these
study designs. Thirdly a summarised description of existing primary care
records database in the UK is presented. Fourthly an overview of the THIN
database then follows.
4.1 Review of study designs in epidemiology
Different study designs provide information of distinct quality. Using the
best possible study design is always desirable but not always practical or
ethically acceptable. Therefore it is essential to evaluate the strengths and
drawbacks of each type of study design, as applied to the research purpose.
In the field of epidemiology, study designs are classified into experimental
studies and observational studies as shown by Figure 6 below.
Figure 6: Types of observational study design (Song and Chung (2010))
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Observational studies
Observational studies are a sub-class of analytic study design that identify
and assess causes, risk factors or outcomes associated with health related
events such as cardiovascular diseases or surgical interventions like total hip
replacement. The researcher in an observational study only observes and sys-
tematically collects information, but does not intervene to alter the subjects.
Case-control study design was introduced by Lane-Claypon et al. (1926)
and its mechanism was fully described and used by Doll and Hill (1950).
Under the case-control study design, displayed by Figure 7, subjects are ad-
mitted into the study by their outcome status at the start of the investigation
period. Outcomes of interest may include death of subjects who underwent
a surgical intervention or experienced a medical complication or diagnosed
with a disease. Upon the identification of subjects with the outcome of inter-
est, they are grouped as cases. Subjects without the outcome of interest are
selected from the same population source and are grouped as controls. Ret-
rospective data about exposure to hypothetical risk factors are then collected
for cases and controls, usually by interviewing the subjects or by extraction
of data from medical database or via surveys.
Figure 7: Case-control study design (Song and Chung (2010))
Case-control studies are efficient and economical because (1) such design
permits the study of several risk factors simultaneously; (2) it permits the in-
vestigation of risk factors for rare conditions whereby there may be problems
in generating a sufficiently large number of subjects with the rare conditions
to produce accurate results and (3) it allows evaluation of confounding and
interacting covariates between cases and controls due to the balanced na-
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ture of the study design. However case-control studies are limited because of
the following disadvantages: (1) case-control study does not involve a time-
sequence and hence does not demonstrate causality; (2) such study design
can only investigate one condition or surgical intervention at a time because
selection of cases and controls is defined according to the condition or surgi-
cal intervention being investigated; (3) case-control study can only estimate
relative risks between cases and controls and (5) case-control study design
may be strongly biased if selection of controls is not carried out appropriately
(Song and Chung,(2010)).
Based on the design of a case-control study, these four methodological
aspects should be addressed carefully before the investigation (Song and
Chung,(2010)):
(1) Selection of subjects as cases is dependent on the outcome of interest
and hence it is important to explicitly define the inclusion and exclusion
criteria for acceptance of subjects as cases. In addition, validity of the
data source for cases’ identification need to be carefully carried out,
such that cases are representative of the target population.
(2) An essential principle during the selection of controls is that distribu-
tion of exposure should be similar among cases and controls. This can
be ensured by selecting cases and controls from the same population
source and adopting the same inclusion criteria for both.
(3) Matching cases to one or more controls based on their background vari-
ables is a key aspect of a case-control study design. This process estab-
lishes comparability between cases and controls and reduces variability
and systematic differences that are insignificant to the investigator.
In a cohort study, an outcome-free study population is first identified by
the exposure or event of interest and followed in time until the disease or
outcome of interest occurs. For example, in survival analysis after a partic-
ular surgery, individuals who underwent the surgical procedure are followed
from the time of surgery until the outcome of interest (death), if it occurs
before the end of the investigation period. Since exposure is identified before
the outcome, cohort studies have a temporal framework to assess causal-
ity and thus have the potential to provide the strongest scientific evidence
(Everitt and Palmer, (2011)). Cohort study designs are beneficial because
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firstly they permit the investigation of causality since the data being analysed
take account of the sequence of outcome of interest and secondly they allow
examination of multiple outcomes for a given exposure. However they are
often criticised for requiring large sample size to produce accurate estimates.
Case-control and cohort studies can be prospective or retrospective. Prospec-
tive studies are carried out from the present time into the future. Since
prospective studies are designed with specific data collection methods, they
have the advantage of being tailored to collect specific exposure data and
may be more complete. The disadvantage of prospective studies is the long
follow-up period while waiting for outcome of interest to occur. Thus, this
study design is inefficient for investigating diseases or conditions with long
latency periods and is vulnerable to a high loss to follow-up rate.
Retrospective studies, also known as historical cohort studies, are carried
out at the present time and look to the past to examine medical events or
outcomes of interest. In other words, a cohort of subjects selected based on
exposure status is chosen at the present time, and outcome data (i.e. disease
status, event status), which was measured in the past, are reconstructed for
analysis. The primary disadvantage of this study design is the limited con-
trol that the investigator has over data collection. The existing data may be
incomplete, inaccurate, or inconsistently measured between subjects (Hulley
et al. (2013)). However with the immediate availability of the data, retrospec-
tive study design is comparatively less costly and shorter than prospective
studies.
Cross-sectional studies, also known as prevalence studies, analyse the data
on disease and exposure at one particular time point only. Since the temporal
relationship between disease occurrence and exposure cannot be established,
cross-sectional studies cannot assess the cause and effect relationship. Cross-
sectional study is one of the most efficient and economical designs because:
(1) it is relatively quick and easy to conduct (no long periods of follow-
up are required); (2) data on all variables are collected only once; (3) it
measures prevalence for all factors under investigation; (4) it allows studies
of multiple outcomes and exposures simultaneously. However cross-sectional
studies are criticised because firstly it is difficult to determine whether the
outcome followed exposure in time or exposure resulted from the outcome
under this study design and secondly cross-sectional studies are not suitable
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for studying rare outcomes or outcomes with a short duration.
Experimental studies
Under the experimental study set-up, the investigator intervenes during the
experiment through a series of actions or decisions and then observes what
happens to the subjects (Hulley et al. (2013)). Experimental studies are of-
ten performed in laboratories and in clinics to establish beneficial effects of
drugs or procedures. Such a study design is considered to provide the most
reliable evidence in epidemiological research. Experimental studies are sub-
divided into either preventative or therapeutic studies (Hulley et al. (2013)).
Therapeutic study trials are conducted among individuals with a particular
disease to assess the effectiveness of an agent or procedure to diminish symp-
toms, prevent recurrence, or reduce mortality from the disease. Preventative
study trials are conducted to evaluate whether an agent or procedure reduces
the risk of developing a particular disease among individuals free from that
disease at the beginning of the trial.
A main characteristic of all experimental studies is that the therapeutic
or preventative intervention being tested, is allocated by the investigator to
a group of two or more study subjects which are then followed prospectively
to compare the group of individuals with intervention to the control indi-
viduals who did not receive the intervention. There are two main types of
experimental studies, namely cross-over trials and randomised controlled tri-
als (Hulley et al. (2013)). A cross-over trial is one in which the subjects are
first assigned to the treatment group and, after a brief interval for cessation
of residual effect of the treatment intervention, are shifted into the control
group. Thus, the subjects act as their own control at the end of the study.
However, such studies are not feasible if there is loss of follow-up due to mor-
tality, or if the disease is easily cured by one of the interventions.
The randomised controlled trial (RCT) is considered to be the most rigor-
ous method of assessing whether a cause-effect relationship exists between an
intervention and outcome. The strength of the RCT design lies in the process
of randomisation that is unique to this type of epidemiological study design.
Generally, study participants are randomly assigned to one of two groups:
the experimental group receiving the intervention that is being tested and a
comparison group (controls) which receives a conventional treatment. These
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groups are then followed prospectively to assess the effectiveness of the in-
tervention compared with the standard treatment. The random allocation of
subjects is used to ensure that the intervention and control groups are similar
in all respects (distribution of potential confounding factors are similar) with
the exception of the therapeutic or preventative treatment being tested and
to ascertain that any observed differences between the treatment groups are
due to differences in the treatment alone.
4.2 Sources of medical data
In the UK, sources of medical data can be segregated into firstly, prospec-
tively collected trial-cohort data and secondly, routinely collected data from
primary and secondary healthcare, disease specific registers or mortality reg-
isters. In this section, the contrast in data collection between these two
sources of medical data is discussed. They are compared in terms of de-
termination of outcome of interest, precision of risk factors, proportion of
missing values, all-cause mortality information, cost of data collection and
the generalisability of the data.
Random trial controls (RCTs) and cohort studies are designed specifi-
cally to prospectively collect data whereby the outcome of interest is explic-
itly specified and recorded together with exposures and risk factors. With
routinely collected data, patients’ information is recorded only when they
visit their primary or secondary healthcare services (MacDonald and Morant
(2008), Wijlaars (2013)). Hence the amount of records for each patient in
routinely collected data highly depends on the frequency of visits by the
patients and also what information the healthcare professionals identify as
relevant to be recorded. This may result in a proportion of patients with un-
known records for different risk factors and outcomes for the periods they did
not visit their primary or secondary healthcare. Thus in contrast to prospec-
tively collected trial-cohort data, routine data collection may not contain
complete records of outcomes or risk factors.
RCTs and cohort studies are carried out under rigid study protocols to
ensure consistency and high precision during the data collection for outcomes
and risk factors measurements. On the contrary, routinely collected data are
recorded in coded form by clinicians. Thus there is a risk that different clin-
icians may use different methods of coding for patients’ records or may even
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employ the incorrect method to record information (MacDonald and Morant
(2008), Hippisley-Cox and Coupland (2010a). In the UK, to ensure that pri-
mary and secondary care records are consistent and of high quality across
all primary and secondary healthcare providers such as general practition-
ers, the Quality and Outcomes Framework (QOF) was introduced in 2004,
as a scheme that pays primary and secondary healthcare to improve their
services (Szatkowski et al. (2012)). In addition, published list of codes for
classification of medical conditions and treatments in UK are also available
as an online repository (See ClinicalCodes (2016)) where researchers can up-
load and download lists of clinical codes that enable researchers to better
validate their studies, to build on previous code lists and to compare medical
conditions’ definitions across several published studies.
Information related to mortality is more consistent and readily available
in routinely collected data, compared to RCT collected data. Primary and
secondary care databases in UK have high precision and consistent all-cause
mortality information because when an individual dies, his general practi-
tioner is notified (HSCIC (2016)). Therefore, precise information on cause
and time of death can be obtained from routinely collected data. Further-
more, RCT collected data and secondary healthcare data hold medical infor-
mation that are specific to one particular medical condition only and cannot
be used to test interaction of new risk factors with other medical condi-
tions. On the other hand, routinely collected data such as primary health-
care records, consist of comprehensive medical history of individuals that are
not specific to one condition only, thereby permits exploration and analy-
sis of new factors that are not measured in RCT’s or secondary healthcare
databases.
Collecting data prospectively is expensive because of the ongoing costs
involved during the investigation period and this may put financial limitation
on the amount of data being recorded leading to the sample size not being
optimal for analysis. On the other hand, routine data collection is associ-
ated with lower cost as it only involves an initial high cost for setting up a
data collection system and training professional healthcare providers to use
the system and a low cost of system maintenance to validate data collection
and to provide a quality assessment of the data. Being less costly, routinely
collected databases have large sample size and represent a rich source of long
follow-up data with frequently updated information that can be used to pro-
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duce the most recent statistics (Wijlaars (2013)).
Analysis of either prospectively collected trial-cohort or secondary care
or disease specific data may not be generalisable to a population as a whole
because such data are relatively small in size and are restricted to specific
conditions that are specified by rigid study protocols. For example, analysis
of secondary care data and disease specific registries can only be applied to
individuals with the conditions being recorded in these databases. On the
contrary, analysis of routinely collected data such as primary care data can
be easily generalised to a population as a whole. In the UK, 99% of the
population is registered to a general practitioner under the National Health
Service (NHS (2013)) and all visits or admissions to secondary care providers
are also recorded by the patients’ general practitioners in primary care records
(Hall (2009)). Therefore primary care data in the UK is representative of all
patients with both mild and severe medical conditions, providing an almost
complete medical history of the patients. However one cannot fully ascertain
that primary care records reflect 100% of a patient’s medical history because
information such as self-medication of over the counter drugs may not be
reported to the primary health care provider.
4.3 Overview of primary care databases in the United
Kingdom
In UK, the National Health Service (NHS) is organised around primary care
and, unless there is an accident or emergency, whenever citizens would like
to use the NHS they have to go through their primary care physician, also
referred as a general practitioner (GP) in the UK. From there, they can be
referred to a specialist at a hospital if required. Secondary care clinicians
can then feedback information to GPs. Since the vast majority of the popu-
lation (99%) is registered with a general practice (NHS (2013)), GP’s act not
only as the main gatekeepers for the NHS but also as essential providers of a
longitudinal electronic health records (Herrett et al. (2015)). There are now
many ongoing primary care databases of anonymised patient records in UK
that can be used for healthcare research. These population-based databases
contain data originating from routine general practice. In this section an
overview of the three largest primary care databases in the UK, namely the
Clinical Practice Research Datalink (CPRD) (Walley and Mantgani (1997)),
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The Health Improvement Network (THIN) (Bourke et al. (2004)) and QRe-
search (Hippisley-Cox et al. (2004)), respectively, is provided.
CPRD, THIN and QResearch databases are often used for cross-sectional
surveys, case–control or cohort studies and for epidemiological, drug safety,
clinical and healthcare usage research purposes. They rely heavily on indi-
vidual general practices voluntarily contributing data via the propriety clin-
ical systems they use to maintain these patient records. CPRD and THIN
include medical records from approximately 600 practices, input using the
Vision clinical system, while QResearch database consists of medical records
from approximately 1000 practices that employ the EMIS clinical system for
data collection. The records are usually anonymised at source by allocating
a unique number to each patient to allow for the updates of the records and
their linkage to other data sets, such as national mortality, national cancer
registration and hospital records as well as with socio-economic, ethnicity
and environmental data sets. Access to these data sets is usually granted af-
ter scientific and ethics review and can be tailored to customer requirements.
Table 6 summarises the main characteristics of the CPRD, THIN and
QResearch databases and three other databases (Quality and Outcomes
Framework, General Household Survey and Health Survey England) that
contribute to CPRD , THIN and QResearch data collection and linkage.
The CPRD (previously known as the General Practice Research Database)
is a not-for-profit research service funded by the NHS National Institute for
Health Research (NIHR) and the Medicines and Healthcare products Regu-
latory Agency (MHRA). It is owned by the UK Department of Health and
consists of records for 11 million patients (4.4 million active) from 674 prac-
tices (Herrett et al. (2015)). The THIN database contains records of 12 mil-
lion patients from approximately 600 general practices that use the Vision
clinical system, set up by In Practice Systems (INPS) and Epidemiology and
Pharmacology Information Core (EPIC) (IMS Health Incorporated (2017)).
QResearch is a research service located at the University of Nottingham and
its database consists of the health records of 18 million patients from 1000
general practices that use the EMIS clinical system (QResearch (2016)).
The key strengths of these databases lie in their size, representativeness of
the UK population, long follow-up periods of patients and high data quality
(Herrett et al. (2015)). They contain important and quality information on
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morbidity and lifestyle, prescriptions, preventive care, current standards of
care and inter-practice variations (Gnani and Majeed (2006)). Since they are
continually updated, they are ideally set up for researchers to investigate and
monitor healthcare trends and effectiveness of new interventions and treat-
ments, with minimum cost. They are increasingly linked to secondary care
and mortality data sets. However, their weaknesses include the fact that
data are extracted from proprietary clinical systems developed for patient
management and not for healthcare research. There are issues such as: (1)
missing data (for example healthier patients are more likely to have incom-
plete records than less healthy patients who visit their GP more frequently),
(2) variable definitions for diagnoses (although this is improved by published
list of clinical diagnoses provided by ClinicalCodes (2016)), (3) incomplete
secondary care data (for instance, incomplete records from hospital admis-
sions) and (4) incomplete capture of wider health data such as treatment
adherence or over the counter medication (Herrett et al. (2015)).
Nevertheless, CPRD, THIN and QResearch are highly regarded within
the research community since they strongly support researchers obtaining
definitive answers for various healthcare debates of considerable public in-
terest. Validity of new or updated primary care records added to these
databases in UK, is checked through external validation by comparing new
records to existing ones. Although these three databases consist of differ-
ent practices and patients, estimates of incidence, prevalence, morbidity and
mortality rates are similar across all three databases when data are adjusted
for gender, age and level of social deprivation of patients’ residential areas
(NHS (2013)). Therefore primary care records databases in the UK are good
source of valid data that can be used to answer research questions under
well-defined study designs.
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4.4 The Health Improvement Network database
The Health Improvement Network (THIN) database is used in this research
for data extraction to investigate variations in mortality risks after THR pro-
cedures in the UK. In this section, the THIN database structure is described
and a discussion of the key strengths of using THIN for the objectives of this
research is provided.
4.4.1 THIN database structure
THIN is an electronic medical research database of anonymised patient records
from approximately 600 different GP practices across the United Kingdom.
The database represents almost 6% of the GP practices population in the
UK. It is also equivalent to roughly 86 million patient-years of data. It
was created by In Practice Systems Ltd (INPS) in collaboration with Epi-
demiology and Pharmacology Information Core (EPIC) in 2003 (IMS Health
Incorporated, (2015)). The INPS data system collection is essentially similar
to other existing operating clinical data recording systems such as EMIS for
QResearch and CPRD databases (See section 4.3) in the UK (Department of
Health, (2011)). EPIC is responsible for the data collection, for the quality
of non-clinical information and for anonymising the records of each patient.
It also connects medical data of patients to their post-code and environment
related indicators (THIN Data Guide, (2011)).
The database is dynamic, in the sense that data is continuously collected
and updated and patients may join and leave the database at different times.
THIN data comes from routine health data that are collected directly and
at regular intervals from the management software of GP practices using a
modem arrangement which does not interrupt the programmes running and
requires no human intervention. These data collections are then processed
to provide coded longitudinal records of demographic details, lifestyle char-
acteristics, medical events, treatment prescriptions, specialist referrals, and
any diagnostic or laboratory results occurring at an individual patient level.
These records also include information on various socio-economic markers
and environmental variables (IMS Health Incorporated (2017)).
Raw data from GP practices are anonymised and restructured so that
they can be manipulated in a simplified and flexible way. The structure of
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THIN database is defined by seven American Standard Code for Information
Interchange (ASCII) standardised files (Wijlaars, (2013)), as illustrated by
Figure 8 below.
Figure 8: Structure of the THIN database (THIN Data Guide (2011))
(1) Patient file provides data on age, sex, registration date when entering
the practice, and date when leaving the practice.
(2) Medical file consists of medical diagnoses, date of diagnosis, and loca-
tion of the event and referrals to hospitals and specialists.
(3) Prescription file provides information on all prescriptions along with the
date issued, formulation, strength, quantity, and dosing instructions,
indication for treatment for all new prescriptions (inferred from cross
reference to medical events on the same date), and events leading to
withdrawal of a drug or treatment.
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(4) Additional Health Data (AHD) file details information on vaccina-
tions and prescription contraceptives; miscellaneous information such
as smoking, height, weight, immunizations, pregnancy, birth, death,
and laboratory results.
(5) Postcode variables indicator (PVI) file list out postcode linked area
based socio-economic, ethnicity and environmental indices.
(6) Consultation file provides details on the date, time and duration of
consultation.
(7) Staff file consists of the gender and roles of staff who entered the data.
In THIN, information is coded using hierarchical Read codes, which per-
mits some standardisation of the method used to record information. In the
context of a medical database, Read codes are defined as a clinical vocabulary
used to store information on diagnostic, symptomatic and procedural data
by codes, but translated into text when accessed. In the UK, Read codes
were developed in 1982 by Dr James Read, a UK GP, and has become the de
facto standard for coding diagnoses, operations, and procedures, signs and
symptoms, and for all national minimum data sets and national statistics
for the hospital and community health services (NHS Digital (2016)). THIN
Read codes are interpreted using ancillary look up tables and dictionaries in
which medical events are coded using the Read system and prescriptions of
drugs are coded using multi-lexical code alongside a British National formu-
lary code. A large part of the codes are allocated to patients’ records by the
consulting GP practices or healthcare providers themselves or by the admin-
istrative staff such as GP practice managers (THIN Data Guide, (2011)).
4.4.2 Generalisability of the THIN database
The degree of generalisability of patient databases such as THIN, to the
general population, is important for interpreting primary care records based
research. This section discusses the representativeness of THIN data to the
UK population with regards to demographics, prevalence of medical con-
ditions, and mortality rates by reporting published comparisons of THIN
dataset to other medical databases in UK.
Blak et al. (2011) investigated the degree of generalisability of THIN pa-
tient database to the general population by comparing the THIN data to the
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National Statistics data for UK and to that of Quality and Outcomes Frame-
work (QOF) for 2006/2007. The authors concluded that THIN primary care
database represents the UK demographically since the distribution of gender
and age in THIN database is consistent with the UK population, although
THIN consisted of a slightly smaller proportion of patients aged under 25,
compared to other data sets used in the study. They also reported that
population size of aﬄuent areas is greater than deprived ones. Therefore
adjusting for gender, age and level of patients’ residential areas deprivation
level, strengthen the representativeness and generalisability of estimates of
THIN data to the UK population (Blak et al. (2011)).
Langley et al. (2011) assessed the validity of THIN data to monitor re-
gional smoking prevalence in UK by comparing THIN dataset to the General
Household Survey (GHS) between 2000 and 2008. The authors reported that
THIN prevalence data on patients smoking status, were generally found to
be highly comparable with GHS data from 2006 onwards. Loomis et al.
(2016) compared prevalence of BMI and its association with prospective risk
of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis
(NASH) from the THIN database to the Humedica EHR database in the
UK. The authors reported that age, gender, smoking status and prevalence
of diabetes were broadly similar between the two databases while the aver-
age BMI (±SD) was higher in Humedica EHR database (28.14±6.43 kg/m2)
than in THIN (26.81±5.57 kg/m2).
Crude prevalence rates for selected medical conditions in THIN are slightly
higher than those of QOF 2006/2007 dataset as reported by Blak et al. (2011).
Crude prevalence for hypertension, ischaemic heart diseases, chronic kidney
diseases and obesity was 0.1%, 0.2%, 0.2% and 0.8%, respectively, higher
than prevalences reported in QOF 2006/2007 dataset, while that of diabetes
is 0.2% higher than in QOF 2006/2007 dataset. Similarly, Gonza´lez et al.
(2009) reported that prevalence of diabetes in THIN for 1995-2005, adjusted
for gender and age, was 0.2% higher than in the Health Survey England
(HSE) database. Hippisley-Cox and Coupland (2010a) found no difference
in gender and age adjusted prevalence rate of chronic kidney diseases in THIN
when compared to that of QResearch data between 2002 and 2008.
MacDonald and Morant (2008) compared prevalence of hypercholesterolemia
and hypertension in THIN to national rates in 1998, 2003 and 2006, respec-
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tively. The authors reported a lower prevalence of hypercholesterolemia and
hypertension in THIN compared to the 1998, 2003 and 2006 national rates,
respectively, and found that prevalence rates of hypercholesterolemia and hy-
pertension from different databases, converge over time and with increasing
age. Lewis et al. (2007) used THIN data from 1986–2003 to conduct case-
control studies of associations between diseases and compare the results to
that GPRD database for the same period. The authors found significant as-
sociations between stroke with hypertension and diabetes mellitus; between
myocardial infarction with hypertension, hypercholesterolemia, obesity, and
smoking, respectively, and also reported that similar associations were ob-
tained with the GPRD database. Hence they concluded that THIN data
that are collected outside of the GPRD, appear as valid as the data collected
in GPRD.
Clegg et al. (2016) compared frailty index of ageing by taking account
of hazards of death, unplanned hospitalisation and nursing home admissions
among elderly people, aged 65–95 from the THIN dataset, to that of Re-
searchOne primary care database for the same age cohort. The authors re-
ported that proportion of patients with mild frailty index of ageing in THIN
is higher by 7% than in ResearchOne primary care database while no signifi-
cant differences were observed in the frailty index of ageing for different levels
of Townsend score of multiple deprivation, between THIN and ResearchOne
primary care database, respectively. Blak et al. (2011) reported that mortal-
ity rates of THIN patients are of similar magnitude to the UK national death
rates when adjusted for demographics and social deprivation indexes. Hall
(2009) also investigated the validity of death data in THIN by comparing
number of deaths due to suicide in THIN database to that of the General
Practice Research Database (GPRD) and concluded that records of death
information in THIN are reliably recorded.
In the light of the above discussion, although it is difficult for investigators
to obtain complete medical information on each patients in THIN database,
in general available information in THIN tends to be valid and precise enough
to develop statistical models for THIN population estimates and to extend
them to the general population in UK. Patients in THIN are representative
of UK population with regards to demographics, prevalence of major medical
conditions and mortality rates, adjusted for gender and level of deprivation.
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4.5 Chapter Summary
In this chapter, study designs and sources of data used for epidemiological
research, are presented and discussed with respect to their strengths and
limitations. Additionally a review of primary care databases in UK is carried
out and their eligibility for research purposes is discussed. In general, all the
primary care databases in UK are comparable to each other when patients
are matched on gender and age. For this research, a retrospective cohort
matched study design is used to analyse longitudinal data from the THIN
primary care database.
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5 Data Description
5.1 Data extraction
This section details the step by step procedure involved in identifying relevant
patient records from the THIN database, stored at the University of East
Anglia data depository, for the purpose of this study. It covers definition of
follow-up time for all patients, data manipulation, identification of cases who
had a total hip replacement (THR) and the selection of controls to match
with cases.
Description of follow-up time
Before leaving the GP practice computer system, patients data are com-
pletely anonymised. However, encrypted identifiers, that are unique to each
patient and each GP practice are available. This allows to link patients to
their GP practices and thus determines the duration of the period they are
registered with their GP. In general, patients in THIN are followed from the
latest of the following dates: (1) Registration date of the patient with the
GP practice; (2) Date on which the practice started to fully use their com-
puter system to record patients’ diagnoses and treatment prescriptions (also
referred as Acceptable Computer Usage, or ACU); and (3) Date by which
computer generated records on patients’ death become fully valid.
The importance of having ACU records arises from the fact that when a
GP practice first starts to use a computerised system to record data instead
of traditional paper records, there is a time delay for the computer recording
system to be fully adopted by the practice and its staff. Therefore records
from this initial period are likely to be incomplete, leading to biases and in-
correct inferences from statistical analyses. To avoid such problem, the time
point at which a GP practice fully utilises its computer recording system
is determined based on empirical evaluation of the quantity of each type of
record.
For a GP practice to have an acceptable ACU level, it needs to have
all of the following records, for each patient, per patient year (McBride
et al. (2010)); (1) an average of at least one medical record, (2) two pre-
scription records, (3) one additional health data record. Dated records of
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patients’ deaths in the practice were assumed to be at an acceptable ACU
level, based on the ”Acceptable Mortality Rate” definition provided by the
database provider (Maguire et al. (2009)). The definition classifies a practice
records as ACU if the observed number of deaths within the practice is con-
sistently within 30% of the total expected number of deaths for that period.
In this study, the complete investigation period for patients selected as
cases starts on the date they underwent a total hip replacement procedure
until July 2011 (date at which the latest ACU records in THIN dataset
available at the University of East Anglia, are provided). Other ending points
for the investigation period include (1) transfer out of patients to another GP
practice and (2) death of patients. When patients are transferred out to either
a GP practice within THIN or to another GP practice not registered with
THIN, they are lost to follow-up. Thus their transfer out date is taken as the
end of their investigation period. Death, which is the main event of interest
in this study, also ends the follow-up period of a patient. The time-line in
Figure 9 displays the investigation period for cases in this study.
Figure 9: Time-line of follow-up of patients
5.1.1 Identification of Cases
A patient in THIN, born between 1920 and 1940 inclusive, is classified as a
case for the purpose of this study if: (1) the patient underwent a total hip
replacement surgery (THR) while the patient is registered with an active GP
practice with ACU type records and valid time of death as described in the
previous section; (2) the medical records of the patient have been accessed
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at least once within the last ten years before their THR procedure date.
Patients in THIN with these criteria are classified as THR cases ; i.e. these
represent individuals who underwent a THR procedure during their lifetime.
Medical events such as THR are coded in THIN by Read codes and thus
getting the appropriate Read codes for THR procedure is essential to identify
THR cases. From the literature review carried out in Chapter 2, a list of the
types of THR procedures was built. It consists of Cemented, Uncemented,
Hybrid and Reverse Hybrid THR procedures. In the THIN database, these
THR procedure types are coded and can be identified by medical Read codes
provided by the THIN database provider data dictionary (THIN Data Guide,
(2011)). The Read codes for THR procedures selected to identify THR cases
for this study, are listed in Table 27 in Appendix A. 40 different Read codes
are identified in THIN and can be used to find patients who underwent
a THR procedure, while they are registered with a GP practice in THIN.
All of these Read codes represent specific types of THR procedures. 21
Read codes correspond to cemented THR procedures, 11 to uncemented THR
procedures, 6 are classified as other types of THR procedures and 2 represent
hybrid THR procedures, respectively (See Table 27 in Appendix A).
THR cases exclusions in the study
There is a list of patients who underwent THR procedures but were excluded
from this study for the following reasons:
(1) This study investigates only unilateral THR procedure. Therefore pa-
tients with bilateral THR surgery are not included in this study. Sur-
vival analysis of these patients would be different due to the presence of
multiple number of surgeries. Bilateral THR procedures are identified
using the same Read codes from Table 27 in Appendix A. Patients
with bilateral THR procedures can be identified in THIN by looking
up the number of THR procedures they underwent. Patients with both
hips replaced, either under one surgery or on two separate events, have
two medical records of THR procedure and are not included into THR
cases in this study.
(2) One of the objective of the study, as discussed in Chapter 1, is to anal-
yse the impact of degenerative and chronic conditions such as arthritis
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on survival of THR cases after their THR procedure. Patients who un-
derwent a THR procedure as a consequence of hip fracture are excluded
from this study. This is because the causal effect of THR procedure
being investigated in this study is different for patients who had a hip
fracture. In THIN, patients with hip fracture can be identified using
the Read codes listed in Table 27 in Appendix A. These Read codes
describe an event of hip fracture or a history of rehabilitation treatment
given to the patient after THR surgery due to hip fracture.
The flowchart described in Figure 10 displays the total number of THR
procedures identified in THIN database and patients excluded in this study.
Figure 10: Identification and exclusions of THR cases in study
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5.1.2 Identification of controls
Patients in THIN, born between 1920 and 1940 inclusive, are classified as
controls in the context of this study if: (1) their medical history is free of any
type of THR procedures while they are registered with an active GP practice
with acceptable level of ACU patient records; (2) the medical records of
the patient have been accessed at least once within the last ten years of
registration with the GP practice and (3) the patient is alive at the time
of THR surgery of the case with which the patient is matched as control.
Initially all patients with these criteria in THIN are grouped in a set called
A. Not all patients of set A will be eligible to be selected as controls for THR
cases because of the matching criteria, defined below, in the context of this
study. The next stage involves a matching process between THR cases and
patients from Set A, based on three different factors, explained below. To
ascribe patients from Set A as controls, THR cases are matched to controls
on:
• Sex : Mortality rate is different for males and females (Shaw (2005)).
• Year of birth category : Taking the year of birth category of the pa-
tients into consideration will help to account for differences in medi-
cal advancements with time (Langholz and Clayton, (1994)). In this
research, patients are grouped by their year of birth as follows: Cate-
gory 1, 2 ,3 and 4, respectively for patients born between 1920–1924,
1925–1929, 1930–1934 and 1935–1940, respectively.
• GP practice: Individuals within the same GP practice are similar to
each other in many ways; they reside in the same area and receive
treatments from the same GP practice. Hence they are likely to be
exposed to the same factors and risks and thus they all share similar
level of frailty in health (Shaw, (2005)). This is an important aspect
that needs to be accounted for during the matching process.
The last step in this matching process is finding the optimal matching
ratio between exposed (cases) and unexposed (controls) patients that will
maximise the efficiency of the statistical analysis of the data. According to
Raboud and Breslow (1989), a matching ratio of 10 is the maximum optimal
ratio. Nevertheless the efficiency of statistical analysis does not change sig-
nificantly for ratios between 5 and 10 inclusive (Raboud and Breslow (1989)).
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Therefore 5 controls are assumed to be the optimal number of matching con-
trols per cases as reported by Hennessy et al. (1999) as well. A matching
ratio of 5 between THR cases and controls is selected for this study.
The matching process of THR cases to controls in Set A is carried out
using a programming language called Python which has built-in functions
for random selection without replacement. For each patient in the set of
THR cases, five active patients of similar gender, GP practice, year of birth
category and who are alive at time of surgery of the THR case, are randomly
selected without replacement as matched controls. Matching randomly with-
out replacement ensures that each THR case is matched to 5 distinct controls;
i.e. the same control cannot be matched to more than one THR case. As
an illustrative example, consider a male THR case, with ID ”aa01”, born
between 1920-1924 from GP practice ”X11”. Based on the above-mentioned
matching process, ”aa01” will be matched to five different male controls
born between 1920-1924 and who are registered with GP practice ”X11” at
surgery time. Finally these five selected controls should be alive at the time
of surgery of case with ID ”aa01”.
5.2 Data Set Description
This section describes the data set extracted from THIN database for the
purpose of this study. The demographic, medical and prescription histories
of THR cases and controls are detailed in the following format and order: for
each variable being reported for the patients, (1) a definition of the variable
in the context of this study, (2) definition and Read codes of the variable
in THIN data dictionary and (3) descriptive statistics such as frequency of
patients and prevalence of each condition among the study population.
5.2.1 Cases and controls
Number of THR cases and matched controls
17, 157 patients from the THIN dataset were found to undergo a unilateral
THR procedure and satisfy the definition of a THR case as presented in
Section 5.1.1. The medical records of these patients include events that are
coded by one of the Read codes from Table 27 in Appendix A. Similarly
85, 785 patients from Set A (described in Section 5.1.2) are selected based
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on the matching process defined in Section 5.1.2 as controls. Their medi-
cal records in THIN dataset do not include Read codes from Table 27 in
Appendix A. These 85, 785 patients satisfy the definition of a control in the
context of this study, as presented in Section 5.1.2. The selected 17, 157 THR
cases and 85, 785 matched controls are all registered with active GP practices
with ACU type records and that code valid time of death. In addition, the
medical records of these selected THR cases and their matched controls have
been accessed at least once within the last ten years before the relevant THR
procedure date.
Comparing THR cases to controls
THR cases were matched to five different controls on the GP practice of the
patient, their year of birth category and gender. In this section, a compari-
son between the number of patients across each of the matching factors for
cases and controls is provided. The proportion of THR cases and matched
controls classified as being male or female is given in Table 32 in Appendix
B. The frequency distribution is 38% males and 62% females among the
selected cases and controls, showing that THR procedures are more common
among female patients, compared to males. The ratio of males to females is
the same for cases and matched controls as gender is employed as a matching
factor in this study.
THIN dataset at the University of East Anglia consists of patients born
between 1920 and 1940 inclusive. However full dates of birth are not available
in THIN dataset for adult patients to protect their anonymity. Only the year
of birth (YOB) for each patient is allocated in THIN (THIN Data Guide,
(2011)). To increase the efficiency of the matching process, i.e. to ensure
that enough controls are available to match cases to controls, the YOB of
the patient was categorised into 4 different categories, each of 5 years dura-
tion; namely 1920-24, 1925-29,1930-34 and 1935-40.
Table 32 in Appendix B shows the number of patients in each category
of YOB for THR cases and controls. Number of male cases differs by a small
margin across all categories of YOB with Category 1930-34 providing the
maximum number of THR male cases. Contrastingly, the frequency of fe-
male cases is highest in 1920-24 and decreases across each category of YOB.
Exactly the same trends for both genders, are obtained for matched controls’
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YOB category as the latter is utilised as a matching factor.
GP practices in THIN can be differentiated from each other via their
unique identifier, referred to as pracid. Identified THR cases and matched
controls are registered with 460 different active GP practices, spread across
the UK. Male cases are spread among 445 distinct GP practices while female
cases are distributed among 456 different GP practices. Eleven GP practices
in THIN provide only female THR cases selected for this study.
GP practice is one of the matching factors to identify 5 different controls
for each THR case (See Section 5.1.2). Therefore, a constant matching ratio
of 5 (referred as MR) is expected across GP practices when comparing the
number of THR cases to matched controls. MR’s across the GP practices are
computed and displayed in Table 31 in Appendix B. MR’s are constant and
equal to 5 across all GP practices, showing a balanced ratio of population
size between the exposed patients and the unexposed ones.
In addition, the ages at time of surgery for THR cases and controls are
also compared to ensure that the exposed population is matched to selected
controls that belong to the same age category at the time of the THR surgery.
The patients are grouped by the GP practice and the mean age at surgery
of THR cases and controls respectively, are determined for each of the 460
different GP practices. Table 31 in Appendix B provides the mean age at
surgery time for THR cases and matched controls, respectively, across the GP
practices. The minimum and maximum differences in age at THR surgery,
between THR cases and matched controls, are −0.981 and 0.977 years re-
spectively. This shows that THR cases are matched with controls whose ages
at surgery time, are on average, within one calendar year or less.
5.2.2 Patient demographics
Table 32 in Appendix B describes the distribution of cases and controls across
gender and their year of birth category. 38% of 17,157 THR cases are male
and 62% are female. This shows that the prevalence of THR procedures is
more common among female patients. The National Joint Registry (NJR)
dataset (Set (2008)), which records data on joint procedures across England,
Wales, Northern Ireland and the Isle of Man, also reported that among pri-
mary THR patients, 40% were male and 60% were female (NJR (2016)).
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Therefore the extracted data from THIN dataset, reflects similar pattern to
the NJR dataset, in respect to the ratio of male cases to female cases.
Figure 11 shows the distribution of the number of THR male and female
cases by year of birth. The number of male THR cases increases for each
year of birth between 1920 and 1932 inclusive and then decreases between
1933 and 1940 inclusive. The number of female cases shows a decreasing
trend between 1920 and 1940 inclusive. THR cases are also categorised by
year of birth category as explained in Section 5.2.1. Table 32 in Appendix B
shows a trend similar to the one displayed by Figure 11 for number of male
and female THR cases across each year of birth category.
Figure 11: Number of patients across years of birth
5.2.3 Variables Related to Total Hip Replacement Procedure
In this section, the following variables are described in the context of this
study: (1) age at surgery time (2) type of THR procedures and (3) revi-
sion surgery after THR procedure. The numbers and percentages of patients
across the levels of these variables are reported in Table 33 in Appendix B.
Age group 65-74 consists of the highest number of THR cases (45.6% for
males and 42.6% for females) while only 2.7% of males and 2.6% of females
were from the age group 18-54 at surgery, respectively. Proportion of pa-
tients aged above 85 at surgery time is also low (3.5% for males and 4.9%
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for females).
According to the 2016 annual report from the National Joint Registry
(NJR (2016)), 81.8% of male and 84.2% of female patients who underwent
a THR procedure are aged between 54 and 84 years, inclusive at time of
surgery (versus 93.7% for male cases and 92.3% for female cases in this re-
search). The report also shows the proportions of males aged 55-64, 65-74
and 75-84, are 25.0%, 34.6% and 22.1%, respectively, versus 17.5%, 45.6%
and 30.6%, respectively, for male THR cases. Similarly, the NJR 2016 report
estimates that the percentage of females aged 55-64, 65-74 and 75-84, are
20.4%, 35.5% and 28.2%, respectively, versus 13.7%, 42.6% and 36.0%, re-
spectively, for female THR cases in this study. Younger age groups in THIN
have a lower number of THR cases than in NJR dataset while proportion
of THR cases aged 55 years or more, is higher in the THIN dataset than in
the NJR one. These differences show that more patients in THIN underwent
their THR procedure at a higher age than patients from the NJR dataset.
The types of fixation techniques identified in THIN are listed in Table
27 in Appendix A and are further classified into cemented, uncemented and
other types. Category other types include THR procedures described as ei-
ther Others or Unspecified type or Hybrid procedure in THIN. Table 33 in
Appendix B displays the number and percentages of THR cases across the
different types of procedures. 45.1% of male and 44.4% of female cases under-
went uncemented THR procedure while 36.3% of male and 37.5% of female
cases underwent cemented THR surgery. According to the 2016 annual re-
port from the UK National Joint Registry (NJR (2016)), by the end of 2015,
31.0% of THR procedures were cemented, 39.3% were uncemented and 29.7%
were either hybrid or described as other types of THR. In this study, pro-
portion of cases who underwent cemented, uncemented and hybrid or other
type of THR procedure is equal to 37.1%, 44.6% and 18.3%, respectively.
Hence a higher percentage of cases in this study underwent cemented and
uncemented hip replacement.
Types of fixation technique employed depends on the age of the patients
at surgery time. According to NJR (2016), uncemented procedures are more
prevalent among younger patients aged 70 or less while cemented procedures
were more common than uncemented ones among older patients, aged 70
year or more. This is because, uncemented procedures have a higher revision
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surgery rates than other procedures and thus more older patients prefer to
undergo cemented or hybrid THR procedures (NJR (2016)). Figure 12 below
shows the variation in number of THR procedures for each type of fixation
methods across gender and age groups. It displays a similar trend explained
by the NJR (2016) report. Among both males and females, uncemented
procedures are more prevalent than cemented and other types of THR for
patients aged between 18 and 74, inclusive, while cemented procedures are
more common among elderly female cases.
Figure 12: Proportion of THR procedures across each type of fixation methods and
age groups
With an increasing number of THR procedures over the last two decades
in UK, the mechanical devices which form the total hip prosthesis inevitably
fail after surgery, in some patients. The latter therefore require a revision
surgery to remove either the failed implant or any bone loss or soft tis-
sue damage. Post-THR revision surgery contributes to an increased risk of
death since it adds more surgical complications to the patients’ medical his-
tory. Type of revision surgery varies at an individual level, depending on the
cause of the implant failure (Berry et al. (2012)).
In THIN, Read codes for revision surgery can be identified in patients’
MED file and are listed in Table 28 in Appendix A. Table 33 in Appendix B
shows the proportion of THR cases who underwent a revision surgery after
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their THR procedure. 1.9% of male and 1.6% of female cases underwent a
revision surgery. According to the 2016 annual report from the UK National
Joint Registry (NJR (2016)), by the end of 2015, 2.6% of patients in England,
Wales, Northern Ireland and Isle of Wight who underwent a primary THR
procedure, had to undergo a revision surgery. Hence the proportion of cases
in this study who underwent a revision surgery (1.8% of cases) is marginally
smaller than the reported proportion of revision surgery in the NJR dataset.
This difference between the NJR dataset may be due to loss of follow-up of
patients transferring out to new GP practices after undergoing their THR
procedure and thus leading to under reporting of revision surgeries in THIN.
5.2.4 Post-Code Variable Indicators
Post-Code Variable Indicators (PVI) are Post-Code related indices derived
using social, ethnicity and environmental factors of the patients’ residential
ward. PVI’s have been added to the THIN database by UK CSD Medical
Research team using the 2001 national survey carried out by the Office for
National Statistics (ONS) in UK (THIN Data Guide (2011)). However PVI’s
are only available for patients who reside in England, Wales and Northern
Ireland. THIN patients from Scotland, do not have records of PVI’s, and thus
their PVI variables are described as unknown. The PVI’s for the residential
ward of each patient from England, Wales and Northern Ireland are stored
in the Demographic file in THIN and can be classified as follows:
• Ethnicity classification
• Urban-Rural classification
• Long-term illnesses classification
• Pollution classification
Each of the above PVI scores are provided in THIN database, split in the
form of quintiles. The scores of each PVI variable were categorised into five
groups of equal size, numbered 1 to 5, to indicate the level of ethnicity, pol-
lution and deprivation in the patients’ residential ward. Quintile 1 refers
to the residential ward with minimum PVI score while quintile 5 refers to
residential wards with the maximum PVI score.
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Ethnicity in the patients’ residential ward is reported by the variables
described below. It is important to account for ethnicity in survival anal-
ysis because mortality rate differs across different ethnic groups. Wild and
McKeigue (1997) showed that mortality across different ethnic backgrounds
varies in England and Wales and also reported that prevalence of cardio-
vascular diseases and cancer differ for different ethnic groups. Gruer et al.
(2016) compared life expectancy across different ethnic groups in Scotland
and reported longer life expectancies for individuals belonging to such ethnic
groups as Asian or Mixed ethnic background, compared to White Scottish
population.
• White ethnicity : Proportion of population in the residential ward clas-
sified as White
• Black ethnicity : Proportion of population in the residential ward clas-
sified as Black
• Asian ethnicity : Proportion of population in the residential ward clas-
sified as Asian
• Mixed ethnicity : Proportion of population in the residential ward clas-
sified as Mixed
• Other ethnicity : Proportion of population in the residential ward clas-
sified as other ethnicity besides White, Black, Asian or Mixed
Table 34 in Appendix B describes the proportion of THR cases and
matched controls across the quintiles of ethnicity. Among all types of eth-
nicity (White, Mixed, Asian, Black and Others), the distribution of THR
cases is close to that of matched controls. Therefore it can be assumed that
the population of THR cases belongs to a similar ethnic background as their
matched controls in this study.
Patients’ residential wards are also described in THIN according to their
level of population. Residential wards with population size exceeding 10,000
are grouped as being urban while a ward with a population size less than
10,000 is classified as a rural area. Residential wards with sparse number of
inhabitants are labelled as village. A full description of these classifications is
provided by the Office for National Statistics 2004 national survey (Office for
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National Statistics (2004)). Table 34 in Appendix B shows the number and
percentage of THR cases and controls whose residential area is categorised
as either Urban, Rural or Village. 63% of THR cases in this study were from
an urban area while 14% and 9% of THR cases lived a rural area and village,
respectively. No Urban-Rural classification were available for 13% and 16%
of THR cases and controls, respectively, and their residential wards’ Urban-
Rural description were unknown in THIN database.
Long-term Illnesses (LLTI) is a term ascribed to individuals who suffer
from long-term physical health conditions such as diabetes or coeliac dis-
ease and they are the most frequent users of health care services. With an
increase in life expectancy, the number of people living with a long-term
condition grows and therefore impacts on the individuals themselves, their
families and their health care services. Hence it is important to account for
the proportion of individuals suffering from LLTI during survival analysis
(Lloyd and Heller, ( 2011)). In THIN, LLTI describes the level (in quintiles)
of population with a limited long-term illness in residential wards. Table 34
in Appendix B shows the distribution of THR cases and controls living in a
residential wards with different levels of LLTI. Across each quintile of LLTI,
the distribution of THR cases is close to that of matched controls, showing
that THR cases and matched controls come from similar residential areas.
The residential wards of 13% of THR cases and 16% of matched controls
were not available in the THIN database and are classified as Unknown.
THIN database also provides information on the level of air pollution
by residential ward. Air pollution level describes the quintile estimates of
the mean level of Nitrogen Dioxide (NO2), Nitrogen Oxides (NOX), Sulphur
Dioxide (SO2) and Particulate Matter (PM) in the residential wards. Level
1 pollution represents the areas with the lowest level of pollution while level
5 corresponds to the maximum level of pollution in that residential area.
Nevalainen and Pekkanen (1998) and Pope et al. (2009) demonstrate that
level of pollution significantly affects life expectancy.
Table 34 in Appendix B shows the distribution of cases and matched
controls living in residential wards with different levels of pollution. It can
be observed that 39% of THR cases (versus 37% for controls) are from a
residential area where the level of NO2 is 4 or 5, 40% of THR cases (versus
38% for controls) are from a residential area where the level of PM is 4 or
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5, 36% of THR cases (versus 34% for controls) are from a residential area
where the level of SO2 is 4 or 5, 39% of THR cases (versus 37% for controls)
are from a residential area where the level of NOX is 4 or 5. Overall, 53%
of THR cases (versus 51% for matched controls) are from a residential area
where there is maximum pollution (Quintiles 4 or 5 for NO2, PM, SO2 or
NOX).
5.2.5 Measures of Deprivation
An increasing availability of administrative data in the UK since the 1970’s
has led to the development of a number of definitions and measures of depri-
vation across the UK. Deprivation is defined, in general terms, as the ease of
access of an individual to resources and distribution of wealth in the society
as a whole (Cook (2000)). In THIN database, three different measures of
deprivation are provided for all patients in the UK; namely Townsend Score,
index of Multiple Deprivation and Mosaic Score, respectively. In this sec-
tion, the distribution of patients by these three different deprivation indices
is provided.
Townsend Score
Townsend score provides an index for the level of deprivation of the patients’
residential ward by combining the following variables of each residential area,
(THIN Data Guide (2011)):
• The proportion of residential accommodation having no access to a
public transport.
• The amount of households that are rented and not occupied by the
owners themselves.
• The percentage of residences that are overcrowded
• The unemployment rate of the active population, aged 16-74 years old
inclusive
The above variables were used by the Office for National Statistics (ONS)
in UK (THIN Data Guide (2011)) and combined into the Townsend score.
The higher the score, the more deprived is the residential ward. Calculated
Townsend scores are provided in quintiles in THIN dataset, with quintile 1
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representing the least deprived area while quintile 5 is associated with the
most deprived area. Data on Townsend Score are available in THIN for all
patients residing in the UK.
Table 35 in Appendix B shows the proportion of THR cases and matched
controls living in residential areas where the levels of deprivation (measured
by Townsend Scores), are rated from level 1 (least deprived) to level 5 (most
deprived). 28%, 22% and 17% of THR cases, respectively (versus 25%, 20%
and 17% for controls, respectively) are from a residential area where the
Townsend score is 3 or less. Table 35 also shows that the proportion of
THR cases decreases as the level of deprivation increases. Only 13% and 7%
of THR cases are from the highly deprived areas (level 4 and 5 Townsend
Scores). This indicates that there are fewer individuals in the most deprived
areas who underwent THR procedures, compared to the more aﬄuent areas.
13% of THR cases and 16% of matched controls have unknown Townsend
score in THIN dataset.
Index of Multiple Deprivation
Index of multiple deprivation (IMD) is a score attributed to a residential area
to describe its level of socio-economic status. It is a combination of several
index domains which measures different types or dimensions of deprivation
within a residential area (English indices of deprivation (2015)). In UK, seven
aspects of deprivation, listed below, are considered in order to estimate the
IMD of a residential ward.
• Household income
• Employment
• Health deprivation and disability
• Education skills and training
• Barriers to housing and services
• Crime rate
• Living environment
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The above variables were used by the Office for National Statistics (ONS)
in UK (THIN Data Guide (2011) to calculate IMD scores that are provided
in quintiles in THIN dataset, with quintile 1 representing the least deprived
area while quintile 5 is associated with the most deprived area. Table 35
in Appendix B shows the distribution of THR cases and matched controls
across the different quintiles of IMD score. For both THR cases and matched
controls, the biggest proportion of patients are from an area where the IMD
score is the lowest (Quintile 1). The percentages of THR cases and matched
controls decreases as the residential areas’ IMD score increases. 2% of THR
cases have unspecified level of IMD in THIN.
Mosaic Score
Mosaic is a UK based geo-demographic classification system that was devel-
oped by a private company called Experian (Experian Ltd (2004)) as a tool
for the consumer segmentation and marketing. It is a tool that enables busi-
nesses to get a better insight of their consumers’ demographics and lifestyles,
thereby allowing businesses to target the right customers at the right lo-
cations. Mosaic is a post code based classification system that categorises
individuals’ households into 15 major socio-economic groups, which can be
further divided into 67 sub-groups as described in Table 29 in Appendix 27.
These classifications occur at the level of the full UK postcode. Therefore
all individuals living in the same accommodation, are assumed to be in the
same Mosaic category (Experian Ltd (2004)).
Table 35 in Appendix B displays the proportions of THR cases and
matched controls across the different Mosaic Groups described in Table 29
in Appendix 27. 35% of THR cases (versus 34% for matched controls) are
from areas where the residents largely belong to the most aﬄuent and most
wealthy families who work in high status positions and who live in privately
owned large detached accommodation (most aﬄuent Mosaic group, namely
A, B and C). 15% of THR cases (17% for controls) are elderly singles or be-
long to mature families who reside in rural areas where most residents own
inexpensive homes and enjoying a comfortable retirement (Mosaic group D,
E and F). 18% of cases (20% for controls) are from areas where most of the
residents belong to relatively young families who have children and aspiring
to become home makers through their own limited resources (Mosaic group
G, H and I). 23% of THR cases (versus 21% for matched controls) are elderly
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individuals relying on financial support from their local government to rent
low cost accommodation in urban rental locations or elderly home owners of
inexpensive homes whose mortgage is nearly paid off (least aﬄuent Mosaic
group, namely J, K, L, M, N and O). The remaining 9% of THR cases and
8% of matched controls had no Mosaic group description in THIN dataset.
5.2.6 Lifestyle variables
Smoking status
Information related to the smoking status of patients in THIN is recorded
in either the Demographic (DEM) or Medical (MED) or Addiditonal Health
Data (AHD) file. The DEM file consists of the recent smoking status record
while the MED and AHD files contain smoking status records that have
been collected, at several time points, during the period the patients were
still active in THIN database. The smoking status of patients in the THIN
database is defined as follows:
(1) Current smoker is ascribed to cases whose closest smoking status record
is prior to their THR surgery date.
(2) Ex-smoker is ascribed to cases’ whose closest smoking status record
before their THR surgery date, is reported as non-smoker but also
having previous records of current smoker or ex-smoker or whose last
record is classified as ex-smoker.
(3) Non-smoker for cases who do not have any records classified as being
current smoker or ex-smoker at any time and a smoking status record
of non-smoker.
(4) For matched controls, their smoking status is determined in the same
way as defined for THR cases in (1)—(3).
Table 36 in Appendix B displays the proportion of smokers, ex-smokers
and non-smokers for cases and matched controls, prior to the relevant THR
procedure data. Proportions of patients who were ex-smokers and smokers,
respectively, prior to their THR procedure, are higher among males than
females for cases and matched controls across all age groups. The latest
records in the data extracted from THIN for this study are dated until July
2011. According to UK (2016), estimated average prevalence of smokers in
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UK as at the end of 2012 was 22.3% for adults aged 64 years or less (versus
9.9% for cases and 7.1% for matched controls) and 10.1% for adults aged
more than 64 years (versus 13.4% for cases and 11.9% for matched controls),
respectively.
Body Mass Index
Body mass index (BMI) determines the healthy weight of an individual ac-
cording to his/her body height. BMI is determined by the ratio of the weight
of a person, in Kilograms, to the square of his/her body height, in metres.
The resulting ratio is then grouped into different categories as described by
the table below, to classify individuals as being underweight, normal weight,
overweight and obese, according to the National institute for Health and
Clinical Excellence (NICE) guidelines (Linsley et al., (2011)).
BMI Type BMI
Underweight <18.5
Normal 18.5 - 24.9
Overweight 25.0 - 29.9
Obese >30
Classification of BMI in UK (Linsley et al. (2011))
In THIN database, the most recent records of weight (in Kilograms),
height (in metres) and BMI measurements, for each patient, are provided in
the DEM file, while historic records of weight, height and BMI measurements
are available in the AHD files. The latest weight and height measurements of
THR cases and matched controls before their THR procedure, are extracted
from the AHD files. Their BMI are calculated and then classified using the
categories described in the table above.
86% of THR cases and 75% of matched controls, respectively, have a
measurement of weight and height, dated before their THR procedure date.
4% of 17,157 THR cases and 15% of 85,785 matched controls respectively,
have no records of height measurements before THR surgery date, but had a
recorded measurement of weight before the surgery. For these patients, their
latest height measurements from the DEM file are used to estimate their
BMI. Since all patients were adults at surgery time, their height measure-
ment at THR surgery time, can safely be assumed to be close to that of the
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most recent record in the DEM file in THIN. 10% of THR cases and 9.6% of
matched controls, respectively, do not have any records of weight measure-
ments prior to THR procedure date. Therefore the BMI of these patients
before THR procedure cannot be determined and is classified as unknown.
Table 37 in Appendix B shows the distribution of THR cases and matched
controls according to their BMI classification by age group prior to their THR
surgery time. Distribution of overweight cases and controls is marginally dif-
ferent across each age groups for each gender. Proportion of male cases
(33.2%) and matched controls (34.5%) who were overweight prior to their
relevant THR surgery is higher across all age groups than female counter-
parts. Prevalence of obesity among female THR cases is higher than that
of male THR cases and female controls prior to their THR surgery, across
all age groups. Proportion of obesity among male THR cases is marginally
higher to that of male controls across all age groups, except for THR cases
aged 75 years or more (prevalence of obesity=17.7% versus 10.3% for male
controls).
According to Health Survey for England (2015), prevalence of obesity by
the end of 2012 was estimated at 24.7% in England, 27.1% in Scotland and
23% for both Wales and Northern Ireland, respectively. This amounts to
an estimated mean prevalence of 24.5% for obesity in UK. In this dataset,
proportions of THR cases and matched controls who are obese prior to their
relevant THR surgery are 30% and 15%, respectively. Obesity is more preva-
lent among THR cases than in the UK on average while that of matched
controls is significantly lower than the estimated UK average prevalence of
obesity in 2012. Lower estimated prevalence of obesity among controls may
be due to missing records of BMI that are dated prior to the relevant THR
surgery time, while a higher prevalence among THR cases may be due to
obesity itself creating the need for THR procedure.
According to Carl Baker (2017) statistics on obesity for England only,
men are more likely to be overweight or obese than women. 68% of men
were overweight or obese in 2015 (versus 50% for male cases and 43% for
controls) compared with 58% of women (versus 68% for female cases and 50%
for controls). These proportions vary by age groups; reported prevalence of
overweight and obesity is between 71% and 75% among all age groups from
45 to 84 (versus 57% for cases and 42% for matched controls, aged between
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45 and 84, respectively). Therefore prevalence of overweight and obesity in
the dataset extracted is lower than the average prevalence of overweight and
obese individuals in England alone.
5.2.7 Medical Variables
In this section, variables describing the medical profiles of THR cases and
matched controls are reported. The list of medical variables include Type 2
diabetes mellitus (DM), cardiovascular diseases such as angina, myocardial
infarction (MI) and stroke, osteoarthritis (OA), rheumatoid arthritis (RA),
bone mass density (BMD), chronic kidney disease (CKD), hypertension (HP)
and hypercholesterolaemia (HC). For each of these variables, the following
items are provided in this section: (1) definition of each medical variable in
the context of this study and (2) description of the prevalence of each vari-
able among THR cases and matched controls.
As mentioned in Chapter 1, one of the objectives of this study is to identify
potential medical conditions before THR surgery, that affects mortality risk
after THR procedures. Therefore all the medical variables described in this
section are dated before the THR surgery of THR cases while for controls, the
medical variables are dated before the THR procedure of their matched THR
cases. In THIN, medical conditions are coded and comparable to that of the
International Classification of Disease 10th revision (ICD–10), provided by
ICD (2015). The list of Read codes for the selected medical conditions in
this study is based on literature review provided in Chapter 2 and are given
in Table 28 in Appendix A.
Diabetes Mellitus
The human body includes of a number of systems and pathways that function
in synchrony to create and maintain a healthy state of physiology. One of
these systems is the ability of the human body to maintain a stable state (also
referred as homoeostasis). Any form of homoeostasis instability can cause
injury or pathological state in various organs. Diabetes (DM) is a condition
where the human body loses its homoeostatic ability to regulate the glucose
level in the blood stream because of a lack of insulin hormones in the body
(Ahmad (2013)). DM can be classified into 4 major types (Ahmad (2013)):
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• Type 1 diabetes : Patients who are diagnosed with an absolute insulin
deficiency condition
• Type 2 diabetes : Patients whose body does not produce enough insulin
or whose body’s cells are inert to insulin
• Gestational diabetes mellitus : Patients diagnosed with DM in the sec-
ond or third trimester of pregnancy
• Other types : Patients diagnosed with specific type of DM due to other
causes such as monogenic diabetes syndromes, diseases of the exocrine
pancreas, and drug- or chemical-induced diabetes such as in the treat-
ment of HIV/AIDS
The risk of developing type 2 DM increases as individuals grow older, es-
pecially after the age of 45 probably because people tend to exercise less,
lose muscle mass and gain weight as they age (Sharma et al., 2016). In this
study, 99.7% of cases and matched controls were aged more than 45 years
at the time of their relevant THR surgery. Hence only type 2 DM records
are extracted for cases and matched controls. 158 male cases and 116 female
cases were diagnosed, respectively, with type 1 DM before their THR surgery
and were excluded from this study.
Table 38 in Appendix B displays the proportions of cases and matched
controls diagnosed with type 2 DM prior to the relevant THR surgery. 6.3%
of female cases (versus 6.8% for female controls) and 8.3% of male cases (ver-
sus 8.8% of male controls) had type 2 diabetes prior to their THR procedure.
Hence prevalence between cases and controls differ by gender for all patients.
Comparing age groups for cases and controls for each gender, prevalence of
type 2 DM increases with age at time of THR surgery for all cases and con-
trols.
Sharma et al. (2016) estimated prevalence of type 2 DM using primary
care records in THIN database, dated between 2000 and 2013, inclusive, in
the UK. The authors estimated the prevalence of type 2 DM in the UK
as 5.32% (versus 7% for cases and 7.5% for controls in this study), with
male type 2 DM being more prevalent than female. They also reported that
prevalence of type 2 DM increases with age, with the age band 60–69 years
having the highest crude percentage of 37.7% for type 2 DM whereas in this
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study, prevalence of type 2 DM is more prevalent among patients aged 75
years or more, for both cases and matched controls.
Chronic Kidney Disease
The human kidney is a complex organ, made up of million of nephrons con-
nected together by interstitial tissues. A nephron is made up of a glomerulus
(blood vessel) and a renal tubule. Supply of blood to the kidney occurs via
the glomerulus arteriole, which acts as a filter for the blood plasma. The
rate at which the human kidney can filter the blood plasma entering via the
glomerulus arterioles is known as the glomerular filtration rate (GFR) and it
depends heavily on the adequacy of the blood supply to the kidney and the
durability of the glomerular capillary blood vessels. GFR is used to estimate
the quality of an individual’s kidney health (Lewis, (2012)).
Kidney is a vascular organ and therefore it is vulnerable to diseases that
affect blood vessels - for example, hypertension and diabetes. These condi-
tions impact negatively on the kidney function by causing a process called
sclerosis. During this process, the blood vessels are hardened and thickened,
preventing normal blood flow to the kidney and thereby stopping filtration
of the blood plasma. Sclerosed glomerulus can never be recovered. Hence
an individual will exhibit a reduced GFR as more glomerular vessels are
sclerosed. Figure 13 below illustrates the mechanism for the progression of
Chronic Kidney Disease (CKD) as a result of self-damaging reduction in the
number of functioning glomeruli (Lewis, (2012)).
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Figure 13: Mechanism for progression of CKD as a result of a reduction in number
of functioning glomeruli due to sclerosis (Lewis, (2012))
CKD manifests differently depending on the amount of sclerosed glomeru-
lar blood vessels. The different stages of CKD can be classified as follows
(Lewis, (2012)):
• CKD Stage 1 (GFR>90 mL/min)
• CKD Stage 2 (GFR = 60-89 mL/min)
• CKD Stage 3a and 3b (GFR = 30–45 mL/min)
• CKD Stage 4 (GFR = 15-29 mL/min)
• CKD Stage 5 (GFR<15 mL/min)
CKD stages 1-3 are classified as early CKD and patients at these stages
have a reduced GFR of the kidney, therefore causing an increase in levels of
urea and creatinine in blood, an increase in level of salt and water overload
and hypertension. Stage 4 is recognised as an advanced CKD and patients
at this stage, suffer from hypocalcaemia, hyperparathyroidism, bone disease,
vascular calcification and anaemia. Stage 5 is referred as the near end-stage
CKD and patients at this stage are, firstly no longer able to remove any waste
and fluids from the body, causing an accumulation of toxins in the blood and
secondly unable to regulate blood pressure. Therefore these patients require
dialysis to remove excess water, solutes and toxins from the blood artificially
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(Lewis (2012)).
THR cases and matched controls who have a Read code for CKD that is
dated prior to their THR procedure date, are assumed to suffer from CKD.
For patients who have multiple records of CKD in their MED file in THIN
database, the closest record of CKD before the THR surgery date is assigned
to the patients to determine the stage of their CKD. Table 38 in Appendix B
shows the distribution of patients diagnosed with CKD stages 1–2 and 3–5,
respectively, prior to their THR surgery. It can be noted that most cases and
controls were aged 65 years or more when they were diagnosed with CKD.
Only 2 female controls were in the age group 55-64 at the time they were
diagnosed with CKD stage 3-5.
Among THR cases and matched controls, proportion of CKD stages 1–2
and 3–5 are respectively highest in age group 85+ for both males and females.
Comparing patients aged 85 years or more, prevalence of CKD stage 3–5 is
higher among females than males for cases and controls. Iwagami et al.
(2017) estimated the prevalence of CKD (all stages altogether) in the UK
by analysing primary care records from the CPRD database, dated between
April 2004 and March 2014, inclusive. Out of 264,628 patients identified with
CKD, the authors reported that CKD stages 1–5 were more prevalent among
females (60.7%) than males and more prevalent among age groups 75–84
(42.3%) and 85+ (15.8%). In this study, out of 830 THR cases identified
with CKD stages 1–5, prevalence of CKD stages 1–5 is more higher among
female THR cases (68%) than male THR cases for all age groups at THR
surgery. The highest proportion of CKD stages 1–5 is found in the age group
85+ for male and female THR cases, which follows closely the same trend as
reported by Iwagami et al. (2017) for prevalence of CKD across different age
groups in UK.
Cardiovascular diseases
The human heart is a muscle that is responsible for pumping blood (via blood
vessels) to the whole human body to allow a constant flow of the blood stream
so that essential nutrients such as Oxygen, and waste products such as urea,
are transported to maintain the human body under homoeostatic conditions.
Any conditions affecting the proper functioning of the human heart or its
blood vessels are classified as cardiovascular disease (CVD) (Jevon, (2012)).
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In this study, the types of CVD being investigated are coronary heart dis-
eases (namely angina and myocardial infarction) and stroke.
Angina is the most common form of coronary heart disease and is defined
as a condition that occurs when an individual’s heart is insufficiently supplied
with oxygenated blood by the coronary blood vessels. This happens because
of atherosclerosis, i.e., the coronary blood vessels are narrowed or partially
blocked by plaques made up of cholesterol and other cells, consequently re-
sulting in a short-lived chest pain or tightness. Angina can be classified into
either stable or unstable (Jevon (2012).
Stable angina occurs when the heart works harder than normal, dur-
ing physical activities, for example. Chest pain or tightness caused by stable
angina has a regular pattern that can be predicted and stopped usually within
a few minutes, either by taking a rest or via medication. However unstable
angina is a more serious chest pain or tightness that cannot be predicted or
ascertained to a particular pattern. It can just as easily occur during physi-
cal movements as it can during resting position. The chest pain or tightness
do not go away with rest and should be treated as an emergency cardiac
condition that can cause further complication such as myocardial infarction
(Jevon (2012).
Myocardial infarction (MI) causes severe chest pain and tightness that
lasts longer than angina and can occur under any circumstances. When a
coronary blood artery, is completely blocked by plaques made up of choles-
terol and other cells, the heart is deprived of oxygenated blood, leading to
the death of part of the heart muscle. Consequently the individual will feel
chest pain and tightness that can spread to the upper part of the human
body (Jevon (2012).
Stroke is clinically defined as a syndrome of rapidly developing symptoms
or signs of loss of cerebral function as a result of vascular problems. It occurs
when the blood supply to the brain is disrupted, causing that part of the
brain to be deprived of oxygenated blood. Consequently, part of the brain
stops working and thus causes loss of sensation in part of the body. The two
main causes of stroke are due to either a blockage or haemorrhage of a blood
vessel supplying blood to the brain.
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Blockage of blood vessels (also referred as occlusion) is formed by blood
clots made up of plaques of cholesterol and other cells. This blockage is either
developed along a blood vessel or travels from a different source. Supply of
blood to the brain is then disrupted, thereby leading to symptoms of stroke.
Stroke occurring as a result of a brain haemorrhage is caused by the leaking
or bursting of the cerebral artery, therefore disrupting the supply of blood
to the brain. Brain cells die, consequently leading to loss of important brain
functions (Lindley, (2008)).
Table 39 in Appendix B shows the distribution of THR cases and matched
controls who had at least one event of angina, MI or stroke before the date
of their relevant THR procedure. Prevalence of angina among male cases
and controls, respectively, is higher than female counterparts across all age
groups. For female cases and controls, angina was the most prevalent among
the age group 85+ while among males, angina was the most prevalent among
the age groups 75–84 for cases and 85+ for matched controls, respectively.
Prevalence of angina is marginally higher among female cases than female
controls (except for the age group 75–84 ) and higher among male cases aged
84 years or less, compared to male controls of the same age categories.
6.2% of female cases (versus 5.9% of female controls) and 12.2% of male
cases (versus 12.1% of male controls) had an event of MI prior to their THR
surgery. Hence MI was more prevalent among males in this study. Propor-
tion of MI increases with increasing age for both cases and controls across
both genders, respectively. MI was the most prevalent among the age group
85+ for female cases and controls, respectively, whereas for male patients,
proportion of MI was the highest in the age group 18–54 among cases and
75–84 among controls, respectively.
3.5% of female cases (versus 8.8% of female controls) and 4.4% of male
cases (versus 9.8% of male controls) had an event of stroke prior to their
THR surgery. Therefore prevalence of stroke among THR cases is marginally
higher in men than in women and lower in THR cases than among matched
controls. Among cases, the youngest age group 18–54 has the highest pro-
portion of stroke events (4.6% for females and 6.2% for males) mainly be-
cause number of patients in the age group 18-54 is the smallest among all
age groups. For controls, age groups 85+ and 75-84, respectively, have the
highest percentage of stroke events among female and male controls, respec-
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tively. Prevalence of stroke prior to the relevant THR procedure increases
with age group for controls whereas among cases, prevalence of stroke across
age groups, for cases aged 55 years or more, is similar.
Using data from the CPRD database, Williams et al. (2014) estimated
the prevalence of angina, MI and stroke in the UK for males and females,
as summarised by the table below. Prevalence of angina and MI before
THR surgery is higher among all age groups for all THR cases and matched
controls, respectively, in this study (see Table 39 in Appendix B) than the
reported prevalence of angina for males and females, respectively, in CPRD
database by Williams et al. (2014), shown in the table below. Prevalence of
stroke prior to THR surgery for age groups 18–54 (4.6% for female versus
6.2% for males), 55–64 (3.8% for females versus 4.6% for males) and 65–74
(3.3% for females versus 4.3% for males) is higher for cases than reported
prevalences of MI by Williams et al. (2014), shown in table below, for the
same age groups for both genders. However male and female THR cases
aged 75 years or more in this study, have a lower prevalence of stroke prior
to THR surgery than those provided by the table below for both genders.
Among selected controls in this study, prevalence of stroke is higher than
those presented in the table below across all age groups for both genders.
Reported prevalence of angina, myocardial infarction and stroke in the UK as of
2013 (Williams et al. (2014))
Gender Male Female
Age group Angina MI Stroke Angina MI Stroke
0-44 0.05% 1.21% 0.11% 0.03% 0.02% 0.11%
45-54 0.92% 1.14% 0.89% 0.50% 0.29% 0.79%
55-64 3.60% 3.55% 2.69% 1.74% 0.89% 1.96%
65-74 8.83% 7.05% 6.40% 4.66% 2.06% 4.39%
75+ 16.96% 12.08% 14.89% 11.15% 5.50% 12.43%
All ages 3.05% 2.46% 2.53% 1.79% 0.87% 1.99%
Osteoarthritis
The most common symptom of joint diseases is joint pain, which is mainly
caused by a degenerative disease known as osteoarthritis (also commonly
referred to as coxarthrosis). The term osteoarthritis (OA) is derived from
three Greek words meaning bone, joint, and inflammation. OA is the most
common form of arthritis and is a progressive disorder of the joints caused by
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gradual loss of cartilage that acts as a protective cushion between the joint.
As the cartilage is gradually worn away, the bone forms areas of abnormal
hardening (commonly referred as spurs) and fluid-filled pockets (known as
subchondral cysts) in the joint. As the disorder continues, pain results from
deformation of the bones and fluid accumulation in the joints. Such a con-
dition causes painful distress to the individual during movements. Figure 2
in section 1.2 illustrates the gradual loss of cartilage between joints due to
OA where in the advanced stage of OA, it can be observed that the cartilage
is completely worn out causing the bone to erode as well, leading to painful
discomfort to the individual’s joint.
OA is the major reason why patients undergo total joint replacement for
hip, knee and shoulder. The 2016 National Joint Registry in UK reported
that 92% of THR, 96% of total knee replacement (TKR) and 53% of total
shoulder replacement procedures, respectively, were carried out because of
degenerative joint OA (NJR (2016)). In this study, the impact of OA on
mortality risk after THR procedure is investigated. THR cases and matched
controls who have at least one record in MED file that is coded by the OA
Read codes in Table 28 in Appendix A and dated before their THR surgery,
are identified as patients diagnosed with OA prior to THR procedure.
Table 40 in Appendix B displays the proportions of THR cases and
matched controls diagnosed with OA prior to their relevant THR surgery.
Prevalence of OA is high across all age groups among THR cases, ranging
from 80.3% among age group 85+ to 88.4% among age group 65–74 for males
and ranging from 78.2% among age group 18-54 to 88.0% among age group
65-74 for females, respectively. On the contrary, very low prevalence of OA
is observed among controls, with only 27.2% of women and 10.7% of men,
diagnosed with OA, prior to their relevant THR surgery date. Compared
to the 2016 report by the National Joint Registry in UK (NJR (2016)), OA
was the predominant diagnosis in 92% of patients who underwent a THR
and is higher than the prevalence of 87% for OA among THR cases in this
study. This difference may be due to under-reporting of OA diagnosis in
THIN medical records for identified THR cases in this study. Since the NJR
dataset is a secondary care database specially for joint replacement patients
in the UK, where records on degenerative conditions such OA, rheumatoid
arthritis and osteoporosis are not under-reported.
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Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a chronic long-lasting inflammatory joint dis-
ease that affects the lining of joints, causing a painful swelling that can
eventually result in bone erosion and joint deformity. It is a disorder that
occurs when an individual’s immune system mistakenly attacks their own
body’s tissues mostly located between joints. When these tissues are com-
pletely worn out, the bones forming the joint erode, leading to limited joint
movement because of severe joint swelling, pain, stiffness or fatigue (Newman
and Matzko (2006)). The major cause of RA is the individual’s abnormal
immune system that destroys lining of joint bones. Therefore RA patients
have a different state of immune system compared to patients with or with-
out OA and thus have different life expectancies as demonstrated by Watson
et al. (2003). The latter study reported that mortality risk is 60% to 70%
higher in patients with RA compared to patients with OA and those with no
arthritis. Hence it is also important to assess the role of RA as a risk factor
for variations in mortality risk after THR procedures.
Table 40 in Appendix B shows the distribution of cases and matched con-
trols, in this study, diagnosed with RA prior to their relevant THR surgery.
Prevalences of RA across all age groups are higher among females than among
males for both cases and controls. 2.6% of male THR cases (versus 1.5%
for male controls) and 4.8% of female THR cases (versus 2.8% for female
controls) suffered from RA before their THR surgery. Siebert et al. (2016)
analysed the prevalence of RA among 502,649 UK patients who are regis-
tered with the UK Biobank organisation for chronic diseases and reported
that 0.74% of males and 1.44% of females suffered from RA, across ages 37-73
years. Thus, the proportion of THR cases and controls in this study, who
were diagnosed with RA prior to THR procedure, is higher.
Osteoporosis
Osteoporosis is a bone condition that is caused by a decrease in bone mass
and a deterioration of the bone structure, thereby leading to an increasingly
fragile bone. In clinical practice, osteoporosis is diagnosed by estimating the
bone mineral density (BMD) of the patients’ bones. BMD test is a surrogate
marker for osteoporosis diagnosis because there exists a strong correlation
between the bone mineral density of a bone and its weight tolerance ability
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(Bhansali and Gogate (2015)). The human bone is made up of organic (30%-
40%) and inorganic (60%-70%) components. BMD test estimates only the
inorganic component of the bone and the results are produced in the form of
T-scores. T-score is a conversion index that measures the deviation of BMD
estimate from that of a reference young patient’s BMD estimate (Bhansali
and Gogate (2015).
The guideline to use T-score as a quantitative definition of osteoporosis
was developed by the World Health Organisation (WHO). T-scores which
are 2.5 standard deviations below that of the reference level (i.e., T-score
of a young adult), can be classified as osteoporosis while a T-score that is
between 1 and 2.5 standard deviation below that of a reference young adult,
is classified as osteopenia, which represents the early stage of a decrease in
bone mineral content (WHO (2017)).
In THIN database, patients suffering from osteoporosis at the hip can be
identified in two ways, namely: (1) using medical Read codes for osteoporosis
diagnosis in the MED file and (2) using BMD test results from the AHD file
in THIN database. The Read codes for osteoporosis at the hip in the MED
file and that for BMD test results in the AHD file are listed in Table 28 in
Appendix A. Only osteoporosis diagnosis or BMD test results that are dated
before the THR cases’ and matched controls’ THR surgery are extracted
from the MED and AHD file respectively. Table 40 in Appendix B displays
the distribution of cases and matched controls diagnosed with osteoporosis
at the hip, prior to their relevant THR procedure.
The proportions of male and female THR cases who were diagnosed with
osteoporosis before THR procedure are 1.8% and 7.3%, respectively, while
prevalence of osteoporosis is 2.9% and 6.3% among male and female controls,
respectively. For both cases and controls, osteoporosis is more prevalent
among females. Comparing across age groups, osteoporosis becomes more
prevalent as age increases among THR cases and matched controls, respec-
tively. Proportion of osteoporosis is significantly lower among THR cases
compared to matched controls. Osteoporosis is strongly associated with hip
fracture (Johnell and Kanis (2005)) and also contributes to an increased
mortality risk among males and females as shown by Johansson et al. (1998).
In this study, THR procedures due to hip fracture are excluded. Hence
the prevalence of osteoporosis among THR cases is significantly lower than
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matched controls, although none of the latter had a hip fracture before their
relevant THR procedure.
Hypercholesterolemia
Cholesterol is a fatty substance that is found in human body cells and it
comes either from self-production by the human liver or from food consump-
tion. It has essential functions in the human body and plays important role
in the movement of substances through a cell. It is also important for the pro-
duction of certain hormones such as progesterone and testosterone, vitamins
such as vitamin D and bile acid. Cholesterol, produced by the liver, is moved
around the human body in the form of lipoproteins while cholesterol from
food consumption is stored in the form of triglycerides. Lipoproteins exist in
two form; namely low density lipoprotein (LDL) and high density lipoprotein
(HDL). LDL transports cholesterol from the liver to different tissues of the
human body while HDL is responsible for the removal of excess cholesterol
from human tissues and brings the excess back to the liver for removal from
the body or for reconversion. Collectively, LDL, HDL and triglycerides are
called blood lipids (Bull and Morrell, (2005)).
The amount of cholesterol in the human body can be determined by a
blood test that estimates the amount of blood lipids, in millimoles per litre
(mmol/L). In the UK, the general guideline for a healthy cholesterol level,
recommends the levels displayed by the table below, for blood lipids in the
human body. When the blood lipids measurement is above the minimum
healthy level, an individual suffers from hypercholesterolemia (HC) or hyper-
lipidemia.
Blood Lipid Type Recommended Healthy Estimate (mmol/L)
Total Cholesterol <5
LDL <3
HDL >1
Recommended Cholesterol Level for Healthy Adults in the UK, according to NHS
UK NHS (2015)
HC usually arises either from dietary factors such as consumption of
highly saturated fats or via an overproduction of LDL in the human body
or via genetic cause such as familial hypercholesterolemia (Bhatnagar et al.,
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(2008)). An increased level of cholesterol in blood vessels affects the human
blood circulatory system and thus leads to cardiovascular diseases as dis-
played by Figure 14 below.
Figure 14: Types of cardiovascular diseases caused by hypercholesterolemia (Bull
and Morrell (2005))
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In the THIN database, HC for a patient can be identified by one or more
of the following methods:
(1) A history of HC in the patients’ records in the MED file, identified by
Read codes, listed in Table 28 in Appendix A
(2) Recorded high cholesterol measurement (total cholesterol≥ 5 mmol/L
or LDL measurement≥ 3 mmol/L or HDL≤ 1 mmol/L in the patients’
records in the AHD file), identified by Read codes (listed in Table 28
in Appendix A)
(3) A prescription of lipid-lowering drug treatment, namely statins (Ator-
vastatin, Fluvastatin, Pravastatin, Rosuvastatin, and Simvastatin), as
recommended by the British National Formulary (BNF), Chapter 2.12
(British National Formulary 2.12, (2014).
Using the above methods to identify HC among THR cases and controls,
four categories of HC were defined in this study, as shown below.
• Category 1 : Patients with no records of HC and statins prescription
prior to THR surgery
• Category 2 : Patients with normal cholesterol level due to statins pre-
scription prior to THR surgery
• Category 3 : Patients with HC despite the statins prescription prior to
THR surgery
• Category 4 : Patients with HC but not with statins prescription prior
to THR surgery
Table 41 in Appendix B displays the proportion of THR cases and matched
controls in this study, across each of the above categories for HC. Proportion
of THR cases and matched controls with normal cholesterol level due to pre-
scription of statins prior to their THR surgery (Category 2 HC), increases
with age at surgery peaking at 49.71% among women and 51.75% among
men for THR cases aged 85 years or more. Similarly, prevalence of Category
2 HC is higher among male cases than female cases across all age groups.
Proportion of controls with Category 2 HC is higher among male and female
controls than among THR cases across all age groups, except for older age
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groups 75–84 and 85+, respectively.
Percentage of cases and matched controls with HC despite having statins
prescription prior to their relevant THR surgery (Category 3 HC) increases as
age of patient at surgery time increases, peaking in the age group 85+ among
THR cases and among female controls, and in the age group 75–84 among
male controls. Prevalence of Category 3 HC is marginally higher across all
age groups for female cases than male cases and matched controls for both
genders while that of male cases is similar to the prevalence of Category
3 HC among male and female controls, across all age groups. Proportion
of patients with HC but not receiving statins prescription as treatment of
HC prior to their relevant THR surgery (Category 4 HC) is highest among
younger age groups and decreases with age at surgery for all THR cases and
female controls, while proportion of Category 4 HC among male controls de-
creases with age at relevant surgery time. Prevalence of Category 4 HC is
lower among women than men for both THR cases and matched controls.
MacDonald and Morant (2008) reported estimates of the prevalence of
HC in the UK using data from the THIN database, from 1998 to 2006. For
patients aged 55 years or older, the prevalence of HC in THIN, at the end
of 2006, was 50.3% among men and 48.0% among women, respectively. For
the same age group, prevalence of HC (Categories 1, 2 and 3, respectively)
among THR cases in this study is 44.6% for females and 45.7% for males
(versus 50.7% for females and 44.7% for males among controls, respectively).
Hence proportion of HC (all categories inclusive) among male THR cases
and controls, respectively, is lower than the reported prevalence of HC by
MacDonald and Morant (2008) for male patients. Prevalence of female THR
cases with any type of HC, is lower than the reported proportion of HC
among female patients by MacDonald and Morant (2008) while that of fe-
male controls is marginally higher.
MacDonald and Morant (2008) also estimated the proportion of patients
with HC and receiving treatment in the form of statins prescription (analo-
gous to Category 2 and 3 HC, inclusive, in this study). They reported that
28.4% of men and 21.7% of women, aged 55 years or more by the end of
2006, respectively, received treatment in the form of statins prescription for
HC. In this study, for the same age group, 38.7% of male THR cases (ver-
sus 33% for male controls) and 38.0% of female THR cases (versus 39% for
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female controls) were on statins prescription for HC, prior to their surgery,
by the end of July 2011. This shows that the prevalence of treated HC in
this study is significantly greater among male and female THR cases and
controls, respectively, than the reported estimates of treated HC for men
and women, respectively, by MacDonald and Morant (2008). This may be
because statins prescription for patients in THIN, was increasing over time
and thus, a higher prevalence is treated HC is obtained in this study.
Hypertension
When blood travels from the heart to different parts of the human body
through arteries and back to the heart through veins, pressure is applied
against the arterial and venous walls. This pressure is referred as blood pres-
sure (BP) and can be measured, in mmHg, using a medical tool called sphyg-
momanometer. The latter measures two types of BP: (1) Systolic BP which
is the pressure in the human blood vessels when the heart beats and (2) Di-
astolic BP which is the pressure in the human blood vessels when the heart
rests between beats (Lip and Hall (2007)). According to the guideline on
BP measurement by the National Institute for Health and Care Excellence
(NICE) (2016), BP is at a normal level if the systolic BP is lower than 140
mmHg and the diastolic BP is less than 90 mmHg. When an individual’s
systolic or diastolic BP (or both of them) exceeds the recommended level as
described by the NICE guidelines, the individual is said to be suffering from
hypertension (HT). HT is strongly associated with cardiovascular diseases,
with patients suffering from HT having the greatest risk of developing car-
diovascular diseases (Nadar and Lip (2015)).
In the THIN database, HT in patients can be identified by one or more
of the following methods:
(1) A history of HT in the patients’ records in the MED file, identified by
Read codes listed in Table 28 in Appendix A.
(2) A recorded clinical measurement of BP readings (systolic BP ≥90
mmHg or diastolic BP ≥140 mmHg, averaged over two successive oc-
casions).
(3) A record of prescription for anti-hypertensive drugs in the patient’s
AHD file, namely (1) α-adrenoceptor blockers (α-blocker) or β-adrenoceptor
153
blockers (β-blocker), unless prescribed for anxiety or with nitrates, (2)
calcium channel blocker (C-blocker), unless prescribed with nitrates
and (3) angiotensin-converting enzyme inhibitors (ACE-inhibitor), un-
less prescribed for congestive heart failure (BNF Chapter 2.12 (2014)).
Using the above methods to identify HT among THR cases and controls,
four categories of HT were defined in this study, as shown below.
• Category 1 : Patients with no records of HT in MED file or with nor-
mal systolic or diastolic BP based on measurements recorded prior to
relevant THR surgery and not receiving any anti-hypertensive drug
prescriptions prior to relevant THR surgery;
• Category 2 : Patients with normal BP level due to prescription of anti-
hypertensive drugs prior to THR surgery;
• Category 3 : Patients with HT despite the prescription of anti-hypertensive
drugs prior to THR surgery;
• Category 4 : Patients with HT but without prescription of anti-hypertensive
drugs prior to THR surgery.
Table 42 in Appendix B displays the distribution of cases and matched
controls, across each category of HT, defined in this study. Comparing cases
and controls with normal BP because of anti-hypertensive drug intake (Cat-
egory 2 HT) prior to their relevant THR surgery, prevalence of Category
2 HT is higher among female cases, aged 74 years or less, than male cases
of similar age groups, respectively, while among controls, Category 2 HT is
more prevalent across all age groups among men than women. Prevalence of
Category 2 HT increases with increasing age at THR surgery for all controls
and for male THR cases only. Category 2 HT is more prevalent among the
age group 65–74 for female THR cases. Proportions of patients with HT
despite being prescribed with anti-hypertensive drugs prior to their relevant
THR surgery (Category 3 HT) increases for older age groups, peaking in the
age group 85+, for both THR cases and matched controls, across all genders.
Prevalence of Category 3 HT is higher across all age groups among women
than men in this study.
Comparing percentage of patients with HT but not taking any anti-
hypertensive drugs for treatment of HT (Category 4 HT), prior to their
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relevant THR surgery, prevalence of Category 4 HT is higher among controls
than THR cases aged 74 years or less while among older age groups, Category
4 HT was marginally higher among THR cases than matched controls, for
both males and females, respectively. Among THR cases, age group 65–74
for men and 85+ for women, respectively, have the highest proportions of
Category 4 HT whereas Category 4 HT is prevalent among the youngest age
group, 18–54, for male and female controls.
In their published paper, MacDonald and Morant (2008) provide esti-
mates of prevalence of HT among THIN patients, aged 55 years or more,
from 1998 to 2006. The authors reported that 55.0% of men and 57.0%
of women, in THIN, suffered from HT by the end of 2006. In this study,
prevalence of HT (Categories 2, 3 and 4, inclusive) among THR cases and
matched controls across all age groups, is estimated at 54.4%, 60.0%, 56.7%
and 61.5% among male cases, female cases, male controls and female controls,
respectively, prior to their relevant surgery. Therefore reported prevalence
of HT by MacDonald and Morant (2008), is close to that of male cases but
marginally lower than prevalence of HT among female cases and all controls
in this study. This small increase in estimated prevalence may be due to
the fact that majority of patients in this study are aged 55 years or more
and thus the study population is relatively older than the study population
analysed by MacDonald and Morant (2008).
Similarly, MacDonald and Morant (2008) also estimated the proportion
of patients, aged 55 years or more, with HT and receiving treatment in the
form of anti-hypertensive drug prescriptions (defined as Category 2 and 3
HT, inclusive, in this study). They reported that 37.5% of men and 39.4% of
women, aged 55 years or more, were receiving treatment for HT as at the end
of 2006. In this study, 41.7% of male cases (versus 38.4% of male controls)
and 51.0% of female cases (versus 41.8% of female controls), aged 55 years or
more, were receiving treatment for HT in the form of anti-hypertensive drug
prescriptions. Hence proportions Category 2 and 3 HT, inclusive, of male
cases and controls (both genders), respectively, are close to the reported
estimates of treated HT by MacDonald and Morant (2008) for males in UK.
However prevalence of Category 2 and 3 HT, inclusive, is higher among female
cases than reported prevalence of treated HT by MacDonald and Morant
(2008) and this may be because of the larger proportion of women at older
ages (55 years or more) in this study population than the one analysed by
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MacDonald and Morant (2008).
5.2.8 Drug prescriptions
This section summarises the list of drug prescriptions that were given to THR
cases and matched controls during the period they were registered with a GP
practice in THIN for the treatment of hypercholesterolemia, hypertension
and also prescriptions of hormone replacement therapy. To ensure that the
information on drug prescriptions that are extracted from the Therapy file in
THIN, consists of all the different types of drugs for the treatment of these
conditions, publications and guidance on drug prescription from the British
National Formulary (BNF Publications, (2016)) is used. Note that in this
section, all drug prescriptions for all patients are dated before THR proce-
dure for cases while for controls, prescriptions are dated before the surgery
of their matched cases.
BNF is a UK based organisation that produces publications incorporat-
ing clinical evidence on medications from different sources such as consen-
sus guidelines from the National Institute for Health and Care Excellence
(NICE), the Scottish Medicines Consortium (SMC), the Scottish Intercolle-
giate Guidelines Network (SIGN) and systematic review databases, and ap-
proved by a panel of clinical experts with the consent of a Joint Formulary
Committee. BNF publications reflect the latest best practice and provide
legal and professional instructions in the management of medicines in the
UK. They issue guidance on the management of drug prescriptions, monitor-
ing, dispensing and administration of medicines and also provide details on
the uses, cautions, contra-indications, side-effects, doses, and relative costs
of medicines (BNF Publications, (2016)).
In THIN, records of drug prescriptions are available in the therapy file and
can be identified using BNF Read codes. The full list of BNF Read codes
used to identify drug prescriptions for treatments of hypercholesterolemia,
hypertension and medication for hormone replacement therapy among cases
and matched controls selected in this study, are presented in Table 30 in
Appendix 27. These drug prescriptions have been cross-checked with the
recommended NICE guidelines for UK population for the treatments of each
condition.
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Table 43 in Appendix B shows the proportion of THR cases and matched
controls who received drug prescriptions for the treatment of the conditions
listed, prior to their relevant THR surgery. 38.9% of male cases (versus 16.7%
of male controls) and 38.0% of female cases (versus 14.2% of female controls)
were on statins prescription prior to their THR procedure. 29.6% of male
cases (versus 31.9% of male controls) and 33.0% of female cases (versus 34.5%
of female controls) received an ACE inhibitor prescription for treatment of
HT prior to surgery. 26.4% of male cases (versus 28.7% of male controls)
and 26.5% of female cases (versus 34.3% of female controls) received an α-
or β-blocker prescription for treatment of HT prior to surgery. Prevalence of
Calcium-blocker prescription is 22.9% among male cases and 29.7% among
female cases (versus 28.4% for male controls and 27.2% for female controls).
Prescriptions of α- or β-blockers and C-blockers are lower than the per-
centage prescriptions of ACE inhibitors because the former two are given in
conjunction with ACE inhibitor for patients in whom ACE inhibitor drugs
are ineffective.
Hormone replacement therapy (HRT) is a treatment used to increase the
level of natural hormones in the body, either in the form of estrogen-alone
therapy, for women who have had a surgical menopause (hysterectomy) or
both estrogen and progesterone therapy are given together to women who
experience menopause naturally at mid-life. HRT helps the female body to
process calcium (essential for the strengthening of bone), aids in controlling a
healthy cholesterol levels, keeps the vagina healthy, relieves menopause symp-
toms and protects the female body against osteoporosis (Genazzani (2002)).
A complete guidelines and instructions on the management and use of HRT
for treatment of menopausal syndromes is provided by the NICE clinical
guideline NG23. In men, testosterone is used as a HRT to treat unnaturally
low levels of testosterone, caused by ageing. It relieves many symptoms such
as reduced libido, lack of energy and concentration or endurance, loss of mus-
cle mass, sexual dysfunction and depression (Kells and Ahlgrimm (2003)).
Among women, 7.6% of THR cases and 8.8% of matched controls received
a prescription of estrogen prior to THR surgery, while 1.7% of cases (versus
0.9% of matched controls) were prescribed progesterone as HRT. Prevalence
of estrogen prescription for HRT is higher than that of progesterone and
marginally smaller among cases than among controls. Among men, 4.2% of
cases had a prescription of testosterone for HRT prior to their THR procedure
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(versus 4.6% for male controls). Thus proportions of drug prescription for
HRT is smaller among males than among females. This is because HRT
prescriptions is mainly given to female patients when they enter the stage of
menopause, a condition that occurs in all women when they reach the age
group 45-55 on average, whereas for men, testosterone prescription is only
given as HRT when male patients suffer from a deficiency of androgens (a
relatively rare condition referred as hypogonadism), which affects the proper
functioning of the male reproductive system.
5.2.9 Missing data
Proportion of missingness
In the dataset extracted from the THIN database for survival analysis of pri-
mary THR procedures, the following variables have missing values for THR
cases and matched controls in this study: smoking status, body mass in-
dex (BMI), Townsend score, index of multiple deprivation (IMD) of patients’
residential area and the Mosaic category of the patients. Other post-code re-
lated variables describing ethnicity, pollution levels, proportion of long term
illnesses and urban/rural classification of patients residential wards, have
missing values only for patients in THIN that reside in Scotland. These vari-
ables are only used for descriptive analysis in this chapter and not included
in survival analysis because missing values are systematic for these variables
as missingness only applies to patients from Scotland. No missing values are
present among medical and drug therapy related variables, because patients
with no records of a particular medical diagnosis or drug therapy, are as-
sumed to be free of the medical condition or the drug therapy before THR
procedure.
Table 7 shows the percentage of missing values for cases and controls,
across each gender for smoking status, BMI, Townsend score, IMD and Mo-
saic category. Proportion of missing data between male and female cases
and between male and female controls, respectively, are close to each other
across all variables. Smoking status of patients has the highest proportion
of missing data (30.0% for THR cases versus 25.0% for matched controls),
whereas the lowest proportion of missing data is observed for IMD (2.1% of
missing data for both cases and controls, respectively).
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Table 7: Proportion of missing data for cases and controls
Variables Female cases Male cases Female controls Male controls
Total number of patients 10646 6511 53230 32555
Body Mass Index 10.5% 9.1% 9.5% 9.8%
Smoking status 30.2% 29.5% 25.0% 25.1%
Townsend score 13.0% 13.7% 16.1% 16.9%
Index of Multiple Deprivation 2.0% 2.3% 2.0% 2.3%
Mosaic category 8.4% 8.4% 7.3% 7.7%
Proportion of patients with and without complete records at time of THR
procedure, are compared to each other with respect to all variables with
complete records, using a χ2-test of independence (Kleinbaum and Klein,
(2005)). The test statistic, χ2, is given by
χ2 =
r∑
i=1
c∑
j=1
(Oij − Eij)2
Eij
, (5.1)
where Oij and Eij represents the observed and expected number of data
points, respectively, in the ith row and the jth column, where r and c are
the number of rows and columns in the contingency table. The test statistic
distribution is approximated by a χ2-distribution with (r− 1)(c− 1) degrees
of freedom. This approximation holds if the lowest number of expected ob-
servations is greater than five. The extracted dataset is sufficiently large,
with sample size equal to 102, 943 subjects for this requirement to hold.
Figure 15 below illustrates the statistical differences between the propor-
tion of patients with and without complete records, respectively, grouped by
all the completely observed covariates. Unshaded cells in Figure 15 indicate
a p-value smaller than 1% and hence there is a significant systematic differ-
ence between proportion of subjects with and without complete records in
that category. For instance, there are significant differences in the propor-
tion of patients with and without complete records, for all covariates, when
grouped by year of birth. The shaded cells indicate no significant differences
(p-values of χ2-test > 1%) in the proportion of subjects with and without
complete records. Figure 15 shows that proportions of missing values dif-
fer significantly across the vast majority of covariates. Therefore, presence
of missing values in the dataset should not be ignored during the analysis
stage. Similarly, it also shows absence of a systematic trend in missingness
in the dataset and thus, data is assumed to be missing at random (MAR) in
the extracted data from THIN.
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Figure 15: Comparing significance of systematic difference between complete and
incomplete records for covariates with missing values
Imputing missing data
Missing data is treated using multiple imputation technique, described in
section 3.8. The dataset extracted from the THIN database is classified as
hierarchical (multilevel) since patients are clustered via their general practice
(GP practice). The extracted dataset represents data at two levels: firstly
at the individual level for each individual in each GP practice and secondly
at the practice level, where a GP practice is a cluster. Patients within each
cluster are assumed to be homogeneous. In the multiple imputation of in-
complete multilevel data, it is essential that the imputation model takes
the multilevel structure of the incomplete data into account to ensure valid
statistical inferences in subsequent multilevel analyses (Black et al. (2011),
Graham et al. (2007), Kleinbaum and Klein (2005)). To account for this,
a random effect corresponding to a practice is added to the model used for
imputing missing data.
In this research, the packages mitml (Grund et al. (2017)) and jomo
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(Matteo and James (2017)) are used to impute missing values for incomplete
records using a joint modelling approach. The function jomoimpute in the
mitml package provides an interface to the jomo package, which uses the
MCMC algorithms presented in section 3.8.2. Through this interface func-
tion, imputations for categorical and continuous variables for a multilevel
dataset, can be generated at level 1 and level 2, by explicitly specifying the
role of each variable in the imputation model in the jomoimpute function.
The variables have to be described as:
• Target variables containing missing data, defined as type 1.
• Predictors with fixed effect on all targets (completely observed), spec-
ified as type 2.
• Predictors with random effect on all targets (completely observed),
described as type 3.
• Grouping variable within which the imputation is run separately, listed
as type -1.
• Cluster indicator variable, defined as type -2.
• Variables not featured in the model are set as type 0.
The list of target variables consists of the following variables: smoking status,
BMI, Townsend score, index of multiple deprivation of residential area of
patients and the Mosaic category of each patients. These target variables are
specified as type 1 in the imputation model. The list of predictors with fixed
effect on all target variables consists of all the variables with complete records,
as listed in Figure 15 above. These completely observed variables are defined
as type 2. GP practice is used to cluster the patients and is thus defined as
type -2 in the imputation model to account for the multilevel structure of
the dataset. Multiple imputation on the incomplete THIN dataset is carried
out at the level 1 (individual) only, but accounting for random effects due
to clustering by GP practice. For the THIN dataset, the burn-in-length
(see section 3.8.2) is set to 500 iterations; the number of iterations until
convergence of estimated model parameters is set to 500 and the number of
imputed datasets to be simulated is set to 10, respectively. Analysis and
description of imputed dataset for the short and long term survival model
developed in this thesis, are presented in Chapter 6 and 7, respectively.
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5.3 Contribution of chapter
In this chapter, the THIN database is presented as the source of data to
complete aims 1–3, described in section 1.4. The information presented in
this chapter helps to address the following aims as follows:
Aim (1) : Firstly, primary care records in THIN can be used to identify primary
THR procedures in UK, although the description of procedure types
can only be categorised as cemented, uncemented, hybrid or as other
types. No information describing the material of the hip prosthesis
(metal or non-metal) used during the procedure, is available in THIN.
Aim (2) : Secondly, the prevalence of co-morbidities described in this chapter is
compared with published studies using similar dataset or other primary
care database such as CPRD and QResearch. Conditions in this study
that have a marginally lower prevalence among THR cases than rele-
vant published results are proportion of smokers, prevalence of angina,
myocardial infarction, osteoarthritis, rheumatoid arthritis, osteoporosis
and hypercholesterolemia. Obesity, type 2 diabetes, stroke among cases
aged 74 or less, treated hypercholesterolemia (Category 2 and 3 HC,
inclusive), treated hypertension (Category 2 and 3 HT, inclusive) and
hypertension (among female cases only) were more prevalent among
THR cases than relevant published studies. Chronic kidney diseases,
hypertension among male THR cases and proportion of stroke among
THR cases aged 75 or more have a prevalence level close to the relevant
published studies.
Aim (3) : Unknown records in body mass index (9.7%), smoking status (25.8%),
Townsend scores (15.9%), Mosaic group (7.6%) and index of multiple
deprivation (2.1%) are missing at random in the extracted dataset and
are treated using multiple imputation in this study.
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6 Short Term Survival Analysis After Pri-
mary Total Hip Replacement
Chapter outline
This chapter details the results of investigating mortality risk within the
first 24 months (short term) after the THR procedure. Firstly, Kaplan-
Meier survival analysis is carried out as preliminary analysis to compare
mortality between THR cases and matched controls, 12- and 24-months after
the procedure, for different gender and THR procedure types. Secondly,
the full procedure to carry out the multiple imputation of missing data is
described and assessed. Thirdly, a multilevel Cox regression model is fitted
to the imputed dataset to compare all-cause hazard ratio of death of THR
cases relative to matched controls. A discussion on the validity of the Cox
regression model is then provided. Fourthly, a multivariate logistic regression
model with frailty is fitted to the imputed data set to estimate all-cause odds
ratio of death within the first 24 months post-surgery. The results of all the
survival and mortality models described in this chapter, are presented using
forest plots and discussed in details.
6.1 Preliminary analysis
Table 8 displays the distribution of deaths and transferred out patients among
THR cases and matched controls within the first two years after THR proce-
dures, across each age group at surgery time and each gender. As a prelim-
inary analysis for the first 24 months after THR procedures, Kaplan-Meier
survival analysis is carried out to estimate survivorship for each age group
and types of THR procedures. Patients who were transferred out to a new
GP practice were assumed to be alive during the 24 months follow-up. The
strength of this assumption is assessed in section 6.4.4.To compare the sta-
tistical difference between survivorship in each category, the log-rank test
(Grambsch and Therneau [1994]), presented in section 3.4, is used.
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Table 8: Distribution of transfers out and deaths after THR procedures during the
first two years after surgery
Gender Age Group
No. of
Patients
No. Transferred
Out
%
No. of deaths
after 2 years
%
THR
Cases
Male 18-54 177 2 1.13% 0 0.00%
55-64 1141 3 0.26% 20 1.75%
65-74 2972 7 0.24% 66 2.22%
75-84 1993 6 0.30% 39 1.96%
85+ 228 2 0.88% 5 2.19%
All ages 6511 20 0.31% 130 2.00%
Female 18-54 281 3 1.07% 0 0.00%
55-64 1457 2 0.14% 32 2.20%
65-74 4538 6 0.13% 85 1.87%
75-84 3847 5 0.13% 58 1.51%
85+ 523 1 0.19% 11 2.10%
All ages 10646 17 0.16% 186 1.75%
Controls Male 18-54 1002 5 0.50% 0 0.00%
55-64 5859 4 0.07% 70 1.19%
65-74 14606 11 0.08% 304 2.08%
75-84 9851 3 0.03% 229 2.32%
85+ 1237 2 0.16% 20 1.62%
All ages 32555 25 0.08% 623 1.91%
Female 18-54 1480 8 0.54% 0 0.00%
55-64 7594 6 0.08% 0 0.00%
65-74 22460 13 0.06% 487 2.17%
75-84 18978 17 0.09% 415 2.19%
85+ 2718 12 0.44% 47 1.73%
All ages 53230 56 0.11% 949 1.78%
Figure 16 shows the differences in survival over two years between male
and female THR cases and their matched controls, respectively. It can be
observed that the survivorship of female THR cases is better than male cases.
Survival of male THR cases was lower than male controls. A similar trend is
observed when comparing female cases to female controls. However by the
end of the two year period, the THR cases survivorship improves significantly
until they are better than matched controls for both genders.
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Figure 16: Survival plot comparing THR cases to matched controls
Comparing the Kaplan-Meier survival curves between THR cases and matched
controls for both gender
Figure 17 shows the differences in survival two years after THR procedures
between different age groups among men and women. There were no death for
the youngest age group (18-54) during the first two years after the procedure
(Table 8) although five cases from this age group category were transferred
out to a new GP practice. Figure 17 shows that survival becomes poorer
for older age groups. There are significant differences in survival of older
age groups, relative to the youngest category (55-64), for both genders. The
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survival of the oldest age category (85+) is the worst among men while the
75-84 age category has the poorest survival among women, one year after
the procedure, respectively.
Figure 17: Survival plot comparing THR cases of different age groups
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Comparing the Kaplan-Meier survival curves of patients across age groups at
surgery time
Figure 18 compares survival of THR cases over two years, across each
types of procedures they underwent. The percentage survivorship for cases
who underwent hybrid or other types of procedures is higher than cemented
and uncemented procedures, respectively. In addition, survival of cases with
cemented THR procedures was better than uncemented procedures during
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the first two years after surgery. However the preliminary variations in sur-
vival of cases depicted in Figure 18 do not account for the fact that the types
of THR procedures carried depend strongly on the age group and health
status of the patients. Thus further analysis, whereby the age group and
medical comorbidities of the patients are factored in, is required to under-
stand and estimate the variations in survival of THR cases with different
types of procedures.
Figure 18: Survival plots comparing types of THR procedures
Comparing the Kaplan-Meier survival curves between cemented, uncemented and
other types of THR procedures
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6.2 Multiple imputation of missing values
6.2.1 The imputation phase
Table 7 in section 5.2.9 displays the proportions of missing data for BMI,
smoking status, Townsend score, Index of multiple deprivation and Mosaic
category among the 17,157 THR cases and 85,785 matched controls, used in
this research. Missing values within these variables are assumed to be missing
at random (See section 5.2.9). In the first stage of multiple imputation, there
are two key aspects that should be considered:
• Defining the measurement scale of the covariates with incomplete records,
and
• Defining the appropriate regression model as the imputation model
(IM).
In the dataset analysed in this chapter, BMI, smoking status, Townsend
scores, Index of multiple deprivation and Mosaic category are categorical in
nature with more than two levels. Therefore the appropriate IM model to
impute missing records for these variables, is defined as a multivariate linear
mixed model (Schafer and Yucel [2002]) and is of the form shown below.
yi = Xiβ + Zibi + εi, i = 1, ...,m,
where yi is the matrix of incomplete multivariate data for the i
th cluster, β
is the matrix of coefficients common to the population (fixed effects), bi is
the matrix of coefficients specific to the ith cluster (random effects), Xi is
the matrix of covariates for fixed effects, Zi is the matrix of covariates for
random effects bi and εi is the matrix of residual errors.
The covariates with complete and incomplete records, and the cluster
variables in this study are categorised as:
• Fixed effect predictors : Case-Control Indicator, Sex, Year of Birth
Category, Transfer Status of patients, Age group at surgery, Survival
time, Type 2 Diabetes, Heart Attack, Angina, Stroke, Chronic Kidney
Disease, Rheumatoid arthritis, Osteoarthritis, Oestrogen prescription,
Progesterone prescription, Testosterone prescription, Hypercholesterol,
Hypertension, Beta Blocker prescription, Statin prescription, Calcium
Blocker prescription, ACE Inhibitor prescription
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• Target variables : Townsend Score, BMI Category, Smoking status, Mo-
saic Category, Index of Multiple Deprivation
• Cluster variable: General Practice
According to van Buuren [2012], the IM used to impute the missing
records in the data set should include all the variables that are used for
data analysis and showed that having over 25 covariates in the IM hardly in-
fluence the explained variance in the imputed datasets. The IM used in this
chapter consists of 28 covariates in total and therefore adding any interaction
between covariates in the IM will hardly have an impact on the generated
datasets.
To carry out the above procedure, the package jomo (Matteo and James
[2017]) in R, is used because it permits to impute data that are hierarchical in
nature. The jomo package imputes the missing records based on a Bayesian
iterative process involving Monte Carlo simulation as described below.
(1) Using the regression coefficients of the IM, missing values for Townsend
Score, BMI Category, Smoker, Mosaic Category and Index of Multi-
ple Deprivation, respectively, are predicted. A random residual term
which is normally distributed with mean zero and variance equal to the
residual variance from the regression of the missing covariate value on
the outcome variable, is added to IM. Adding random residual terms to
the mean vector and the covariance matrix of IM produces parameter
estimates that differ randomly to those that produced the coefficient
estimates of the first IM set up in the first step of the imputation phase.
A new dataset (Dnew) with observed and imputed values is obtained.
(2) Using Dnew, the new sample means (µˆnew) and the covariance matrix
(Cˆnew) are determined.
(3) Using µˆnew and Cˆnew, a new posterior distribution is defined and used
to obtain a new set of plausible estimates for the missing values.
(4) Steps (1)–(3) are iterated continuously until convergence of the esti-
mated regression coefficients is achieved. This iteration process of con-
vergence is referred as the burn-in-length and is set to 500 iterations
for the imputation of missing records in this dataset.
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Once the designated number of burn-in-length has been completed in this
dataset, then the entire imputation process is repeated ten times to generate
ten imputed datasets. The observed data stays the same across the ten
imputed datasets. Only the values that had originally been missing will
differ. Table 9 below compares the average distribution of patients in this
study across the ten imputed datasets generated to the dataset with full case
records only. All imputed variables have a distribution close to that of the
incomplete dataset.
Table 9: Comparing average distribution of imputed variables across ten imputed
datasets to full case dataset for short term mortality analysis
Variables Levels Full Case Dataset* Average Distribution (SD) in 10 Imputed Datasets**
Townsend Scores 1 30.5% 29.3% (5%)
2 24.9% 22.8% (1%)
3 19.8% 20.7% (1%)
4 15.9% 15.6% (2%)
5 9.0% 12.6% (3%)
Missing** 16.3%
Body Mass Index Normal 46.6% 46.6% (2%)
Overweight 34.0% 32.5% (5%)
Obese 19.4% 21.6% (1%)
Missing** 9.9%
Smoking Non-smoker 69.6% 70.2% (3%)
Ex-smoker 13.1% 13.3% (2%)
Smoker 16.4% 16.5% (1%)
Missing** 26.3%
Mosaic Categeory Cat A-C 37.5% 37.6% (3%)
Cat D-F 17.5% 17.6% (5%)
Cat G-I 20.6% 20.3% (1%)
Cat J-O 24.4% 24.5% (4%)
Missing** 7.8%
Index of Multiple Deprivation 1 23.5% 23.5% (4%)
2 21.9% 22.0% (1%)
3 19.9% 19.9% (1%)
4 18.1% 18.1% (1%)
5 16.6% 16.7% (2%)
Missing** 2.0%
*Proportions determined out of a total of 74,787 patients with complete records
only.
**Average proportions calculated out of a total of 102,942 patients with complete
and imputed data, across 10 imputed datasets.
Average distribution of Townsend scores, smoking status, BMI, Mosaic category
and index of multiple deprivation across the 10 imputed datasets, is close to that
of the full cases only dataset.
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6.2.2 Checking for convergence of imputed regression coefficients
and comparing distribution of complete and imputed datasets
For the analysis of imputed datasets to yield reliable results, it must be en-
sured that the iterative algorithm, described above, has converged and that
the imputed datasets are approximately independent draws from the predic-
tive distribution (Gill (2014)). The first option to check for convergence is
to examine the potential scale reduction factor, also called Rˆ (Gelman and
Rubin (1992)) for the parameters of the imputation model (See section 3.8
for a full theoretical description of Rˆ).
The summary output for the imputation carried out using the jomo pack-
age in R is shown in Figure 19. In this analysis, Rˆ is estimated at Rˆ = 1.007,
represented by Psi in Figure 19, and is very close to one, showing that es-
timated variance within and between imputed datasets is low and close to
one. In addition, the summary also shows how the estimated coefficients of
imputation model (represented by Beta in Figure 19) used to predict the
missing values evolve against the percentage of missing data imputed. It is
observed that the estimated Beta has a minimum and maximum value of
1.00, indicating that estimated coefficients of the imputation model did not
change each time a missing variable is imputed. The estimated variance of
random effects between the ten imputed datasets have a maximum estimated
value of 1.001 (represented by Sigma in Figure 19). This means that the es-
timated variance of random effects between two randomly imputed datasets
in this imputation differ by a maximum of 0.001 only.
171
Figure 19: Summary output from multiple imputation of dataset for short term
mortality
10 datasets were generated after carrying out multiple imputation for missing values in BMI, Townsend scores, Index of
multiple deprivation, smoking status and Mosaic group, respectively. The potential scale reduction value (Psi) is estimated
at Rˆ = 1.007 and is very close to one, showing that estimated variance within and between imputed datasets is close to
one. Estimated coefficients of the imputation model stays unchanged with the number of missing data imputed (Minimum and
maximum value of Beta = 1.00). Estimated variance of random effects between the 10 imputed data sets (Sigma) is very low
and differs by a maximum of 0.001 only across the 10 data sets.
The second option to check convergence of the IM parameters is through
diagnostic trace plots that graphically represent the MCMC chain for each
imputed covariate at each iteration. Figure 20 below displays the associated
convergence plots for each of the imputed variables. They appear to converge
to a common value after about 400 iterations.
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6.3 Multilevel Cox’s Regression Analysis
6.3.1 Model development strategy
In this section, two separate multilevel Cox’s regression models are fitted to
the imputed THIN dataset to estimate all-cause hazard ratio of death after
THR procedures at one year and two years, respectively, after the surgery.
To address the objectives set out in Chapter 1, a retrospective case con-
trol study where THR patients are matched up to five controls with the
same gender, year of birth category and GP practice, is used. This allows
the estimation of the relative hazard ratio of death between THR cases and
controls, taking into account the preoperative history of comorbidities and
related treatments, lifestyle factors and residential demographics of the pa-
tients.
The two level Cox’s regression model (see section 3.5.9) fitted to the data,
is of the form
h(t, x) = Zh0(t) exp(β;x),
where h0(t) is the baseline hazard rate, x is the set of covariates fitted and Z
is the random effect (frailty) added to the Cox’s regression model to account
for the clustering effect of patients by their GP practice. The frailty Z is
assumed to have an expected value of one and has a multiplicative effect on
the individual hazard rate. It either increases (Zˆ > 1) or decreases (Zˆ < 1)
the individual all-cause hazard ratio of death, where Zˆ is the realisation of
Z for a GP practice in question.
The set of variables used to fit the above Cox’s regression model is pro-
vided in Table 44 in Appendix C. The outcome of interest in this analysis
is death after THR procedure before the end of target study periods. Pa-
tients who left their GP practice before the end of the investigation period,
were censored. For each of the one and two years survival models presented
in this section, the model selection is carried out using the backward elim-
ination method for both the full case analysis and for the imputed dataset
analysis. Initially a full model with all variables listed in Table 44 in Ap-
pendix C and without interaction terms, is set up and backward elimination
is carried out using a significance level of 5% until the best model is achieved.
The short term follow-up time for THR cases and controls is described in Ta-
ble 10 which defines the start and follow-up time to the target time. The
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chosen target times are one and two years after the THR procedure.
Table 10: Follow-up time for THR cases and matched controls for the one and two
years survival models
Follow-up THR Cases Controls Target end of study period
Start of
follow-up
THR procedure date
Date at which relevant matched
THR case underwent the procedure
1 and 2 years exactly
after surgery (for
cases) and after procedure
date of relevant THR cases
(for controls).
End of
follow-up
The earliest of either
transfer out date or
death date or
the end of study period
The earliest of either transfer out
date or death date or
the end of the study period
6.3.2 Multilevel Cox’s regression analysis one and two year after
THR procedure
Table 11 displays the results of the one and two years multilevel Cox’s re-
gression models fitted to the full case and imputed datasets to compare the
all-cause hazard ratio of death after THR procedures between THR cases and
matched controls. The final one year survival models (full case analysis and
imputed dataset analysis) consist of the following variables which have signif-
icant effect on all-cause hazard ratio of death: type of THR procedure, year
of birth category, gender, smoking status, Mosaic category, body mass index
(BMI) category, osteoarthritis, type 2 diabetes, angina, myocardial infarc-
tion, stroke and hypercholesterolemia (HC), respectively. Estimated hazard
ratios from the full-case analysis are marginally higher than estimated hazard
ratios from the imputed data sets analysis, showing that removal of patients
with incomplete data caused a marginal but not significant overestimation
of hazard ratios. Similarly, the two-year survival model fitted using full case
records includes the same list of variables as the one-year survival model in
addition to rheumatoid arthritis and hypertension, respectively, but excludes
Mosaic category (Table 11).
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The estimates of all-cause hazard ratio of death from the full-case analysis
are marginal but not significantly higher than the estimates obtained using
the multiple imputation method, showing that the exclusion of patients with
incomplete records from the analysis, lead to a slight underestimation of
the hazard ratios obtained from the survival model using patients with full
records only.
The proportionality of the hazards is a critical assumption of Cox propor-
tional hazards analysis. Specifically, the model assumes that each covariate
has a multiplicative effect in the hazards function that is constant over time.
Violation of the PH assumption can raise questions regarding the validity of
the model, and possibly lead to misleading and erroneous scientific findings.
To test for the validity of this assumption in this case-control study, a corre-
lation test of Schoenfeld residuals and event time (Grambsch and Therneau
[1994]) for each variable contributing significantly to the fitted Cox’s regres-
sion model, is carried out. Table 12 shows the estimated correlation between
Schoenfeld residuals and the event time, and their associated statistical sig-
nificance for each variable kept in the fitted one-year and two-year survival
models (complete case and imputed dataset analysis).
For the one-year survival model (complete case and imputed dataset anal-
ysis, respectively), there is no significant correlation between the Schoen-
feld residuals and the event time for only Mosaic category, pre-operative os-
teoarthritis, angina and myocardial infarction, respectively. These variables
satisfy the assumption of proportional hazards. However the remaining co-
variates in the model have strong correlation between the Schoenfeld residuals
and the event time. In addition, the global test of proportional hazards for
the multivariate Cox regression model is also strongly significant (Table 12),
indicating that the one-year model does not satisfy the assumption of pro-
portional hazards. Similarly, for the two-year survival model (complete case
and imputed dataset analysis, respectively), there are significant correlations
between the Schoenfeld residuals and the event time for all covariates kept in
the model (Table 12). In addition, the global test of proportional hazards for
the two-year multivariate Cox’s regression model is also strongly significant,
indicating that the model does not satisfy the assumption of proportional
hazards.
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Figures 32, 33, 34 and 35 in Appendix C show the plot of Schoenfeld resid-
uals versus time of death for the one- and two-year Cox regression models
fitted to the multiple imputed dataset. Graphical inspection for the one-
year model shows violation of the proportional hazards assumption for all
covariates, except for Mosaic category, pre-operative osteoarthritis, angina
and myocardial infarction. This shows that the estimated hazard ratio of
death is not constant over time for the first year model. Similarly, the graph-
ical check of the Schoenfeld residuals plots for the second year model shows
violation of the proportional hazards assumption for all covariates kept in
the two-year Cox regression model, indicating that the estimated hazards of
death is time dependent during the first 2 years after surgery.
Additionally, the assumption of proportional hazards was also checked
for Cox’s survival models fitted using the imputed data set at 1-, 3- and
6-months after the procedures. The aim was to determine whether hazard
ratios estimated using the 1-, 3- and 6-months survival models were time in-
dependent. The global test of proportional hazards were strongly significant
for the 1-month (p-value< 2.00 × 10−16), 3-months (p-value= 2.04 × 10−08)
and 6-months (p-value= 1.19×10−11) survival models, showing that violation
of the assumption of proportional hazards. Therefore estimated hazard ra-
tios were time dependent at 1-, 3-, 6-, 12- and 24-months after the procedure.
As a conclusion, the estimated all-cause hazards of death for the first
two years after THR procedures cannot be validated and used to explain
variation in short term mortality risk. Consequently, to estimate the short
term mortality risk, a multilevel logistic regression model, explained in detail
in the following section, is fitted to estimate the all-cause odds of death after
THR procedures.
6.4 Multilvel Logistic Regression Analysis
6.4.1 Study design, list of variables and model development strat-
egy
To address the objectives described in Chapter 1, a retrospective matched
cohort study design is used. The strengths and limitations of such study
design are discussed in Chapter 4. Using a matched cohort study allows esti-
mation of mortality risk at 24 months, associated with THR cases, compared
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to controls. In this study, THR cases were matched to 5 controls of the same
gender, year of birth category and general practice. The list of variables
used to fit a multivariate logistic regression model with frailty to the data is
presented in Table 44 in Appendix C. Under a multilevel logistic modelling
set-up, the length of time survived by cases and controls during the two-year
investigation period is not used. Instead, the number of deaths (represented
by death status in Table 44 in Appendix C) within the study population
within 24 months, is used to estimate the odds ratio of death between cases
and matched controls.
A multivariate logistic regression model with frailty term for GP practice,
of the form given by equation (3.74) is used to estimate the effect of THR
procedure on all-cause odds of death within the first 24 months after the
procedure. The follow-up period for THR cases started from the time they
underwent their surgery, while matched controls were followed up from the
time their matched case underwent their THR procedure. The end point of
the follow-up period is similar for both cases and controls and is defined as the
earlier of the following: (1) until patients die, (2) until patients transfer out
to a new GP practice, or (3) until the end of the investigation, at exactly 24
months after the procedure. The following models were fitted to the imputed
and full case datasets to address the different aspects of the data.
(1) Two main effects only models for full cases analysis (model mfull) and
multiple imputation analysis (model mimp),
(2) Two models with second order interaction effects for full cases analysis
(model modelfull) and imputed dataset analysis (model modelimp), and
respectively.
(3) One model with second order interaction effects for imputed dataset
analysis (model modeltrans) that exclude transferred out patients, re-
spectively.
For the main effects only model, the initial models include all covariates
presented in Table 44 in Appendix C (excluding survival time variable). For
models with interaction effects, second-order interactions between all vari-
ables in Table 44 in Appendix C (excluding survival time) with the matching
factors gender and year of birth category, THR procedure type and medi-
cal variables, respectively, are set up. A similar procedure is set up for the
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model that excludes censored patients who are transferred out before the
end of the 2 year investigation period. Backward elimination is then carried
out on each of the above mentioned models to achieve the most efficient and
economical model, with the alpha level set to 5% for fixed effects and 1%
for interaction terms, respectively. Finally each of the models also includes
a random effect due to clustering effect of general practice (frailty term) to
adjust for the in-between patients’ correlation within the same GP practice.
The models are compared to each other with respect to covariates that con-
tribute significantly to the model. The significance of the contribution of
each variable kept in the final model, after backward elimination, is tested
by decomposing the multivariate logistic regression model using analysis of
variance (ANOVA).
For the remaining sections in this chapter, the outline is as follows: a
comparison of mfull and mimp for the fixed effects only logistic regression
models, (2) a comparison of modelfull and modelimp for logistic regression
models including interaction effects and (3) a comparison of modeltrans model
that excludes censored patients versus the modelimp model including censored
observations. Each comparison comprises of the estimated effect size of the
odds ratio of death (95 % confidence interval) and their significance, and are
graphically displayed using forest plots.
6.4.2 Logistic regression model with main effects only
Results
The following variables had significant effect (p-value< 5%) on all-cause odds
of death after THR procedures for the full case and multiple imputation anal-
ysis models: sex, age at surgery, year of birth category, smoking status, BMI,
type 2 diabetes, angina, myocardial infarction, stroke, osteoarthritis, hyperc-
holesterolemia and types of THR procedure. Table 13 displays the estimated
odds ratio (OR-95% confidence interval) for each covariate kept in both mod-
els and their associated p-value for statistical significance. There are small
differences in the estimated odds ratio of death from the full case analysis
and imputed dataset analysis. This shows the importance of accounting for
missing data during the analysis. Completely ignoring the effect of missing
data in the analysis would have led to an underestimation or overestimation
of the odds ratio of death.
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The random effect (frailty term) due to grouping of patients within GP
practice, was significant (p-value < 2 × 10−16) in the model fitted to the
imputed dataset. This showed that odds ratio of death (OR) in this study
varied strongly between GP practices. OR of death within 24 months var-
ied between 0.87 (0.76,0.96) and 6.14 (4.51,7.61) across GP practices. OR
of death of THR cases were higher than matched controls (OR=1.00) for
all types of THR procedures. OR was the highest for THR cases who un-
derwent cemented procedures [OR=1.41 (1.19,1.66)] followed by uncemented
procedures [1.39 (1.19,1.61)] and other types of procedures [1.25 (1.19,1.31)],
respectively. Male patients had a higher OR [1.93 (1.45,2.45)] compared to
females. The youngest patient in the study was 18 years old at the time
of surgery and yearly increase in age at the time of surgery caused the OR
to increase by 1.06 (1.01,1.10). Relative to patients born in the 1920-1924
(OR=1.00), patients from the 1925-1929, 1930-1934 and 1935-1940 year of
birth categories had a lower OR of death estimated at 0.67 (0.59,0.66), 0.65
(0.61,0.69) and 0.59 (0.51,0.69), respectively.
Lifestyle factors such as smoking status and BMI prior to the surgery
also had significant effect on the short term OR of death after THR proce-
dures. Relative to non-smokers (OR=1.00), patients who were ex-smokers
and smokers prior to the surgery, had an OR of death estimated at 1.66
(1.40,1.97) and 2.04 (1.78,2.35). Compared to patients with normal BMI
(OR=1.00) prior to the surgery, patients who were overweight and obese be-
fore the procedure had a lower OR of death estimated at 0.84 (0.79,0.88) and
0.85 (0.80,0.89), respectively.
Among preoperative medical conditions that had significant effect on
OR of death, patients with type 2 diabetes had an estimated OR of 2.09
(1.73,2.51) compared to those without the condition (OR=1.00). Similarly
having an event of angina before the procedure increased OR of death to 1.34
(1.19,1.51), relative to patients without angina (OR=1.00). Myocardial in-
farction (MI) also doubled OR to 2.05 (1.75,2.40) relative to those without MI
(OR=1.00). Additionally, having stroke increased OR to 1.57 (1.51%,1.62) ,
compared to patients without the condition prior to the surgery (OR=1.00).
Osteoarthritis (OA) caused OR of death to increase to 1.27 (1.22,1.31) rela-
tive to patients not diagnosed with this degenerative condition (OR=1.00).
Preoperative hypercholesterolemia (HC) also increased OR of death fol-
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lowing THR procedures for all patients. Relative to participants without
hypercholesterolemia, patients with normal cholesterol level due to statins
prescription (HC category M1 in Table 13) had an estimated OR of death of
1.43 (1.38,1.49), while those with HC despite being on statins prescription
(HC category M2) had an estimated OR of 1.76 (1.64,1.88). Similarly, the
OR of death for patients with HC but not on statins prescription (HC cat-
egory M3) was estimated at 1.83 (1.44,2.33) and was therefore higher than
HC category M1 [1.43 (1.38,1.49)] and M2 [1.76 (1.64,1.88)], respectively.
Model comparisons and performance
Two models with main effects only are presented in this section; model mfull
for the full case analysis and model mimp for the model fitted using imputed
datasets. Both models include the same predictors, indicating that miss-
ing data did not have any influence on the selection of significant covariates
in the optimal model. Relative to the estimated adjusted OR of death of
mfull, short term OR of death from mimp is higher by 9% for uncemented
procedures, 5% for uncemented procedures and 0.80% for other types of pro-
cedures. These differences in the estimated OR of death during the first 24
months after the surgery arise due to the of exclusion of patients with incom-
plete records from the analysis. Incorporating missing data into the model
using multiple imputation technique showed the underestimation of the OR
of death under the full case analysis method.
Furthermore, the McFadden’s pseudo R2 value (Gordon [2012]) for model
mfull is estimated between 10.80% and 13.15% (versus 16.40% to 20.56%
for model mimp) and thus explains only between 10.80% and 13.15% of
the variation in short terms adjusted OR of death following THR proce-
dure. Therefore model mimp explains a higher degree of variability than
mfull. In addition, for 10 separate portions of the dataset used to fit the
model, the test statistics for the Hosmer-Lemeshow test is estimated at 9.65
(p-value=18.71%) for mfull and 12.41% (p-value=26.21%) for mimp, respec-
tively. Both mfull and mimp are good fit for the data with model mimp
performing better than model mfull.
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Discussion of estimated short term OR of death
In this short term mortality study, adjusted OR of death following THR
procedure were estimated using a multilevel logistic regression model with
main effects only. The results showed higher OR of death associated with
the male gender, increasing age at surgery, preoperative smoking status and
medical conditions such as type 2 diabetes, angina, MI, stroke, osteoarthritis
and hypercholesterolemia, respectively. These results are in agreement with
a number of studies which reported similar findings when comparing THR
cases to a control population: Fender et al. (1997), Lie et al. (2002), Nun-
ley and Lachiewicz (2003), Blom et al. (2006), Pedersen et al. (2011), Jones
et al. (2014), Lie et al. (2000), Williams et al. (2002), Ramiah et al. (2007),
Aynardi et al. (2009), NHS Scotland (2002), Lie et al. (2000), Hunt et al.
(2013), NHS Scotland (2002) and Lovald et al. (2014). However the model
estimated a lower OR among patients who were overweight or obese prior to
their relevant THR procedure. This result is similar to the reported findings
by Bozic et al. (2012) and Memtsoudis et al. (2012) who both reported a
lower 90-day mortality for THR cases who were either overweight or obese
pre-operatively, compared to patients with normal BMI.
However several studies, reviewed in chapter 2 of this thesis, demon-
strated that mortality risk during the first 24 months after the procedure
varied significantly for patients with various combinations of preoperative
characteristics or medical conditions. Table 14 summarises the different pub-
lications who investigated the effect of interactions between various medical
conditions and gender, age group and procedure types, respectively, on short
term mortality risk after the surgery.
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Table 14: Studies investigating effect of interactions between covariates on short
term mortality after THR
Significant interaction term reported Studies
Gender and Procedure types
Barett et al. (2005), Lie et al. (2010), Pedersen et al. (2011),
Lovald et al. (2014), Xu et al. (2017)
Age group and Procedure types
Lie et al. (2010), Pedersen et al. (2011), Lovald et al. (2014),
Xu et al. (2017)
Osteoarthritis and Procedure types Lie et al. (2000, 2002)
Osteoarthritis and Gender Lie et al. (2000, 2002)
Rheumatoid Arthritis and Procedure types Lie et al. (2002)
Diabetes and Gender Pedersen et al. (2011)
Diabetes and Procedure types Pedersen et al. (2011)
Cardiovascular diseases and Procedure types Pedersen et al. (2011), Hunt et al. (2013), Jones et al. (2014)
The studies in this table tested the signficance of the mentioned interaction terms using either a Cox’s regression or Logistic
regression model. All authors reported a significant p-value (p-value < 1%) for these interaction terms and used the estimated
hazard ratios of death or odds ratio of death to further explain the variations in short term mortality risk for each sub-category
of THR cases, relative to controls.
Based on the reported findings in Table 14, it is highly desirable to have
a mortality risk model that includes the effects of interactions between co-
variates on short term mortality risk. In this section, the two level logistic
regression model for the full case analysis and imputed datasets analysis,
respectively, only tested the main effects of the covariates included in the
model. To have a deeper insight on the variability of adjusted OR of death
at 24 months after the procedure, second order interaction terms are added
to the models presented in this section and their effects on the OR of death
within 24 months are reported in section 6.4.3.
6.4.3 Logistic regression model with interaction terms
Model selection strategy
In order to obtain a deeper insight on the variability of OR of death after
THR procedures, several interaction terms of second order are added to the
main effect models developed in section 6.4.2. Initially a full model with all
variables listed in Table 44 from Appendix C and that includes the following
interaction terms, listed below, is set up.
1. THR procedure types and demographic variables (age at surgery, gen-
der)
2. THR procedure types and lifestyle factors (smoking status, BMI)
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3. THR procedure types and social deprivation indices (Townsend score,
Mosaic score)
4. THR procedure types and preoperative medical conditions (angina, my-
ocardial infarction, stroke, osteoarthritis, rheumatoid arthritis, osteo-
porosis, hypertension, hypercholesterolemia, chronic kidney diseases)
5. THR procedure types and drug prescriptions (Ace-inhibitor, oestrogen,
progesterone, testosterone)
6. Gender and lifestyle factors (smoking status, BMI)
7. Gender and preoperative medical conditions (angina, myocardial in-
farction, stroke, osteoarthritis, rheumatoid arthritis, osteoporosis, hy-
pertension, hypercholesterolemia, chronic kidney diseases)
8. Age at surgery and lifestyle factors (smoking status, BMI)
9. Age at surgery and preoperative medical conditions (angina, myocar-
dial infarction, stroke, osteoarthritis, rheumatoid arthritis, osteoporo-
sis, hypertension, hypercholesterolemia, chronic kidney diseases)
Backward elimination is carried out firstly by excluding, one at a time,
interaction terms having no significant effect (p-value > 1%) on the OR of
death from the model and secondly, by removing main effect covariates, one
at a time, that do not statistically explain variation in the OR of death (p-
value > 5%) in order to achieve the most efficient and economical model.
Finally, the model with interaction terms also includes a random effect term
due to grouping of patients via their GP practice to adjust for between pa-
tients’ correlation within the same GP practice. Two separate multivariate
logistic regression models are developed and compared; one for a full case
analysis for patients with complete records only (modelfull) and a second
model (modelimp) using the 10 imputed datasets. modelimp is fitted using
Rubin’s rules (See section 3.87). modelfull and modelimp are compared to
each other with respect to covariates that contribute significantly to the
model. The significance of the contribution of each variable kept in the final
model, after backward elimination, is tested by decomposing the multivariate
logistic regression model using ANOVA (analysis of variance).
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Results
After backward elimination, modelimp and modelfull include the same pre-
dictors and interaction terms, as shown in Table 15. modelimp and modelfull
include the following main effects: (1) gender, (2) year of birth category,
(3) age at surgery, (4) smoking status, (5) body mass index (BMI), (6) type
2 diabetes, (7) angina, (8) myocardial infarction (MI), (9) stroke, (10) os-
teoarthritis, (11) hypercholesterolemia, respectively, and significant interac-
tion terms between (1) procedure types and gender, (2) procedure types and
smoking status, (3) procedure types and BMI, (4) procedure types and MI,
(5) gender and type 2 diabetes and (6) smoking status and BMI. The results
from modelimp presented in Table 15, are converted into OR of death (95%
confidence interval) and discussed in this section. To explain the effect of
interaction terms on short term OR of death, the results are presented using
forest plots to compare the variations in OR between several categories of
THR cases and controls.
modelimp does not include interaction between types of THR procedures
and (1) age at surgery, (2) year of birth category, (3) angina, (4) stroke,
(5) osteoarthritis and (6) hypercholesterolemia, indicating that there was
no difference in short term OR of death between THR cases and matched
controls in these categories or with these preoperative comorbidities. For all
patients in this study, yearly unit increase in age at surgery time raises the
adjusted OR of death by 30% (18%,44%) while OR of death for patients born
between 1925-29, 1930-34 and 1935-40, are equal to 0.65 (0.53,0.80), 0.64
(0.47,0.88) and 0.63 (0.44,0.91), respectively, relative to patients born in the
1920-24 year of birth category (OR=1.00). This shows that younger patients
are at a lower odds of death than older ones within the first 24 months after
THR and may also reflect the advancement in modern technology in surgical
interventions such as THR procedure with time.
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Preoperative angina, stroke and osteoarthritis increased short term ad-
justed OR of death to 1.33 (1.16,1.53), 1.40 (1.13,1.73) and 1.19 (1.05,1.36),
respectively, compared to patients without these medical conditions in this
study (OR=1.00). Preoperative hypercholesterolemia did not cause any sig-
nificant difference in OR of death between cases and controls. Relative to pa-
tients with no HC (OR=1.00), OR of death increased to: (1) 1.38 (1.09,1.76)
for patients with normal cholesterol level due to statins prescription prior
to THR surgery (Category M1), (2) 1.54 (1.27,1.88) for patients with HC
despite the statins prescription prior to THR surgery (Category M2) and
(3) 1.82 (1.62,2.04) for patients with HC but not on statins prescription
prior to THR surgery, respectively. Furthermore, OR of death for patients
with preoperative type 2 diabetes did not vary significantly between THR
cases and matched controls, but differed between female (OR=1.00) and male
[OR=2.40 (1.95,2.72)] patients in this study.
modelimp shows significant interaction between types of THR procedures
and (1) gender and (2) MI, respectively (Table 15). This indicates that
OR of death varies between male and female THR cases and matched con-
trols. Figure 21 shows the variation in adjusted OR of death for cases and
controls for both genders. Relative to female controls [OR=1.00], female
THR cases have a higher OR of death for cemented procedures [OR=1.24
(1.06,1.45)], uncemented procedures [OR=1.21 (1.08,1.35)] and other types
of procedures [OR=1.03 (1.02,1.04)], respectively. Furthermore, male con-
trols [OR=1.87 (1.66,2.11)] and male THR cases [OR=2.99 (2.45,3.52) for
cemented procedures, OR=2.66 (2.22,3.04) for uncemented procedures and
OR=2.02 (1.76,2.36) for other types of procedure, respectively] have a higher
OR of death than female controls [OR=1.00]. Thus, being male increases
the short term OR of death for controls and cases across all types of THR
procedures, with cemented procedures having the highest risk of mortality,
followed by uncemented and other types of THR procedures. Relative to
controls with no MI (OR=1.00), OR of death increases for controls with
MI [OR=1.88 (1.42,2.49)] and THR cases with MI [OR=2.95 (2.51,3.42) for
cemented procedures, OR=2.63 (2.28,2.98) for uncemented procedures and
OR=2.15 (1.81,2.39) for other types of procedure, respectively]. Hence hav-
ing an event of MI before the surgery, increases OR of death for all types of
THR procedures.
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Variations in short term OR are furthermore explained by significant in-
teractions between types of THR procedures and BMI, and also between
smoking status and BMI, respectively. This shows that preoperative BMI
and smoking status has strong effects on the estimated OR of death of differ-
ent THR procedures. Relative to controls who are non-smokers with normal
BMI [OR=1.00], a higher OR of death is estimated among obese and over-
weight controls and THR cases for all types of procedures. Figure 23 below
shows the difference in adjusted OR of death for the first 24 months after the
surgery for cases and controls with different level of preoperative BMI and
smoking status.
Figure 22 below displays the movement of OR of death for THR cases and
matched controls across different types of BMI and smoking status. Among
overweight patients, cemented procedures are associated with the highest OR
of death, followed by uncemented procedures, other types and matched con-
trols for both ex-smokers and smokers, respectively. However among obese
patients, uncemented procedures have the highest estimated OR of death,
followed by cemented procedures, other types of procedures and matched
controls among ex-smokers and smokers, respectively. Hence obesity causes
the highest increase in short term OR for uncemented procedures, while be-
ing overweight pre-operatively yields the highest increase in OR of death for
cemented procedures, for both ex-smokers and smokers, respectively.
Figure 22: Comparing OR of death for different types of THR procedures
Movement of OR for cases and controls across BMI types and smoking status. For overweight patients, cemented procedures
are associated with the highest OR of death, for all types of smoking status, while for obese patients, uncemented procedures
had the highest OR of death for smokers and ex-smokers.
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Figure 23: Variations in short terms OR of death due to second order interaction
between procedures types, BMI and smoking status
Significant interactions between types of procedures and BMI, and between BMI and smoking status showed additional source
of variability in short term OR of death. Being overweight and obese raised OR of death for all cases and controls, compared
to normal BMI patients. Relative to non-smokers, OR were higher for ex-smokers and smokers.
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OR of death within the first 24 months varied considerably between GP
practices. Variance of random effects due to GP practice is estimated at 0.021
and the 95% confidence interval of the short term OR of death associated
with GP practice is 0.88 to 6.91. For some GP practices, estimated OR of
death shows better mortality risk (OR< 1.00) and worse for different GP
practices (OR> 1.00). Adjusting for the age groups, gender, lifestyle factors
and comorbidities of the patients provides a more precise estimation of OR of
death among patients in this study. This shows the importance of accounting
for all possible sources of variations in the data. In addition, a general
practice can serve different types of patients with regards to the deprivation
level of their residential areas (Townsend scores) and socio-economic group
(Mosaic group). However, in this analysis, these factors do not significantly
explained variations in short term odds of death following THR procedure.
Thus, short term mortality after THR does not significantly depend on the
deprivation level and socio-economic group of the patients. Perhaps this
effect was confounded with the effect of GP practice on short term OR of
death in this analysis.
Multiple imputation model diagnostics and performance assess-
ment
In this section, the multivariate logistic regression model with interaction
terms fitted to estimate short term mortality after THR is assessed using di-
agnostic plots firstly to check non-linearity among predictors using Pearson
residual plots and secondly to check for the presence of outliers that can be
influential. Figures 36 and 37 in Appendix C, show the plots of the Pear-
son residuals for each predictor kept in the short term multivariate logistic
regression model in this study. Visual inspection of these plots demonstrate
no trend associated with each predictor. Figure 38 in Appendix C displays
the diagnostic plots combining Cook’s distance, studentized residuals and
hat-values. Observations indexed as 17154, 22000 and 45756 are most likely
to be outliers since they have the largest studentized residuals. To assess
whether these three observations are influential, a plot of studentized residu-
als against hat-values is used as shown in Figure 39 in Appendix C, in which
the size of the circle around each observation point is proportional to Cook’s
distance. Observations indexed as 17154, 22000 and 45756, respectively, have
the largest Cook’s distance, but moderate hat values.
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According to Martin and Pardo (2009), 0.2 is suggested as the thresh-
old for acceptable leverage, and Cook’s distance should not be greater than
4/(N − p− 1), where N is the number of observations and p is the number
of predictors in the model, respectively. In this study, the maximum value
for leverage and Cook’s distance are estimated at 0.067 and 3.15 × 10−4,
respectively, and are therefore, smaller than the cut off values suggested
by Martin and Pardo (2009). Estimated Cook’s distance of 3.15 × 10−4 is
associated with observation indexed at 45756. As a sensitivity check, this
observation was removed and the new estimates of the short term logistic
regression model were obtained and compared to the results of the model
that included observation indexed as 45756. There are very small differences
of order 1 × 10−4 between the estimates of the two models. Removal of the
suspected influential observation from the model does not significantly affect
the results of the model and thus, it can be concluded that no outliers are
influential in the model fitted to estimate short term OR of death within the
first 24 months after THR procedures.
The McFadden’s pseudo R2 value (Gordon (2012)) is estimated between
18.5% and 22.1% and thus, the fitted model explains 18.5% to 22.1% of the
variations in short term odds of death following THR in this study. Similarly,
the Hosmer-Lemeshow test is used to assess the goodness of fit of the short
term logistic model. For 10 separate segments of the dataset used to fit the
model, the test statistic for the Hosmer-Lemeshow test is estimated at 19.54
with p-value equal to 26.52%. Therefore, there is no significant difference
between the predicted OR of death among observed proportions of deaths
and that of the data set, indicating that the multivariate logistic regression
model is a good fit for the data.
Comparing performance of full case analysis to imputed data set
analysis and to the model with main effects only
Table 15 shows the summary of the full case analysis model denoted by
modelfull and fitted to observations with complete records only (N= 74,787
patients). Both models, modelimp and modelfull, respectively, include the
same predictors and interaction terms. Relative to estimated OR of death
of modelimp, estimated OR of death from modelfull, at the baseline level, are
lower by 0.05% for controls and 0.04% for other types of procedures, respec-
tively, and higher for cemented and uncemented procedures by 0.04% and
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0.01%, respectively. There are marginal differences between the estimated
OR of death of modelfull and modelimp, respectively, because the full case
analysis may include patients that are on average more sick than those ex-
cluded from the analysis due to missing records. Completeness of primary
care records depends heavily on the ill-health status of a patient and thus,
sicker patients are more likely to have more complete primary care data
records as they visit their GP practice more often.
In addition, the McFadden’s pseudoR2 value (Gordon (2012)) formodelfull
is estimated between 11.5% and 14.1% (versus 18.5% to 22.1% for modelimp)
and thus, the modelfull explains 11.5% to 14.1% of the variations in short
term odds of death following THR. Hence modelimp explains a higher degree
of variations in short term OR following THR, compared to modelfull. More-
over, for 10 separate portions of the dataset used to fit the model, the test
statistic for the Hosmer-Lemeshow test is estimated at 11.36 with p-value
equal to 16.08%. Therefore, modelfull is also a good fit for the data. How-
ever the Hosmer-Lemeshow test statistic of modelimp (test statistic=19.54%,
p-value=26.52%) is higher and more significant than that of modelfull, sug-
gesting that modelimp performs better than modelfull.
Comparing the model with main effects only, denoted by mimp (section
6.4.2) to the model including second order interaction terms, denoted by
modelimp (section 6.4.3), this section outlines the main differences between
these models and provides a discussion on why modelimp represents the best
approach in estimating variations in adjusted OR of death within 24 months
for THR cases and matched controls. mimp only provides an overall estimate
of the OR of death for cases and controls, but does not provide a deeper
insight about which preoperative characteristics or comorbidities cause sig-
nificant variation in OR of death for different types of THR procedures, rela-
tive to matched controls. modelimp shows that gender, smoking status, BMI,
type 2 diabetes and MI cause significant variations among sub-categories of
patients in this study. This improves the proportion of explained variability
in the estimation of OR of death.
6.4.4 Assessing the impact of patients transferred out
Table 8 in section 6.1 shows the proportion of patients who are transferred
out to new GP practice during the first 24 months. In total, 37 cases and 81
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controls transferred out during the short term investigation period. These pa-
tients are censored and information on their death status are thus, unknown.
Models mimp and modelimp, respectively, assume that patients transferred
out, are still alive at the end of the investigation period. To assess the valid-
ity of this assumption, a sensitivity analysis whereby the patients transferred
out are excluded from the analysis, is carried out and presented in this sec-
tion. This will aid in assessing the impact of transfer out patients on the
estimated OR of death.
Firstly the 118 transferred out patients are excluded from the dataset
and multiple imputation method (similar to section 6.2) is carried out again
to generate ten imputed datasets. A similar imputation model design to
section 6.2, is used to impute missing values for this sensitivity analysis. A
multivariate logistic regression model with frailty effect to account for the
grouping effect of GP practice, given by equation (3.74), is fitted using the
10 imputed datasets to estimate the effect of THR procedure on all-cause
OR of death within the first 24 months after the procedure. A full model
with all variables listed in Table 44 from Appendix C fixed as main effects
and that also includes the interaction terms listed in section 6.4.3, is set up.
Backward elimination is then carried out firstly by excluding, one at a time,
interaction terms having no significant effect (p-value > 1%) on the OR of
death from the model and secondly, by removing main effect covariates, one
at a time, that does not statistically explain variation in the OR of death
(p-value > 5%) in order to achieve the most efficient and economical model.
The final model obtained, is labelled as modeltrans and includes the same
main effect and interaction terms as modelimp. Table 16 provides a compar-
ison of the estimated coefficients of modeltrans and modelimp, respectively.
∆trans, the percentage difference between estimated coefficients of modeltrans
and modelimp, respectively, is determined using equation (6.1).
∆trans =
Cˆimp − Cˆtrans
Cˆimp
× 100% , (6.1)
where Cˆimp and Cˆtrans are the estimated coefficients of modeltrans and
modelimp, respectively. Estimated ∆trans varies between -0.99% and 1.97%
(Table 16). Therefore, relative to Cˆimp, excluding patients who are trans-
ferred out before the end of the investigation period overestimates Cˆtrans by
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a maximum value of 0.99% for the following covariates in the model: (1) year
of birth category, (2) smoking status, (3) hypercholesterolemia status and (4)
interaction between procedure types and smoking status, respectively, while,
the remaining Cˆtrans are smaller than Cˆimp by a maximum of 1.97%.
In addition, the McFadden’s pseudoR2 value (Gordon (2012)) formodeltrans
is estimated between 18.2% and 21.8%, versus 18.5% to 22.1% for modelimp.
Therefore modeltrans only causes a marginal decrease in explained degree of
variations in short term OR following THR, compared to modelfull. This
reduction can mainly be associated to the exclusion of 118 observations from
the analysis. Moreover, for 10 separate portions of the dataset used to fit
modeltrans, the test statistic for the Hosmer-Lemeshow test is estimated at
17.76 with p-value equal to 28.08%. Therefore, modeltrans is also a good fit
for the data.
As a check for non-linearity among predictors in modeltrans, visual in-
spection of Pearson residual plots demonstrates no trend associated with
each predictor kept in modeltrans. Similarly, graphical check of the plot of
studentized residuals against Cook’s distance reveals the presence of six out-
liers in modeltrans. These outliers are not influential because they have low
Cook’s distance. The maximum value of Cook’s distance is estimated at
2.1 × 10−02 and is associated with observation 65152. Exclusion of this ob-
servation from the analysis as a sensitivity check, does not impact on the
estimated parameter of modeltrans.
As a conclusion, this sensitivity analysis shows that exclusion of patients
who are transferred out before the end of the investigation period causes
marginal differences in the estimated coefficients of modeltrans, when com-
pared to the estimated coefficients of modelimp. There are also marginal
differences in the performance and model fit of modeltrans and modelimp.
Therefore keeping transferred out patients in the study and assuming that
they stay alive until the end of the study, is a reasonable assumption that
impacts marginally on the estimation of short term OR of death.
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6.5 Discussion and validation of results
In this chapter, adjusted OR of death for the first 24 months after THR
procedures for UK patients born between 1920 and 1940, inclusive, are esti-
mated using a multilevel logistic regression model. Estimated OR of death
for cases with no preoperative medical comorbidities undergoing cemented,
uncemented and other types of THR procedures are higher than estimated
OR for matched controls, higher for male cases compared to female ones
and yearly increase in age of patients at surgery, increases short term OR,
respectively (Table 15 and Figure 21). These results are in agreement with
the following publications which reported that for the first 24 months after
the surgery, survival of male THR cases is worse than that of female THR
cases, matched controls and increases for patients undergoing the procedure
at older ages: Fender et al. (1997), Lie et al. (2002), Nunley and Lachiewicz
(2003), Blom et al. (2006), Pedersen et al. (2011), Jones et al. (2014), Lie
et al. (2000), Williams et al. (2002), Ramiah et al. (2007), Aynardi et al.
(2009), NHS Scotland (2002), Lie et al. (2000), Hunt et al. (2013), NHS
Scotland (2002) and Lovald et al. (2014).
In addition, the Kaplan Meier survival analysis revealed that the excess
mortality for THR cases peaks during the first 3 months and then decreases
and converges to that of matched controls between 12 to 24 months after the
procedure, for both genders(Figure 16). Barrett et al. (2005) found that du-
ration of excess mortality associated with THR cases, compared to age and
gender matched controls, peaks at about 30 to 60 days after the surgery and
then decreases slowly to zero until about 90 days after the surgery. Further-
more Lie et al. (2002) reported a similar trend with the duration of excess
mortality in the short term continuing up to 24 months after the procedure.
Hence estimated duration of excess mortality following THR in this study is
consistent with published articles.
Compared to controls with normal BMI, this study concluded that being
overweight prior to THR increases short term OR of death for all types of
THR procedures. This result is in accordance to the studies by Bozic et al.
(2012) and Memtsoudis et al. (2012), Bozic et al. (2012) and Memtsoudis
et al. (2012), respectively. Preoperative obesity on its own increases OR of
death for all types of THR procedures, compared to controls with normal
BMI in this study. Furthermore being overweight and obese pre-operatively
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increased short term OR of death for all types of THR procedures among ex-
smokers or smokers prior to their THR procedure, respectively, compared to
non-smoking controls with normal BMI (Figure 23). The results of this short
term study also revealed significant effects on short term OR of death due to
the interaction between BMI and smoking status among cases and controls.
No study in literature reviewed in Chapter 2 reported effects of preoperative
smoking status and BMI, either as main effects or as interaction effects on
short term OR of death after THR.
Pre-surgery myocardial infarction (MI) significantly increases short term
OR of death for all types of THR procedures compared to controls with no
history of MI. This result is in agreement with Hunt et al. (2013), which
estimated a three-fold increase for mortality after THR for cases with preop-
erative events of MI, relative to controls without a history of MI. Similarly,
Comba et al. (2012) reported that a history of cardiovascular diseases prior
to THR procedure increased the risk of mortality of THR cases eight-fold,
relative to controls without cardiovascular diseases. However the authors did
not distinguish between the types of cardiovascular disease as carried out in
this study for different types of THR procedures.
Finally this study found no significant difference in short term OR of
death of cases and matched controls with either preoperative angina, stroke,
hypercholesterolemia (HC) or type 2 diabetes. However these comorbidities
increase odds of death of patients given these preoperative medical condi-
tions, compared to those without. Osteoarthritis is the main reason for THR
in this study but for cases with OA, OR of death for cemented, uncemented
and other types of procedures do not differ significantly. Thus, OA increases
OR of death to the same level for all patients in this study. Similar finding
is shown in studies by Fender et al. (1997), Lie et al. (2000), Williams et al.
(2002), Barrett et al. (2005), Pedersen et al. (2011), Xu et al. (2017) and
Boniello et al. (2017), respectively.
Among the preoperative medical conditions that do not vary significantly
for different type of procedures in this study, only the effect of preoperative
type 2 diabetes on short term mortality at 3 months after the procedure,
was investigated by Pedersen et al. (2011), who also reported no significant
difference in mortality between cases and controls diagnosed with type 2
diabetes before the surgery.
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6.6 Strengths and limitations
In this short term investigation, primary care data that are routinely collected
in the THIN database, are used to estimate odds of death at 24 months after
THR. THIN data is representative of the UK population for various demo-
graphic, lifestyle factors and medical conditions (Blak et al. (2011), Langley
et al. (2011), Gonza´lez et al. (2009), Hippisley-Cox and Coupland (2010a),
MacDonald and Morant (2008)). Therefore primary care database such as
THIN provides good coverage of THR cases during the study period and also
allows to generalise the findings of this study to the general UK population.
This study is designed as a matched cohort study. This allows to directly
estimate the effect of different types of THR procedures on short term odds
ratio of death of cases compared to controls, matched on gender, year of
birth category and GP practice, while adjusting for a number of confounders
such as preoperative lifestyle factors, demographic covariates, comorbidities
and interactions between each of these confounders. In literature reviewed in
Chapter 2, no previous study has adjusted for so many confounders. Further-
more, this study found several preoperative lifestyle factors (smoking status)
and medical conditions (obesity and MI), that significantly cause a difference
in odds ratio of death for cases undergoing different types of THR procedures.
These findings may be used by healthcare professionals for medical and risk
management for THR cases and patients waiting to undergo THR, respec-
tively.
However, no information describing the type of prosthesis, surgical ap-
proach and surgeon experience is available in THIN. These variables have
significant effect on survival after THR procedure (Whitehouse et al. (2014)).
Estimated odds of death in this analysis are not adjusted for these variables
and survival after THR could not be differentiated for various types of pros-
thesis, surgical approach and surgeon experience. Additionally, patients who
are transferred out before the end of the two years investigation period are
lost to follow-up and their death status is unknown for the remaining period
of the investigation. However these patients are assumed to be alive until the
end of the two year period. The strength of this assumption has been tested
using a sensitivity analysis whereby it is shown that exclusion of transfer
out patients from the analysis does not impact significantly on the estimated
odds ratio of death.
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Variables related to pollution levels and ethnicity are not available for
patients from Scotland and Northern Ireland. Pollution levels and ethnicity
were thus not included in the analysis since these variables had values not
missing at random. However missing values for variables that were missing
at random for all English, Welsh, Northern Irish and Scottish patients (BMI,
Townsend scores, IMD, smoking status and Mosaic groups) were handled by
employing the multiple imputation method. Finally, estimated short term
OR was adjusted for drug prescriptions given prior to THR procedure. One
limitation with this approach is that patient’s adherence to the drug therapy
is unknown, thereby not precisely reflecting the effects of drug therapy on
short term mortality following THR.
6.7 Conclusions
The study described in this chapter estimated the adjusted all-cause odds of
death at 24 months after total hip replacement procedures. Odds ratio of
death for THR cases were higher than matched controls for both genders and
increased for with age at surgery. Short term odds ratio of death was the
highest for cemented procedures, followed by uncemented and other types of
procedures. Among preoperative risk factors that significantly impacted on
short term odds ratio of death, obesity, smoking and myocardial infarction
increased odds of death for all types of THR procedures, compared to cases
without these preoperative conditions and lifestyle factors.
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7 Long Term Survival Analysis After Primary
Total Hip Replacement
Chapter outline
This chapter presents the long term survival analysis after had a total hip
replacement procedures. The dataset used for this analysis is described in
Chapter 5 and represents patients who survived their first two years after the
surgery. Firstly, Kaplan-Meier survival analysis is carried out as preliminary
analysis to compare the survival between THR cases and matched controls
for different gender, age groups and THR procedure types. Secondly, the full
procedure to carry out the multiple imputation of missing data is described
and assessed. Thirdly, multilevel Cox’s regression analysis is used to fit
survival models for full case data, using complete records only and for survival
analysis of the multiple imputed datasets, to compare the results of these two
approaches. A discussion on the validity of each Cox’s regression models,
evaluated in terms of performance, both internally and externally, is then
provided. These survival models explain variations in the estimated hazard
ratios between cases and controls and also between various general practices
in the UK. Finally, the results of these survival models are presented using
forest plots and their validity is discussed in details.
7.1 Model development strategy
7.1.1 Patients exclusion
According to the review of 15 published studies carried out in Chapter 2,
section 2.3, long term survival analysis after total hip replacement (THR)
procedures included patients who only survived at least one year after the
procedure. This is because in the early post-operative period after surgery,
there is an excess mortality risk associated with THR cases, compared to
controls. This excess mortality disappears between 12 and 24 months after
the procedure. Therefore to allow for this change in mortality among THR
cases, several authors (see section 2.3) developed their long term survival
models conditional on the assumption that the patients survived the short
term period where their risk of mortality was highest.
In this research, the follow-up period for the short term study (Chapter
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6) was defined as the first 24 months after the surgery. Thus, patients who
died or transferred out within that follow-up period, were excluded from the
dataset used in this long term study. Table 17 below shows the proportion of
THR cases and controls who were transferred out or died within the first 24
months after the procedure and in those surviving more than 24 months. In
total, 2006 patients died or transferred out in the first 24 months of follow-up
and they are excluded from the dataset used in this chapter. Therefore, all
survival models developed in this long term analysis are conditional on the
patients staying in the study for at least 24 months after the surgery.
Table 17: Distribution of transfers out and deaths after THR procedures in the
first 24 months and after 24 months
Gender Age group
0-2 years follow-up 2+ years follow-up*
No. of
Patients
Transfers
out
%
No. of
Deaths
%
No. of
Patients
Transfers
out
%
No. of
Deaths
%
THR
Cases
Male 18-54 177 2 1.13% 0 0.00% 175 100 57.1% 39 22.3%
55-64 1141 3 0.26% 20 1.75% 1118 605 54.1% 298 26.7%
65-74 2972 7 0.24% 66 2.22% 2899 1144 39.5% 728 25.1%
74-85 1993 6 0.30% 39 1.96% 1948 730 37.5% 582 29.9%
85+ 228 2 0.88% 5 2.19% 221 60 27.1% 82 37.1%
All ages 6511 20 0.31% 130 2.00% 6361 2639 41.5% 1729 27.2%
Female 18-54 281 3 1.07% 0 0.00% 278 150 54.0% 62 22.3%
55-64 1457 2 0.14% 32 2.20% 1423 729 51.2% 309 21.7%
65-74 4538 6 0.13% 85 1.87% 4447 1794 40.3% 926 20.8%
74-85 3847 5 0.13% 58 1.51% 3784 1462 38.6% 879 23.2%
85+ 523 1 0.19% 11 2.10% 511 131 25.6% 107 20.9%
All ages 10646 17 0.16% 186 1.75% 10443 4266 40.9% 2283 21.9%
Controls Male 18-54 1002 5 0.50% 0 0.00% 997 497 49.8% 195 19.6%
55-64 5859 4 0.07% 70 1.19% 5785 2697 46.6% 1252 21.6%
65-74 14606 11 0.08% 304 2.08% 14291 4884 34.2% 3482 24.4%
74-85 9851 3 0.03% 229 2.32% 9619 2649 27.5% 3353 34.9%
85+ 1237 2 0.16% 20 1.62% 1215 135 11.1% 528 43.5%
All ages 32555 25 0.08% 623 1.91% 31907 10862 34.0% 8810 27.6%
Female 18-54 1480 8 0.54% 0 0.00% 1472 689 46.8% 237 16.1%
55-64 7594 6 0.08% 0 0.00% 7588 3168 41.8% 1232 16.2%
65-74 22460 13 0.06% 487 2.17% 21960 7467 34.0% 4226 19.2%
74-85 18978 17 0.09% 415 2.19% 18546 5370 29.0% 5009 27.0%
85+ 2718 12 0.44% 47 1.73% 2659 318 12.0% 948 35.7%
All ages 53230 56 0.11% 949 1.78% 52225 17012 32.6% 11652 22.3%
*Proportion of transfers out and deaths for various age groups determined after excluding patients who dropped out or died
within the first 24 months after the procedure
7.1.2 Follow-up time, outcome and censoring
Cases join the study period from the time they undergo their THR procedure
while controls follow up period starts on the date when their matched THR
case undergo their surgery. Cases and controls are both followed up until
the earliest of the following outcomes: (1) the end of the study period on
1st July 2011, (2) the date of transfer out to new GP practice and, (3) the
date of death. The main outcome of interest in this long term study is
time to death after THR procedures. For patients with death dates before
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the end of the investigation period (1st July 2011), their follow-up time is
completely observed. For patients who are alive at 1st July 2011, the outcome
of interest is unknown (right censoring) and their follow-up time is estimated
as the difference between the time they underwent their surgery until 1st
July 2011. Patients who are transferred out to new GP practice before 1st
July 2011, are also right censored as their death information is also unknown
and their follow-up time is defined as the difference between the time they
joined the study and their transfer out date. Male and female cases have a
mean follow-up time of 9.63 years (range: 2.01-52.15 years) and 9.53 years
(range: 2.01-58.07 years) respectively. Male and female controls have a mean
follow-up time of 9.93 years (range: 2.01-56.08 years) and 9.98 years (range:
2.01-59.50 years) respectively. The overall mean follow-up time for cases and
controls combined, is 9.89 years (range: 2.01-59.50 years).
7.1.3 Multiple imputation of missing data
The imputation phase
Table 7 in section 5.2.9 displays the proportions of missing data for BMI,
smoking status, Townsend score, Index of multiple deprivation and Mosaic
category among THR cases and matched controls, included in this study.
Missing values within these variables are assumed to be missing at random
(see section 5.2.9). In the first stage of multiple imputation, there are two
key aspects that should be considered:
• Defining the measurement scale of the covariates with incomplete records,
and
• Defining the appropriate regression model as the imputation model
(IM).
In the dataset analysed in this chapter, BMI, smoking status, Townsend
scores, Index of multiple deprivation and Mosaic category are categorical in
nature with more than two levels. Therefore the appropriate IM model to
impute missing records for these variables, is defined as a multivariate linear
mixed model (Schafer and Yucel [2002]) and is of the form shown below.
yi = Xiβ + Zibi + εi, i = 1, ...,m,
where yi is the matrix of incomplete multivariate data for the i
th cluster, β
is the matrix of coefficients common to the population (fixed effects), bi is
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the matrix of coefficients specific to the ith cluster (random effects), Xi is
the matrix of covariates for fixed effects, Zi is the matrix of covariates for
random effects bi and εi is the matrix of residual errors.
The covariates with complete and incomplete records, and the cluster
variables in this study are categorised as:
• Fixed effect predictors : Case-Control Indicator, Sex, Year of Birth
Category, Transfer Status of patients, Age group at surgery, Survival
time, Type 2 Diabetes, Heart Attack, Angina, Stroke, Chronic Kidney
Disease, Rheumatoid arthritis, Osteoarthritis, Oestrogen prescription,
Progesterone prescription, Testosterone prescription, Hypercholesterolemia,
Hypertension, Beta Blocker prescription, Statin prescription, Calcium
Blocker prescription, ACE Inhibitor prescription
• Target variables : Townsend Score, BMI Category, Smoking status, Mo-
saic Category, Index of Multiple Deprivation
• Cluster variable: General Practice
According to van Buuren [2012], the IM used to impute the missing
records in the data set should include all the variables that are used for
data analysis, and having over 25 covariates in the IM hardly influences the
explained variance in the imputed datasets. The IM used in this chapter con-
sists of 28 covariates in total and therefore adding any interactions between
covariates in the IM will hardly have an impact on the generated datasets.
To carry out the multiple imputation, the package jomo (Matteo and
James [2017]), is used because it permits to impute data that are hierarchical
in nature. The jomo package imputes the missing records based on a Bayesian
iterative process involving Monte Carlo simulation as described below.
(1) Using the regression coefficients of the IM, missing values for Townsend
Score, BMI Category, Smoker, Mosaic Category and Index of Multi-
ple Deprivation, respectively, are predicted. A random residual term
which is normally distributed with mean zero and variance equal to
the residual variance from the regression of the missing covariate value
on the outcome variable, is added to the IM. Adding random residual
terms to the mean vector and the covariance matrix of the IM produces
parameter estimates that differ randomly to those that produced the
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coefficient estimates of the first IM initiated in the first step of the
imputation phase. A new dataset (Dnew) with observed and imputed
values is obtained.
(2) Using Dnew, the new sample means (µˆnew) and the covariance matrix
(Cˆnew) are determined.
(3) Using µˆnew and Cˆnew, a new posterior distribution is defined and used
to obtain a new set of plausible estimates for the missing values.
(4) Steps (1)–(3) are iterated continuously until convergence of the esti-
mated regression coefficients is achieved. This iteration process of con-
vergence is referred as the burn-in-length and is set to 500 iterations
for the imputation of missing records in this dataset.
Once the designated number of burn-in-length has been completed in this
dataset, the entire imputation process is repeated ten times to generate ten
imputed datasets. The observed data stay the same across the ten imputed
datasets. Only the values that had originally been missing will differ. Table
18 below compares the average distribution of patients across the ten imputed
datasets generated to the dataset with full case records only. All imputed
variables have a distribution close to that of the incomplete dataset.
208
Table 18: Comparing average distribution of imputed variables across ten imputed
datasets to incomplete full cases only, dataset for long term survival analysis
Variables Levels Incomplete Dataset* Average Distribution (SD) in imputed dataset**
Townsend Score
1 29.5% 29.3% (5%)
2 23.8% 22.8% (1%)
3 20.9% 20.7% (1%)
4 14.3% 15.6% (2%)
5 11.5% 12.6% (3%)
Missing** 16.3% 0%
Body Mass Index
Normal 45.6% 46.6% (2%)
Overweight 33.6% 32.5% (5%)
Obese 20.8% 21.6% (1%)
Missing** 9.9% 0%
Smoking
Non-smoker 62.6% 68.8% (3%)
Ex-smoker 13.8% 14.1% (2%)
Smoker 23.6% 24.3% (1%)
Missing** 26.3% 0%
Mosaic Categeory
Cat A-C 36.5% 36.6% (3%)
Cat D-F 17.4% 17.4% (5%)
Cat G-I 23.2% 23.2% (1%)
Cat J-O 22.9% 23.0% (4%)
Missing** 7.8% 0%
Index of Multiple Deprivation
1 23.3% 23.4% (4%)
2 21.9% 22.0% (1%)
3 20.1% 20.1% (1%)
4 18.1% 18.1% (1%)
5 16.6% 16.6% (2%)
Missing** 2.2% 0%
*Proportions determined out of a total of 74,762 patients with complete records
only.
**Average proportions calculated out of a total of 100,936 patients with complete
and imputed data, across 10 imputed datasets.
Average distribution of Townsend scores, BMI, smoking status, Mosaic category
and index of multiple deprivation across the 10 imputed datasets, is close to that
of the full cases only dataset.
Checking for convergence of imputed regression coefficients and
comparing distribution of complete and imputed datasets
For the analysis of imputed datasets to yield reliable results, it must be
checked that the iterative algorithm, described above, has converged and that
the imputed datasets are approximately independent draws from the predic-
tive distribution (Gill (2014)). The first option to check for convergence is
to examine the potential scale reduction factor, also called Rˆ (Gelman and
Rubin (1992)) for the parameters of the imputation model (See section 3.8
for a full theoretical description of Rˆ).
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Figure 19 shows the summary output for the multiple imputation carried
out using the jomo package in R. Rˆ, represented by Psi in Figure 19, is
estimated at 1.011 and is very close to one, showing that estimated variance
within and between imputed datasets is low and close to one. Furthermore,
the summary also shows how the estimated coefficients of imputation model,
represented by Beta in Figure 19, used to predict the missing values, change
against the percentage of missing data imputed. It is observed that the es-
timated Beta has a minimum and maximum value of 1.00, indicating that
estimated coefficients of the imputation model did not evolve each time a
missing variable is imputed during the iterative process. The estimated vari-
ance of random effects between the ten imputed datasets have a maximum
estimated value of 1.001 (represented by Sigma in Figure 24). This means
that the estimated variance of random effects between two randomly imputed
datasets in this imputation differ by a maximum of 0.001 only.
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Figure 24: Summary output for multiple imputation of dataset for long term mor-
tality
10 datasets were generated after carrying out multiple imputation for missing values in BMI, Townsend scores, Index of multiple
deprivation, smoking status and Mosaic group, respectively. The potential scale reduction value (Psi) is estimated at 1.011
and is very close to one, showing that estimated variance within and between imputed datasets is close to one. Estimated
coefficients of the imputation model stay unchanged with the number of missing data imputed (Minimum and maximum value
of Beta = 1.00). Estimated variance of random effects between the 10 imputed data sets (Sigma) is very low and differs by a
maximum of 0.001 across the 10 data sets.
The second option to check convergence of the IM parameters is through
visual inspection of diagnostic trace plots that graphically represent the
MCMC chain for each imputed covariate at each iteration. Figure 25 below
displays the associated convergence plots for each of the imputed variables.
The parameters of the IM model have converged to a common value after
500 iterations.
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7.2 Kaplan-Meier survival analysis
As a preliminary analysis, Kaplan-Meier survival analysis is carried out to
compare the long term survival of patients for each gender, age group and
types of THR procedures, respectively. Patients who were transferred out to a
new GP practice were censored. To compare the statistical difference between
survivorship in each category, the log-rank test (Grambsch and Therneau
[1994]), presented in section 3.4, is used.
Figure 26 shows the differences in survival between male and female THR
cases and their matched controls who stayed in the study for more than two
years after the procedure. It can be observed that the survivorship of fe-
male THR cases is better than male cases (p-value of log-rank test=0.0003).
Survival of male THR cases is better than male controls (p-value of log-
rank test=0.0011) up to about 30 years after the surgery while survival of
female cases stays higher than that of female controls (p-value of log-rank
test=0.0086) and male controls (p-value of log-rank test=0.0009), respec-
tively, until the end of the study period.
Figure 27 compares the differences in survival between different age groups
for THR cases surviving the first two years after surgery. It can be observed
that survival of younger patients are better than older age groups. There are
significant differences in survival of older age groups, relative to the youngest
category (18-54). The p-values of the log-rank test comparing each category
to the 18-54 age group are all significant (p-value< 0.05).
Figure 28 compares the long term survival of THR cases across proce-
dure types. The percentage survivorship for male cases who underwent hy-
brid or other types of procedures is higher than cemented procedures until
about 18 years after the surgery (p-value of log-rank test=0.0004) and unce-
mented procedures until about 23 years after the surgery (p-value of log-rank
test=0.0002), respectively. Similarly, survival of female cases who under-
went hybrid or other types of procedures is higher than cemented (p-value
of log-rank test=0.0010) and uncemented procedures (p-value of log-rank
test=0.0004), respectively, until about 25 years after the surgery.
In addition, survival of male cases with uncemented THR procedures was
better than cemented procedures until about 10 years after surgery (p-value
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of log-rank test=0.0018). Among female cases, survival of uncemented THR
procedures was better than cemented THR procedures until about 25 years
after the surgery (p-value of log-rank test=0.0002). However the preliminary
variations in survival of male and female cases, depicted in Figure 28, do not
account for the fact that the types of THR procedures carried out, depend
strongly on the age group and health status of the patients. Thus further
analysis, whereby the age group and medical comorbidities of the patients are
factored in, is required to understand and estimate the variations in survival
of THR cases with different types of procedures.
Figure 26: Survival plot comparing THR cases to matched controls
Comparing the Kaplan-Meier survival curves between THR cases and matched controls for both genders
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Figure 27: Survival plot comparing THR cases of different age groups
Comparing the Kaplan-Meier survival curves for THR cases across age groups at surgery time
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7.3 Multilevel Cox’s regression analysis
7.3.1 Model development strategy
To answer the research objectives set out in chapter one, a retrospective case
control study where THR cases are matched to five controls with the same
gender, year of birth category and GP practice, is used. This permits the
estimation of the relative hazard ratio (HR) of death between THR cases
and controls, taking into account the preoperative history of comorbidities
and related treatments, lifestyle factors and residential demographics of the
patients. The strengths of a case control study design, applied to this long
term survival analysis, are discussed in section 4.1.
The two level Cox’s regression model (see section 3.5.9) fitted to the data,
is of the form
h(t, x) = Zh0(t) exp(β;x),
where h0(t) is the baseline hazard rate, x is the set of covariates fitted and Z
is the random effect (frailty) added to the Cox regression model to account
for the clustering effect of patients by their GP practice. The frailty Z is
assumed to have an expected value of one and has a multiplicative effect on
the individual HR of death. It either increases (Z > 1) or decreases (Z < 1)
the individual all-cause hazard ratio of death. Including a second level ran-
dom effect, Z, in the regression model allows the estimation of the variation
in HR of death between clusters (GP practices) of patients.
The set of variables used to fit the above Cox’s regression model is pro-
vided in Table 44 in Appendix C. The outcome of interest in this analysis is
death after THR procedures. Patients who left their GP practice before the
end of the investigation period, were censored. Section 7.1.2 for details.
For the main effects only model, a full model with all variables listed in
Table 44 in Appendix C as main effects, is set up and backward elimina-
tion is carried out using a significance level of 5% until the best model is
achieved. For survival models including second-order interaction terms, an
initial full model with all variables listed in Table 44 in Appendix C as main
effects and second-order interaction effects, listed in section 7.3.3, is set up.
Backward elimination is then carried out using a significance level of 5% for
main effects and 1% for second-order interaction terms, respectively, until
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the optimal model is achieved. Four survival models are presented in this
section, namely the main effect model (1) for full case analysis (Lfull) and (2)
for multiple imputation analysis (Limp), respectively, and the survival model
with interaction effects for (3) full case analysis (Longfull) and (4) multiple
imputation analysis (Longimp), respectively.
7.3.2 Cox’s regression models with main effects only
Results
Table 19 shows the analysis of variance table for the final models with main
effects only, fitted using the full case and imputed datasets. The full case
analysis results show that the final model, denoted by Lfull, consists of the
following main effects: (1) GP practice, (2) Sex, (3) Townsend score, (4)
Mosaic category, (5) Type of procedure, (6) Smoking status (7) Stroke, (8)
BMI, (9) Osteoarthritis, (10) Osteoporosis, (11) Hypercholesterolemia and
(12) Type 2 diabetes, respectively. In addition to these variables, the Cox’s
model fitted using ten imputed datasets, labelled as Limp, showed that pre-
operative myocardial infarction (MI) and angina also had significant effect
on the variations of estimated hazard ratios of death. This shows the impor-
tance of comparing the results of full case analysis to multiple imputation
analysis since the latter also reveals that MI and angina are risk factors for
long term mortality after THR procedures. Under the full case analysis,
majority of the patients who had an event of MI or angina before surgery
were excluded from the survival analysis because they had missing records
for other covariates. Therefore the full case Cox’s model failed to detect MI
and angina as risk factors.
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Table 19: Analysis of variance results comparing full case analysis to multiple
imputation analysis for main effects only model
Variables
Full Case Analysis Multiple Imputation Analysis
Loglik Chisq Df P-value Loglik Chisq Df P-value
Empty Model -171429 -171426
GP Practice -171313 233.25 301 <2.0E-16 -171288 211.53 401 <2.0E-16
Stroke -171250 124.32 1 <2.0E-16 -171235 102.98 1 <2.0E-16
Townsend Scores -171097 307.62 4 <2.0E-16 -171096 284.04 4 <2.0E-16
Mosaic Category -171066 61.68 3 1.26E-13 -171060 48.10 3 9.9E-11
Procedures Types -171064 0.43 3 2.11E-01 -171036 15.82 3 5.8E-04
Myocardial Infarction NA -170923 21.25 1 2.1E-06
Angina NA -170889 72.95 1 <2.0E-16
BMI -170935 258.19 2 <2.0E-16 -170863 240.12 2 <2.0E-16
Osteoarthritis -170891 89.20 1 <2.0E-16 -169894 78.76 1 <2.0E-16
Osteoporosis -170891 5.17 1 1.32E-02 -169557 15.98 1 3.4E-05
Hypercholesterolaemia -169915 1951.33 3 <2.0E-16 -169497 1940.36 3 <2.0E-16
Type 2 Diabetes -169574 681.99 1 <2.0E-16 -167223 664.01 1 <2.0E-16
Sex -169520 107.56 1 <2.0E-16 -167223 89.92 1 <2.0E-16
Smoking Status -167242 4555.86 2 <2.0E-16 -167208 4551.33 2 <2.0E-16
The above results show that the full case model is a subset of the multiple imputation final model fitted using 10 imputed
datasets. In addition to the covariates kept in the full case model, myocardial infarction and angina were also significant risk
factors causing variations in long term hazard ratio of death estimated from the Cox’s model fitted using multiple imputation
analysis.
Assessing assumption of proportional hazards
The proportionality of the hazards is a critical assumption of Cox propor-
tional hazards analysis. Specifically, the model assumes that each covariate
has a multiplicative effect in the hazard function that is constant over time.
Violation of the proportional hazards (PH) assumption can raise questions
regarding the validity of the model, and possibly lead to misleading and erro-
neous scientific findings, when interpreting the estimated parameters of the
fitted Cox’s regression model. To test for the validity of the PH assumption
in this analysis, a correlation test between Schoenfeld residuals and event
time (Grambsch and Therneau [1994]) for each variable contributing signifi-
cantly to the fitted Cox regression model, is carried out.
Table 20 shows the estimated correlation between Schoenfeld residuals
and the event time, and their associated statistical significance for each vari-
able kept in Lfull and Limp, respectively. For both models, there is no signif-
icant correlation between the Schoenfeld residuals and the event time for all
covariates kept in the model (p-value of Chi-square test > 5%). Therefore
these variables satisfy the assumption of proportional hazards. Furthermore,
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the global test of proportional hazards test for both Lfull and Limp, respec-
tively, is also insignificant (Table 20), indicating that estimated HR of death
for both models are independent of time.
Table 20: Assessing assumption of proportional hazards for main effects model
Variables Levels
Full Case Analysis Multiple Imputation Analysis
rho chisq P-value rho chisq P-value
Stroke No
Yes 0.0170 0.547 4.1E-01 0.0230 0.669 3.49E-01
Townsend Scores 1
2 -0.0028 1.067 2.3E-01 0.0062 1.143 2.11E-01
3 0.0049 0.221 7.6E-01 0.0091 0.292 6.39E-01
4 0.0142 0.953 2.5E-01 0.0241 1.108 2.18E-01
5 0.0054 0.292 6.4E-01 0.0071 0.405 5.12E-01
Mosaic Category Cat A-C
Cat D-F -0.0046 0.198 8.1E-01 0.0007 0.351 5.66E-01
Cat G-I 0.0025 0.059 1.6E-01 0.0066 0.272 6.67E-01
Cat J-O -0.0080 0.675 3.5E-01 -0.0026 0.702 3.35E-01
Procedures Types Controls
Cemented 0.0236 1.311 1.8E-01 0.0311 1.319 1.80E-01
Uncemented 0.0376 1.071 2.3E-01 0.0456 1.203 1.99E-01
Others 0.0756 1.050 2.3E-01 0.0850 1.179 2.04E-01
Angina No
Yes NA -0.0082 1.038 2.33E-01
Myocardial Infarction No
Yes NA -0.0258 0.875 2.75E-01
BMI Normal
Overweight -0.0121 1.235 1.9E-01 0.0093 1.405 1.67E-01
Obese -0.0268 0.052 1.7E-01 0.0673 0.152 9.48E-01
Ostearthritis No
Yes 0.0054 0.254 7.0E-01 0.0077 0.264 6.80E-01
Osteoporosis No
Yes 0.0644 0.965 2.5E-01 0.0151 1.135 2.12E-01
Hypercholesterolaemia HC Category 0
HC Category 1 -0.0008 1.006 2.4E-01 0.0030 1.048 2.31E-01
HC Category 2 0.0140 1.500 1.5E-01 0.0136 1.579 1.44E-01
HC Category 3 -0.0028 0.068 1.9E-01 0.0349 0.782 3.05E-01
Type 2 Diabetes No
Yes 0.0043 0.159 9.2E-01 -0.0541 0.263 6.82E-01
Sex Female
Male 0.0342 1.276 1.9E-01 -0.0628 1.497 1.54E-01
Smoking Non-Smoker
Ex-smoker -0.0578 0.797 3.0E-01 0.0448 0.960 2.52E-01
Smoker -0.0692 1.114 2.2E-01 0.0929 1.302 1.82E-01
Global Test of Proportional hazards NA 15.050 1.4E-01 NA 20.942 3.58E-01
All variables kept in the full case and multiple imputation analysis models, respectively, have a p-value greater than 5%, showing
that the estimated hazard ratio of death associated with these covariates are independent of survival time in this study. A similar
results are obtained for the global test of proportional hazards assumption for both models.
HC Category 0 refers to patients with no records of hypercholesterolemia and statins prescription prior to THR surgery. HC
Category 1 represents patients with normal cholesterol level due to statins prescription prior to THR surgery. HC Category 2
are patients with HC despite the statins prescription prior to THR surgery. HC Category 3 are patients with HC but not on
statins prescription prior to THR surgery
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Appendix D shows the plots of Schoenfeld residuals versus time of death
for Lfull (Figures 40 and 41) and Limp (Figures 42 and 43), respectively.
Graphical inspection of these plots shows no observed trend against event
time among the Schoenfeld residuals associated with each covariate kept in
both models. These residuals do not vary with time and thus there are no
violation of the proportional hazards assumption for all covariates kept in
Lfull and Limp, respectively, in this long term survival analysis.
Estimated hazard ratios of death
This section details out the variations in the long term hazard ratios (HR
[95% CI]) of death, estimated from Limp. Table 21 displays the estimated HR
of death for patients with demographic characteristics, lifestyle factors and
preoperative comorbidities that were detected as risk factors for mortality in
this analysis.
Relative to controls (HR=1.00), cases undergoing cemented, uncemented
and other types of THR procedure have a lower HR of death estimated at
0.86 [0.84,0.89], 0.75 [0.71,0.79] and 0.88 [0.86,0.90], respectively. Therefore
THR cases who survived their first two years after surgery, have a lower HR
of death than matched controls, indicating that THR procedure improves
mortality in the long term. Similarly, being overweight or obese prior to the
procedure is beneficial for long term mortality. Estimated HRs of death for
obese (0.83 [0.80,0.86]) and overweight (0.80 [0.78,0.83]) patients are lower
than for those with normal weight (HR=1.00). Higher BMI appears to have
a long term protective effect on survival of patients who survived the first
two years of the study.
The rest of the findings apply equally to cases and controls. The frailty
term, GP practice was the most significant variable in the model. This shows
that HR of death varies significantly between GP practices, with estimated
HR of death ranging from 0.68 [0.58,0.79] to 2.64 [2.16,2.97], respectively
(variance of random effects due to frailty terms estimated at 0.0325). Male
participants in this study have a higher HR of death (HR=1.16 [1.14,1.19])
than female patients (HR=1.00).
Relative to non-smokers (HR=1.00), ex-smokers (1.81 [1.63,2.00]) and
smokers (2.58 [2.19,3.03]), respectively, have a higher HR of death. HR of
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death increases for patients who are from more deprived residential areas
(measured by Townsend scores). Compared to the least deprived residential
ward (Townsend score=1 and HR=1.00), the estimated HR of death increases
to 1.09 [1.07,1.10], 1.12 [1.09,1.14], 1.16 [1.13,1.19] and 1.19 [1.16,1.23] for
residential areas with Townsend scores of 2, 3, 4 and 5 (most deprived), re-
spectively.
In comparison to patients belonging to the socio-economic group where
majority of individuals belong to the most aﬄuent and wealthy families with
high status jobs and private detached accommodation (Mosaic groups A, B
and C, respectively, HR=1.00), patients who are elderly singles or belong to
mature families who reside in rural areas and owning inexpensive accommo-
dation (Mosaic groups D, E and F, respectively) have HR of death estimated
at 1.07 [1.03,1.11]. Similarly, patients from socio-economic group where most
individuals belong to relatively young families with children and aspiring to
become home owners through their own limited resources (Mosaic groups
G, H and I, respectively), also have a higher HR of death estimated at 1.13
[1.09,1.16], than patients from Mosaic groups A, B and C. Patients from
Mosaic groups J–O, inclusive, represent the least aﬄuent and least wealthy
socio-economic group where majority of the individuals are elders who rely
on financial support from their local government to rent low cost accommo-
dation in urban areas or elderly home owners of inexpensive accommodation
whose mortgage is nearly paid off. Estimated hazard of death for patients
from Mosaic groups J–O is estimated at 1.06 [1.02,1.09] relative to Mosaic
groups A–C.
Preoperative angina, myocardial infarction and stroke increase HR of
death to 1.62 [1.49,1.75], 1.43 [1.35,1.52] and 1.37 [1.30,1.44], respectively,
compared to patients without these comorbidities. Degenerative conditions,
namely, osteoarthritis and osteoporosis also raise estimated HRs of death to
1.08 [1.04,1.13] and 1.49 [1.40,1.60], respectively, relative to patients without
these conditions. Patients with type 2 diabetes have a higher HR of death,
estimated at 2.14 [1.88,2.44], compared to those without this co-morbidity.
Relative to patients with no hypercholesterolemia (HC) and no statins pre-
scription (Category 0, HR=1.00), patients with normal cholesterol due to
statins prescription (Category 1) and those with HC despite the intake of
statins prescription (Category 2), have a higher HRs of death estimated at
1.14 [1.09,1.18] and 1.62 [1.49,1.76], respectively. Similarly, compared to Cat-
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egory 0, patients with HC but not on statins prescription (HC Category 3)
have a HR of death estimated at 1.70 [1.55,1.87]. Thus patients with pre-
operative HC have higher HRs of death than those without, while intake of
statins improve HR of death for some patients.
Table 21: Long term Cox’s regression analysis and estimated all-cause hazard ratios
(95% confidence interval) of death after THR procedures
Variables Levels
Full Case Analysis, Lfull Multiple Imputation Analysis, Limp
HR (95% CI) P-value HR (95% CI) P-value RIV*
Sex Female Ref (1.00) Ref (1.00)
Male 1.15 (1.11,1.18) <2.0E-16 1.16 (1.14,1.19) 2.3E-03 2.9E-03
Procedure Type Controls Ref (1.00) Ref (1.00)
Cemented 0.85 (0.78,0.92) 7.8E-03 0.86 (0.84,0.89) 2.9E-03 5.9E-03
Uncemented 0.73 (0.68,0.78) 3.3E-05 0.75 (0.71,0.79) 1.5E-03 4.9E-03
Others 0.86 (0.78,0.96) <2.0E-16 0.88 (0.86,0.90) 1.2E-02 4.4E-03
Townsend Scores 1 Ref (1.00) Ref (1.00)
2 1.08 (1.04,1.13) <2.0E-16 1.09 (1.07,1.10) 1.8E-02 7.8E-03
3 1.12 (1.06,1.18) 3.2E-04 1.12 (1.09,1.14) 2.5E-03 6.3E-04
4 1.19 (1.12,1.27) 9.4E-06 1.16 (1.13,1.19) 7.7E-03 1.1E-03
5 1.24 (1.15,1.33) 8.5E-09 1.19 (1.16,1.23) 3.2E-03 2.4E-03
Mosaic Category Cat A-C Ref (1.00) Ref (1.00)
Cat D-F 1.06 (1.02,1.11) 2.5E-09 1.07 (1.03,1.11) 2.3E-02 3.1E-03
Cat G-I 1.14 (1.07,1.17) 2.4E-02 1.13 (1.09,1.16) 3.8E-03 7.5E-03
Cat J-O 1.06 (1.01,1.09) 8.1E-06 1.06 (1.02,1.09) 3.5E-02 6.8E-03
Smoking Non-Smoker Ref (1.00) Ref (1.00)
Ex-smoker 1.67 (1.59,1.76) <2.0E-16 1.81 (1.63,2.00) 3.4E-03 1.0E-03
Smoker 2.52 (2.40,2.65) <2.0E-16 2.58 (2.19,3.03) 8.6E-03 5.4E-03
BMI Normal Ref (1.00) Ref (1.00)
Overweight 0.79 (0.76,0.82) 3.4E-03 0.80 (0.78,0.83) 2.7E-02 1.1E-03
Obese 0.84 (0.80,0.87) 2.0E-15 0.83 (0.80,0.86) 8.8E-03 1.3E-03
Angina No NA Ref (1.00)
Yes 1.62 (1.49,1.75) 2.3E-03 1.4E-03
Myocardial Infarction No NA Ref (1.00)
Yes 1.43 (1.35,1.52) 2.8E-03 6.7E-03
Stroke No Ref (1.00) Ref (1.00)
Yes 1.34 (1.28,1.41) <2.0E-16 1.37 (1.30,1.44) 3.8E-03 7.7E-03
Ostearthritis No Ref (1.00) Ref (1.00)
Yes 1.09 (1.05,1.13) <2.0E-16 1.08 (1.04,1.13) 1.3E-02 2.3E-03
Osteoporosis No Ref (1.00) Ref (1.00)
Yes 1.39 (1.29,1.5) 4.4E-06 1.49 (1.40,1.60) 7.0E-03 1.1E-03
Hypercholesterolaemia Category 0 Ref (1.00) Ref (1.00)
Category 1 1.14 (1.07,1.22) <2.0E-16 1.14 (1.09,1.18) 3.0E-03 2.7E-05
Category 2 1.57 (1.51,1.63) <2.0E-16 1.62 (1.49,1.76) 4.8E-03 3.6E-03
Category 3 1.69 (1.6,1.79) <2.0E-16 1.70 (1.55,1.87) 1.7E-02 5.0E-03
Type 2 Diabetes No Ref (1.00) Ref (1.00)
Yes 2.08 (1.97,2.19) 3.4E-06 2.14 (1.88,2.44) 7.2E-03 6.7E-03
HC Category 0 refers to patients with no records of hypercholesterolemia and statins prescription prior to THR surgery. HC
Category 1 represents patients with normal cholesterol level due to statins prescription prior to THR surgery. HC Category 2
are patients with HC despite the statins prescription prior to THR surgery. HC Category 3 are patients with HC but not on
statins prescription prior to THR surgery.
* RIV indicates the reduction in value of estimated model coefficients if the results of the 10 imputed dataset were
not combined into a single effect size using Rubin’s rule.
223
Performance and comparison of the models
This section assesses the performance of Lfull and Limp, respectively, by com-
paring the estimated Royston’s R2, Harrell’s concordance and shrinkage of
the models (Table 45 in Appendix D). Lfull explains 23.4% to 28.5% of the
differences in survival of patients, compared to between 22.6% and 27.4%
for Limp. Harrell’s concordance for Lfull is estimated at 70.3% (95% CI:
67.4%-73.1%) and hence, there exists 67.4% to 73.1% agreement between
the estimated HR of death and the observed survival time, compared to be-
tween 67.9% and 74.8% for Limp. This is a reasonably good performance
for both Lfull and Limp, respectively, as it lies in the range of 60%–70%,
as recommended by Therneau and Grambsch (2013) for survival analysis of
medical data. Estimated shrinkage slope indicates that the adjusted HRs of
death were overestimated by 3.2% for Lfull and by 2.4% for Limp, respec-
tively. These small shrinkage slope values suggest that the estimated results
of these survival models are robust.
Furthermore, ∆L, the percentage difference between estimated coefficients
of Lfull and Limp, described by equation 6.1 in section 6.4.4, is computed as
a sensitivity check, see Table 46 in Appendix D. Estimated ∆L ranged from
-18% to a maximum of 21%, showing that the full case analysis underesti-
mates the model coefficients between 1%-18% for Townsend Score 3, 4, and
5, Mosaic categories G-I and J-O, types of THR procedures, overweight, OA
and HC category 1, respectively, and overestimates those of stroke, Townsend
Score 2, Mosaic Category D-F, obese, osteoporosis, HC categories 2 and 3,
type 2 Diabetes, sex and smoking status, respectively, between 1% and 18%.
Furthermore, the multiple imputation analysis also reveals that preoper-
ative angina and myocardial infarction are risk factors for mortality in this
long term study, unlike the full case analysis. This is mainly because the ma-
jority of the low number of patients with preoperative angina and myocardial
infarction in this study, were excluded during the full case analysis and thus
their effects on HR of death were insignificant in the analysis. These argu-
ments show the importance of including all possible patients, using multiple
imputed datasets because such analysis improves the estimation of the model
parameters and provide precise and unbiased estimates of variability in the
data.
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Validation and discussion of results
The results of model Limp show that THR procedures improve survival of
THR cases who survived their first 24 months after surgery, for all types of
THR procedures, with the highest improvement in mortality associated with
other types of procedures, followed by uncemented and cemented. Long term
survival of female patients were better than male patients. These results are
in agreement with the following studies, which reported similar findings at
3 to 15 years after the procedure: McMinn et al. (2012), Paavolainen et al.
(2002), Whitehouse et al. (2014), Barrett et al. (2005), Lovald et al. (2014),
Lie et al. (2000), Maradit-Kremers et al. (2016), Visuri et al. (1994), Ritter
et al. (1998), Ramiah et al. (2007), Visuri et al. (1997), Pedersen et al. (2011)
and Ma¨kela¨ et al. (2014).
However no studies on survival after THR in literature investigated preop-
erative treated or untreated hypercholesterolemia. This may be because the
studies reviewed in literature (See section 2.3) used secondary care databases
in which measurements of hypercholesterol and treatments of hypercholes-
terolemia were not available. It is well established that mortality risk for
smokers is significantly higher than non-smokers (Doll et al. (2004)). The
results are adjusted for smoking status in the analysis, thus producing more
precise estimates. Among all studies reviewed in section 2.3, none of the
authors adjusted for smoking status.
In addition, preoperative cardiovascular diseases (angina, myocardial in-
farction and stroke) increase long term HRs of death, compared to those
without these conditions. Pedersen et al. (2011) found that estimated mor-
tality rates per 100,000 person-years (MR) for THR cases with preoperative
cardiovascular diseases (MR=28.5%) was lower than controls with similar
conditions (MR=17.8%), implying that an interaction between procedure
type and cardiovascular diseases, which is investigated and presented in sec-
tion 7.3.3). However the authors did not distinguish between the types of
cardiovascular diseases as carried out in this study.
Survival model Limp also indicates that there is a statistically significant
protective effect of being overweight or obese at the baseline for long term HR
of death. This finding is also observed among other interventions for treat-
ments of chronic conditions (Curtis et al. (2005), Bakaeen and Chu (2011),
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Stamou et al. (2011)) and is referred as the obesity paradox. No studies in the
literature reviewed investigated effects of being overweight and obese prior to
surgery, on long term survival after THR. Whitehouse et al. (2014) excluded
BMI from their Cox’s regression model due to large number of missing data
for BMI.
HR of death increased for patients living in residential areas with high
deprivation level. This result is in agreement with Whitehouse et al. (2014),
which reported that unit increase in index of multiple deprivation score of
an individual residential ward, causes a 1% increase in post-THR risk of
death. Similarly, less wealthy and less aﬄuent socio-economic groups (Mo-
saic groups D-F, G-I and J-O, respectively) have a higher estimated HRs
of death than the most wealthy and aﬄuent groups. No previous studies
adjusted for socio-economic factors in their long term survival analysis.
Preoperative osteoporosis, osteoarthritis, hypercholesterolemia, type 2 di-
abetes and smoking status of patients increase long term HR of death. Long
term survival analyses by Holmberg (1992), Pedersen et al. (2011), Lie et al.
(2000), Barrett et al. (2005) and Whitehouse et al. (2014) demonstrate that
mortality among patients diagnosed with osteoarthritis and osteoarthritis, is
higher than those without these degenerative conditions. Similarly Pedersen
et al. (2011) and Barrett et al. (2005) also found type 2 diabetes as risk fac-
tors for mortality in their results comparing THR cases to controls.
Several studies (See section 2.3) demonstrated that long term mortal-
ity risk after THR procedure varies significantly for patients with various
preoperative characteristics or medical conditions. Table 22 summarises the
different publications that investigated the effect of second order interactions
between procedure types and gender, age group and various medical con-
ditions, respectively, on mortality risk after the surgery. Having a survival
model that tests for such second order interactions between various covari-
ates assist in explaining further sources of variations in survival among THR
cases. In this section, the two-level Cox’s regression models (Lfull and Limp)
only tested the main effects of the covariates. To have a deeper insight of
explained variability in adjusted HR of death, second order interaction terms
are added to the models presented in this section and their effects on the HRs
of death are reported in section 7.3.3.
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Table 22: Studies investigating effects of interactions between covariates on long
term survival analysis after THR
Interaction with types of THR tested Studies
Age at surgery McMinn et al. (2012), Whitehouse et al. (2014)
Gender
McMinn et al. (2012), Makela et al. (2014),
Whitehouse et al. (2014)
Ethnicity Lovald et al. (2014)
Deprivation of residential ward Whitehouse et al. (2014)
Type 2 diabetes, Cardiovascular diseases Barett et al. (2005)
Osteoarthritis/Osteoporosis/Rheumatoid Arthritis
Holmberg et al. (1992), Lie et al. (2000), Barrett et al. (2005),
McMinn et al. (2012), Lovald et al. (2014)
The above authors investigated and reported the significant effects of interactions between types of THR procedures and the
above variables on the long term survival of THR cases. Such analysis permitted the authors to further investigate which
categories of THR cases were associated with the highest improvement in long term survival/mortality.
7.3.3 Cox’s regression models with interaction effects
Second order interaction terms investigated
To obtain a deeper insight of variability in long term HRs of death after THR
procedures, several second order interaction terms, listed below, are added
to the main effect models presented in section 6.4.2.
1. THR procedure types and demographics variables (age at surgery, gen-
der)
2. THR procedure types and lifestyle factors (smoking status, BMI)
3. THR procedure types and social deprivation indices (Townsend score)
and socio-economic group (Mosaic score)
4. THR procedure types and preoperative medical conditions (angina, my-
ocardial infarction, stroke, osteoarthritis, rheumatoid arthritis, osteo-
porosis, hypertension, hypercholesterolemia, chronic kidney diseases)
5. THR procedure types and drug prescriptions (Ace-inhibitor, oestrogen,
progesterone, testosterone)
6. Gender and lifestyle factors (smoking status, BMI)
7. Gender and preoperative medical conditions (angina, myocardial in-
farction, stroke, osteoarthritis, rheumatoid arthritis, osteoporosis, hy-
pertension, hypercholesterolemia, chronic kidney diseases)
8. Age at surgery and lifestyle factors (smoking status, BMI)
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9. Age at surgery and preoperative medical conditions (angina, myocar-
dial infarction, stroke, osteoarthritis, rheumatoid arthritis, osteoporo-
sis, hypertension, hypercholesterolemia, chronic kidney diseases)
Initially a full model with all variables listed in Table 44 from Appendix
C as main effects and that also includes the above second order interaction
terms is created. Backward elimination is then carried out using a significance
level of 5%. Two separate multivariate Cox’s regression models are developed
and compared in this section; one for full case analysis (longfull) and a second
model (longimp), using the 10 imputed datasets.
Abbreviations
The following set of abbreviations are used for discussions of all results that
follow in this section.
• MI: Myocardial Infarction
• BMI: Body Mass Index
• OA: Osteoarthritis
• HC Category 0: Patients with no records of hypercholesterolemia and
statins prescription prior to THR surgery
• HC Category 1: Patients with normal cholesterol level due to statins pre-
scription prior to THR surgery
• HC Category 2: Patients with HC despite being on statins prescription
prior to THR surgery
• HC Category 3: Patients with HC but not on statins prescription prior to
THR surgery
Results
Table 23 displays the main effects and interaction terms that were kept in
the full case analysis model (longfull) and multiple imputation analysis model
(longimp), respectively. Model longfull consists of the following main effects:
(1) GP practice, (2) Townsend scores, (3) Mosaic category, (4) angina, (5)
osteoporosis, (6) sex, (7) type 2 diabetes, (8) procedure type, (9) BMI, (10)
smoking status, (11) MI, (12) OA and (13) HC, respectively, in addition to
the following interaction terms:
(1) types of procedures and MI,
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(2) types of procedures and BMI,
(3) types of procedures and OA
(4) types of procedures and HC
(5) sex and type 2 diabetes
(6) smoking status and BMI.
Similarly model longimp includes the same list of main effects and inter-
action effects as in longfull in addition to preoperative angina (Table 23).
Therefore the multiple imputation analysis showed angina as an additional
risk factor to survival for all patients. This is because under the full case
analysis, majority of the low number of patients diagnosed with angina are
excluded from the analysis since they have missing records for other vari-
ables. Thus the analysis fails to pick angina as a significant risk factor to
long term survival.
Table 23: Analysis of variance results comparing full case analysis to multiple
imputation analysis for model including interaction terms
Variables
Full Case Analysis, longfull Multiple Imputation Analysis, longimp
Loglik Chisq Df P-value Loglik Chisq Df P-value
Empty Model -171429 -171420
GP Practice -171313 1233.25 301 <2.0E-16 -171309 217.05 401 8.1E-16
Stroke -171250 24.32 1 4.2E-07 -171228 12.15 1 2.6E-04
Townsend Scores -171097 37.62 4 6.4E-08 -171073 28.67 4 4.3E-06
Mosaic Category -171066 41.68 3 2.3E-09 -171056 53.31 3 7.7E-12
Procedures Types -171064 12.94 3 2.2E-03 -171062 23.11 3 1.8E-05
MI -170843 24.18 1 4.6E-07 -170930 24.62 2 2.3E-06
Angina NA -170880 8.09 1 2.4E-03
BMI -170707 21.46 2 1.1E-05 -170873 16.35 1 2.8E-05
OA -170660 9.28 1 1.3E-03 -169894 19.89 3 8.5E-05
Osteoporosis -169998 9.48 1 1.1E-03 -169554 6.48 1 6.1E-03
HC -169738 18.23 3 1.9E-04 -169496 29.25 1 3.3E-08
Type 2 Diabetes -169413 6.26 1 7.0E-03 -167239 9.41 2 4.5E-03
Sex -169379 66.75 1 <2.0E-16 -167203 74.69 1 <2.0E-16
Smoking Status -168139 28.59 2 3.1E-07 -167207 22.91 1 8.8E-07
Procedures Types*MI -168134 11.15 3 5.1E-03 -167203 0.04 4 8.6E-03
Procedures Types*BMI -168116 35.79 6 1.4E-06 -167198 0.09 8 7.5E-06
Procedures Types*OA -168115 17.82 3 2.3E-04 -167185 0.03 3 6.3E-02
Procedures Types*HC -168027 22.15 9 3.0E-03 -167170 22.96 9 2.3E-03
Type 2 Diabetes*Sex -168017 18.37 1 9.6E-06 -167156 24.90 2 2.0E-06
BMI*Smoke -167026 1.14 8 8.8E-03 -167136 39.73 4 2.3E-08
The above results show that the full case analysis is a subset of the multiple imputation analysis final model fitted using 10
imputed datasets. In addition to the covariates kept in the full case analysis model, angina was also a significant source of
variation hazard ratio of death estimated from the Cox’s model fitted using multiple imputation analysis. MI, BMI, OA, HC
and smoking status cause significant difference in HR of death for each types of procedures.
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Assessing assumption of proportional hazards and model compar-
ison
To test for the validity of the assumption of Cox’s proportional hazards, a
correlation test between Schoenfeld residuals and event time (Grambsch and
Therneau [1994]) for each variable and second order interactions contribut-
ing significantly to the fitted Cox’s regression models, namely, longfull and
longimp, respectively, is carried out. Table 24 shows the associated statistical
significance of these correlation tests for longfull and longimp, respectively.
There is no significant correlation between the Schoenfeld residuals and the
event time for all covariates kept in the model (p-value of Chi-square test
> 5%). Therefore these variables satisfy the assumptions of proportional
hazards. Furthermore, the global test of proportional hazards test for both
longfull and longimp, respectively, is insignificant (Table 20), indicating esti-
mated HRs of death for both models are independent of time.
Appendix D shows the plots of Schoenfeld residuals versus time of death
for longfull (Figures 44, 45 and 46) and longimp (Figures 47, 48 and 43),
respectively. Graphical inspection of these plots shows no trends over event
time among the Schoenfeld residuals associated with covariates and interac-
tion terms kept in both models. These residuals do not vary with time and
thus there are no violation of the proportional hazards assumption for all
covariates kept in longfull and longimp, respectively.
∆long, the percentage difference between estimated coefficients of longfull
and longimp, described by equation 6.1 in section 6.4.4, is computed as a
sensitivity check, see Table 25. Estimated ∆long shows the full case analysis
underestimates the model coefficients between 0.5%-4.0% and overestimates
some coefficients between 0.1%−3.9%, respectively. Compared to the models
of main effects only (Lfull and Limp), the models with interaction terms (Table
25) have significantly lower values for ∆long.
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Table 24: Assessing assumption of proportional hazards for models with interaction
effects
Variables Levels
Full Case Analysis Multiple Imputation Analysis
rho chisq P-value rho chisq P-value
Sex Female
Male 0.0202 1.0328 6.9E-01 0.0355 0.3772 4.6E-01
Procedures Types Controls
Cemented -0.0047 0.1836 3.3E-01 0.0264 0.7432 6.1E-01
Uncemented 0.0075 0.4627 5.0E-01 0.0545 1.3707 7.6E-01
Others 0.0133 1.4693 7.7E-01 0.0774 1.3046 7.5E-01
Townsend Scores 1
2 -0.0031 0.0838 2.3E-01 0.0002 0.7727 6.2E-01
3 0.0043 0.1706 3.2E-01 0.0278 1.1512 7.2E-01
4 0.0134 0.7474 6.1E-01 0.0283 0.3221 4.3E-01
5 0.0035 0.1210 2.7E-01 0.0300 1.1358 7.1E-01
Mosaic Category Cat A-C
Cat D-F -0.0029 0.0774 2.2E-01 0.0085 0.4518 5.0E-01
Cat G-I 0.0042 0.1701 3.2E-01 0.0123 0.3863 4.7E-01
Cat J-O -0.0067 0.4634 5.0E-01 -0.0077 0.3252 4.3E-01
BMI Normal
Overweight -0.0239 1.1450 7.2E-01 -0.0059 1.1812 7.2E-01
Obese -0.0256 1.3325 7.5E-01 -0.0029 1.4715 7.7E-01
Smoking Non-Smoker
Ex-smoker -0.0495 1.2574 7.4E-01 -0.0478 1.5795 7.9E-01
Smoker -0.0579 1.2665 7.4E-01 -0.0623 1.0306 6.9E-01
Stroke No
Yes 0.0154 1.0916 7.0E-01 0.0211 0.6895 5.9E-01
Angina No
Yes -0.0623 1.0306 6.9E-01
MI* No
Yes 0.0236 1.4738 7.8E-01 0.0965 1.0782 7.0E-01
OA** No
Yes 0.0010 0.0083 7.2E-02 0.0251 0.1747 3.2E-01
Osteoporosis No
Yes -0.0102 0.092 2.4E-01 0.0681 0.3689 4.6E-01
HC*** Category 0
Category 1 0.0111 1.0619 7.0E-01 0.0149 1.1750 7.2E-01
Category 2 0.0320 0.9744 6.8E-01 0.0217 1.0875 7.0E-01
Category 3 0.0176 0.6973 6.0E-01 -0.0006 1.6007 7.9E-01
Type 2 Diabetes No
Yes -0.0019 0.0324 1.4E-01 0.0085 0.8365 6.4E-01
Procedures Types*MI Controls & No MI
Cemented & MI 0.0079 0.547 5.4E-01 0.0180 0.9395 6.7E-01
Uncemented & MI 0.0078 0.508 5.2E-01 0.0158 0.6482 5.8E-01
Others & MI -0.0025 0.054 1.8E-01 0.0039 0.5192 5.3E-01
Procedures Types*BMI Controls & Normal BMI
Cemented & Obese 0.0218 0.050 1.8E-01 0.0246 0.1270 2.8E-01
Uncmented & Obese 0.0146 0.556 5.4E-01 0.0186 0.1585 3.1E-01
Others & Obese -0.0022 0.040 1.6E-01 0.0208 0.5832 5.5E-01
Cemented & Overweight 0.0196 0.745 6.1E-01 0.0443 0.1314 2.8E-01
Uncemented & Overweight 0.0119 1.200 7.3E-01 0.0254 0.7458 6.1E-01
Others & Overweight -0.0077 0.505 5.2E-01 0.0155 1.2356 7.3E-01
Procedures Types*OA Controls & OA
Cemented & OA 0.0076 0.494 5.2E-01 0.0087 0.5494 5.4E-01
Uncmented & OA 0.0105 0.945 6.7E-01 0.0232 0.6065 5.6E-01
Others & OA 0.0074 0.464 5.0E-01 0.0240 1.0009 6.8E-01
Procedures Types*HC Controls & No HC
Cemented & HC Category 1 -0.0161 0.751 6.1E-01 0.0056 0.5150 5.3E-01
Uncmented & HC Category 1 -0.0168 1.394 7.6E-01 -0.0029 0.8069 6.3E-01
Others & HC Category 1 -0.0164 1.321 7.5E-01 -0.0072 1.4497 7.7E-01
Cemented & HC Category 2 -0.0179 1.765 8.2E-01 -0.0115 1.4214 7.7E-01
Uncmented & HC Category 2 -0.0182 0.790 6.3E-01 0.0047 1.8760 8.3E-01
Others & HC Category 2 -0.0129 1.389 7.6E-01 -0.0021 0.8503 6.4E-01
Cemented & HC Category 3 -0.0123 1.272 7.4E-01 0.0065 1.4104 7.7E-01
Uncmented & HC Category 3 0.0055 0.258 3.9E-01 0.0083 1.3461 7.5E-01
Others & HC Category 3 -0.0125 1.310 7.5E-01 0.0095 0.3508 4.5E-01
Type 2 Diabetes*Sex Controls & No Type 2 diabetes
Male & Type 2 diabetes 0.0038 0.120 2.7E-01 0.0085 1.3957 7.6E-01
BMI*Smoke Normal Weight & Non-smoker
Obese & Ex-smoker 0.0164 1.030 6.9E-01 0.0260 0.1229 2.7E-01
Overweight & Ex-smoker 0.0096 1.798 8.2E-01 0.0345 1.0747 7.0E-01
Obese & Smoker 0.0079 0.547 5.4E-01 0.0230 1.8698 8.3E-01
Overweight & Smoker 0.0114 1.118 7.1E-01 0.0214 0.6043 5.6E-01
Global Test OF PROPORTIONAL HAZARDS NA 36.2913 1.1E-01 NA 44.3622 3.0E-01
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Table 25: Comparison of estimated coefficients of longfull and longimp
Variables Levels
Full Case Analysis Multiple Imputation Analysis Estimated
Delta, ∆longEstimate S.Error P-value Estimate Std.Er P-value RIV
Sex Female
Male 0.1319 0.0173 1.4E-14 0.1366 0.0320 1.23E-04 3.5E-03 3.4%
Procedures Types Controls
Cemented -0.3304 0.0946 2.2E-03 -0.3370 0.0967 2.66E-02 6.2E-03 1.9%
Uncemented -0.5102 0.0860 1.5E-09 -0.5078 0.1060 4.24E-04 2.9E-03 -0.5%
Others -0.3008 0.0902 4.4E-04 -0.3030 0.0956 2.08E-03 7.7E-03 0.7%
Townsend Scores 1
2 0.0769 0.0234 5.4E-04 0.0783 0.0135 3.40E-02 5.6E-03 1.7%
3 0.1136 0.0267 1.1E-05 0.1171 0.0188 1.07E-03 6.4E-03 2.9%
4 0.1732 0.0314 1.8E-08 0.1769 0.0195 7.60E-04 7.4E-03 2.1%
5 0.2029 0.0363 1.2E-08 0.1955 0.0178 6.43E-04 7.7E-03 -3.8%
Mosaic Category Cat A-C
Cat D-F 0.0544 0.0270 2.6E-02 0.0545 0.0093 5.33E-03 6.5E-03 0.2%
Cat G-I 0.1192 0.0299 3.5E-05 0.1212 0.0149 1.13E-02 2.1E-04 1.6%
Cat J-O 0.0567 0.0244 1.2E-02 0.0589 0.0159 1.28E-02 2.0E-03 3.9%
BMI Normal
Overweight -0.2565 0.0217 <2.0E-16 -0.2643 0.0903 1.62E-05 6.9E-04 3.0%
Obese -0.2731 0.0277 <2.0E-16 -0.2741 0.0626 3.46E-05 4.9E-04 0.4%
Smoking Non-Smoker
Ex-smoker 0.8539 0.0351 <2.0E-16 0.8713 0.0445 4.71E-07 6.1E-03 2.0%
Smoker 1.0110 0.0307 <2.0E-16 1.0183 0.1837 5.38E-07 4.6E-03 0.7%
Stroke No
Yes 0.2780 0.0244 <2.0E-16 0.2883 0.0268 1.96E-05 4.6E-03 3.6%
Angina No
Yes NA 0.3816 0.0915 7.12E-04 1.3E-04 NA
MI* No
Yes 0.4191 0.0252 <2.0E-16 0.4219 0.1007 4.40E-06 2.6E-03 0.7%
OA** No
Yes 0.0824 0.0196 1.4E-05 0.0849 0.0105 2.36E-03 6.0E-03 3.0%
Osteoporosis No
Yes 0.0712 0.0103 8.1E-05 0.0728 0.0199 3.76E-03 4.1E-04 2.2%
HC*** Category 0
Category 1 0.1618 0.0481 <2.0E-16 0.1631 0.0632 9.22E-05 7.3E-03 0.8%
Category 2 0.3938 0.0203 <2.0E-16 0.4010 0.0984 4.96E-07 6.6E-03 1.8%
Category 3 0.5779 0.0317 1.7E-07 0.5796 0.1044 9.35E-04 7.8E-03 0.3%
Type 2 Diabetes No
Yes 0.7977 0.0359 <2.0E-16 0.8077 0.1025 1.37E-06 4.8E-03 1.2%
Procedures Types*MI Controls & No MI
Cemented & MI 0.2518 0.0644 5.0E-03 0.2557 0.0799 2.78E-02 5.5E-03 1.5%
Uncemented & MI 0.1552 0.0846 4.0E-02 0.1555 0.0968 5.23E-03 5.4E-03 0.2%
Others & MI 0.3043 0.0979 1.2E-02 0.3077 0.0386 1.14E-02 7.2E-03 1.1%
Procedures Types*BMI Controls & Normal BMI
Cemented & Obese 0.1523 0.0934 6.5E-02 0.1543 0.0450 6.72E-03 7.1E-03 1.3%
Uncmented & Obese 0.3127 0.0743 1.3E-05 0.3208 0.0908 2.35E-03 1.9E-03 2.5%
Others & Obese 0.2530 0.0749 1.6E-02 0.2587 0.0144 5.40E-03 4.9E-03 2.2%
Cemented & Overweight 0.2300 0.0892 5.6E-03 0.2349 0.0825 3.21E-02 3.8E-03 2.1%
Uncemented & Overweight 0.2418 0.0704 3.2E-04 0.2484 0.0769 7.81E-03 3.4E-03 2.6%
Others & Overweight 0.1136 0.0337 3.5E-02 0.1092 0.0305 3.73E-02 5.5E-03 -4.0%
Procedures Types*OA Controls & OA
Cemented & OA 0.1374 0.0560 1.9E-03 0.1381 0.0317 5.16E-02 5.4E-03 0.5%
Uncmented & OA 0.4177 0.1012 2.3E-02 0.4327 0.0887 1.81E-02 4.9E-04 3.5%
Others & OA 0.3789 0.0987 2.6E-03 0.3821 0.0118 6.75E-03 4.7E-03 0.8%
Procedures Types*HC Controls & No HC
Cemented & HC Category 1 0.0385 0.0951 1.3E-03 0.0398 0.0092 4.59E-02 6.2E-03 3.2%
Uncmented & HC Category 1 0.1421 0.0825 2.4E-03 0.1444 0.0459 2.42E-02 3.7E-03 1.6%
Others & HC Category 1 0.1236 0.0271 2.7E-03 0.1265 0.0104 4.59E-02 4.9E-03 2.3%
Cemented & HC Category 2 0.6780 0.1005 1.9E-09 0.6790 0.0324 5.15E-04 2.8E-03 0.1%
Uncmented & HC Category 2 0.9909 0.0952 <2.0E-16 1.0222 0.2808 3.01E-05 4.9E-03 3.1%
Others & HC Category 2 0.3547 0.0988 1.0E-02 0.3650 0.0593 9.30E-02 5.4E-03 2.8%
Cemented & HC Category 3 0.5409 0.1007 9.9E-04 0.5202 0.1050 9.54E-02 5.0E-03 -4.0%
Uncmented & HC Category 3 0.4674 0.1019 4.6E-05 0.4766 0.0634 3.95E-03 5.9E-03 1.9%
Others & HC Category 3 0.4932 0.0972 2.3E-03 0.5116 0.1048 5.32E-03 2.1E-03 3.6%
Type 2 Diabetes*Sex Controls & No Type 2 diabetes
Male & Type 2 diabetes 0.2416 0.0515 1.4E-06 0.2480 0.0564 7.21E-04 4.8E-04 2.6%
BMI*Smoke Normal Weight & Non-smoker
Obese & Ex-smoker 0.1833 0.0388 4.3E-03 0.1845 0.0730 2.73E-02 6.5E-03 0.6%
Overweight & Ex-smoker 0.2112 0.0553 7.0E-05 0.2117 0.0714 6.02E-03 4.1E-03 0.3%
Obese & Smoker 0.1292 0.0373 1.5E-02 0.1277 0.0437 2.53E-02 5.3E-03 -1.2%
Overweight & Smoker 0.1921 0.0534 1.7E-04 0.1976 0.0840 5.41E-03 4.7E-03 2.7%
Estimated ∆long ’s between full case and multiple imputation analyses are low and therefore indicate a marginal difference
between estimated coefficients.
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Estimated hazard ratios of death
This section details the estimated in long term hazard ratios (HR [95% CI])
of death in the model longimp. The frailty term, GP practice was the most
significant variable in the model, indicating that HR of death varies signifi-
cantly between GP practices, with estimated HRs of death ranging from 0.60
[0.57,0.64] to 3.64 [3.21,4.06], respectively (variance of random effects due to
frailty terms estimated at 0.0218).
Types of THR procedures is a significant risk factor for long term sur-
vival in this analysis. Therefore there is significant difference in HRs of death
between controls and different types of cases. Figure 29 shows that, com-
pared to controls without any preoperative medical condition (HR=1.00),
estimated HRs of cases who undergo cemented, uncemented and other types
of THR are equal to 0.71 (0.52,0.88), 0.60 (0.53,0.68) and 0.74 (0.65,0.83),
respectively. Therefore for cases who survived the first 24 months after the
surgery, their survival is better than matched controls.
Figure plot 29 is a forest plot showing the variation in long term HRs
of death between cases and controls with preoperative MI, OA and HC.
Model longimp includes significant interaction between types of THR proce-
dures with MI, OA and HC. Therefore, for patients with these comorbidities,
survival varies between cases and controls, and also between types of THR
procedures. Relative to controls without MI (HR=1.00), preoperative MI in-
creases HR of death to 1.52 (1.35,1.68), 1.41 (1.38,1.43), 1.07 (0.91,1.23) and
1.53 (1.38,1.68) for controls, cemented, uncemented and other types of THR
procedures with MI, respectively. Degenerative condition OA causes HRs of
death to increase to 1.33 (1.07,1.56), 1.09 (1.03,1.16), 1.23 (1.11,1.36) and
1.44 (1.26,1.65) for controls, cemented, uncemented and other types of THR
procedures with the condition, respectively, compared to controls without
OA.
Compared to controls without HC (HR=1.00), controls with normal choles-
terol due to statins prescriptions (HC 1 in Figure 29) have a higher HR of
death (1.18 [1.02,1.28]), while estimated HR of death is lower for cemented
procedures (0.81 [0.70,0.92]), uncemented procedures (0.76 [0.61,0.88]) and
other types of procedures (0.91 [0.81,0.98]) with HC category 1, respectively.
This shows that THR cases with HC category 1 still have better survival
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than matched controls with and without HC category 1, but have higher
estimated HR of death than cases without HC category 1. However for cases
and controls who either have HC despite being on statins prescriptions (HC
category 2) or not on statins prescriptions (HC category 3), HR of death is
higher than in controls without HC (HR=1.00). HR of death increases to 1.49
(1.41,1.58), 2.10 (1.94,2.27), 2.50 (1.95,3.05) and 1.59 (1.47,1.71) for controls,
cemented, uncemented and other types of procedures with HC category 2,
respectively, and rises to 1.79 (1.58,1.99), 2.51 (2.39,2.64), 2.41 (2.20,2.62)
and 2.49 (2.38,2.59) with HC category 3, respectively. These results show
that HC causes HR of death to increase for all patients but statins prescrip-
tions are beneficial for the long term survival of THR cases, i.e., for those
who take statins prescription (HC category 1).
Variations in HR of death are furthermore explained by significant in-
teractions between types of THR procedures and BMI, and also between
smoking status and BMI, respectively. Figure 30 shows the difference in ad-
justed HRs of death for cases and controls with different levels of preoperative
BMI and smoking status. Relative to controls who are non-smokers and with
normal BMI (HR=1.00), HRs of death among overweight cases are estimated
at 0.94 (0.88,0.99) for cemented procedures, 0.80 (0.76,0.84) for uncemented
procedures, 0.85 (0.81,0.90) for other types of procedures, respectively. Simi-
larly, compared to non-smoking controls with normal BMI (HR=1.00), obese
cases have a lower HR of death estimated at 0.90 (0.85,0.95) for cemented
and 0.89 (0.84,0.95) for uncemented procedures, respectively.
Relative to non-smokers with normal BMI (HR=1.00), HR of death in-
creases significantly for ex-smokers and smokers present in this study popula-
tion. Figure 30 below displays the variations of HRs of death for THR cases
and matched controls across different types of BMI and smoking status. For
all overweight and obese patients, HR of death associated with ex-smokers
and smokers are higher than for non-smokers. Ex-smokers and smokers’ HRs
are highest for controls followed by other types of procedures, uncemented
and cemented procedures, respectively, for the overweight category, while
among obese patients, HR is highest for controls, followed by cemented,
other types of procedures and uncemented procedures, respectively.
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The remaining findings reported applied to both cases and controls equally.
Patients who were diagnosed with preoperative angina and stroke have a
higher HRs of death estimated at 1.46 (1.22,1.75) and 1.33 (1.27,1.41), re-
spectively, compared to patients without these conditions. Patients with os-
teoporosis have an estimated HR of death of 1.08 (1.03,1.12) relative to those
without this degenerative condition. Similarly, patients diagnosed with type
2 diabetes have a higher HRs of death estimated at 3.29 (2.59,4.04) and 2.24
(1.83,2.74) among males and females, respectively, compared to male patients
(HR=1.15 [1.08,1.22]) and female patients (HR=1.00) without this condition.
Relative to patients living in residential areas with the lowest deprivation
index (Townsend score=1, HR=1.00), HRs of death increase in more deprived
areas. Estimated HR for patients from residential areas with Townsend score
of 2, 3, 4 and 5 are 1.08 (1.05,1.11), 1.12 (1.08,1.17), 1.19 (1.15,1.24), and
1.22 (1.17,1.26), respectively. In comparison to patients belonging to the
top socio-economic groups (Mosaic groups A, B and C, HR=1.00), patients
who are elderly singles or belong to mature families who reside in rural areas
and owning inexpensive accommodation (Mosaic groups D, E and F) have
HRs of death estimated at 1.06 (1.04,1.08). Similarly, patients from socio-
economic group where most individuals belong to relatively young families
with children and aspiring to become home owners through their own lim-
ited resources (Mosaic groups G, H and I), also have a higher HR of death
estimated at 1.13 (1.10,1.16). Patients from Mosaic groups J–O, inclusive,
represent the least aﬄuent and least wealthy socio-economic group where ma-
jority of the individuals are elders who rely on financial support from their
local government to rent low cost accommodation in urban areas or elderly
home owners of inexpensive accommodation whose mortgage is nearly paid
off. Estimated hazard ratio of death for patients from Mosaic group J–O is
estimated at 1.06 (1.03,1.09) relative to Mosaic group A–C.
Performance statistics
This section assesses the performance of the models longfull and longimp by
comparing the estimated Royston’s R2, Harrell’s concordance and shrinkage
of the models (Table 47 in Appendix D). Model longfull explains 22.7% to
28.1% of the differences in survival of patients, compared to between 22.1%
and 27.6% for longimp. Harrell’s concordance for model longfull is estimated
at 71.6% (95% CI: 68.4%-74.2%) and hence, there exists 68.4% to 74.2%
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agreement between the estimated HR of death and the observed survival
time, compared to between 68.9% and 75.4% for model longimp. This is a
reasonably good concordance for both models longfull and longimp, as it lies in
the range of 60%–70%, as recommended by Therneau and Grambsch (2013)
for survival analysis of medical data. Estimated shrinkage slopes indicate
that the adjusted HR of death were overestimated by 3.9% for models longfull
and by 3.1% for longimp, respectively. These small shrinkage slope values
suggest that the estimated results of these survival models are robust.
Validation and discussion of results
The results of model longimp showed that THR procedure improved survival
of THR cases who survived their first 24 months after surgery, for all types
of THR procedures, while female patients had lower HR of death than male
individuals. The following studies also reported similar findings, 3 to 15
years after the procedure: McMinn et al. (2012), Paavolainen et al. (2002),
Whitehouse et al. (2014), Barrett et al. (2005), Lovald et al. (2014), Lie
et al. (2000), Maradit-Kremers et al. (2016), Visuri et al. (1994), Ritter et al.
(1998), Ramiah et al. (2007), Visuri et al. (1997), Pedersen et al. (2011) and
Ma¨kela¨ et al. (2014). The highest improvement in survival was associated
with uncemented procedures, followed by cemented and other types of proce-
dures, respectively. These findings are also reported by Visuri et al. (1997),
Kendal et al. (2013) and Ma¨kela¨ et al. (2014).
Among cardiovascular diseases included in this analysis, only MI caused
significant increase in HR of death for different procedure types, unlike stroke
and angina, which did not cause a difference in survival of different types of
cases and controls. This finding is supported by Visuri et al. (1997), Barrett
et al. (2005) and Pedersen et al. (2011) who found that THR cases with
a history of cardiovascular diseases before surgery, had higher HR of death
compared to controls and THR cases without these medical conditions. How-
ever these studies did not differentiate between the types of cardiovascular
diseases in their study, whereas this analysis compared survival of patients
with preoperative stroke, angina and MI.
Both osteoporosis and OA increased HR of death, a finding also reported
by Holmberg (1992), Lie et al. (2000), Barrett et al. (2005), Pedersen et al.
(2011) and Whitehouse et al. (2014, while Pedersen et al. (2011) also reported
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that higher HR of death is associated with osteoporosis, compared to OA.
Furthermore, only OA was found as a risk factor for variation in survival of
various kinds of THR in this current study (Figure 29). Whitehouse et al.
(2014 also reported higher survival among uncemented THR cases with OA
compared to cemented ones.
This study also found that preoperative HC increased HR of death for
all patients, compared to those without HC, except for THR cases who had
normal cholesterol due to intake of statins (HC category 1), see Figure 29.
Patients with HC not controlled (HC categories 2 and 3) had poorer survival
compared to those without HC. HR was lower than controls without HC
for cases with HC category 1. This may be due to the long term benefits
of statins on survival (Gitsels et al. (2016)), coupled with the improvement
in survival due to the THR procedure itself. No studies in literature were
found to investigate preoperative treated or untreated hypercholesterolemia.
This may be because the studies reviewed in literature (see section 2.3) used
secondary care databases in which measurements of hypercholesterol and
treatments of hypercholesterolemia were not available.
Type 2 diabetes increased long term mortality risk for cases and controls
in this study. However it did not cause significant difference in survival of
various types of THR procedures. This is in agreement with the results of
Pedersen et al. (2011) and Barrett et al. (2005), respectively, who reported
type 2 diabetes as a risk factor for mortality when comparing THR cases to
controls. It is well established that mortality risk for smokers is significantly
higher than non-smokers (Doll et al. (2004)). The results are adjusted for
smoking status in this analysis, and showed that HR of death is highest for
smokers and ex-smokers, respectively. Among all studies reviewed in section
2.3, none of the authors adjusted for smoking status.
Being overweight or obese had a protective effect on long term HR of
death in this study and improved longevity for THR cases without any pre-
operative comorbidities. This is referred as the obesity paradox and several
studies reported this relationship between being overweight or obesity and
longevity in men and women of all ages, races, and ethnicities (Curtis et al.
(2005), Adams et al. (2006), Bakaeen and Chu (2011), Stamou et al. (2011)).
No studies in the literature reviewed investigated effects of being overweight
or obese prior to surgery, on long term survival after THR while Whitehouse
239
et al. (2014) excluded BMI from their Cox’s regression model due to large
number of missing data for BMI. Further research is needed to investigate
why higher levels of BMI before the surgery is beneficial for long term sur-
vival after THR procedures whereas being overweight or obese is associated
with a higher overall mortality risk in the general population (Banack and
Kaufman (2014)). A comparison of BMI readings pre and post-THR surgery
may aid in understanding the improvement in survival associated with higher
BMI levels.
HR of death increases for patients living in residential areas with high
deprivation level. This result is in agreement with Whitehouse et al. (2014)
who reported that unit increase in index of multiple deprivation score of an
individual residential ward, causes a 1% increase in post-THR risk of death.
Similarly, patients from less wealthy and less aﬄuent socio-economic groups
(Mosaic groups D-F, G-I and J-O, respectively) have a higher estimated HR
of death than the most wealthy and aﬄuent categories. No previous studies
adjusted for socio-economic factors in their long term survival analysis.
7.4 Strengths and limitations
In this research, routinely collected primary care data from the THIN database
is used as the source of data to investigate long term survival after THR.
These data are representative of the UK population as explained in section
4.4.2 for various demographic, lifestyle factors and medical conditions (Blak
et al. (2011), Langley et al. (2011), Gonza´lez et al. (2009), Hippisley-Cox and
Coupland (2010a), MacDonald and Morant (2008)). Primary care records
consist of an extensive availability of socio-demographic, lifestyle factors and
medical information, thereby improving coverage of THR cases during the
study period and also allowing to validate the results of this study to the
general UK population.
Furthermore, this study is designed as a case control study, allowing es-
timation of effect of THR procedures on long term survival between THR
cases and controls matched on gender, year of birth category and GP prac-
tice, while adjusting for several confounders such as preoperative lifestyle
factors and demographic variables. No previous study has adjusted esti-
mated mortality risk by so many confounders in literature. Additionally,
this study estimated HR of death after THR given the preoperative medical
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history of the patients. The results of this study can therefore be used to
inform healthcare professionals on medical and risk management for patients
waiting to undergo THR and for THR cases after the procedure.
In THIN database, data on the type of prosthesis, surgical approach
and surgeon experience are not available. These variables were reported
to have significant effect on long term survival following THR (Whitehouse
et al. (2014)). Therefore estimates of long term mortality risk in this study
were not adjusted by these variables and survival after THR could not be
distinguished for different types of prosthesis, surgical approach and surgeon
experience, respectively. Another limitation in this study is the presence
of missing values for lifestyle factors. Variables related to pollution levels
and ethnicity were not available for patients from Scotland and Northern
Ireland and were thus not included in the survival model. However, missing
values for variables that were available for the whole UK population (BMI,
Townsend scores, IMD, smoking status and Mosaic groups) were dealt with
using multiple imputation analysis, which is the widely accepted method
to deal with bias and lack of precision in estimates when missing values
are present (Enders (2010)). Additionally, drug therapy was included as a
confounder in this study. However one limitation with this approach is that
adherence of patients to the drug therapy is unknown, thereby, not precisely
reflecting the effects of drug therapy on long term mortality risk following
THR.
7.5 Conclusions
The findings of this study suggest that adjusted HR of death of THR cases
with no preoperative medical condition, are lower than matched controls, for
cemented, uncemented and other types of THR procedures. HR of death is
higher for males for all types of procedures. Preoperative stroke and angina,
respectively, increase HR of death for cases and controls, but did not vary be-
tween different types of THR procedures, compared to patients without these
cardiovascular diseases. Preoperative type 2 diabetes, hypercholesterolemia
and osteoporosis, respectively, increase hazards of death for all types of THR
procedure compared to those without these conditions. Furthermore THR
cases who were on statins prescriptions for treatment of hypercholesterolemia
have better long term survival than those without the same prescriptions. Be-
ing overweight and obese prior to the procedure improved long term survival
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of THR cases for all types of THR procedures, compared to controls with
normal BMI. However survival of ex-smokers and smokers across all types of
THR procedures is worse than non-smoking controls and THR cases, respec-
tively.
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8 Discussion
Introduction
This thesis is relevant to the development of mortality risk models using
primary care data to estimate all-cause short term odds ratio (OR) and
long term hazards ratio (HR) of death, following THR procedures in the
UK. This chapter firstly, summarises the results and contributions of this
research findings to the existing evidence available in literature. Secondly,
the objectives of this research are addressed and an evaluation of its clinical
and actuarial validity and implications are presented, and thirdly, a review
of the strengths and limitations of this research follows.
8.1 Main findings
8.1.1 Short term mortality risk model
In this large study, age at surgery, year of birth category, types of THR
procedure, lifestyle factors (smoking status and BMI) and preoperative med-
ical conditions (Type 2 diabetes, angina, myocardial infarction, stroke, os-
teoarthritis and hypercholesterolemia) were the most important risk factors
for OR of death during the first 24 months after the procedure. Estimated
OR of death after primary THR procedures were higher among THR cases
than matched controls, given they had no preoperative medical conditions.
Estimated OR of death increased for older THR cases and were higher for
male THR cases compared to female cases. These findings are similar to
published studies by Fender et al. (1997), Lie et al. (2002), Nunley and
Lachiewicz (2003), Blom et al. (2006), Pedersen et al. (2011), Jones et al.
(2014), Lie et al. (2000), Williams et al. (2002), Ramiah et al. (2007), Ay-
nardi et al. (2009), NHS Scotland (2002), Lie et al. (2000), Hunt et al. (2013),
NHS Scotland (2002) and Lovald et al. (2014).
The findings of this research demonstrated that OR of death within the
first 24 months for patients with preoperative medical conditions such as
Type 2 diabetes, angina, stroke, osteoarthritis and hypercholesterolemia in-
creased estimated OR of death in the first 2 years equally for cases and
controls, respectively, compared to patients without these conditions. These
results are in accordance with previous studies by Gaston et al. (2007) and
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Pedersen et al. (2011). Although a proportion of patients in this research
were from deprived areas, variations in short term OR of death were not dif-
ferent by deprivation levels (Townsend scores, Index of multiple deprivation)
and socio-economic categories (Mosaic group).
Across types of THR procedures, OR of death was the highest for ce-
mented procedures, followed by uncemented and other types of THR proce-
dures. This result is in agreement with previous studies by Lie et al. (2000),
Nunley and Lachiewicz (2003), Ramiah et al. (2007), Hunt et al. (2013)
and Bozic et al. (2012). Furthermore, preoperative myocardial infarction in-
creased OR of death for all types of THR procedures compared to patients
without the condition - a result in accordance with Hunt et al. (2013) and
Comba et al. (2012).
BMI and smoking status prior to THR surgery contributed to variations
in short term OR of death for different type of procedures. Being overweight
and obese before the surgery increased short term OR of death for all types
of THR procedures. This result is also reported by Bozic et al. (2012) and
Memtsoudis et al. (2012), respectively. Ex-smokers and smokers also have an
increased OR of death for all types of procedures, compared to non-smokers.
No studies in literature adjusted for the effect of smoking status prior to THR
procedure while investigating short term mortality following THR, improving
precision of estimated OR of death.
8.1.2 Long term mortality risk model
Among patients who survived longer than 2 years after the procedure, varia-
tions in estimated all-cause HR of death were significantly contributed to by
gender, types of THR procedure, deprivation level (Townsend scores), socio-
economic status (Mosaic groups), preoperative lifestyle factors (BMI and
smoking status) and medical conditions (stroke, angina, myocardial infarc-
tion, hypercholesterolemia, osteoarthritis, osteoporosis and type 2 diabetes).
Estimated HR of death for THR cases without any preoperative medical
conditions was lower than matched controls without any medical condition
and was lower for female patients than male individuals. These results are
in accordance with McMinn et al. (2012), Paavolainen et al. (2002), White-
house et al. (2014), Barrett et al. (2005), Lovald et al. (2014), Lie et al.
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(2000), Maradit-Kremers et al. (2016), Visuri et al. (1994), Ritter et al.
(1998), Ramiah et al. (2007), Visuri et al. (1997), Pedersen et al. (2011) and
Ma¨kela¨ et al. (2014), who also found significant improvement in long term
survival of THR cases, compared to controls. Preoperative stroke, angina,
osteoporosis and Type 2 diabetes increased long term HR of death equally for
both cases and controls compared to patients without these comorbidities.
These results agree with Pedersen et al. (2011).
Deprivation and socio-economic factors are considered to be main in-
dicators of health and health related behaviours (Macintyre et al. (2002),
Diez Roux (2001), Pickett and Pearl (2001)) and (Pickett and Pearl (2001)).
This is reflected in the higher HR of death associated firstly, with residential
areas with high level of deprivation (Townsend scores ≥ 3) —a finding sim-
ilar to the results provided by Whitehouse et al. (2014), and secondly, with
socio-economic factor Mosaic category, where HR of death was higher among
patients from less aﬄuent categories.
Compared to matched controls, estimated long term HR of death was the
lowest for uncemented procedures, followed by cemented and other types of
THR procedures, respectively. This result is in agreement with Lie et al.
(2000) and McMinn et al. (2012). Preoperative diagnosis of osteoarthritis
also increased long term hazard of death for various types of procedures; a
result also reported by Holmberg (1992), Pedersen et al. (2011), Lie et al.
(2000), Barrett et al. (2005) and Whitehouse et al. (2014).
HR of death of THR cases with preoperative hypercholesterolemia was the
highest among those not on statins prescriptions, followed by those on statin
prescription. However for those with normal cholesterol level due to statins
prescription, their HR of death was lower than controls without hypercholes-
terolemia, showing the survival benefits of statins on long term survival as
shown also by Gitsels et al. (2016). No previous studies considered for effects
of preoperative hypercholesterolemia on survival of THR cases.
Being overweight or obese before the surgery decreased HR of death for
all types of THR procedures among non-smokers, indicating a protective
effect on long term survival of cases, compared to controls with normal BMI.
This obesity paradox is reported in men and women of all ages, races, and
ethnicities for various surgeries (Curtis et al. (2005), Adams et al. (2006),
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Bakaeen and Chu (2011), Stamou et al. (2011)). However this protective
effect disappears among THR cases who were either smokers or ex-smokers
prior to their THR surgery. Estimated HR of death increased for smokers
and ex-smokers who are either overweight or obese, compared to controls
with normal BMI.
8.2 Is association between THR and mortality risk a
result of study bias?
Introduction
Almost all studies are prone to error because they use samples drawn from a
population to estimate what is occurring or what might occur in the whole
population. These errors can broadly be divided into random error and sys-
tematic error, respectively. Random error is the play of chance and results in
an estimate of effect being equally likely to be above or below the true value
and is assessed with statistical measures such as p-values and confidence in-
tervals. Systematic error is called bias and also leads to the estimate being
above or below the true value. This section addresses how various sources of
bias are addressed and discusses whether the research findings can be a result
of study bias. The presence of study bias commonly causes the association
between exposure and outcome among those selected for the analysis to dif-
fer from the association among those eligible for the experiment (Szklo and
Nieto (2000)). Study biases can be classified as causal effect, confounding
result or selection bias (Herna´n et al. (2004)).
Figure 31 shows a directed acylic graph (Greenland (2003)) that depicts
the causal association between THR procedures and death. The green arrow
shows the direct causal path between THR and death while, the pink arrows
shows the ancestors that are also predictors of THR and death, respectively.
In this research, measured covariates can be grouped into two categories: (1)
predictors of THR procedure such as age, gender, degenerative inflammatory
conditions such as OA and BMI (Scha¨fer et al. (2010), Smith et al. (2012)),
and (2) predictors of death itself, such as demographic variables and history
of medical comorbidities before the procedure. Because of the relationships
between the measured covariates (Figure 31) and death, not adjusting the
selection of patients and analysis for these links will result in biased conclu-
sions.
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Figure 31: Directed acylic graph depicting the causal association between THR
procedures and death
1. Cause and effect
Cause and effect relationship can give rise to bias as a consequence of reverse
causation. If the outcome of interest precedes the measured covariates, then
the association of the outcome with the measured covariates can partially
represent bias attributable to the outcome’s effect on measured exposure
(Herna´n et al. (2002)). In both case-control studies carried out in this re-
search, all measured covariates were measured before the THR procedure and
before death, the outcome of interest. Therefore the risk of incorporating bias
as a result of reverse causation has been minimised.
2. Confounders
Generally when the exposure and outcome of interest have a common cause,
the estimated relationship measure is different from the effect measure be-
tween exposure and outcome (Herna´n et al. (2004)), giving rise to confound-
ing results. Figure 31 shows the structure of the link between measured
covariates that are predictors of THR procedure and death, respectively. In
this research, predictors of THR procedure are age, gender, diagnosis of in-
flammatory conditions such as OA and BMI (Scha¨fer et al. (2010), Smith
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et al. (2012)), and measured covariates that are also predictors of death are
age, gender, BMI, lifestyle factors and history of medical comorbidities be-
fore the procedure. To minimise the bias due to these confounders on the
data analysis, all mortality risk models developed, are adjusted for these
covariates so that estimated odds and hazard ratios of death are unbiased.
3. Selection bias
Selection bias is present when the exposure status of cases or controls affects
the likelihood that they are accepted into the experiment. All cases should
be equally likely to be included in the study population. If cases or controls
are kept in, or excluded from, a study on criteria related to exposure to the
risk factor under examination, estimated effect will be biased. Selection bias
arises due to several sources during the study design and data collection pro-
cess.
Firstly, selection bias may be present in a case-control study if there is
inappropriate selection of controls. In this research, patients identified as
controls were not selected due to their medical comorbidities. The only con-
dition to be accepted as controls in both studies carried out was that they did
not undergo a THR procedure. Moreover, controls were randomly matched
to cases using gender, year of birth category and GP practice to ensure that
both cases and controls might be assumed were exposed to the same level of
measured and unmeasured covariates. Selecting controls in this way avoided
introducing selection bias into the study design.
Secondly, loss to follow-up (censoring) can cause selection bias in esti-
mated effects if the censoring is informative. This is because conditioning on
censored variable to estimate the effect of interest will yield biased results
(Herna´n et al. (2002)). In the short term study, a sensitivity analysis com-
paring the model that included censoring due to transfer outs and another
model that excluded transferred out patients, revealed marginal differences
in estimated OR of death, indicating that selection bias due to patients lost
for follow-up after transferring to new GP practice had insignificant impact
on the data analysis. A reason for this ma be the low volume of transfer outs
during the first 24 months after surgery. In the long term study, transferred
out patients were also censored.However, the analysis revealed no significant
effect of transfer outs on HR of death, when the patients’ transfer to new
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GP practice was treated as a factor. Thus, the long term results were not
affected by selection bias due to loss to follow-up.
Thirdly, data analysis that excludes measured covariates with missing
data (full case analysis) yields biased results (Spratt et al. (2010), van Buuren
(2012)). In this research, missing data for Townsend score, index of multi-
ple deprivation, Mosaic category, body mass index and smoking status were
imputed using multiple imputation technique (Enders (2010)). Sensitivity
analyses carried out to compare the difference in results between full case
analysis and multiple imputation analysis showed differences in results that
would have been undetected under full case analysis, leading to inappropriate
conclusions from the analysis. Therefore data analysis in both studies carried
out was not affected by selection bias arising due to missing data because
missing data were included in the analysis by employing multiple imputation
techniques.
Conclusion
In the light of the arguments presented in this section, potential sources of
bias due to confounders and selection bias were controlled during the design
and analysis stage of both studies carried out in this research. This helped
to minimise systematic errors and to produce appropriate unbiased results.
Therefore, it can be concluded that the reported association between THR
and mortality risk in this research is due to the surgical procedure itself,
although perfect causal effect of THR on mortality cannot be attributed be-
cause of the presence of random errors. Nonetheless, the use of confidence
intervals for all estimated results helped to account for errors occurring ran-
domly.
8.3 Research implications
8.3.1 An evaluation of research objectives
The first aim of this research was to identify THR procedures from routinely
collected data in primary care records using the THIN database. Table 27
in Appendix A displays the Read codes for identification of primary THR
procedures in THIN. These Read codes have been validated by comparing
them to the International Classification of Disease (ICD-10) for surgical in-
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tervention. Therefore primary care records in THIN can be used to identify
primary THR procedures in UK. However the description of procedure types
can only be categorised as cemented, uncemented, hybrid or as other types.
No information describing the material of the hip prosthesis (metal or non-
metal) used during the procedure, is available in THIN.
The second aim was to estimate the preoperative prevalence of various
medical conditions among patients identified as THR cases in this research
and compare with the relevant literature for the UK population. Preva-
lence of preoperative smoking, angina, myocardial infarction, osteoarthritis,
rheumatoid arthritis, osteoporosis and hypercholesterolemia was marginally
lower in this study population, compared to relevant publications using pri-
mary care records. However obesity, type 2 diabetes, stroke among cases
aged 74 or less, treated hypercholesterolemia and hypertension (among fe-
male cases), respectively, were more prevalent among THR cases than rele-
vant published studies on these comorbidities. Prevalence of chronic kidney
diseases, hypertension among male THR cases and stroke among THR cases
aged 75 or more, is similar to relevant published studies. These lower esti-
mated prevalences may be due to under reporting of records in THIN because
patients with no records of a particular preoperative medical condition, were
assumed to be free of that co-morbidity prior to their procedure.
The third aim was to account for missing data in the study popula-
tion when developing mortality/survival models. Smoking status (27.5%),
Townsend scores (14.9%), BMI (9.7%), Mosaic group (8.4%) and index of
multiple deprivation (2.1%), respectively had unknown records in THIN for
THR cases and matched controls. These unknown observations were assumed
to be missing at random and handled using multiple imputation technique in
this research. For both short and long term mortality models, results from
the full case analysis for patients with complete records were compared to re-
sults for the analysis from the imputed datasets in terms of estimated model
parameters, performance and evaluation.
The fourth aim was to estimate the short and long term mortality risk
after THR procedures. Short term odds ratio of death were higher among
THR cases than matched controls during the first 2 years after the proce-
dure. Estimated all-cause odds ratio of death was the highest for cemented
procedures, followed by uncemented and other types of procedures. How-
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ever, for patients surviving the first two years after surgery, estimated long
term all-cause hazards ratio of death among THR cases were lower than
matched controls, and was the lowest for uncemented procedures, followed
by cemented and other types of procedures. These findings suggest that
THR procedures improve mortality risk in the long term, given the patients
survived the first 24 months after surgery.
The fifth aim was to investigate how the presence of preoperative medical
conditions affects the short and long term mortality risk after THR. Risk
factors for variations in short term odds ratio of death following THR pro-
cedures include gender, myocardial infarction, BMI and smoking status. For
the long term model, risk factors for THR cases for all-cause hazards ratio
of death include myocardial infarction, smoking status, BMI, osteoarthritis
and hypercholesterolemia. Hazards of death associated with the comorbidi-
ties remained constant during the follow-up after the procedure. This shows
that irrespective of the number of years the patients had already survived
with the co-morbidity, they were still at a higher hazard of death than those
without the condition.
The sixth aim was to identify socio-economic factors that explained varia-
tions in short and long term risk of death following THR procedures. During
the first 24 months after the procedure, estimated odds ratio of death do not
vary significantly between different levels of deprivation of patients residential
wards and between different socio-economic groups. However estimated long
term hazards ratio of death is higher for cases from more deprived residential
areas and from low income and less aﬄuent categories (Mosaic group G-O in
Table 29 in Appendix A). Explanation for variations in long term hazards of
death for different levels of deprivation and Mosaic groups can be explained
by poor ecology, lifestyle and access to transport and medical facilities in
highly deprived areas is poor, and thus, patients from these residential areas
have poorer health status than those from less deprived areas.
8.3.2 Clinical relevance of findings
Age and gender
Short term study concluded that OR of death was higher among elderly pa-
tients after the surgery indicating that the longer elderly patients are made to
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wait for their THR, the higher is the immediate post-operative mortality risk.
The researched study population comprised of a majority of elderly individu-
als who were aged 60 years or more and therefore included riskier age groups
with higher prevalence of medical comorbidities (obesity, stroke, angina, my-
ocardial infarction, hypertension and hypercholesterolemia). However in the
long run, this research found that age at surgery did not significantly affect
all-cause HR of death. This indicates that for patients who survived the early
post-operative months, THR procedure is beneficial to each age group.
Gender was also an important factor for short and long term mortality
after THR procedure. Male cases had higher mortality risk than female cases
and controls. Interaction between gender and types of procedures was only
significant in the short term with the highest OR of death attributed to
cemented procedures, followed by uncemented and other types of procedure
among male cases. This interaction disappeared in the long term. Long term
HR of death associated with different types of procedures did not differ by
gender. These short and long term findings classified both age and gender as
risk factors for mortality after THR and similar conclusions were reported by
Visuri et al. (1997), Lie et al. (2000), NHS Scotland (2002), NHS Scotland
(2002), Ramiah et al. (2007), Aynardi et al. (2009), Pedersen et al. (2011),
Ma¨kela¨ et al. (2014) and Lovald et al. (2014), respectively.
Cemented versus cementless procedures
For both short and long term studies, mortality risk of THR cases with no
preoperative medical comorbidities was the highest for cemented procedures,
followed by uncemented and other types of procedures, respectively, com-
pared to matched controls. Cemented procedures, which are also described
as a biologic fixation, have been strongly linked with a progressive time de-
pendent loss of fixation function (Amstutz et al. (1988), Hozack et al. (1990))
occurring due to loosening of the artificial joint (Harris and McGann (1986)).
This is a common cause of complications after surgery according to system-
atic review by Abdulkarim et al. (2013) and is a determinant factor in causing
a higher mortality risk for cemented procedures, in contrast to uncemented or
hybrid THR. On the contrary, uncemented procedures have been associated
with greater joint fixation stability (Engh et al. (2006)) because loosening of
the joint in cementless procedures were less common and not found to cause
further complications (Ro¨der et al. (2010)).
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Nevertheless, despite the proven benefits of cementless THR, such proce-
dure still remains the second most used type of fixation technique for THR,
after cemented ones, firstly, due to the high cost of the uncemented com-
ponents (Unnanuntana et al. (2009)) and, secondly, because of the posible
formation of blood clots in deep veins around the joint after surgery which
eventually travel up the leg to the lungs, causing pulmonary embolism. Such
complication is more prevalent among uncemented procedures, compared to
cemented ones (Blom et al. (2006), Aynardi et al. (2009), Pedersen et al.
(2011), Hunt et al. (2013) and Jones et al. (2014)). These findings suggest
that while clinicians should recommend cementless procedures, an assess-
ment of the risk of developing pulmonary embolism should also be carried
out such that the benefits of cementless procedures on mortality risk are not
overshadowed by that of pulmonary embolism.
Cardiovascular and inflammatory diseases
Mortality risk of patients with inflammatory diseases such as osteoarthritis
(OA) and osteoporosis was found to be higher than individuals without these
conditions. Unlike the short term study, in the long run OA was a risk factor
for mortality after THR, with HR of death being the lowest for cemented pro-
cedures, followed by uncemented and other types of procedures. This finding
strengthens the previous comment on why cemented procedures are more
prevalent than cementless ones despite being associated with lower mortality
risk. This is mainly attributed to the fact that THR is a treatment allo-
cated mostly to patients diagnosed with OA and thus, cemented procedures
represent the least risky procedure compared to cementless procedures. OA
is the main cause of the degenerative wear and tear condition that causes
painful hip joint inflammation and dysfunction (Berenbaum (2013)). The
most common treatment modality for symptomatic osteoarthritis is joint re-
placement, a procedure that itself brings about degenerative inflammation
like OA (Haynes et al. (2004)), thereby, explaining the perceived increase in
mortality risk after surgery for patients with OA and osteoporosis. Diagnosis
of joint OA and osteoporosis before the procedure should be carried out and
followed by clinicians since such information could help in selecting the type
of THR procedure to carry out.
Cardiovascular conditions such as stroke, angina and myocardial infarc-
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tion (MI) increased mortality risk among the study population and these
conform to results from previous studies by Gaston et al. (2007) and Peder-
sen et al. (2011). Firstly, no difference in mortality risk between cases and
controls, both with either stroke or angina was observed. Thus selection
of fixation type (cemented versus cementless) can be independent of their
medical history of stroke and angina. However for cases with a preoperative
history of MI, mortality risk varied for different types of procedures with
HR of death being lowest among uncemented procedures, followed by other
types of THR and cemented procedures. This finding showed that a history
of preoperative MI increased mortality risk among patients who underwent
cemented procedures and can therefore aid clinicians in advising patients
with a history of MI towards cementless procedures such as hybrid or unce-
mented hip joint replacement. Inflammatory diseases such as OA is the most
common diagnosis for THR procedures. Hansson and Hermansson (2011)
and Libby and Hansson (2012, 2015) showed that the pathological process
of cardiovascular disease is causally related to inflammatory process so that
conditions like OA increased the risk of cardiovascular events (Kaplan and
McCune (2003), Mason and Libby (2014)).
Hypercholesterolemia
Hypercholesterolemia (HC) was associated with an increase in short term OR
of death for all patients but did not vary for different types of procedures.
In the long run however, HC was a risk factor for mortality varying across
different types of procedures. Table 26 summarises the effect of hypercholes-
terolemia on the long term survival after THR.
Table 26: Effects of hypercholesterolemia on long term survival for different pro-
cedure types
Increasing
HR of death
No HC
No HC due to
statins prescription
HC despite
statins prescription
HC but not on
statins prescription
Lowest HR Uncemented Uncemented Controls Controls
Cemented Cemented Cemented Uncemented
Other types Other types Uncemented Other types
Highest HR Controls Controls Other types Cemented
Patients with no HC due to statins prescription may be directed to un-
cemented procedures as this will minimise the risk of mortality after the
procedure, in comparison to cemented ones. Additionally, cases with HC
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and statin prescription have reduced mortality risk compared to those with
HC but not on statins; a valid finding also reported by Gitsels et al. (2016).
Therefore, patients with HC but not on statins should be referred to their
general practitioner so that they can be prescribed statins before they un-
dergo their THR procedure since this will reduce their potential mortality
risk after the procedure.
Body mass index
In the short term, OR of death for overweight (26-30 kg/m2) and obese
(> 30kg/m2) patients were higher than individuals with normal BMI (19-25
kg/m2). Significant interaction between BMI and procedure types showed
OR of death was higher for cemented procedures compared to cementless
procedures, for both obese and overweight patients; a result also reported bu
Hunt et al. (2013) and Ja¨msen et al. (2013), respectively. However this excess
mortality risk disappears in the long term as being overweight and obese be-
fore the procedure, resulted in a protective effect on long term HR of death,
with uncemented procedures resulting in the highest improvement in HR,
followed by cemented and other types, respectively, for both overweight and
obesity; a result in accordance with Adams et al. (2006), Bakaeen and Chu
(2011) and Stamou et al. (2011).
In this research, approximately two-thirds of the THR cases were either
overweight or obese before the procedure and had higher prevalence for di-
abetes, hypertension, hypercholesterolemia and osteoarthritis, respectively,
across all age groups, compared to THR cases with normal BMI. However
obese and overweight patients had their surgical procedure at a younger age
compared with normal BMI patients, suggesting that obese and overweight
patients should most likely be referred for THR procedure at younger age to
experience the protective effect on mortality risk in the long term.
The protective effect of overweight and obesity on long term survival after
THR procedures is a paradoxical finding because high BMI is associated with
an increased risk of developing conditions such as coronary heart diseases,
hypercholesterolemia or hypertension. However, once the condition is mani-
fested, overweight or obesity protects against increasing mortality risk when
compared to patients with normal BMI. This result is also observed among
obese patients for other chronic conditions and in heart surgeries (Curtis
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et al. (2005), Bakaeen and Chu (2011), Stamou et al. (2011) and Haass et al.
(2011).
Type 2 Diabetes and smoking status
Type 2 diabetes increased short and long term mortality risk for all patients
in this research, but did not vary for different types of THR procedures.
Furthermore, there was significant interaction between gender and diabetes
showing that diagnosis of type 2 diabetes and being a male patient, increased
mortality risk. This is in agreement with the results of Pedersen et al. (2011)
and Barrett et al. (2005) who reported type 2 diabetes as a risk factor for
mortality when comparing THR cases to controls. It is well established that
mortality risk for smokers is significantly higher than non-smokers (Doll et al.
(2004)) due to the various health complications it causes. Mortality risk esti-
mated in this research was adjusted for smoking status and findings showed
significant increase in mortality among smokers and ex-smokers compared to
non-smokers, after the procedure.
Deprivation index and socio-economic classification
Short term OR of death did not vary significantly across residential areas
with various levels of deprivation and across socio-economic classifications.
However, variations in long term survival were significantly different between
residential areas with low and high deprivation level, measured by Townsend
score. Long term HR of death increased for patients residing in areas clas-
sified as highly deprived (Townsend score > 3). Similarly patients from less
wealthy socio-economic groups, indexed using post code based Mosaic clas-
sification, had a higher estimated HR of death than patients from the most
wealthy and aﬄuent areas.
Deprivation level was also reported to significantly increase mortality risk
after THR procedures among patients from highly deprived residential ar-
eas by Clement et al. (2011), Whitehouse et al. (2014) and Xu et al. (2017).
However, no previous studies adjusted for socio-economic factors in their long
term survival analysis. One reason for this may be that data and census tools
needed to classify patients by their socio-economic factors were not readily
available, in contrast to this research. Patients from deprived residential ar-
eas (Townsend score > 3) and poor socio-economic groups (Mosaic category
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G-O) have limited access to a public transport, consist of families who are
not house owners and are mostly unemployed, leading to less healthy lifestyle
in comparison to less deprived areas and more aﬄuent socio-economic groups.
Blak et al. (2011) demonstrated significant association between poor health
outcomes such as death and social deprivation using primary care data; a
finding which validates the results of this research where mortality risk af-
ter THR increases in highly deprived residential areas and for patients from
poor socio-economic groups. Furthermore, mortality risk varied significantly
between general practices in this research. This result is supported by the
conclusion of Blak et al. (2011) which helps to explain why some GP practices
are associated with poor survival after THR procedure, both in the short and
long term. GP practices in highly deprived residential areas are more likely
to provide care for patients with poor health and thus associated with higher
risk of mortality. This research demonstrated the impact of residential de-
privation and patients’ socio-economic classification on survival after THR
procedures and this points that post code related variables can be used as an
informative tool for clinicians to have a preliminary assessment of the THR
case health status before the procedure.
8.3.3 Actuarial relevance of findings
Understanding and management of the mortality risks from various medical
interventions and treatments is an important part of actuarial research in the
area of life insurance and pensions. The pricing of life assurance and pension
products sold to customers is highly dependent on the assumption or model
used to estimate mortality risks after the medical intervention. In actuarial
terms, mortality risk is defined as the uncertainty caused by future signifi-
cant changes in mortality rates (Barrieu et al., (2012)). With the increasing
number of THR procedures, the potential number of customers for life insur-
ance companies undergoing THR procedures rises. An accurate estimation
and interpretation of mortality risk of customers who underwent THR proce-
dure is therefore highly informative for the insurance industry. This research
demonstrated a temporary higher risk of death among individuals who had
the procedure in comparison to those who did not have THR. In the long
term however, given that the individuals survived the first 24 months, THR
procedure is found to improve survival compared to those who did not have
the intervention.
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This variation affects the mortality risk assumptions and pricing for life
assurance and pension products. Traditionally for life assurance products,
individuals are required to go through a series of medical check-ups that help
to estimate the mortality risk of the individuals so that their contract can
be underwritten and priced accordingly. THR procedure is excluded from
the medical history requested by underwriters. The findings of this research
demonstrated that THR procedures significantly impact on mortality risk.
Failing to account for the impact of THR procedure on mortality will classify
individuals who had THR in the same cohort as those without the procedure
and will thus give rise to basis risk. Under such a scenario, the overall
profitability of the portfolio of life assurance products will consequently be
affected since appropriate mortality risk assumptions was not tuned in the
pricing of the products. Therefore there is an incentive for actuaries and
underwriters to request information about the timing of THR procedure in
order to price their insurance products using the appropriate mortality risk
assumptions.
THR procedure is a surgical intervention mostly performed on people
aged more than 55 years. Thus it is a procedure that affects the cohort of
individuals either close to retirement age or pensioners receiving their bene-
fits. The findings of the long term survival analysis in this research showed
improvement in mortality risk, suggesting that life expectancy of THR cases
to exceed that of controls. This information can aid actuaries and pension
fund managers firstly, to adjust the pricing of their pension products such
that the fund collected is enough to cover for the increase in life expectancy
among those who have THR before retirement, and secondly, to adjust the
benefits paid out to pensioners who have THR during retirement period so
that the pension fund is not outlived by the individuals life expectancy. Not
adjusting variation in mortality risk assumption due to THR procedure, may
lead to an increasing liability for actuaries if the pension pot is not big enough
to pay the financial benefits to individuals who had THR.
8.4 Strengths
The study population in this research was obtained using primary care records
that were representative of the UK population after adjusting for gender,
age and deprivation (Blak et al. (2011), Langley et al. (2011), Gonza´lez
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et al. (2009), Hippisley-Cox and Coupland (2010a), MacDonald and Morant
(2008)). These primary care records consist of medical histories that provide
extensive insight on the clinical practice of medical conditions, diagnoses, in-
terventions and treatments among the general population. Similarly, primary
care data provide extensive socio-demographic, lifestyle factors and medical
information. Therefore, selected THR cases and matched controls in this
research were more representative of THR patients in the UK than previous
UK based studies which selected patients either through hospital admissions
or using secondary care databases. Furthermore, this research selected THR
cases and matched controls from the same population source and thus, com-
parisons between THR cases and controls are valid because using cases and
controls from the same source eliminates selection bias (Raboud and Breslow
1989).
The mean follow-up period for the long term study in this research was
9.8 years. The long follow-up allowed monitoring of changes in medical con-
ditions, interventions, treatments and lifestyle factors of patients over time,
thereby providing detailed insights on the past and present health status of
the study population. Hence potential risk factors for variations in long term
hazards of death could be identified by testing whether the effects of med-
ical conditions, interventions, treatments and lifestyle factors on long term
survival, vary over time. Similarly, the long follow-up period meant that
the event of interest (death) could be observed over a long period of time,
thereby estimating hazards of death more accurately. With an increasing life
expectancy in UK population, estimating hazards of death more accurately
becomes more important for medical management and resource allocation as
well as for retirement planning.
The short and long term mortality risk models developed in this research
are designed as matched cohort studies in which THR cases are compared to
matched controls from the same general population. Such a design permits
the estimation of the effect of THR procedure on short and long term sur-
vival between patients who underwent the procedures (cases) and those who
did not (controls). Furthermore, the estimated short term odds and long
term hazards of death were both adjusted for a range of risk factors that
are known to cause variations in survival following THR procedures, thereby
improving precision of estimated effects on mortality risk after the proce-
dure. Interactions between all risk factors were tested and not limited to
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testing only interactions between the main exposure, gender and age group.
This allowed the investigation of variations in short and long term mortality
risk in more comprehensive details, thereby permitting the formulation of
recommendations for patients with different medical histories, interventions,
treatments and retirement plans.
Patients in the short and long term studies were grouped by their GP
practice and were assumed to be exposed to the same level of unmeasured
frailty within the GP practice. This permits to include correlations of pa-
tients within each GP practice. Therefore, inferences from the results of
this research can not only be extended to the GP practices in the short and
long term study, but also to the whole UK population (Brown and Prescott
(2014)).
Finally, the methodology used to develop short and long term mortality
risk models, permits the use of the research findings for medical management
of patients by healthcare professionals and for planning of retirement bene-
fits. Presented short and long term survival models include risk factors that
are routinely collected by primary care providers in the UK and are available
patients. Therefore estimates of mortality risk in the short and long term
can be determined for patients with various medical conditions and lifestyle
factors. Similarly, the findings of this research are important and instruc-
tive for medical management of patients with respect to the administration
of their health status, ongoing treatments and medical interventions. With
respect to planning retirement period and benefits, the findings of this re-
search are useful for individuals who want to estimate their life expectancy
after THR procedures for financial planning during retirement, for actuaries
to determine the price of annuity products for the insurance industry and
for assisting the government or other regulatory bodies in the UK to bring
changes to the UK pension system.
8.5 Limitations
National death records for UK population are not linked with the THIN
database. Moving to a new GP practice may also indicate a change in pa-
tients residential area. According to Uren and Goldring (2007), national
trends for the UK population show that patients from the age group 60-69
moves from more aﬄuent areas in good health whereas the age group 70 or
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older move from deprived areas in worse health conditions. The mortality risk
models developed in this research, assumed that patients who transferred to
a new GP practice, had similar mortality rate to patients who did not move
to a new GP practice. This assumption was tested via sensitivity analysis
and it was concluded that transfer outs were not informative of changes in
short and long term mortality risks after THR procedures.
This research focussed on analysing the impact of degenerative and chronic
conditions such as arthritis on survival of THR cases after unilateral THR
procedure. Exclusion of bilateral THR procedures from the analysis may
limit the generalisability of the findings to the UK population in the sense
that the results may only apply to individuals having unilateral procedure.
A further research using time dependent survival model that accounts for the
time span between the two THR procedures may be employed to estimate
the effect of mortality risk after the bilateral procedure.
Gossec et al. (2005), Scha¨fer et al. (2010) and Smith et al. (2012) reported
that age, gender, body mass index, duration of symptoms affecting the nor-
mal functioning of the hip joint, measurement level of hip pain and movement
using indices such as the Oxford hip score (Wylde et al. (2005)), the WOMAC
(Wolfe (1999)) and the Harris hip score (Nilsdotter and Bremander (2011)),
respectively, are predictors of THR procedure. Among these reported pre-
dictors for THR, age, gender and body mass index were also found to be
predictors for mortality risk after the procedure. THIN data has no informa-
tion with respect to measurement indices such as the WOMAC, Oxford and
Harris hip score and thus, the analysis did not adjust for these predictors of
THR.
The long follow-up period for the long term study meant that over time,
the reasons for, and methods of collecting data by general practitioners, have
changed (Marston et al. (2010)). For instance, pre-1990 data collection in
primary care databases required no clinical audits but this process became
contractual in the early 1990 while, as from 2004, the Quality and Outcomes
Framework (QOF) was set up to provide financial incentives for general prac-
titioners to collect data. Consequently, quality of primary care records and
management of common chronic diseases, preventative and therapeutic mea-
sures, medical interventions and lifestyle choices improved (Campbell et al.
(2007), Langley et al. (2011), Sharma et al. (2010)). In this research, no
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significant interactions between year of birth category of patients with other
risk factors, were observed for the short and long term mortality models.
Therefore, short term odds and long term hazards of death following THR
procedures did not vary over time.
Medical records extracted from the THIN database are incomplete for
lifestyle factors (BMI and smoking status) and post-code related variables
(Townsend scores, Index of multiple deprivation and Mosaic group). Ac-
counting for missingness during the data analysis phase for the short and
long term mortality risk models required additional analyses and model as-
sumptions, thereby reducing the precision of the estimates from both mod-
els. Missingness in this was dealt with by employing the method of multiple
imputation. The distributions of complete records are close to that of the
imputed ones, while the survival model based on cases with complete records
only, estimated similar hazard ratios and performance statistics as the model
based on the imputed dataset, for both short and long term model.
In THIN database, data on the type of prosthesis, surgical approach
and surgeon experience are not available. Therefore estimates of short and
long term mortality risk in this study were not adjusted for these variables,
and survival after THR could not be distinguished for different types of
prosthesis, surgical approach and surgeon experience. Additionally, drug
therapy was included as a confounder for both short and long term models.
However one limitation with this approach is that adherence of patients to
the drug therapy is unknown, thereby, not precisely reflecting the effects of
drug therapy on mortality risks following THR.
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B Data Description Tables
Table 31: Mean age (THRage) at THR procedure and ratio of frequency of THR
cases to controls, (MR), across GP practices
Practice ID THR Cases Controls MR Cases THRage Controls THRage
a6706 58 290 5 72.88 72.71
a6732 38 190 5 70.74 70.62
a6744 63 315 5 72.38 72.58
a6775 100 500 5 72.29 72.50
a6802 53 265 5 73.05 72.87
a6810 123 615 5 70.26 70.22
a6811 163 815 5 69.92 69.81
a6873 5 25 5 67.48 68.03
a6875 50 250 5 72.50 72.42
a6883 37 185 5 71.09 70.95
a6897 123 615 5 71.10 70.98
a7714 38 190 5 72.54 72.53
a7778 66 330 5 71.95 71.69
a7832 99 495 5 70.85 70.77
a7840 95 475 5 71.31 71.51
a7916 93 465 5 71.17 71.19
a7939 48 240 5 73.69 73.76
a9000 90 450 5 70.98 70.88
a9799 3 15 5 73.05 73.12
a9800 22 110 5 68.11 68.11
a9849 20 100 5 71.19 71.09
a9854 102 510 5 69.09 69.10
a9856 13 65 5 72.82 72.70
a9870 78 390 5 70.88 70.68
a9873 90 450 5 70.71 70.36
a9874 26 130 5 70.44 70.19
a9884 86 430 5 70.84 70.48
a9887 59 295 5 70.32 70.39
a9889 39 195 5 73.90 74.17
a9898 32 160 5 71.95 71.61
a9899 46 230 5 71.62 71.98
a9910 95 475 5 70.54 70.41
a9914 112 560 5 71.08 70.99
a9915 36 180 5 69.40 69.61
a9916 2 10 5 68.12 67.62
a9918 48 240 5 69.06 69.13
a9919 76 380 5 70.92 70.55
a9923 100 500 5 73.01 73.02
a9925 37 185 5 72.27 72.05
a9928 45 225 5 71.00 70.75
a9937 66 330 5 70.96 70.90
a9939 54 270 5 70.46 70.76
a9945 48 240 5 69.81 69.78
a9957 22 110 5 69.78 69.62
a9968 53 265 5 71.82 71.48
a9975 14 70 5 70.62 70.95
a9977 40 200 5 71.54 71.08
a9984 7 35 5 72.22 71.90
a9990 5 25 5 59.96 59.68
a9991 81 405 5 70.59 70.27
a9992 33 165 5 70.04 69.58
b6702 12 60 5 71.19 71.62
b6732 24 120 5 72.66 72.61
b6797 48 240 5 74.21 73.84
b6834 2 10 5 73.15 74.05
b6837 31 155 5 73.15 72.72
b6862 11 55 5 77.15 76.97
b6868 4 20 5 70.74 70.89
b6876 7 35 5 76.42 76.05
b6878 20 100 5 69.81 69.90
b6882 97 485 5 72.86 72.82
b6883 38 190 5 72.14 72.43
b6884 65 325 5 72.29 72.26
b6887 44 220 5 68.23 68.01
b6888 27 135 5 69.40 69.21
b6892 43 215 5 71.35 71.08
b6894 22 110 5 70.07 69.94
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b7691 91 455 5 72.41 72.42
b7858 114 570 5 70.78 70.64
b7915 3 15 5 76.60 76.54
b7938 46 230 5 71.36 71.61
b7942 5 25 5 76.61 77.37
b9000 63 315 5 68.94 68.86
b9774 21 105 5 73.30 73.58
b9814 25 125 5 70.32 70.91
b9818 53 265 5 70.80 69.98
b9846 14 70 5 74.14 73.21
b9849 8 40 5 69.72 70.27
b9856 70 350 5 70.41 70.29
b9857 62 310 5 71.85 71.52
b9867 82 410 5 71.34 71.29
b9870 33 165 5 70.11 69.39
b9872 40 200 5 72.39 72.41
b9878 58 290 5 69.58 69.66
b9880 6 30 5 73.29 72.62
b9884 80 400 5 73.30 73.43
b9885 50 250 5 70.59 70.37
b9889 29 145 5 72.51 72.35
b9892 123 615 5 70.55 70.35
b9898 32 160 5 70.69 70.71
b9908 67 335 5 72.97 72.68
b9909 28 140 5 71.73 71.50
b9916 23 115 5 70.30 70.52
b9925 97 485 5 70.89 70.72
b9927 25 125 5 71.15 71.09
b9928 10 50 5 70.18 70.36
b9931 11 55 5 74.45 75.23
b9960 8 40 5 72.49 72.04
b9964 62 310 5 71.15 71.22
b9989 26 130 5 70.18 70.60
b9990 51 255 5 69.81 69.65
b9997 68 340 5 71.45 71.04
b9998 36 180 5 69.96 69.99
c6698 4 20 5 71.34 72.19
c6705 7 35 5 67.39 67.02
c6709 18 90 5 69.78 69.70
c6724 11 55 5 73.61 72.69
c6746 6 30 5 73.00 72.39
c6816 16 80 5 72.24 72.03
c6830 64 320 5 70.34 70.27
c6850 12 60 5 75.56 76.06
c6854 6 30 5 65.00 64.94
c6871 23 115 5 71.97 71.89
c6876 2 10 5 76.12 76.19
c6878 18 90 5 74.22 74.54
c6880 16 80 5 69.41 69.78
c6889 18 90 5 74.38 74.69
c6899 75 375 5 72.58 72.24
c7699 2 10 5 70.83 70.05
c7781 18 90 5 71.76 71.54
c7805 3 15 5 74.10 74.77
c9774 11 55 5 71.81 71.45
c9782 23 115 5 69.47 69.96
c9785 54 270 5 71.37 71.43
c9800 29 145 5 70.21 70.42
c9855 73 365 5 70.28 69.93
c9857 68 340 5 72.00 71.92
c9885 24 120 5 72.36 72.01
c9894 72 360 5 67.78 67.57
c9896 12 60 5 66.85 66.94
c9897 43 215 5 68.81 68.49
c9898 169 845 5 71.78 71.72
c9905 32 160 5 68.74 68.41
c9906 86 430 5 71.86 72.01
c9910 118 590 5 70.09 70.00
c9913 52 260 5 71.63 71.53
c9953 85 425 5 69.39 69.29
c9972 26 130 5 71.19 71.08
c9975 110 550 5 71.67 71.66
c9981 12 60 5 69.33 68.59
c9991 17 85 5 73.94 73.59
c9993 17 85 5 71.44 71.03
c9996 73 365 5 70.31 70.54
c9998 60 300 5 69.99 69.84
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d6710 27 135 5 71.64 72.07
d6727 44 220 5 72.49 72.49
d6753 20 100 5 73.76 73.45
d6764 23 115 5 69.48 69.65
d6804 2 10 5 78.01 77.21
d6808 10 50 5 69.32 69.60
d6838 35 175 5 72.73 73.04
d6857 7 35 5 63.79 63.91
d6869 4 20 5 61.65 60.85
d6878 4 20 5 65.17 65.47
d6879 3 15 5 70.99 71.72
d6883 28 140 5 72.50 72.01
d7700 3 15 5 73.79 74.13
d7793 44 220 5 71.17 71.33
d7813 9 45 5 70.27 69.59
d7907 10 50 5 71.05 71.53
d7941 4 20 5 73.03 73.39
d9779 6 30 5 75.18 74.71
d9783 28 140 5 71.70 71.67
d9795 9 45 5 73.93 72.95
d9832 17 85 5 71.47 70.81
d9834 28 140 5 68.00 67.25
d9864 66 330 5 71.11 70.96
d9866 7 35 5 70.79 71.25
d9905 101 505 5 71.27 71.03
d9908 23 115 5 70.84 70.62
d9914 64 320 5 71.32 70.76
d9918 70 350 5 68.76 68.93
d9928 49 245 5 72.11 72.04
d9935 10 50 5 73.36 74.34
d9937 33 165 5 72.22 72.32
d9953 68 340 5 70.26 70.09
d9957 36 180 5 71.71 71.70
d9961 54 270 5 70.04 70.03
d9965 152 760 5 69.86 69.75
d9970 14 70 5 70.76 70.77
d9971 164 820 5 69.47 69.41
d9974 140 700 5 70.90 70.64
d9978 7 35 5 67.73 66.76
d9986 32 160 5 71.25 71.44
d9997 15 75 5 70.78 71.15
e6765 47 235 5 73.94 73.90
e6776 5 25 5 67.47 67.55
e6799 24 120 5 72.52 72.53
e6802 112 560 5 70.76 70.71
e6806 69 345 5 70.92 70.69
e6817 95 475 5 72.09 72.09
e6857 33 165 5 70.09 70.60
e6866 10 50 5 74.19 73.25
e6867 8 40 5 70.33 69.63
e6877 48 240 5 70.85 70.76
e6881 2 10 5 74.11 73.60
e6888 5 25 5 69.42 70.30
e7686 22 110 5 71.55 71.32
e7692 40 200 5 71.43 71.50
e7712 11 55 5 70.23 70.58
e7734 6 30 5 66.73 67.29
e7805 9 45 5 71.59 70.99
e7916 21 105 5 74.58 74.37
e7923 2 10 5 72.51 72.41
e9003 6 30 5 64.41 64.01
e9776 34 170 5 70.15 70.07
e9820 26 130 5 70.09 70.06
e9825 49 245 5 72.09 71.93
e9846 58 290 5 70.26 69.98
e9857 10 50 5 75.86 75.64
e9881 25 125 5 67.17 67.15
e9888 96 480 5 72.71 72.71
e9908 38 190 5 69.39 68.92
e9909 28 140 5 72.42 72.00
e9912 33 165 5 67.10 67.17
e9914 31 155 5 71.27 71.13
e9924 4 20 5 64.34 63.48
e9931 48 240 5 70.87 70.49
e9935 27 135 5 71.60 71.38
e9957 21 105 5 69.91 69.67
e9972 26 130 5 70.64 70.66
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e9973 108 540 5 71.07 70.81
e9981 17 85 5 70.76 70.39
e9986 6 30 5 63.44 64.24
e9990 19 95 5 68.49 67.74
e9994 65 325 5 71.61 71.67
f6704 2 10 5 73.11 72.24
f6718 11 55 5 70.42 71.07
f6749 16 80 5 72.82 72.53
f6753 44 220 5 72.59 71.92
f6772 59 295 5 70.58 70.49
f6797 80 400 5 71.61 71.39
f6803 47 235 5 71.37 71.39
f6808 100 500 5 72.96 72.90
f6809 11 55 5 71.65 70.90
f6811 9 45 5 67.97 67.61
f6818 59 295 5 72.08 72.01
f6860 5 25 5 75.75 75.35
f6871 5 25 5 72.73 72.69
f6890 35 175 5 71.37 71.01
f7687 6 30 5 72.31 72.58
f7713 77 385 5 70.66 70.70
f7812 17 85 5 71.31 71.95
f7815 7 35 5 70.80 71.15
f7849 68 340 5 73.00 72.86
f9100 5 25 5 68.19 67.91
f9772 27 135 5 70.68 70.42
f9776 5 25 5 74.42 74.90
f9790 4 20 5 67.73 67.95
f9793 13 65 5 72.25 72.51
f9794 16 80 5 69.82 69.60
f9814 18 90 5 71.62 71.62
f9823 7 35 5 71.02 70.30
f9837 27 135 5 69.65 69.49
f9846 33 165 5 71.02 71.24
f9866 35 175 5 74.78 74.87
f9878 142 710 5 71.24 71.19
f9882 72 360 5 69.62 69.30
f9885 15 75 5 70.14 70.46
f9892 59 295 5 71.95 71.95
f9897 3 15 5 68.24 69.11
f9913 22 110 5 75.66 75.73
f9919 73 365 5 72.29 72.24
f9921 34 170 5 70.11 69.53
f9923 81 405 5 72.30 72.21
f9931 3 15 5 68.72 68.59
f9932 74 370 5 71.86 71.92
f9934 81 405 5 71.70 71.64
f9936 51 255 5 70.80 70.46
f9948 20 100 5 66.52 66.22
f9954 23 115 5 69.36 69.92
f9955 48 240 5 72.75 72.25
f9956 60 300 5 72.52 72.33
f9959 40 200 5 71.34 71.05
f9961 50 250 5 70.36 70.31
f9962 66 330 5 72.68 72.61
f9964 95 475 5 72.07 71.96
f9967 25 125 5 73.12 73.24
f9971 33 165 5 68.80 68.26
f9983 3 15 5 59.09 59.89
f9991 73 365 5 69.35 68.95
f9994 85 425 5 72.07 71.81
f9995 135 675 5 69.38 69.08
g6714 24 120 5 69.63 69.80
g6736 30 150 5 70.14 69.69
g6857 8 40 5 77.34 78.22
g6868 2 10 5 75.23 74.93
g6878 2 10 5 73.18 74.01
g6884 80 400 5 71.99 72.08
g6895 3 15 5 68.28 68.95
g6896 4 20 5 78.11 78.11
g6897 7 35 5 70.57 70.05
g7688 3 15 5 69.79 70.39
g7779 31 155 5 71.96 71.95
g7788 46 230 5 73.43 73.11
g7807 7 35 5 71.54 71.11
g7856 63 315 5 71.73 71.68
g7858 1 5 5 77.13 77.13
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g9781 34 170 5 69.55 69.88
g9807 10 50 5 68.84 68.16
g9835 20 100 5 71.92 72.21
g9840 8 40 5 70.14 69.88
g9846 12 60 5 71.77 71.52
g9851 42 210 5 72.00 71.42
g9853 13 65 5 68.45 68.56
g9859 29 145 5 69.41 69.28
g9861 12 60 5 71.54 70.59
g9884 67 335 5 71.97 71.97
g9885 19 95 5 70.01 70.35
g9895 27 135 5 67.75 67.68
g9910 14 70 5 69.96 69.71
g9911 78 390 5 70.71 70.85
g9912 29 145 5 70.12 69.47
g9917 107 535 5 69.22 68.98
g9920 138 690 5 71.56 71.52
g9936 13 65 5 68.65 68.46
g9938 64 320 5 69.14 68.97
g9956 24 120 5 69.72 69.83
g9959 41 205 5 70.54 70.45
g9965 74 370 5 69.99 70.01
g9987 42 210 5 69.35 68.70
g9993 4 20 5 73.43 72.55
h6720 36 180 5 72.32 72.45
h6744 6 30 5 69.28 69.88
h6748 17 85 5 73.21 72.92
h6755 18 90 5 65.60 65.43
h6800 5 25 5 64.59 65.11
h6812 13 65 5 68.84 69.16
h6813 5 25 5 69.01 69.73
h6871 19 95 5 72.46 72.28
h6872 28 140 5 72.51 72.74
h6873 8 40 5 72.06 72.06
h6879 12 60 5 72.66 72.86
h7691 67 335 5 70.78 70.23
h7694 168 840 5 73.26 73.15
h7706 1 5 5 73.86 74.76
h7711 121 605 5 74.34 74.21
h7753 12 60 5 76.66 76.66
h7822 16 80 5 72.81 73.10
h7954 7 35 5 75.29 75.23
h9004 31 155 5 70.80 70.64
h9781 12 60 5 66.25 66.03
h9784 48 240 5 72.33 71.99
h9799 29 145 5 70.83 70.98
h9819 29 145 5 71.24 71.04
h9832 14 70 5 75.49 75.40
h9845 23 115 5 71.79 71.64
h9860 42 210 5 71.05 71.01
h9864 12 60 5 71.34 72.29
h9882 59 295 5 68.90 68.66
h9888 77 385 5 70.74 70.62
h9899 69 345 5 71.02 70.62
h9900 85 425 5 71.67 71.57
h9901 24 120 5 68.93 68.79
h9921 12 60 5 74.91 73.98
h9936 2 10 5 71.34 71.53
h9938 100 500 5 71.50 71.45
h9946 21 105 5 67.07 66.71
h9950 10 50 5 72.12 72.40
h9957 45 225 5 69.62 69.59
h9959 30 150 5 72.22 72.14
h9973 11 55 5 73.32 72.52
h9978 83 415 5 72.38 72.32
h9981 12 60 5 71.73 70.98
h9986 4 20 5 74.18 73.43
h9987 36 180 5 65.16 64.90
h9988 37 185 5 69.72 69.13
h9990 56 280 5 70.63 70.44
h9995 81 405 5 73.48 73.20
h9998 53 265 5 71.91 71.54
i6714 26 130 5 70.33 70.21
i6727 12 60 5 70.64 70.01
i6731 2 10 5 62.43 62.93
i6732 12 60 5 69.31 70.14
i6744 9 45 5 71.09 71.61
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i6749 21 105 5 73.52 73.07
i6750 21 105 5 71.28 71.29
i6783 40 200 5 72.69 72.77
i6805 13 65 5 69.76 69.87
i6859 37 185 5 71.27 70.82
i6861 34 170 5 74.62 74.68
i6880 12 60 5 70.74 70.52
i6894 3 15 5 75.81 75.87
i6895 8 40 5 72.71 72.51
i6897 7 35 5 65.26 65.63
i7689 20 100 5 71.73 71.18
i7698 54 270 5 72.46 72.78
i7816 27 135 5 73.37 73.76
i7876 30 150 5 75.01 75.17
i7927 13 65 5 73.85 72.88
i9777 21 105 5 72.81 72.21
i9820 8 40 5 68.59 68.02
i9823 88 440 5 70.12 69.97
i9829 15 75 5 74.93 75.45
i9840 8 40 5 73.24 73.28
i9859 22 110 5 72.84 72.43
i9863 17 85 5 72.28 72.12
i9869 18 90 5 69.11 68.65
i9881 16 80 5 72.79 72.36
i9898 9 45 5 70.06 69.33
i9907 55 275 5 71.63 71.35
i9912 6 30 5 71.27 70.37
i9916 35 175 5 71.94 71.69
i9922 6 30 5 69.87 68.93
i9934 32 160 5 69.42 69.67
i9949 112 560 5 72.04 71.92
i9952 10 50 5 70.19 69.93
i9955 60 300 5 69.36 68.73
i9966 14 70 5 69.47 69.02
i9983 10 50 5 70.72 70.66
i9984 30 150 5 69.34 69.47
i9986 4 20 5 72.03 72.63
i9990 105 525 5 71.16 71.37
i9993 41 205 5 71.51 71.60
i9994 55 275 5 70.00 69.81
j6725 11 55 5 73.60 74.29
j6737 24 120 5 72.42 72.10
j6739 17 85 5 72.43 73.23
j6744 7 35 5 79.07 80.01
j6811 6 30 5 71.16 70.33
j6865 1 5 5 69.61 68.69
j6871 32 160 5 74.29 73.52
j6887 1 5 5 71.99 71.05
j6890 32 160 5 70.08 69.67
j7696 4 20 5 72.96 72.96
j7710 100 500 5 72.76 72.45
j7712 3 15 5 78.77 78.37
j7733 8 40 5 68.85 68.80
j7785 7 35 5 74.34 74.70
j7877 49 245 5 71.04 71.59
j7915 3 15 5 77.05 77.32
j7922 17 85 5 72.94 73.19
j7924 8 40 5 75.33 75.63
j7927 27 135 5 73.08 73.12
j7934 16 80 5 66.79 67.10
j7951 2 10 5 66.56 66.46
j9100 2 10 5 68.10 67.60
j9855 45 225 5 73.51 73.23
j9864 16 80 5 69.65 70.17
j9870 19 95 5 73.86 73.87
j9881 47 235 5 70.18 69.96
j9884 19 95 5 71.47 71.67
j9885 10 50 5 66.29 65.63
j9904 24 120 5 75.54 75.41
j9916 35 175 5 70.15 70.01
j9919 9 45 5 73.18 74.03
j9926 22 110 5 72.93 72.70
j9930 7 35 5 75.71 76.36
j9945 43 215 5 73.60 73.88
j9953 4 20 5 74.32 73.37
j9956 131 655 5 71.96 71.89
j9961 5 25 5 70.90 71.34
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j9963 2 10 5 72.18 72.98
j9969 5 25 5 69.15 69.07
j9973 213 1065 5 72.83 72.70
j9977 54 270 5 74.16 73.97
j9981 31 155 5 66.92 66.33
j9987 13 65 5 71.89 72.29
j9989 103 515 5 71.21 71.02
j9998 27 135 5 68.90 68.74
Each THR cases are matched to 5 controls of the same gender, year of birth cat-
egory and GP practice. Mean age at THR of cases is within plus-minus one year
to that of matched controls across each GP practices. Hence THR cases are ei-
ther younger by a maximum of one year or older by a maximum of one year than
matched controls.
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Table 34: Number and percentage of patients by PVI variables, measured in quin-
tiles level
Variable Description Levels THR Cases % Controls %
White ethnicity 1 3151 18 15457 18
(Quintile) 2 3385 20 16398 19
3 3091 18 15072 18
4 2884 17 13342 16
5 2392 14 11417 13
Unknown 2254 13 14099 16
Mixed ethnicity 1 2223 13 10531 12
(Quintile) 2 3012 18 14275 17
3 3215 19 15341 18
4 3418 20 16556 19
5 3035 18 14983 17
Unknown 2254 13 14099 16
Asian ethnicity 1 2700 16 13044 15
(Quintile) 2 2726 16 13148 15
3 3003 18 13965 16
4 3325 19 16062 19
5 3149 18 15467 18
Unknown 2254 13 14099 16
Black ethnicity 1 1888 11 8649 10
(Quintile) 2 3448 20 16554 19
3 2828 16 13769 16
4 3809 22 17997 21
5 2950 17 14717 17
Unknown 2234 13 14099 16
Other ethnicity 1 1967 11 9086 11
(Quintile) 2 2786 16 13209 15
3 3692 22 17548 20
4 3571 21 17637 21
5 2887 17 14206 17
Unknown 2254 13 14099 16
Urban/Rural Classification Urban 10867 63 52678 61
(Quintile) Rural 2418 14 11830 14
Village 1618 9 7178 8
Unknown 2254 13 14099 16
Long term illnesses 1 (Lowest) 2858 17 13748 16
(Quintile) 2 3463 20 16155 19
3 2879 17 13902 16
4 2648 15 13219 15
5 (Highest) 3055 18 14662 17
Unknown 2254 13 14099 16
Mean level of Nitrogen Dioxide 1 (Lowest) 2381 14 11354 13
2 2986 17 14272 17
3 2844 17 13617 16
4 3588 21 17520 20
5 (Highest) 3104 18 14923 17
Unknown 2254 13 14099 16
Mean level of particulate Matter 1 (Lowest) 1871 11 8989 10
2 2880 17 13506 16
3 3277 19 15844 18
4 3566 21 17536 20
5 (Highest) 3309 19 15811 18
Unknown 2254 13 14099 16
Mean level of Sulphur dioxide 1 (Lowest) 2599 15 12320 14
2 3019 18 14466 17
3 3149 18 15301 18
4 2518 15 12038 14
5 (Highest) 3618 21 17561 20
Unknown 2254 13 14099 16
Mean level of Nitrogen oxides 1 (Lowest) 2372 14 11325 13
2 2967 17 14127 16
3 2863 17 13741 16
4 3598 21 17567 20
5 (Highest) 3103 18 14926 17
Unknown 2254 13 14099 16
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Figure 38: Diagnostic plots for short term logistic regression model with interaction
terms fitted using 10 imputed datasets
The above figure displays the Cook’s distance, studentized residuals and hat values associated with each observations in
modelimp. Observations indexed at 17154, 22000 and 45756 are mostly likely to be outliers because they have the three
largest Cook’s distance.
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Figure 39: Assessment of influential outliers in short term logistic regression model
with interaction terms fitted using 10 imputed datasets
In the above figure, studentized residuals are plotted against hat-values. The diameter of the circle around each observation
is proportional to Cook’s distance. Observation indexed at 45756 has the largest circle (Cook’s distance=0.315) and is thus
suspected to be an influential outlier. However, as a sensitivity check, removal of observation 45756 did not significantly impact
on the estimated parameters of modelimp.
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Figure 40: Schoenfeld residuals distribution for model Lfull- Part 1
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death, due to stroke, Townsend scores, Mosaic categories, procedure types and
obesity, respectively, are independent of the event time.
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Figure 41: Schoenfeld residuals distribution for model Lfull- Part 2
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death, due to overweight, osteoarthritis, osteoporosis, hypercholesterolemia, type
2 diabetes, sex and smoking status are independent of the event time.
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Figure 42: Schoenfeld residuals distribution for model Limp- Part 1
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death, due to stroke, Townsend scores, Mosaic categories, procedure types and
obesity, respectively, are independent of the event time.
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Figure 43: Schoenfeld residuals distribution for model Limp- Part 2
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death, due to overweight, osteoarthritis, osteoporosis, hypercholesterolemia, type
2 diabetes, sex, smoking status, angina and myocardial infarction are independent of the event time.
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Table 45: Performance statistics comparison for long term survival models of main
effects only
Statistics Fullcaseanalysis Multipleimputationanalysis
Royston’s R2 26.1% [23.4%-28.5%] 25.2% [22.6%-27.4%]
Harrell’s Concordance, C 70.3% [67.4%-73.1%] 71.5% [67.9%-74.8%]
Shrinkage 0.968 0.976
The estimated performance statistics (Royston’s R2, Harrell’s concordance and shrinkage) of models fitted using full case and
multiple imputation analysis are close to each other. R2 is marginally higher for the full case record model. Estimated shrinkage
is marginally less for the model fitted using multiple imputation.
Table 46: Comparing coefficients of full case and multiple imputation analyses
Coefficients Full Case Analysis Multiple Imputation Analysis ∆L
Stroke 0.2960 0.3122 5%
Townsend Score 2 0.0803 0.0830 3%
Townsend Score 3 0.1146 0.1092 -5%
Townsend Score 4 0.1773 0.1519 -17%
Townsend Score 5 0.2129 0.1763 -21%
Mosaic Category D-F 0.0550 0.0655 16%
Mosaic Category G-I 0.1292 0.1246 -4%
Mosaic Category J-O 0.0602 0.0594 -1%
Uncemented THR -0.1669 -0.1487 -12%
Cemented THR -0.3167 -0.2875 -10%
Other THR -0.1478 -0.1278 -16%
Obese -0.1787 -0.1878 5%
Overweight -0.2364 -0.2211 -7%
OA* 0.0831 0.0760 -9%
Osteoporosis 0.3278 0.4021 18%
HC** Category 1 0.1317 0.1303 -1%
HC** Category 2 0.4531 0.4814 6%
HC** Category 3 0.5265 0.5327 1%
Type 2 Diabetes 0.7313 0.7626 4%
Sex 0.1363 0.1512 10%
Ex-smoker 0.5126 0.5933 14%
Smoker 0.9248 0.9475 2%
Angina NA 0.4795 NA
MI NA 0.3578 NA
*OA=Osteoarthritis, **HC=Hypercholesterolemia
Estimated ∆L’s between full case and multiple imputation analyses indicate that full case analysis underestimate (−∆L) and
overestimate (+∆L) for most model coefficients.
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Figure 44: Schoenfeld residuals distribution for model longfull- Part 1
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death are independent of time.
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Figure 45: Schoenfeld residuals distribution for model longfull- Part 2
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death are independent of time.
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Figure 46: Schoenfeld residuals distribution for model longfull- Part 3
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death are independent of time.
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Figure 47: Schoenfeld residuals distribution for model longimp- Part 1
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death are independent of time.
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Figure 48: Schoenfeld residuals distribution for model longimp- Part 2
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death are independent of time.
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Figure 49: Schoenfeld residuals distribution for model longimp- Part 3
Plots of Schoenfeld residuals versus event time for the full case analysis model show that the assumption of proportional hazards
is not violated. Variations in hazard ratio of death are independent of time.
Table 47: Performance statistics comparison for long term survival models includ-
ing interaction effects
Statistics Fullcaseanalysis Multipleimputationanalysis
Royston’s R2 25.7% [22.7%-28.1%] 25.4% [22.1%-27.6%]
Harrell’s Concordance, C 71.6% [68.4%-74.2%] 72.3% [68.9%-75.4%]
Shrinkage 0.961 0.969
The estimated performance statistics (Royston’s R2, Harrell’s concordance and shrinkage) of models fitted using full case and
multiple imputation analysis are close to each other. R2 is marginally higher for the full case record model. Estimated shrinkage
is marginally less for the model fitted using multiple imputation.
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